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Abstract 
The aim of this thesis was to characterise the T-cell component of the lymph node (LN) 
microenvironment in chronic lymphocytic leukaemia (CLL). It is well established that the 
proliferation of the neoplastic clone in CLL occurs primarily within the secondary lymphoid 
tissues and that within LNs these cells are in close contact with T-cells and other elements of 
the microenvironment. First I present a phenotypic study of the T-cells of the CLL LN obtained 
by fine needle aspiration. I found that, compared to CLL peripheral blood (PB), CLL LNs 
contain an excess of effector memory CD4+ T-cells and that the LN T-cells express more PD-
1 than those from the PB; suggesting ongoing activation. Multiparameter immunofluorescence 
microscopy on LN biopsy sections showed that proliferating Ki67+ CLL cells are in contact 
with CD4+ PD-1+ T-cells. Next I sought to characterise the T-cell receptor (TCR) repertoire of 
flow sorted LN and PB CD4+ T-cells by spectratyping. This revealed oligoclonality in both 
compartments, with a significant reduction in TCR diversity in the PD-1hi subset. All subsets 
were skewed compared to healthy age matched PB. The spectratype profiles were distinct 
between the LN and PB and therefore likely a result of interaction with different antigens. This 
data was complemented by high throughput sequencing of the TCR, which showed more 
sequence overlap between 2 LNs taken from the same CLL patient, than between the LN and 
PB. Finally I present a preliminary in-vitro study aimed at recapitulating the events in CLL LNs. 
This study showed that PD-L1 can be upregulated on PB CLL cells by CD3/CD28 stimulation 
of accompanying T-cells, and that blocking PD-1 can lead to increased secretion of interferon 
gamma. Taken together these findings suggest that CLL CD4+ T-cells are subject to chronic 
activation and have undergone antigen driven oligoclonal expansion within the LN.  
  
- 4 - 
Table of Contents  
Declaration ............................................................................................................................... 2 
Abstract .................................................................................................................................... 3 
Table of Contents ..................................................................................................................... 4 
Table of Figures ..................................................................................................................... 14 
Table of Tables ...................................................................................................................... 23 
Acknowledgments .................................................................................................................. 25 
Abbreviations ......................................................................................................................... 26 
Chapter 1 General Introduction .............................................................................................. 33 
1.1 Background to Chronic Lymphocytic Leukaemia ......................................................... 33 
1.1.1 Definition ................................................................................................................ 33 
1.1.2 Epidemiology ......................................................................................................... 33 
1.1.3 Diagnosis ............................................................................................................... 34 
1.1.4 Clinical Features .................................................................................................... 36 
1.1.5 Prognosis ............................................................................................................... 37 
1.1.6 Prognostic Biomarkers ........................................................................................... 39 
1.1.7 Treatment of CLL ................................................................................................... 45 
1.2 Background to the Normal Immune System................................................................. 47 
1.2.1 Introduction ............................................................................................................ 47 
1.2.2 Normal B-cell Development ................................................................................... 47 
1.2.3 Normal T-cell Development ................................................................................... 54 
1.3 Pathology of CLL B-cells .............................................................................................. 62 
1.3.1 Introduction ............................................................................................................ 62 
1.3.2 Cell of Origin .......................................................................................................... 62 
1.3.3 Immunoglobulin Repertoire .................................................................................... 63 
1.3.4 BCR Signalling and Antigen Drive ......................................................................... 64 
- 5 - 
1.4 T-cells in CLL ................................................................................................................ 65 
1.4.1 Introduction ............................................................................................................ 65 
1.4.2 T-cell Accumulation in CLL .................................................................................... 66 
1.4.3 T-helper Perturbations in CLL ................................................................................ 67 
1.4.4 Evidence of T-cell Stimulation ............................................................................... 69 
1.4.5 Functional Abnormalities ....................................................................................... 70 
1.4.6 CLL TCR Repertoire .............................................................................................. 73 
1.4.7 Pro-tumour Role of T-cells in CLL ......................................................................... 74 
1.4.8 CMV and CLL ........................................................................................................ 75 
1.4.9 Telomeres .............................................................................................................. 77 
1.5 NK Cells ........................................................................................................................ 77 
1.6 Lymph Node Microenvironment in CLL ........................................................................ 77 
1.6.1 Introduction ............................................................................................................ 77 
1.6.2 CLL Cells in the Lymph Node Microenvironment .................................................. 78 
1.6.3 CLL Cells Sustained by the Microenvironment ...................................................... 81 
1.6.4 T-Cells Derived from the CLL Microenvironment .................................................. 84 
1.7 Aim of Thesis ................................................................................................................ 85 
Chapter 2 General Materials and Methods ............................................................................ 86 
2.1 Ethics ............................................................................................................................ 86 
2.2 Primary Patient Material ............................................................................................... 86 
2.2.1 Peripheral Blood Sample Collection ...................................................................... 86 
2.2.2 Isolating PB Mononuclear Cells (PBMCs) ............................................................. 86 
2.2.3 Cryopreservation of Cells ...................................................................................... 86 
2.2.4 Defrosting Cells...................................................................................................... 87 
2.2.5 Negative B-cell Isolation ........................................................................................ 87 
- 6 - 
2.2.6 LN FNA Sample Collection .................................................................................... 87 
2.2.7 Lymph Node Sections ............................................................................................ 88 
2.3 Reagents ...................................................................................................................... 88 
2.3.1 General Chemicals, Consumables and Kits .......................................................... 88 
2.4 Media / Buffers / Solutions............................................................................................ 91 
2.4.1 Phosphate Buffered Saline (PBS) ......................................................................... 91 
2.4.2 TBE ........................................................................................................................ 91 
2.4.3 Citrate Buffer .......................................................................................................... 91 
2.4.4 Paraformaldehyde Fixation Buffer (4%) ................................................................ 91 
2.4.5 CLL Media .............................................................................................................. 91 
2.4.6 Jurkat Culture Media .............................................................................................. 91 
2.5 Cell Culture ................................................................................................................... 92 
2.5.1 CLL PBMC Culture ................................................................................................ 92 
2.5.2 Jurkat Cell Culture ................................................................................................. 92 
2.6 Antibodies ..................................................................................................................... 92 
2.6.1 Flow Cytometry Antibodies .................................................................................... 92 
2.6.2 Indirect Immunofluorescence Antibodies ............................................................... 94 
2.7 Flow Cytometry ............................................................................................................. 95 
2.7.1 Staining Cell Surface Antigens for Flow Cytometry ............................................... 95 
2.7.2 Foxp3 Intracellular Cell Staining Protocol .............................................................. 96 
2.7.3 Intracellular Cytokine Staining Protocol ................................................................. 96 
2.7.4 Flow Cytometry Viability Assay .............................................................................. 96 
2.7.5 Compensation Matrix ............................................................................................. 97 
2.7.6 BD FACSCanto II (BD Biosciences) ...................................................................... 97 
2.7.7 Flow Cytometry Data and Statistical Analysis ....................................................... 99 
- 7 - 
Chapter 3 Characterisation of the T-cell Component of the CLL Tumour Microenvironment by 
Immunophenotyping ............................................................................................................. 100 
3.1 Introduction ................................................................................................................. 100 
3.1.1 Experimental Approach ....................................................................................... 101 
3.1.2 Principles of Multiparameter Flow Cytometry ...................................................... 102 
3.1.3 Multiparameter Flow Cytometry of Lymph Node Fine Needle Aspirates............. 105 
3.2 Aim.............................................................................................................................. 106 
3.3 Materials and Methods ............................................................................................... 106 
3.3.1 Ethics ................................................................................................................... 106 
3.3.2 Primary Patient Material ...................................................................................... 106 
3.3.3 Flow Cytometry Panels ........................................................................................ 107 
3.3.4 Flow Cytometry Antibodies .................................................................................. 110 
3.3.5 Staining Cell Surface Antigens for Flow Cytometry ............................................. 111 
3.3.6 Compensation Matrix ........................................................................................... 111 
3.3.7 BD FACSCanto II (BD Biosciences) .................................................................... 111 
3.3.8 Flow Cytometry Data and Statistical Analysis ..................................................... 111 
3.4 Patient Material ........................................................................................................... 112 
3.4.1 Demographics of Patients and Normal Controls ................................................. 112 
3.5 Results ........................................................................................................................ 114 
3.5.1 LN FNA feasibility ................................................................................................ 114 
3.5.2 There is marked T-cell expansion in the PB of CLL patients compared to healthy 
controls ......................................................................................................................... 114 
3.5.3 CLL LN FNA and PB samples show differences in forward and side scatter reflecting 
their compartment ......................................................................................................... 118 
3.5.4 There is a higher percentage of CD3+ T-cells in CLL LN FNA samples than the PB
 ...................................................................................................................................... 120 
- 8 - 
3.5.5 The CLL LN FNA has a higher proportion of CD4+ T-cells than the PB ............. 121 
3.5.6 There is a higher proportion of T-cells in CLL LN FNA compared to PB, biased 
towards CD4+ effector memory phenotype .................................................................. 124 
3.5.7 CLL LNs contain relatively higher proportion of Tregs than the PB .................... 127 
3.5.8 CLL LN derived T-cells show similar levels of CD25 expression as those from the 
PB ................................................................................................................................. 128 
3.5.9 CD40L expression cannot be detected on resting CLL cells from the PB or LN FNA
 ...................................................................................................................................... 130 
3.5.10 Co-stimulatory molecules show differential expression between LN FNA and PB 
in CLL ............................................................................................................................ 131 
3.5.11 Assessment of negative regulators of T-cells .................................................... 133 
3.5.12 PD-1 expression is higher on the PB T-cells of CLL patients than normal controls
 ...................................................................................................................................... 134 
3.5.13 PD-1 expression levels are markedly increased on T-cells derived from the CLL 
LN compared to PB of the same patient ....................................................................... 136 
3.5.14 The known PD-1 ligands PDL1 and PDL2 are not expressed on resting CLL cells 
from the PB or LN ......................................................................................................... 139 
3.5.15 PD-1 expression is also identified to be present on CLL cells .......................... 139 
3.5.16 There is no difference in T follicular helper cell numbers between CLL PB and LN 
samples ......................................................................................................................... 140 
3.5.17 The impact of CMV seropositivity ...................................................................... 142 
3.5.18 CMV serostatus did not influence levels of T-cell PD-1 expression .................. 147 
3.6 Discussion .................................................................................................................. 151 
Chapter 4 Investigation of the T-cells in CLL Lymph Nodes by Multi-parameter 
Immunofluorescence Microscopy ........................................................................................ 161 
4.1 Introduction ................................................................................................................. 161 
4.1.1 Experimental Approach ....................................................................................... 161 
- 9 - 
4.1.2 Immunofluorescence Microscopy ........................................................................ 163 
4.2 Aim.............................................................................................................................. 164 
4.3 Materials and Methods ............................................................................................... 164 
4.3.1 Ethics ................................................................................................................... 164 
4.3.2 Patient Material .................................................................................................... 164 
4.3.3 PBMC Slide Preparation ...................................................................................... 165 
4.3.4 FFPE Antigen Retrieval ....................................................................................... 165 
4.3.5 Immunofluorescence Antibodies .......................................................................... 165 
4.3.6 Immunofluorescence Labelling ............................................................................ 167 
4.3.7 Microscopy and Image Acquisition ...................................................................... 167 
4.4 Results 1 – Optimisation Experiments ....................................................................... 168 
4.4.1 Immunofluorescence labelling of settled cells ..................................................... 168 
4.4.2 Fluorescence labelling of lymph node sections ................................................... 170 
4.4.3 Multiparameter immunofluorescence of lymph node sections ............................ 176 
4.5 Results 2 - Image Analysis ......................................................................................... 184 
4.5.1 Analysing co-expression of CD4 and PD-1 on FFPE LN samples ...................... 184 
4.5.2 CD4+ and PD-1+ co-expression on FFPE LN samples mirrors the findings of the 
LN FNA ......................................................................................................................... 186 
4.5.3 The majority of Ki67+ cells in CLL lymph node are contacting a CD4+ PD-1+ T-cell
 ...................................................................................................................................... 188 
4.5.4 The majority of PD-1+ T-cells in CLL LN samples do not have a Tfh phenotype 192 
4.6 Discussion .................................................................................................................. 195 
Chapter 5 Investigating the T-cell Receptor Repertoire in CLL Lymph Nodes .................... 198 
5.1 Introduction ................................................................................................................. 198 
5.2 Experimental Approach .............................................................................................. 201 
5.2.1 TCRV Repertoire Assessment ........................................................................... 201 
- 10 - 
5.2.2 Starting Material ................................................................................................... 206 
5.2.3 Flow Cytometric Cell Sorting ............................................................................... 209 
5.3 Aim.............................................................................................................................. 209 
5.4 Materials and Methods ............................................................................................... 210 
5.4.1 Ethics ................................................................................................................... 210 
5.4.2 Primary Patient Material ...................................................................................... 210 
5.4.3 Jurkat Cells .......................................................................................................... 211 
5.4.4 Antibodies for FACS Cell Sorting......................................................................... 211 
5.4.5 Staining Cell Surface Antigens for Flow Cytometry ............................................. 211 
5.4.6 FACS Sorting ....................................................................................................... 211 
5.4.7 RNA Extraction .................................................................................................... 211 
5.4.8 RNA Quantification .............................................................................................. 214 
5.4.9 First Strand cDNA Synthesis ............................................................................... 214 
5.4.10 Ligation of Novel Oligonucleotide to Single Stranded cDNA ............................. 215 
5.4.11 Polymerase Chain Reaction Methods ............................................................... 215 
5.4.12 TBE Agarose Gel ............................................................................................... 218 
5.4.13 DNA Gel Extraction ............................................................................................ 219 
5.4.14 PCR Product Sequencing .................................................................................. 219 
5.4.15 TCRVβ Spectratyping Fragment Analysis ......................................................... 219 
5.4.16 TCRVβ Spectratyping Profile Analysis .............................................................. 219 
5.4.17 Statistical Analysis ............................................................................................. 221 
5.4.18 High Throughput Sequencing Analysis ............................................................. 222 
5.5 Results ........................................................................................................................ 222 
5.5.1 Demographics of patients and normal controls for spectratyping ....................... 222 
5.5.2 Ligation anchored PCR ........................................................................................ 224 
- 11 - 
5.5.3 Gene sequencing of TCRV ................................................................................ 227 
5.5.4 TCRV spectratyping in primary patient material ................................................ 229 
5.5.5 Jurkat cell TCRV spectratyping ......................................................................... 229 
5.5.6 Cell sorting for TCRV spectratyping of primary patient T-cells .......................... 230 
5.5.7 RNA quantification ............................................................................................... 233 
5.5.8 PCR of control housekeeping genes from sorted subpopulations ...................... 234 
5.5.9 TCRV PCR products were successfully amplified from the sorted cell populations
 ...................................................................................................................................... 235 
5.5.10 TCRVβ spectratyping ......................................................................................... 236 
5.5.11 Diversity and complexity scores ........................................................................ 238 
5.5.12 There is increased skewing of the TCRV spectratype in PD-1hi T-cells compared 
to PD-1lo T-cells in both LN and PB compartments in CLL.......................................... 243 
5.5.13 There is skewing of the TCRV spectratype in PD-1hi CD4+ T-cells compared to 
PD-1lo CD4+ T-cells in normal PB ............................................................................... 246 
5.5.14 There is increased skewing of the CLL PB TCRV spectratype compared to age 
matched normal controls in both PD-1hi and PD-1lo CD4+ T-cell subsets .................. 248 
5.5.15 TCRVβ family skewing ....................................................................................... 250 
5.5.16 Concordance of skewing ................................................................................... 253 
5.5.17 High throughput TCRVβ sequencing ................................................................. 255 
5.5.18 Demographics of patients and normal controls for HTS .................................... 256 
5.5.19 Average Vβ gene usage differs between CLL and normal PB .......................... 257 
5.5.20 There is commonality of TCRVβ family usage between CD4+ T-cells from CLL PB 
and LNs ......................................................................................................................... 258 
5.5.21 The starting number of T-cells is proportionate to the number of unique sequences 
derived .......................................................................................................................... 259 
5.5.22 There is more clonality of the CD4+ T-cells from the LN FNA than the PB ...... 260 
- 12 - 
5.5.23 CLL CD4+ T-cells derived from LNs have more commonality of TCR usage with 
each other than with matched PB ................................................................................. 262 
5.6 Discussion .................................................................................................................. 264 
Chapter 6 An in vitro model of CLL LN T-cells and effects of blocking the PD-1 / PD-L1 
axis ....................................................................................................................................... 271 
6.1 Introduction ................................................................................................................. 271 
6.1.1 Experimental Approach ....................................................................................... 273 
6.2 Aim.............................................................................................................................. 274 
6.3 Materials and Methods ............................................................................................... 274 
6.3.1 Ethics ................................................................................................................... 274 
6.3.2 Primary Patient Material ...................................................................................... 274 
6.3.3 PBMC Culture ...................................................................................................... 274 
6.3.4 CD3/CD28 Stimulation of T-cells ......................................................................... 274 
6.3.5 Blocking PD-1 ...................................................................................................... 275 
6.3.6 Intracellular Cytokine Measurement .................................................................... 275 
6.3.7 Flow Cytometry Antibodies .................................................................................. 275 
6.3.8 Flow Cytometry Panels ........................................................................................ 276 
6.3.9 Staining Cell Surface Antigens for Flow Cytometry ............................................. 278 
6.3.10 Intracellular Cytokine Staining ........................................................................... 278 
6.3.11 Compensation Matrix ......................................................................................... 278 
6.3.12 BD FACSCanto II (BD Biosciences) .................................................................. 279 
6.3.13 Flow Cytometry Data and Statistical Analysis ................................................... 279 
6.4 Patient Material ........................................................................................................... 279 
6.4.1 Demographics of Patients .................................................................................... 279 
6.5 Results ........................................................................................................................ 281 
6.5.1 T-cells are viable after 48 hours of culture following stimulation ......................... 281 
- 13 - 
6.5.2 Activation markers can be induced on PB CLL T-cells by CD3/CD28 bead 
stimulation ..................................................................................................................... 281 
6.5.3 Negative regulators of the immune system upregulate upon T-cell CD3/CD28 
stimulation ..................................................................................................................... 285 
6.5.4 PD-1 can be induced on CLL T-cells by CD3/CD28 bead stimulation ................ 286 
6.5.5 Resting levels of CD25 were higher on T-cells from cryopreserved CLL PBMCs 
compared to fresh whole blood and CD3/CD28 bead stimulation raised the level of CD25 
higher still ...................................................................................................................... 287 
6.5.6 Levels of CTLA-4 on CD4+ T-cells were the same on fresh and cryopreserved PB 
but CD3/CD28 bead stimulation does not mimic the levels found in the LN ................ 290 
6.5.7 CD3/CD28 bead stimulation upregulates PD-1 on PB T-cells to levels similar to 
those found in LN FNA.................................................................................................. 291 
6.5.8 PD-L1 can be induced on CLL cells by co-culture with stimulated T-cells .......... 293 
6.5.9 PB T-cells upregulate PD-L1 following CD3/CD28 bead stimulation .................. 296 
6.5.10 PD-L2 is not expressed by PB CLL, CD4+ or CD8+ cells ................................. 298 
6.5.11 Blocking the PD-1 / PD-L1 axis ......................................................................... 298 
6.5.12 Effects of blocking PD-1 on CLL PB T-cell CD25 expression ........................... 298 
6.5.13 Blocking PD-1 does not alter CD69 expression on CD4+ or CD8+ PB T-cells . 301 
6.5.14 Blocking PD-1 does not alter CTLA-4 expression on CD4+ PB T-cells ............ 303 
6.5.15 Blocking PD-1 does not change PD-1 expression levels on PB T-cells or CLL cells
 ...................................................................................................................................... 304 
6.5.16 Blocking PD-1 does not alter PD-L1 expression on PB CLL cells ..................... 307 
6.5.17 Intracellular IFN-γ secretion ............................................................................... 308 
6.6 Discussion .................................................................................................................. 309 
Chapter 7 Final Discussion .................................................................................................. 313 
References ........................................................................................................................... 324 
 
- 14 - 
Table of Figures 
Figure 1-1 PB film in CLL. Magnification x20. Courtesy of King’s Haematological Malignancy 
Diagnostic Centre. .................................................................................................................. 35 
Figure 1-2 The germinal centre reaction of a lymph node. Adapted from Küppers et al. ...... 50 
Figure 1-3 Chronic active BCR signalling. Adapted from Young at el. .................................. 52 
Figure 1-4 B7-CD28 superfamily crosstalk between APC and T-cells. Adapted from Sharpe et 
al. ............................................................................................................................................ 59 
Figure 3-1 Fluorochrome spectral overlaps (Ref: BD Biosciences) ..................................... 103 
Figure 3-2 CLL patients and healthy control volunteers are age matched .......................... 112 
Figure 3-3 Increased percentage of CD3+ T-cells in the lymphocyte gate of normal controls 
compared to CLL cohort ....................................................................................................... 115 
Figure 3-4 Increase in the total CD3+ T-cell count in CLL patients compared to normal controls
 ............................................................................................................................................. 116 
Figure 3-5 The absolute CD4+ count is higher in CLL patients PB than normal controls ... 116 
Figure 3-6 There is an expansion in the absolute CD8+ T-cell count in CLL patients compared 
to normal controls ................................................................................................................. 117 
Figure 3-7 There was no difference in PB CD4/CD8 ratio between CLL cohort and healthy 
controls ................................................................................................................................. 117 
Figure 3-8 There is no correlation between the total WCC and CD4/CD8 ratio in CLL PB . 118 
Figure 3-9 Forward and side scatter dot plot of CLL PB ...................................................... 119 
Figure 3-10 Differences in the SSC versus FSC dot plots comparing PB and LN FNA ...... 119 
Figure 3-11 Gating of CD3+ T-cells from the lymphocyte gate ........................................... 120 
Figure 3-12 The lymphocyte gate contains more CD3+ T-cells in the LN FNA compared to PB
 ............................................................................................................................................. 121 
Figure 3-13 Gating strategy for CD4+ and CD8+ T-cells from the CD3+ T-cells in lymphocyte 
gate ...................................................................................................................................... 122 
Figure 3-14 CD4+ T-cells were found at relatively higher frequency in the LN FNA compared 
to PB ..................................................................................................................................... 123 
Figure 3-15 CD8+ T-cells were less abundant in lymphocyte gate of the LN FNA compared to 
PB ......................................................................................................................................... 123 
- 15 - 
Figure 3-16 Gating strategy for T-cell memory subsets ....................................................... 124 
Figure 3-17 There are fewer naïve CD4+ cells in the LN FNA than the PB of the same patient
 ............................................................................................................................................. 125 
Figure 3-18 There are fewer CD4+ TCM cells in the LN FNA than the PB of the same patient
 ............................................................................................................................................. 125 
Figure 3-19 There are more CD4+ TEM cells in the LN FNA compared to the PB of the same 
patient ................................................................................................................................... 126 
Figure 3-20 There are more CD4+ TEMRA cells in the LN FNA than the PB of the same patients
 ............................................................................................................................................. 126 
Figure 3-21 There were more Tregs in the CLL LN compared to the PB taken simultaneously
 ............................................................................................................................................. 128 
Figure 3-22 There is no difference in the percentage of CD4+ T-cells expressing CD25 in LN 
FNA or PB ............................................................................................................................ 129 
Figure 3-23 There is no difference in the percentage of CD8+ T-cells expressing CD25 
between the LN FNA and PB ............................................................................................... 129 
Figure 3-24 CD40L expression in CD4+ T-cells of LN FNA compared to negative control . 130 
Figure 3-25 There was no upregulation of CD40L in the CLL LN........................................ 131 
Figure 3-26 There was higher levels of CD28 on CD4+ T-cells in the LN compared to PB 132 
Figure 3-27 There was higher levels of CD28 on CD8+ T-cells in the LN compared to PB 132 
Figure 3-28 There was a trend toward an increase in CTLA-4+ expression on CD4+ T-cells 
derived from the  LN FNA compared to PB ......................................................................... 133 
Figure 3-29 There was a statistically higher percentage of CD8+ T-cells that expressed CTLA-
4+ in the LN FNA compared to PB ....................................................................................... 134 
Figure 3-30 There is a higher percentage of PD-1+ CD4+ T-cells in CLL PB compared to 
healthy controls .................................................................................................................... 135 
Figure 3-31 There is a higher percentage of PD-1+ CD8+ T-cells in CLL PB compared to 
healthy controls .................................................................................................................... 135 
Figure 3-32 Representative dot plot of PD-1+ / CD4+ T-cells of PB compared to LN FNA 136 
Figure 3-33 The MFI of PD-1 was higher in the LN FNA CD4+ T-cells compared to PB .... 137 
- 16 - 
Figure 3-34 There is more PD-1 expressed on the CD4+ T-cells of the LN compared to PB
 ............................................................................................................................................. 137 
Figure 3-35 The MFI of PD-1 was higher in the LN FNA CD8+ T-cells compared to PB .... 138 
Figure 3-36 There is more PD-1 expressed on the CD8+ T-cells of the LN compared to PB
 ............................................................................................................................................. 138 
Figure 3-37 No difference in the level of expression of PD-L1 in the CLL PB or LN FNA ... 139 
Figure 3-38 Higher frequency of PD-1+ CLL cells in the LN FNA than PB ......................... 140 
Figure 3-39 Increased CXCR5+ CD4+ cells in CLL PB vs healthy PB ............................... 141 
Figure 3-40 There was no difference in the frequency of CD4+ / CXCR5+ T-cells found in the 
PB or LN FNA in CLL ........................................................................................................... 141 
Figure 3-41 The size of the CLL PB CD3+ expansion is not influenced by CMV serostatus
 ............................................................................................................................................. 143 
Figure 3-42 The percentage of CD4+ T-cells in CLL PB is not influenced by CMV serostatus
 ............................................................................................................................................. 143 
Figure 3-43 The percentage of CD8+ T-cells in CLL PB is not influenced by CMV serostatus
 ............................................................................................................................................. 144 
Figure 3-44 CMV serostatus does not influence the percentage of naïve CD4+ T-cells found 
in the PB or LN of CLL patients ........................................................................................... 145 
Figure 3-45 CMV serostatus does not influence the percentage of TCM CD4+ T-cells found in 
the PB or LN of CLL patients ............................................................................................... 145 
Figure 3-46 CMV serostatus does not influence the percentage of TEM CD4+ T-cells found in 
the PB or LN of CLL patients ............................................................................................... 146 
Figure 3-47 CMV serostatus does not influence the percentage of TEMRA CD4+ T-cells found 
in the PB or LN of CLL patients ........................................................................................... 146 
Figure 3-48 PD-1 expression is higher on LN CD4+ T-cells than PB CD4+ T-cells in CMV 
seronegative CLL patients ................................................................................................... 147 
Figure 3-49 PD-1 expression is higher on LN CD4+ T-cells than PB CD4+ T-cells in CMV 
seropositive CLL patients ..................................................................................................... 148 
Figure 3-50 PD-1 expression is higher on LN CD8+ T-cells than PB CD8+ T-cells in CMV 
seronegative CLL patients ................................................................................................... 148 
- 17 - 
Figure 3-51 PD-1 expression is higher on LN CD8+ T-cells than PB CD8+ T-cells in CMV 
seropositive CLL patients ..................................................................................................... 149 
Figure 3-52 CMV serostatus does not impact on levels of PD-1 on CD4+ T-cells in PB or LN
 ............................................................................................................................................. 150 
Figure 3-53 CMV serostatus does not impact on levels of PD-1 on CD8+ T-cells in PB or LN 
compartment ........................................................................................................................ 151 
Figure 4-1 Fluorescence microscope light beam path (Axiovert 200 diagram modified from 
Carl Zeiss) ............................................................................................................................ 164 
Figure 4-2 Autofluorescence in unstained CLL lymph node in FITC channel, magnification x10
 ............................................................................................................................................. 171 
Figure 4-3 CD23+ CLL cells labelled with Cy5 (red), magnification x10 ............................. 172 
Figure 4-4 CD4 labelled with Cy3 (blue) in a CLL lymph node, magnification x10.............. 172 
Figure 4-5 PD-1 labelled with Cy5 (red) in a normal reactive lymph node, magnification x10
 ............................................................................................................................................. 173 
Figure 4-6 PD-1 labelled with Cy5 (red) in a CLL lymph node, magnification x10 .............. 173 
Figure 4-7 Ki67 green labelled with FITC (green) in a normal germinal centre, magnification 
x10 ........................................................................................................................................ 174 
Figure 4-8  Ki67 cells labelled with FITC (green) in a CLL lymph node, magnification x10 175 
Figure 4-9 The nuclear staining of Ki67 can be appreciated at high power, magnification x 40
 ............................................................................................................................................. 175 
Figure 4-10 CD23 labelled with Cy5 (red) and Ki67 labelled with Cy3 (green) in a CLL lymph 
node, magnification x10 ....................................................................................................... 176 
Figure 4-11 CD23 labelled with Cy5 (red) and Ki67 labelled with Cy3 (green) in a CLL lymph 
node, magnification x40 ....................................................................................................... 177 
Figure 4-12 Ki67 labelled with FITC (green) and CD4 with Cy3 (blue) in a normal lymph node, 
magnification x10 ................................................................................................................. 177 
Figure 4-13 Ki67 labelled with FITC (green) and CD4 with Cy3 (blue) in a CLL lymph node, 
magnification x10 ................................................................................................................. 178 
Figure 4-14 CLL lymph node triple labelled with CD23 (red), CD4 (blue) and Ki67 (green), 
magnification x40 ................................................................................................................. 179 
- 18 - 
Figure 4-15 Ki67 labelled with FITC (green) and PD-1 labelled with Cy5 (red) in a germinal 
centre of a normal lymph node, magnification x10 .............................................................. 180 
Figure 4-16 Ki67 labelled with FITC (green) and PD-1 labelled with Cy5 (red) in a CLL lymph 
node, magnification x40 ....................................................................................................... 180 
Figure 4-17 Normal germinal centre in a reactive lymph node. Ki67 (green), CD4 (blue) and 
PD-1 (red), magnification x10 .............................................................................................. 181 
Figure 4-18 Normal germinal centre in a reactive lymph node. Ki67 (green), CD4 (blue) and 
PD-1 (red), magnification x40. The blue and red positive cells (CD4 and PD-1) are pink/purple. 
High power visualisation of the germinal centre of the normal reactive LN shown in Figure 
4-17. The overlay image in higher magnification shows clearly the cells that are CD4+ and 
PD-1+ are pink/purple. ......................................................................................................... 182 
Figure 4-19 CLL lymph node stained for Ki67 labelled with FITC (green), CD4 with Cy3 (blue) 
and PD-1 with Cy5 (red), magnification x10. ....................................................................... 183 
Figure 4-20 CLL lymph node stained for Ki67 labelled with FITC (green), CD4 with Cy3 (blue) 
and PD-1 with Cy5 (red), magnification x40. ....................................................................... 183 
Figure 4-21 Thresholding and Overlap ................................................................................ 186 
Figure 4-22 Percentage of CD4+ T-cells expressing PD-1 across the 9 CLL samples. ...... 187 
Figure 4-23 Comparison between percentage CD4+ T-cells expressing PD-1 in fresh LN FNA 
samples and FFPE LN biopsy sections. .............................................................................. 188 
Figure 4-24 Objects and Regions of interest ....................................................................... 189 
Figure 4-25 Percentage of Ki67+ cells overlapping with a CD4+ PD-1+ T-cell ................... 191 
Figure 4-26 No correlation between number of Ki67+ cells per field and the likelihood of 
touching a CD4+ PD-1+ T-cell ............................................................................................. 191 
Figure 4-27 CXCR5 staining of a CLL LN with DyLight™ 549 (red) reveals all cells to be 
positive ................................................................................................................................. 193 
Figure 4-28 The majority of CD4+ T-cells in the CLL LN are not Tfh cells .......................... 194 
Figure 5-1 Methods of analysing the TCR by HTS. Adapted from Baum et al and Bolotin et al.
 ............................................................................................................................................. 206 
Figure 5-2 Typical TCRVβ spectratype profile ..................................................................... 220 
Figure 5-3 Spectratype scoring system ............................................................................... 221 
- 19 - 
Figure 5-4 Age demographics of patients and normal controls ........................................... 223 
Figure 5-5 Actin in successfully amplified in Jurkat cell line ................................................ 225 
Figure 5-6 Successful TCR amplification in Jurkat cell line (lane 6) .................................... 226 
Figure 5-7 Lane 2 shows the cleaned up Jurkat TCR PCR product .................................... 227 
Figure 5-8 Snapshot of sequencing data of PCR product ................................................... 227 
Figure 5-9 BLAST search ..................................................................................................... 228 
Figure 5-10 Dominant peak in Jurkat V spectratype profile ............................................... 230 
Figure 5-11 Number of each CD4+ T-cell subset in CLL FACS sort ................................... 231 
Figure 5-12 No difference in the number of cells sorted of each subpopulation ................. 231 
Figure 5-13 Number of sorted CD4+ PB cells normal vs CLL ............................................. 232 
Figure 5-14 Quantity of RNA extracted from each CD4+ T-cell subpopulation in CLL patients
 ............................................................................................................................................. 234 
Figure 5-15 Abl amplification in PB and LN sorted CD4+ cell populations .......................... 235 
Figure 5-16 Representative figure from one patient showing 24 TCRVβ families amplification 
in the 4 sorted CD4+ T-cell populations ............................................................................... 236 
Figure 5-17 Example Vβ spectratype profile from CLL PB. ................................................. 237 
Figure 5-18 Example Vβ spectratype profile from normal PB.............................................. 237 
Figure 5-19 The overall diversity of the TCRV families from PD-1hi and PD-1lo PB and LN 
subpopulations in 6 CLL patients ......................................................................................... 240 
Figure 5-20 The diversity of the TCRV from PD-1hi and PD-1lo PB and LN subpopulations 
in 6 CLL patients .................................................................................................................. 241 
Figure 5-21 A comparison of the overall TCRV diversity in the PB PD-1hi and PD-1lo 
subpopulations of 6 CLL patients and normal controls ........................................................ 242 
Figure 5-22 There is more skewing in the CD4+ PD-1hi T-cells than CD4+ PD-1lo T-cells of 
both PB and LN in CLL ........................................................................................................ 243 
Figure 5-23 The CLL CD4+/PD-1hi population are skewed whether derived from the PB or LN
 ............................................................................................................................................. 244 
Figure 5-24 The complexity score was the same in all subpopulations of CLL ................... 245 
Figure 5-25 Decreased diversity score in the PD-1lo CD4+ T-cells in normal PB .............. 246 
Figure 5-26 Complexity is preserved in the PD-1hi CD4+ T-cells of normal PB ................. 247 
- 20 - 
Figure 5-27 CLL CD4+ T-cells have more skewing than normal PB ................................... 248 
Figure 5-28 TCRV repertoire in normal PB is more complex than in CLL ......................... 249 
Figure 5-29 The frequency of TCRV family skewing of PB CD4+ T-cells across the cohort is 
greater in CLL patients (n=6) than in normal controls (n=6) in both PD-1hi and PD-1lo 
subpopulations ..................................................................................................................... 250 
Figure 5-30 Frequency of skewing of the TCRV families in CLL CD4+ PB and LN 
subpopulations; n=6 ............................................................................................................. 251 
Figure 5-31 Frequency of skewing of the TCRV families in LN PD-1hi compared to PD-1lo 
subpopulations; n=6 ............................................................................................................. 252 
Figure 5-32 Frequency of skewing of the TCRV families in CLL PB PD-1hi vs PD-1lo 
subpopulations; n=6 ............................................................................................................. 252 
Figure 5-33 Frequency of skewing of the TCRV families in CLL LN CD4+ PD-1-hi vs CLL PB 
CD4+ PD-1hi subpopulations; n=6. ..................................................................................... 253 
Figure 5-34 Scoring the concordance of skewing ................................................................ 254 
Figure 5-35 Concordance of skewing of TCRVβ spectratyping profiles of CLL CD4+ PD-1+ T-
cells from different compartments ........................................................................................ 255 
Figure 5-36 Frequency of TCRVβ family usage in normal CD4+ PB T-cells (n=6) and CLL PB 
T-cells (n=6) ......................................................................................................................... 257 
Figure 5-37 Frequency of sorted CD4+ T-cells TCRVβ family usage in matched CLL PB and 
LN (n=6) ............................................................................................................................... 258 
Figure 5-38 No difference in the number of unique sequences (complexity) of the CD4+ TCR 
repertoire in CLL PB and LN by HTS ................................................................................... 259 
Figure 5-39 Number of unique sequences correlates with starting CD4+ cell number. ...... 260 
Figure 5-40 The CLL LN CD4+ T-cells are more clonal than those derived from the PB ... 261 
Figure 5-41 More commonality of TCR usage between two separate LNs from same patient 
than between the LN and matched PB ................................................................................ 262 
Figure 5-42 More overlapping TCR sequences (a higher overlap score) between two LNs than 
between LN and PB ............................................................................................................. 263 
Figure 6-1 CD69 is upregulated on CD4+ T-cells from CLL PB following CD3/CD28 stimulation 
at 24 hours and further still at 48 hours ............................................................................... 282 
- 21 - 
Figure 6-2 CD69 is upregulated on CD8+ T-cells from CLL PB following CD3/CD28 stimulation
 ............................................................................................................................................. 283 
Figure 6-3 CD25 is upregulated on CD4+ T-cells from CLL PB following CD3/CD28 stimulation
 ............................................................................................................................................. 284 
Figure 6-4 CD25 is upregulated on CD8+ T-cells from CLL PB following CD3/CD28 stimulation
 ............................................................................................................................................. 284 
Figure 6-5 CTLA-4 is upregulated on CD4+ T-cells from CLL PB following CD3/CD28 
stimulation ............................................................................................................................ 285 
Figure 6-6 PD-1 is upregulated on CD4+ T-cells from CLL PB on CD3/CD28 stimulation . 286 
Figure 6-7 PD-1 is upregulated on CD8+ T-cells from CLL PB on CD3/CD28 stimulation . 287 
Figure 6-8 CD25 was present on a smaller percentage of CLL PB CD4+ T-cells when cells 
had been previously cryopreserved compared to fresh PB ................................................. 288 
Figure 6-9 CLL CD4+ T-cells that have been stimulated with CD3/CD28 beads have a higher 
percentage that are CD25+ compared to fresh LN FNA CD4+ T-cells ............................... 289 
Figure 6-10 CTLA-4 expression is similar between CD4+ PB cells whether or not previously 
cryopreserved ...................................................................................................................... 290 
Figure 6-11 The level of PD-1 expression on CD4+ T-cells is unaffected by cryopreservation, 
and stimulation  of T-cells with CD3/CD28 beads for 24 hours increases PD-1 levels on CD4+ 
T-cells to the same level as found on LN FNA derived CD4+ T-cells. ................................. 291 
Figure 6-12 The level of PD-1 expression on CD8+ T-cells is unaffected by cryopreservation, 
and stimulation  of T-cells with CD3/CD28 beads for 24 hours increases PD-1 levels on CD8+ 
T-cells to the same level as found on LN FNA derived CD8+ T-cells .................................. 292 
Figure 6-13 There was no difference in the baseline PD-L1 expression on fresh or previously 
cryopreserved CLL cells ....................................................................................................... 293 
Figure 6-14 PD-L1 can be upregulated on CLL cells by co-culture with CD3/CD28 bead 
stimulated T-cells ................................................................................................................. 294 
Figure 6-15 Indirect CD3/CD28 bead stimulation of T-cells in co-culture with CLL cells for 24 
hours increases the PD-L1 on CLL cells from PB to levels above that found in the LN ...... 295 
Figure 6-16 PD-L1 upregulates on CD4+ CLL T-cells following CD3/CD28 bead stimulation 
and the upregulation increases further still with prolonged stimulation ............................... 296 
- 22 - 
Figure 6-17 PD-L1 upregulates on CD8+ CLL T-cells following CD3/CD28 bead stimulation 
and the upregulation increases further still with prolonged stimulation ............................... 297 
Figure 6-18 Blocking PD-1 signal transduction did not alter CD25 expression in CD4+ T-cells.
 ............................................................................................................................................. 299 
Figure 6-19 Blocking PD-1 signal transduction does not alter CD25 expression on CD8+ T-
cells, except for pre-stimulated CD8+ T-cells at 24 hours ................................................... 300 
Figure 6-20 Blocking PD-1 signal transduction does not alter CD69 expression in CD4+ T-
cells ...................................................................................................................................... 301 
Figure 6-21 Blocking PD-1 signal transduction does not alter CD69 expression in CD8+ T-
cells ...................................................................................................................................... 302 
Figure 6-22 Blocking PD-1 signal transduction does not alter CTLA-4 expression in CD4+ T-
cells ...................................................................................................................................... 303 
Figure 6-23 Blocking PD-1 signal transduction does not alter PD-1 expression in CD4+ T-cells
 ............................................................................................................................................. 304 
Figure 6-24 Blocking PD-1 signal transduction does not alter PD-1 expression on CD8+ T-
cells ...................................................................................................................................... 305 
Figure 6-25 Blocking PD-1 signal transduction does not alter PD-1 expression on CLL cells
 ............................................................................................................................................. 306 
Figure 6-26 Blocking PD-1 signal transduction does not alter PD-L1 expression on CLL cells
 ............................................................................................................................................. 307 
Figure 6-27 IFN-γ increased following stimulation and PD-1 blocking in this experiment ... 308 
  
- 23 - 
Table of Tables 
Table 1-1 Revised CLL scoring system ................................................................................. 36 
Table 1-2 Rai and Binet CLL clinical staging systems ........................................................... 38 
Table 1-3 Stages of B-cell development. (Adapted from Janet M. Decker, University of Arizona 
http://www2.nau.edu) ............................................................................................................. 48 
Table 2-1 General chemicals, consumables and kits ............................................................ 88 
Table 2-2 Flow cytometry antibodies ..................................................................................... 93 
Table 2-3 Primary antibodies for immunofluorescence microscopy ...................................... 94 
Table 2-4 Secondary fluorescently conjugated antibodies for immunofluorescence microscopy
 ............................................................................................................................................... 95 
Table 2-5 FACSCanto II configuration ................................................................................... 98 
Table 3-1 Lymph node source material ............................................................................... 102 
Table 3-2 Considerations when designing multiparameter flow cytometry panels .............. 105 
Table 3-3 Flow cytometry antibodies ................................................................................... 110 
Table 3-4 Demographics of CLL patients ............................................................................ 113 
Table 3-5 The CD4+ T-cell subsets in CLL PB and LN FNA ............................................... 127 
Table 4-1 Primary antibodies for immunofluorescence microscopy .................................... 166 
Table 4-2 Secondary fluorescently conjugated antibodies for immunofluorescence microscopy
 ............................................................................................................................................. 166 
Table 4-3 Immunofluorescence control slide matrix ............................................................ 168 
Table 4-4 Staining matrix of settled CLL B-cells on slides ................................................... 169 
Table 4-5 Analysis of Ki67 on CLL FFPE sections .............................................................. 190 
Table 5-1 Starting material ................................................................................................... 207 
Table 5-2 Antibodies for flow cytometric sorting .................................................................. 211 
Table 5-3 Ligation PCR oligonucleotide and primer design ................................................. 215 
Table 5-4 Beta actin primer set ............................................................................................ 216 
Table 5-5 Abl primer set ....................................................................................................... 217 
Table 5-6 Vβ primer set for TCR sequencing ...................................................................... 218 
Table 5-7 Demographics of CLL patients for spectratyping ................................................. 223 
Table 5-8 Review of published methods for ligation anchored PCR ................................... 225 
- 24 - 
Table 5-9 Total cell numbers of T-cell sub-populations collected in FACS sort .................. 230 
Table 5-10 Number of sorted cells from healthy control PB ................................................ 232 
Table 5-11 Quantity of RNA extracted ................................................................................. 233 
Table 5-12 Diversity and complexity scores from CD4+ PD-1hi and PD-1lo populations from 
CLL PB and LN .................................................................................................................... 238 
Table 5-13 Demographics of CLL patients for HTS ............................................................. 256 
Table 6-1 Flow cytometry antibodies ................................................................................... 276 
Table 6-2 Demographics of CLL patients ............................................................................ 280 
  
- 25 - 
Acknowledgments  
I am thankful to my supervisors, Professor Stephen Devereux and Dr Andrea Buggins, for 
giving me the opportunity to work with them in the Rayne Institute, King’s College London. I 
am grateful for their unending support and guidance whilst I undertook this research project 
and for helping me complete this thesis. Without their vision, hard work and perseverance it 
would not have been possible. 
I acknowledge the British Society of Haematology, who kindly awarded me a start-up grant to 
undertake this project. 
I would like to acknowledge Professor Shaun Thomas who, in the role of postgraduate 
coordinator, for the duration of my laboratory work, offered me invaluable advice and 
motivation. 
I am thankful for the technical assistance, teaching and camaraderie of my laboratory 
colleagues; Will Townsend, Marta Pasikowska, Shahram Kordasti, Nicholas Lea, Aytug 
Kizilors, Jamal Anwar, Costas Chronis, Jane Moorhead, Lok Lam, Winston Vetharoy and 
especially my friend Emma Hamilton PhD. 
I am particularly grateful to Professor Ghulam Mufti, Head of Department, Haematological 
Medicine, King’s College Hospital, for his generosity and support which enabled me to 
complete this thesis. 
I am overwhelmingly thankful to all the patients, who so generously donated samples for 
research and allowed me to poke needles in their necks, with no benefit to themselves.   
I am especially indebted to my friends and clinical colleagues at King’s College Hospital; Dr 
Shireen Kassam, Dr Robin Ireland, Dr Piers Patten and Dr Victoria Potter for helping me 
achieve this goal and for being nice. 
Finally I would like to thank my mum, Paulette, and sister, Becky, for their love regardless of 
my endeavours, and in loving memory of my Dad, David, who was taken from us too soon.  
  
- 26 - 
Abbreviations  
Abbreviation Meaning 
7-AAD 7-Amino-Actinomycin D 
ABL Abelson Murine Leukaemia Viral Oncogene Homolog 1 
ADP Adenosine Diphosphate 
AID Activation Induced Deaminase 
AIHA Autoimmune Haemolytic Anaemia 
AKT Protein Kinase B 
AMCA Aminomethylcoumarin Acetate 
APC Allophycocyanin 
APC Antigen Presenting Cell 
APRIL A Proliferation Inducing Ligand 
ATM Ataxia Telangiectasia Mutated 
ATP Adenosine Triphosphate 
BAFF B-Cell Activating Factor 
BAFF-R BAFF Receptor 
BAX Bcl-2 Associated X Protein 
BCL B-Cell Lymphoma 
BCL-XL BCL Extra Large 
BCMA B-Cell Maturation Antigen 
BCR B-Cell Receptor 
BCSH British Committee for Standards in Haematology 
BFGF Basic Fibroblast Growth Factor 
BLK B Lymphocyte Kinase 
BM Bone Marrow 
BP Base Pair 
BSA Bovine Serum Albumin 
BTK Bruton's Tyrosine Kinase 
CAR Chimeric Antigen Receptor 
- 27 - 
CARD11 Caspase Recruitment Domain Family Member 11 
CAV1 Caveolin-1 
CCR7 CC Chemokine Receptor 7 
CD  Cluster of Differentiation 
CDNA Complementary DNA 
CDR Complementarity Determining Region 
CFSE Carboxyfluorescein Succinimidyl Ester 
CLL Chronic Lymphocytic Leukaemia 
CML Chronic Myeloid Leukaemia 
CMV Cytomegalovirus 
CPG Cytosine-Phosphate-Guanine 
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 
CXCR5 CXC Chemokine Receptor 5 
CY Cyanine 
DAPI 4',6-Diamidino-2-Phenylindole 
DATP Deoxyadenosine Triphosphate 
DCTP Deoxycytidine Triphosphate 
DEPC Diethylpyrocarbonate 
DGTP Deoxyguanosine Triphosphate 
DLBCL Diffuse Large B-Cell Lymphoma 
DMSO Dimethyl Sulphoxide 
DNA Deoxyribonucleic Acid 
DNase Deoxyribonuclease 
DNTP Deoxyribonucleotide Triphosphate 
DTT Dithiothreitol 
DTTP Deoxythymidine Triphosphate 
E2F1 E2F Transcription Factor 1 
EDTA Ethylenediaminetetraacetic Acid 
EFS Event Free Survival 
ERK Extracellular Signal Regulated Kinase 
- 28 - 
FACS Fluorescence Activated Cell Sorting 
F-Actin Filamentous Actin 
FBC Full Blood Count 
FBS Foetal Bovine Serum 
FC Fludarabine and Cyclophosphamide 
FCR Fludarabine, Cyclophosphamide and Rituximab 
FDC Follicular Dendritic Cell 
FFPE Formalin Fixed Paraffin Embedded 
FISH Fluorescence In Situ Hybridisation  
FITC Fluorescein Isothiocyanate 
FMC7 Flinders Medical Centre 7 
FNA Fine Needle Aspirate 
FOXP3 Forkhead Box P3 
FSC Forward Scatter 
FYN Proto Oncogene Tyrosine Protein Kinase Fyn 
GC Germinal Centre 
G-CSF Granulocyte Colony Stimulating Factor  
GM-CSF Granulocyte Macrophage Colony Stimulating Factor  
H&E Haematoxylin and Eosin 
HTA Human Tissue Authority 
HUVEC Human Umbilical Vein Endothelial Cell 
ICAM Intercellular Adhesion Molecule 
ICOS Inducible T-Cell Co-Stimulator 
IFN  Interferon  
IG Immunoglobulin 
IGH Immunoglobulin Heavy Chain 
IGHV Immunoglobulin Variable Heavy Chain 
IGL Immunoglobulin Light Chain 
IGV  Immunoglobulin Variable Region 
IKK Inhibitor of NF-KB Kinase 
- 29 - 
IL Interleukin 
ILS-600 Internal Lane Standard 600 
IMGT International ImMunoGeneTics Information System 
IRF Interferon Regulatory Factor 
ITAM Immunoreceptor Tyrosine-Based Activation Motif  
IWCLL International Workshop on Chronic Lymphocytic 
Leukaemia  
KCHFT King’s College Hospital Foundation Trust 
KCL King’s College London 
KD Kilodalton  
LCK Lymphocyte Specific Protein Tyrosine Kinase 
LDH Lactate Dehydrogenase 
LDT Lymphocyte Doubling Time 
LFA-1 Lymphocyte Function Associated Antigen 1 
LN Lymph Node 
LREC Local Research Ethics Committee 
LYN Tyrosine Protein Kinase Lyn 
MAB Monoclonal Antibody 
MALT Mucosa Associated Lymphoid Tissue 
MALT1 MALT Lymphoma Translocation Protein 1 
MAP Mitogen Activated Protein 
MAPK  MAP Kinase 
MAPKK MAPK Kinase 
MAPKKK MAPKK Kinase 
MBL Monoclonal B Lymphocytosis 
MCL-1 Myeloid Cell Leukaemia 1 
MDSC Myeloid Derived Suppressor Cell 
MFI Mean Fluorescence Intensity 
MHC Major Histocompatibility Complex 
MTOR Mammalian Target Of Rapamycin 
- 30 - 
MW Megawatt 
NCI National Cancer Institute 
NFAT Nuclear Factor Of Activated T-Cells 
NF-kB Nuclear Factor Kappa B 
NK Natural Killer Cells 
NLC Nurse Like Cell 
NM Nanometres 
NRES National Research Ethics Service 
NT Nucleotide 
OS Overall Survival 
PB Peripheral Blood  
PBMCS Peripheral Blood Mononuclear Cells 
PBS Phosphate Buffered Saline 
PC Proliferation Centre 
PCR Polymerase Chain Reaction 
PD-1 Programmed Death 1 
PD-L1 Programmed Death Ligand 1 
PD-L2 Programmed Death Ligand 2 
PE Phycoerythrin 
PECAM Platelet Endothelial Cell Adhesion Molecule 
PERCP Peridinin Chlorophyll Protein 
PFA Paraformaldehyde 
PFS Progression Free Survival 
PHA Phytohaemagglutinin 
PI Propidium Iodide 
PI3K Phosphatidylinositol 3-Kinase 
PKC Protein Kinase C 
PLC Phospholipase C 
PLL Prolymphocytic Leukaemia 
PMA Phorbol Myristate Acetate 
- 31 - 
PMT Photomultiplier Tube 
PV Polycythaemia Vera 
RAG Recombination Activation Gene 
RBC Red Blood Cell 
RhA Rheumatoid Arthritis 
RNA Ribonucleic Acid 
RNASE Ribonuclease 
ROR-1 Receptor Tyrosine Kinase Like Orphan Receptor 1  
RPM Revolutions Per Minute 
RPMI Roswell Park Memorial Institute Medium 
RT Room Temperature 
RT Reverse Transcriptase 
SDF Stromal Derived Factor 
SEER Surveillance, Epidemiology, and End Results Program  
SHM Somatic Hypermutation 
SHP Src Homology Domain Containing Tyrosine Phosphatase 
SLE Systemic Lupus Erythematosus 
SLL Small Lymphocytic Lymphoma 
SMIG Surface Immunoglobulin 
SNP Single Nucleotide Polymorphism 
SRC Proto Oncogene Tyrosine Protein Kinase 
SSC Side Scatter 
STAT1 Signal Transducer and Activator of Transcription 1 
SYK Spleen Tyrosine Kinase 
TACI Transmembrane Activator and Calcium Modulator and 
Cyclophilin Ligand Interactor 
TBE Tris / Borate / EDTA 
TBS Tris Buffered Saline 
TCM Central Memory T-Cell 
TCR T-Cell Receptor 
- 32 - 
TdT Terminal Deoxynucleotidyl Transferase 
TEM Effector Memory T-Cell 
TEMRA Terminal Differentiated Effector Memory T-Cell  
TFH Follicular Helper T-Cell 
TGF-β Transforming Growth Factor Beta 
TH Helper T-Cell 
TK Thymidine Kinase 
TLR Toll Like Receptor 
TNAIVE  Naïve T-Cell 
TNF Tumour Necrosis Factor 
TP53 Tumour Protein 53 
TRAF Tumour Necrosis Factor Receptor Associated Factors  
TREG Regulatory T-Cell 
TRITC Tetramethylrhodamine Isothiocyanate 
UK United Kingdom 
US United States 
V/V Volume / Volume 
VCAM Vascular Cell Adhesion Molecule 
VEGF Vascular Endothelial Growth Factor 
VEGFR Vascular Endothelial Growth Factor Receptor 
VOL Volume 
Vβ Variable Beta 
W/V Weight / Volume 
WBC White Blood Cell 
WCC White Cell Count 
WHO World Health Organisation 
WM Waldenström Macroglobulinaemia 
WT Weight 
ZAP-70 Zeta Associated Protein 70 
β2-M Beta-2 Microglobulin 
 
- 33 - 
Chapter 1 General Introduction 
1.1 Background to Chronic Lymphocytic Leukaemia  
1.1.1 Definition 
Chronic Lymphocytic Leukaemia (CLL) is a clonal neoplasm of mature B-cells with a 
characteristic immunophenotype. Malignant B-cells accumulate within the peripheral blood 
(PB), secondary lymph node tissue (LN), bone marrow (BM) and other organs of affected 
patients. As the disease progresses this accumulation leads to the clinical features of 
lymphocytosis, immune dysfunction, lymphadenopathy, splenomegaly, hepatomegaly and 
ultimately bone marrow failure in advanced disease. In 2008, The International Workshop on 
Chronic Lymphocytic Leukaemia (iwCLL) updated the National Cancer Institute guidelines to 
define CLL as a B lymphocytosis with a CLL immunophenotype and an absolute clonal B-cell 
count of >5000 cells/µl. Previously an absolute lymphocyte count of >5000 cells/µl was used 
as a diagnostic criteria. This change in classification has resulted in 40% of patients previously 
labelled as early stage CLL being reclassified as monoclonal B-lymphocytosis of CLL 
phenotype (MBL) (Shanafelt, Kay et al. 2008). 
1.1.2 Epidemiology  
CLL is the commonest leukaemia in the western world, accounting for 30% of all cases of 
leukaemia and 16% of all haematological malignancies. Cancer registration statistics for the 
United Kingdom (UK) are published by the Office for National Statistics, the Welsh Cancer 
Intelligence and Surveillance Unit and the Northern Ireland Cancer Registry. The UK incidence 
of CLL is reported as 3 persons per 100,000 population and there are approximately 3300 
new cases diagnosed every year. The United States (US) National Cancer Institute 
Surveillance, Epidemiology, and End Results Program (SEER) Cancer Statistics Review 
1975-2011, reported the age-adjusted incidence rate of CLL at 4.2 per 100,000 per year 
(Oscier, Dearden et al. 2012). In the UK there is significant geographical variation in CLL 
incidence, which is reflected by differences in regional demographics. In the most part this is 
explained by the difference in the mean age of the population in different locations in the UK; 
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reflecting that the incidence of CLL increases with age. The SEER dataset showed 89% 
percent of patients are aged over 55 at diagnosis and the median age at presentation is 72. 
Worldwide epidemiological studies have shown CLL is most common in Caucasians and is 
20-30 times less common in India, China and Japan, but no environmental factors have been 
definitively implicated. CLL is twice as common in males compared to females, which in the 
most part remains poorly understood. CLL does show a degree of inheritable predisposition 
with an increased risk of CLL and MBL in first and second degree relatives of patients with 
CLL (Rawstron, Yuille et al. 2002, Goldin, Landgren et al. 2010). Overall there is a sevenfold 
increase in the incidence of CLL and more than doubling of the risk of being diagnosed with 
another lymphoid malignancy, such as lymphoplasmacytoid lymphoma and hairy cell 
leukaemia, in the relatives of patients with CLL (Goldin, Bjorkholm et al. 2009, Goldin, 
Landgren et al. 2010). In some families with CLL the phenomenon of genetic anticipation has 
been documented (Yuille, Houlston et al. 1998, Goldin, Sgambati et al. 1999). To attempt to 
understand the mechanism behind the familial association several genome wide studies have 
been undertaken. These have identified a number of single nucleotide polymorphisms (SNP) 
at multiple susceptibility loci, which seem to correlate with an increased risk of developing CLL 
(Speedy, Di Bernardo et al. 2014). 
1.1.3 Diagnosis 
A full blood count (FBC) is one of the most commonly requested blood tests across UK 
haematology laboratories. Laboratories define the normal range for total lymphocyte counts 
and participate in national external quality assurance schemes to ensure the validity of the 
results. Parameters will be set by the laboratory for automated cell counters to trigger a 
request for a blood film and manual differential count. In CLL the PB lymphocytosis can be 
just outside the normal range to over a hundred fold above the upper limit. CLL is very 
commonly detected as an incidental finding from routine blood tests taken for unrelated 
indications. The PB smear morphology in CLL is characteristic and typically shows a fairly 
uniform population of small mature lymphocytes with clumped chromatin and a high nuclear 
to cytoplasmic ratio. Nucleoli are usually small and inconspicuous. So-called “smear cells” are 
a hallmark feature and relate to the fragility of CLL cells and the content of the cytoskeletal 
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protein vimentin. (Brown, Hallam et al. 2001). Interestingly the number of smear cells remains 
constant over time in an individual patient and is an independent prognostic factor 
(Nowakowski, Hoyer et al. 2007). A typical PB film from a CLL patient is shown in Figure 1-1. 
There can be a variable number of prolymphocytes present but these must be <10% of total 
lymphocytes, otherwise a diagnosis of CLL/PLL (prolymphocytic leukaemia) is more 
appropriate. The blood film can also indicate the degree of anaemia. Anaemia is typically 
normocytic normochromic when as a consequence of bone marrow involvement, but if the 
CLL is complicated by autoimmune haemolytic anaemia, spherocytes and polychromasia can 
be seen. Neutropenia is rare and thrombocytopenia at diagnosis usually indicates advanced 
disease. 
 
Figure 1-1 PB film in CLL. Magnification x20. Courtesy of King’s Haematological Malignancy 
Diagnostic Centre. 
 
Lymphocytosis and a typical PB film will usually prompt a haematological referral. Many B-cell 
malignancies can be distinguished by their individual pattern of cell surface markers 
expression by PB immunophenotyping. The World Health Organisation (WHO) classification 
of tumours outlines the current diagnostic criteria for the haematological malignancies. The 
Marsden CLL score has been devised and subsequently revised based on the expression of 
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the following 5 cell surface markers; weak monotypic surface immunoglobulin, CD5, CD23, 
weak FMC7 and weak CD22 or CD79b (Matutes, Owusu-Ankomah et al. 1994, Moreau, 
Matutes et al. 1997). The widely adopted modified scoring system is shown in Table 1-1. A 
CLL score of 4-5/5 strongly supports the diagnosis of CLL and encompasses 92% of CLL 
cases.  
Table 1-1 Revised CLL scoring system 




SmIg Weak Strong 
CD5 Positive Negative 
CD23 Positive Negative 
FMC7 Negative Positive 
CD22 or CD79b Weak Strong 
 
In cases where there is diagnostic uncertainty a bone marrow trephine or lymph node biopsy 
can be performed. The bone marrow is invariably involved in CLL and classically fits two 
patterns of involvement; either nodular or diffuse infiltration. The presence of pale staining 
“proliferation centres” (PC) is supportive of the diagnosis. The bone marrow trephine has 
clinical utility in determining whether PB cytopenias are related to bone marrow failure or 
autoimmunity. Surgical lymph node biopsy is usually only required for diagnostic purposes in 
patients where the degree of lymphadenopathy is out of keeping with the PB picture; for 
example when there is a solitary bulky node, or when a high grade transformation is 
suspected.   
1.1.4 Clinical Features 
CLL is characteristically a heterogeneous disease and the way in which the patient presents 
to the clinician reflects this. 70-80% of new cases are detected incidentally by the presence of 
isolated lymphocytosis on a FBC performed for an unrelated indication (Oscier, Fegan et al. 
2004). Clinical presentations are very variable and reflect the various sequelae of the disease 
process. Tumour proliferation and bulk can lead to palpable lymphadenopathy, abdominal 
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discomfort from hepatosplenomegaly or even compressive symptoms, such as dysphagia or 
cough, from extrinsic pressure from lymph nodes. Bone marrow involvement can lead to 
symptoms of anaemia with fatigue, shortness of breath or pallor. Non-specific malignancy 
associated “B-symptoms” frequently reflect disease bulk and include unintentional weight loss 
and night sweats. Infections are a very common due to the complex immune dysfunction in 
CLL, and infections are ultimately responsible for up to 50% of CLL deaths (Hamblin 1987). 
85% of CLL patients are hypogammaglobulinaemic. Infection risk in CLL correlates with 
hypogammaglobulinaemia which begins to appear at early stages of the disease (Rozman, 
Montserrat et al. 1988, Rossi, Sozzi et al. 2009, Morrison 2010). Although depletion of normal 
B-cells, as a result of expansion of the neoplastic clone, undoubtedly contributes to low 
immunoglobulin levels, there is also evidence that aberrant expression of CD30 by T-cells 
supresses immunoglobulin class switching and thus the production of IgG and IgA (Cerutti, 
Kim et al. 2001). There are numerous defects in cell mediated immunity and T-cell dysfunction 
which will be discussed later. 
1.1.5 Prognosis 
Clinical staging systems are extremely useful in dividing the heterogeneous CLL patient 
population into defined prognostic groups. The two universally accepted CLL staging systems 
devised by Rai et al (Rai, Sawitsky et al. 1975) and Binet et al (Binet, Auquier et al. 1981) are 
the best validated tools for predicting prognosis and still play an integral role in clinical decision 
making. Table 1-2 below shows the staging systems, the percentage of patients that fall into 
each category and their median survival in the chemotherapy era. 
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 0 Lymphocytosis 30 12 years 
 I Lymphocytosis plus lymphadenopathy 35 9 years 
 II Lymphocytosis plus splenomegaly  
and/or hepatomegaly 
25 7 years 
 III Lymphocytosis plus Hb <11g/dl 7 5 years 
 IV Lymphocytosis plus platelets <100 x109/l  3 1 year 
Binet Stage 
 A Less than three areas of lymphoid sites involved 65 9 years 
 B Three or more areas of lymphoid sites involved 30 5 years 
 C Hb <10g/dl or platelets <100 x109/l 5 2 years 
 
These clinical staging systems are useful to subgroup individuals with CLL patients but they 
do not help the clinician predict which individual early stage patient will progress to an 
advanced clinical stage.  The clinical course of CLL generally follows one of four patterns; the 
first group have stable disease, which changes little over time, these patients do not require 
chemotherapy and the disease has a little impact on life expectancy. The second group slowly 
progress over months and years and may eventually require therapy. The third group rapidly 
progress in weeks resulting in death without treatment. The fourth have a sudden “Richter’s” 
transformation event and rapid deterioration (Zenz, Mertens et al. 2010, Zenz, Gribben et al. 
2012). Predicting, at diagnosis which course an individual patient is likely to follow would be 
invaluable in informing a patient of their prognosis, their likelihood of requiring therapy and 
their need for monitoring. Age, performance status and sex can add some additional 
information. Older patients have an overall shorter survival from CLL, but they also have a 
shorter predicted life expectancy and therefore the biggest impact of shortened survival is 
apparent in young patients (Jaksic, Vitale et al. 1991). Female patients tend to have a slightly 
longer survival than males although whether this reflects an intrinsic difference in the biology 
of the disease remains unclear (Molica 2006). The clinical staging systems do reflect bone 
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marrow involvement, but morphological features identified prior to bone marrow failure can 
help predict the aggressiveness of disease. It is evident that patients with a diffuse pattern of 
bone marrow infiltration have a shorter life expectancy than those with a nodular non diffuse 
pattern of infiltration (Han, Barcos et al. 1984, Rozman, Montserrat et al. 1984). Markers of 
the disease kinetics and therefore proliferative index of the disease also correlate with more 
aggressive disease. Clinically the lymphocyte doubling time (LDT) is a well-established 
method of identifying patients with aggressive disease, but has the disadvantage of being a 
retrospective analysis. The LDT is defined as how long it takes for the total lymphocyte count 
to double in size and a period of time <12 months defines a group of patients with a shorter 
overall survival and shorter time to treatment than those whose LDT is >12 months. This holds 
true for all clinical stages of disease (Montserrat, Sanchez-Bisono et al. 1986). 
1.1.6 Prognostic Biomarkers 
Many biological parameters have been identified which correlate with prognosis in CLL and 
some can assist in predicting which patients with early stage CLL will progress to advanced 
disease. These markers may reflect tumour burden, proliferative index or refractoriness to 
treatment.  
1.1.6.1 Serum Markers 
A raised lactate dehydrogenase (LDH) is associated with shorter survival in CLL patients (Lee, 
Dixon et al. 1987) but this is a non-specific marker which is frequently raised in malignancies 
and in CLL may reflect autoimmune haemolysis.  High levels of Beta 2 microglobulin (β2-M) 
is another non-specific marker of tumour burden which has been independently correlated 
with a poor outcome in CLL (Hallek, Wanders et al. 1996). The German CLL subgroup and 
others have also consistently reported that serum thymidine kinase (TK) correlates strongly 
with outcome, presumably because it reflects overall tumour proliferation (Hallek, Wanders et 
al. 1996, Konoplev, Fritsche et al. 2010). Recently serum TK was incorporated into a 
prognostic model based on multivariant analysis of 1948 cases of CLL entered into 
prospective clinical trials (Pflug, Bahlo et al. 2014). Specific tumour markers are often used in 
prognostication of malignancies. CLL cells can release membrane proteins into the sera, but 
validation has proven to be poor between laboratories; due to in part to factors like age of 
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sample and renal function. Some groups have shown soluble CD23 levels to be predictive of 
disease progression in stage A CLL and associated with other poor prognosis markers 
(Sarfati, Chevret et al. 1996, Knauf, Ehlers et al. 1997). Soluble CD44 has also been correlated 
with advanced disease and shorter progression free survival even within the stage A disease 
subgroup (Molica, Vitelli et al. 2001).  
1.1.6.2 Cell Surface Markers 
CD38 
High levels of cell surface CD38 expression on CLL cells has been shown to correlate with 
poor prognosis in numerous studies and is an independent poor prognostic factor (Damle, 
Wasil et al. 1999, Del Poeta, Maurillo et al. 2001, Ibrahim, Keating et al. 2001, Morabito, 
Mangiola et al. 2001, Durig, Naschar et al. 2002, Hamblin, Orchard et al. 2002, Krober, Seiler 
et al. 2002, Morabito, Mangiola et al. 2002). CD38 is a transmembrane protein that is highly 
conserved in evolution and functions as an enzyme essential in regulating intracellular 
calcium. As such it has been implicated in many diverse processes from cell activation, 
proliferation and immune responses to egg fertilisation and muscle contraction (Malavasi, 
Deaglio et al. 2008). CD38 also has receptor-like properties and with its ligand CD31 is 
implicated in CLL homing and migration (Deaglio, Aydin et al. 2010). CD38 levels have 
significant associations with other poor prognosis markers, such as bulky lymphadenopathy, 
LDT, LDH, β2-M, sCD23, mutation status and cytogenetic abnormalities (Van Bockstaele, 
Verhasselt et al. 2009). Different groups have chosen different percentage positive cut-off 
markers to define positivity, which has been a contentious issue. Additionally CD38 has been 
shown by many groups to be dynamic through the course of the disease (Matrai 2005).  Levels 
of 30%, 20% and 7% have been proposed, as have methods that measure the CD38 mean 
fluorescence intensity (MFI), but a universal consensus remains unachieved. Some patients 
have a bimodal CD38 expression, which demonstrates that intraclonal variability can occur 
within the same patient, it has been suggested the most positive population defines the 
prognosis (Ghia, Guida et al. 2003, Hayat, O'Brien et al. 2006).    
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ZAP-70 
ZAP-70 (70kd T-cell receptor (TCR) zeta associated protein) is a tyrosine kinase that was 
originally identified because of its role in T-cell activation. It is normally expressed by T-cells, 
NK cells, bone marrow pro B-cells and a subset of tonisillar and splenic B-cells (Nolz, 
Tschumper et al. 2005, Crespo, Villamor et al. 2006, Cutrona, Colombo et al. 2006). Gene 
expression profiling studies performed on CLL patients initially reported differential expression 
of ZAP-70 in cases with mutated and unmutated immunoglobulin heavy chain genes (IGHV) 
(Rosenwald, Alizadeh et al. 2001), however subsequent studies have revealed more 
discordance (Van Bockstaele, Verhasselt et al. 2009). Its function in CLL appears to be as an 
adapter protein that enhances B-cell receptor signalling (Chen, Huynh et al. 2008), although 
it is also believed to play a role in transendothelial migration (Deaglio, Vaisitti et al. 2007). The 
main limitation of using ZAP-70 as a prognostic marker has been the non-standardisation of 
its measurement between laboratories.    
CD49d 
Integrins are surface membrane proteins that are made up of two heterodimers; α and β 
chains. CD49d is a member of the integrin α chain family and makes up the α4 subunit of the 
lymphocyte homing receptor α4β1. Expression of CD49d has been shown to correlate with 
bulky lymphadenopathy, compatible with its function as an adhesion receptor involved in 
transendothelial migration (Till, Lin et al. 2002). CD49d expression on the CLL B-cell surface 
has also been shown to promote CLL cell proliferation (Zucchetto, Bomben et al. 2006, Burger 
2012). Patients with high levels of CD49d have been shown to have a short survival by several 
groups (Gattei, Bulian et al. 2008, Rossi, Zucchetto et al. 2008, Shanafelt, Geyer et al. 2008, 
Nuckel, Switala et al. 2009, Majid, Lin et al. 2011). A recent worldwide collaborative study of 
over 3000 patients identified a level of CD49d positivity of greater than 30% to be strongest 
predictor of shorter overall survival and treatment free survival in CLL, independent of CD38 
and ZAP-70 (Bulian, Shanafelt et al. 2014). Majid et al reported a correlation between with 
expression of CD49d and the chemokine receptor CXCR4 suggesting a role in trafficking of 
CLL cells into lymph nodes (Majid, Lin et al. 2011). CXCR4 expression confers a poor survival 
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even when associated with good risks factors, such as mutated immunoglobulin (Pepper, 
Buggins et al. 2015).  
1.1.6.3 Cytogenetic Aberrations 
Cytogenetic aberrations are very common in CLL, and were first noted in the 1970’s. 
Conventional cytogenetic banding techniques reveals abnormalities in around 40-50% of CLL 
cases (Juliusson, Oscier et al. 1990). These conventional techniques have a significant lack 
of sensitivity due to the low mitotic index of the CLL cells in vitro. In vitro incubation with CpG 
oligonucleotides and interleukin 2 (IL-2) causes proliferation of CLL cells and has enabled 
cytogenetic abnormalities to be detected in up to 80% of cases (Dicker, Schnittger et al. 2006). 
Fluorescence in situ hybridization (FISH) allow detection of abnormalities of cells in interphase 
and reveals cytogenetic abnormalities in more than 80% of CLL cases (Dohner, Stilgenbauer 
et al. 2000). This important study of 325 patients by Dohner et al found several recurring 
aberrations; 13q deletion in 55%, 11q deletion in 18%, trisomy 12q in 16%, 17p deletion in 7% 
and deletion 6q in 7%. Interestingly these different abnormalities were correlated with marked 
differences in the patients survival; 13q deletion (133 months), 11q deletion (79 months), 
trisomy 12q (114 months), 17p deletion (32 months), normal karyotype (111 months). There 
have now been many large cohort studies investigating the relative frequency of each 
abnormality and the consequence of each marker on prognosis (Krober, Seiler et al. 2002, 
Dewald, Brockman et al. 2003, Glassman and Hayes 2005). This has led to cytogenetic 
categories being proposed, with 11q- and 17p- poor prognosis and 13q- good prognosis. 
These abnormalities have provided some new insights into the pathogenesis of CLL. Deletion 
of 17p deletes the p53 tumour suppressor gene, which plays a role in promoting apoptosis 
following DNA damage. Of note, purine analogues and alkylating agents require a functioning 
p53 pathway, which explains the resistance of 17p deleted patients to these chemotherapeutic 
agents (Dohner, Fischer et al. 1995). Deletion of 11q deletes the ataxia telangiectasia mutated 
(ATM) gene, which also encodes a protein in the DNA damage response pathway. 11q deleted 
patients tend to present at a more advanced stage and with bulky lymphadenopathy (Austen, 
Powell et al. 2005). The role of genes on 13q is less well established but two microRNAs; miR-
15a and miR-16-1 are located in this region, which are thought to be involved in regulation of 
- 43 - 
the bcl-2 (B-cell lymphoma 2) anti-apoptotic pathway (Calin, Dumitru et al. 2002). Deletion of 
the equivalent region in mice leads to dysregulated B-cell proliferation and the development 
of a “CLL like” disorder (Klein, Lia et al. 2010).  
In addition to the gross structural abnormalities identified by conventional cytogenetics and 
FISH in CLL, many additional genetic aberrations have now been identified by next generation 
sequencing. Although point mutations occur commonly in CLL, no single abnormality is 
present at a high frequency so, unlike disorders such as chronic myeloid leukaemia (CML), 
polycythaemia vera (PV) and Waldenström macroglobulinaemia (WM), it has not been 
possible to define a single pathogenic driver. The most frequent and best characterised 
lesions are those occurring in the NOTCH1, SF3B1 and BIRC3 genes (Fabbri, Rasi et al. 
2011, Puente, Pinyol et al. 2011, Wang, Lawrence et al. 2011, Quesada, Conde et al. 2012). 
NOTCH1 regulates B-cell maturation and NOTCH1 activating mutations have been described 
in 10% of new CLL cases and up to 20% of relapsed cases; most frequently in unmutated CLL 
and found in conjunction with trisomy 12. SF3B1 encodes for the subunits of the spliceosome, 
which controls splicing of genes controlling cell cycle regulation and apoptosis. SF3B1 
mutations are found in approximately 10% of new and 17% of progressive cases of CLL 
(Rossi, Bruscaggin et al. 2011). BIRC3 encodes for an inhibitor of apoptosis protein that binds 
to tumour necrosis factor receptor-associated factors 1 and 2 (TRAF1 and TRAF2), it also 
promotes NF-κB (nuclear factor kappa B) signalling and therefore CLL cell survival. BIRC3 
mutations therefore constitutively activate the NF-κB pathway and render the cells less 
chemotherapy sensitive (Rossi, Fangazio et al. 2012). Other mutations such as those of 
MYD88, which encodes for an adapter of the Toll-like receptor complex, are found at lower 
frequency (Puente, Pinyol et al. 2011). The presence of point mutations found by whole 
genome sequencing correlates with clinical parameters such as progression free survival 
(PFS), overall survival (OS) and the response to therapy, although results to date have been 
somewhat variable. In a retrospective analysis, NOTCH1 mutated cases were shown to have 
a poor outcomes equivalent to abnormalities of p53 (Rossi, Rasi et al. 2012).  
Another important feature of CLL is the process of clonal evolution where new genetic 
abnormalities appear during the course of the disease. It is not clear how frequently this occurs 
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overall, due to the highly selected patient groups analysed in different research studies, but it 
has been reported in up to 60% of patients. This also has a negative impact on overall 
prognosis (Oscier, Fitchett et al. 1991, Shanafelt, Witzig et al. 2006, Stilgenbauer, Sander et 
al. 2007). A better understanding of the heterogeneous clonal evolution is being elucidated by 
utilising whole genome sequencing (Schuh, Becq et al. 2012, Wu 2012, Kriangkum, Motz et 
al. 2015, Ojha, Ayres et al. 2015, Vollbrecht, Mairinger et al. 2015). 
1.1.6.4 Mutational Status of Immunoglobulin Heavy Chain Genes 
Somatic hypermutation is a crucial process in normal B-cell development. In this process 
antigen is presented to a B-cell within a germinal centre (GC) of the secondary lymphoid 
tissue, classically by follicular dendritic cells. Affinity maturation is the process by which 
random somatic mutations occur in the variable region of the B-cells immunoglobulin (IgV) 
gene to change the antibody’s affinity for the antigen. B-cells with a high affinity for an antigen 
are the population that survive. B-cells which have undergone somatic hypermutation, i.e. 
have mutated immunoglobulin genes, are therefore generally thought to be post germinal 
centre antigen experienced B-cells. Initially there was thought to be a lack of somatic 
hypermutation in CLL and as such it was a disease of pre-follicular B-cells. However important 
studies revealed there were both somatically mutated and unmutated CLL patients. A cut-off 
of 98% was subsequently chosen to define two groups of mutated (less than 98% homology 
to the germline) and unmutated (more than 98% homology to the germline) CLL (Damle, Wasil 
et al. 1999, Hamblin, Davis et al. 1999). The unmutated group of patients have a significantly 
shorter survival than the mutated group; median 9 years versus 24 years. This finding has 
now been consistently shown by many groups (Jelinek, Tschumper et al. 2001, Matrai, Lin et 
al. 2001, Hamblin, Orchard et al. 2002, Lin, Sherrington et al. 2002, Tobin, Thunberg et al. 
2005). There are notable exceptions, there is a subset of mutated CLL cases which express 
VH3-21 have a poor survival, comparable to the unmutated group, which may relate to p53 
dysfunction (Lin, Manocha et al. 2003, Thorselius, Krober et al. 2006).  
1.1.6.5 Telomere Length 
Telomeres shorten with each cell cycle division and therefore telomere length is an indicator 
of a cells proliferative history. In CLL, some groups have demonstrated that patients with high 
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telomerase activity and therefore shorter telomeres have shorter median survival (Hultdin, 
Rosenquist et al. 2003, Damle, Batliwalla et al. 2004, Grabowski, Hultdin et al. 2005, Ricca, 
Rocci et al. 2007, Terrin, Trentin et al. 2007, Roos, Krober et al. 2008, Sellmann, de Beer et 
al. 2011). Some studies go on to suggest that telomere length can add additional prognostic 
information to IGHV mutational status (Grabowski, Hultdin et al. 2005, Ricca, Rocci et al. 2007, 
Britt-Compton, Lin et al. 2012, Lin, Norris et al. 2014, Strefford, Kadalayil et al. 2015).  
1.1.6.6 Markers of Angiogenesis 
Increased microvascularity of the bone marrow and lymph node in CLL has been reported to 
correlate with clinical stage and aggressive disease (Kini, Kay et al. 2000). CLL cells are 
known to produce variable amounts of vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF), and high levels of these pro-angiogenic molecules correlates 
with aggressive disease (Molica, Vacca et al. 2002). CLL cells also express VEGF receptors; 
VEGFR-1 and VEGFR-2; VEGFR-2 levels also correlates with advanced clinical stage and 
shorter median survival (Ferrajoli, Manshouri et al. 2001). 
1.1.7 Treatment of CLL 
Treatment of CLL is undergoing a paradigm shift as a result of increased understanding of the 
pathobiology of the disease. Until very recently CLL has been viewed as an incurable 
malignancy and treatment solely based on a backbone of conventional cytotoxic 
chemotherapy. The anti-CD20 monoclonal antibody Rituximab was the first targeted 
therapeutic agent, which improved survival of CLL patients when used in combination with 
cytotoxic chemotherapy. The most effective front line chemoimmunotherapy option for fit 
patients being the fludarabine, cyclophosphamide and rituximab (FCR) combination. Although 
this regimen can produce deep and durable remissions in a subset of patients, relapses were 
inexorable.  Additionally FCR delivers suboptimal responses in those harbouring TP53 
mutations and deletions and is unsuitable for the older patient with comorbidities. Analysis of 
a subset of cases in the German CLL 8 study, comparing FC and FCR in previously untreated 
CLL, showed mutations in TP53 predicted for reduced PFS and OS after FCR. There was no 
role for NOTCH-1 mutation in predicting OS and PFS, whilst those with SF3B1 mutations had 
a reduced PFS. Given the interactions between mutations and therapy, and the known 
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confounding effect of underpowered subgroup analyses, it is clear that precisely defining the 
impact of point mutations on clinical outcome is going to require the analysis of large, complete 
cohorts of uniformly treated patients. 
Now targeted, cellular and immunotherapies in CLL are set to revolutionise the treatment 
options of the future. This has been driven by the ability to target the B-cell receptor (BCR) 
signalling pathways in CLL, as well as targeting pro-apoptotic pathways, the cell cycle and 
disrupting the supportive microenvironment. BCR signalling inhibition has become the fastest 
growing area for pharmaceutical agents. Two oral agents; Ibrutinib, an inhibitor of Bruton’s 
tyrosine kinase and Idelalisib, an inhibitor of phosphoinositol-3 kinase delta have shown very 
promising results indeed. These and other molecules directly targeting the BCR signalling 
pathways are quickly finding their place in the treatment algorithms. The CLL tumour 
microenvironment is also a very attractive therapeutic target. Lenalidomide has been proven 
efficacious in CLL. Its mechanism of action of is not entirely clear but its immunomodulatory 
properties may improve the T-cell defects in CLL. Newer molecules in development include 
ABT-199 which supress anti-apoptotic proteins such as BCL-2 and so far have given 
astonishing clinical results. Molecules which inhibit the cell cycle are also being rapidly being 
developed. Probably one of the most revolutionary developments is that of the chimeric 
antigen receptor T-cells (CAR T-cells); allogeneic or autologous T-cells are manipulated to 
express a T-cell receptor (TCR) targeting the CD19 on B-cells leading to removal of CLL cells 
via their cytotoxic effects.  
These new therapeutic strategies are best understood in the context of understanding the 
pathobiology of CLL and the normal immune system which is discussed below. 
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1.2 Background to the Normal Immune System 
1.2.1 Introduction 
In order gain insight into the pathobiology of CLL it needs to be considered in the context of 
an understanding of the function and maturation of the normal immune system. The human 
immune system is a highly evolved complex interaction of molecules, cells, tissues and organs 
together defending the body from pathogenic attack. The system has classically been divided 
into two; the innate and the adaptive immune system. The innate or non-specific immune 
system provides the first defence of the body against attack in a non-specific manner. 
Evolutionarily it precedes the adaptive system and provides no memory. It starts with the most 
basic physical barriers of skin, mucous membranes, secretions containing soluble anti-
bacterial agents and physiological barriers of temperature, pH and oxygen tension, followed 
by the more advanced processes of phagocytosis by cells such as neutrophils and 
macrophages. However, it is the adaptive immune system that leads to a specific response 
against pathogens and “non-self” antigens. Antigen is presented to the immune system, 
usually within the secondary lymphoid tissues and specific receptors trigger cell priming, 
activation and differentiation finally leading to a directed effector response to the target site. It 
is in the understanding this adaptive system and revealing the ways in which it is disrupted 
that gives a better appreciation of the complex immunopathology displayed in CLL. The aim 
of this thesis is to specifically focus on the relationship between T and B lymphocytes in CLL. 
1.2.2 Normal B-cell Development 
In normal adult B-cell development, haematopoietic stem cells differentiate to progenitor B-
cells within the bone marrow, where they constitute approximately 2% of the mononuclear 
cells. The cells mature from progenitor early pro B-cells to late pro B-cells to precursor pre B-
cells then to immature B-cells. Immature B-cells are released into the periphery and develop 
into mature naïve B-cells. These mature B-cells then circulate in the blood and traffic to and 
within the secondary lymphoid system. The B-cells ultimately differentiate into antibody 
secreting plasma cells or long-lived memory B-cells, ready to mount an immediate response 
if the same antigen is reencountered. A summary of stages of B-cell development is shown in 
Table 1-3. 
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Table 1-3 Stages of B-cell development. (Adapted from Janet M. Decker, University of Arizona 
http://www2.nau.edu)  
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1.2.2.1 B-Cell Receptor 
In order to trigger a directed immune response, B-cells need to produce an antigen specific 
receptor and the population of B-cells needs to encompass a vast number of possible 
pathogens. The BCR determines the cell’s antigen specificity. In order to create B-cells with 
such different specificities, the naïve B-cell rearranges the genes that encode for the BCR. 
The BCR is composed of a heavy and either a kappa (κ) or lambda (λ) light chain. The 
immunoglobulin heavy chain gene rearrangement precedes the light chain. There are four 
segments of genes which encode the BCR. These are the variable (V), diversity (D), joining 
(J) and constant (C) regions. The V region has 25-100 genes, the D region approximately 25 
genes, the J approximately 50 genes. These different genes can be brought together in many 
different combinations to form vastly different gene sequences to encode the BCR. This 
process is under strict control by recombination activation genes (RAG-1 and RAG-2). The 
sequence of events involves a J segment joining to a D segment, looping out the intervening 
section, then adding the V segment. Additional diversity is caused by the nucleases and 
ligases which cut and splice the variable sections together, introducing inaccuracies and 
frameshifts leading to sequences that encode for different amino acids. This process is called 
junctional diversity. Further alterations in the sequence are caused by 
deoxyribonucleotidyltransferase inserting random nucleotides, again leading to a shift in the 
reading frame. If the process is successful the gene encodes for the mu (µ) heavy chain and 
is expressed with a “surrogate” light chain on the cell surface, this expression triggers the light 
chain to be rearranged. The resultant B-cell expresses IgM with only one light chain; kappa or 
lambda. The normal kappa / lambda ratio in adults is 60:40. Therefore at the end of this 
process each immature B-cell is left with a distinct BCR and the population as a whole covers 
a huge number of antigen specificities. The stepwise development is shown in Table 1-3. 
During B-cell development there is a process of positive and negative selection. Positive 
selection occurs by antigen independent survival signalling through the BCR. Negative 
selection occurs when the B-cell BCR binds self-antigen, then the B-cell will then either be 
deleted, edit its BCR, become anergic or is ignored in a process called central tolerance.   
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B-cells can come into contact with antigen either directly or via antigen presenting cells (APCs) 
such as follicular dendritic cells (FDCs) in the B-cell zone of the primary follicle of a lymph 
node. The diversity of the BCR is broadened further following the B-cell exposure to antigen 
in the dark zone of the germinal centre. Here the B-cell receives T-cell help, which initiates 
immunoglobulin class switching of the heavy chain genes and somatic hypermutation of the 
immunoglobulin variable chain. Both FDCs and T-cells play a role in selecting only the B-cells 
expressing high affinity BCRs within the light zone. A schema of the germinal centre reaction 
is shown in Figure 1-2, adapted from Küppers et al (Kuppers 2003). 
 
 
Figure 1-2 The germinal centre reaction of a lymph node. Adapted from Küppers et al.  
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1.2.2.2 BCR Signalling 
On engagement of the BCR by antigen a series of complex downstream signalling events take 
place. Activation of the BCR leads to recruitment of proto-oncogene tyrosine protein kinase 
(SRC) family members including tyrosine protein kinase Lyn (LYN), proto-oncogene tyrosine 
protein kinase Fyn (FYN) and B-lymphocyte kinase (BLK), which phosphorylate CD79a and 
CD79b via their immunoreceptor tyrosine-based activation motifs (ITAMs). This then leads to 
recruitment of spleen tyrosine kinase (SYK), Bruton’s tyrosine kinase (BTK) and/or 
phosphatidylinositol 3-kinase (PI3K). Ultimately this leads to calcium mobilisation, 
downstream activation of mitogen-activated protein (MAP) kinases, RAS, phospholipase C 
(PLC), protein kinase C (PKC) and caspase recruitment domain containing protein 11 
(CARD11). Activation of protein kinase B (AKT), NF-kB or extracellular signal regulated kinase 
(ERK) pathways lead to cell survival and proliferation (Shaffer, Young et al. 2012).  
Figure 1-3 shows a schematic cartoon of chronic active BCR signalling, adapted from Young 
et al (Young and Staudt 2013). These normal B-cell signalling pathways are becoming 
increasingly important as targets for therapy in CLL which is revolutionising the treatment 
paradigm.   
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Figure 1-3 Chronic active BCR signalling. Adapted from Young at el.  
BTK (Bruton’s tyrosine kinase); CARD11 (caspase recruitment domain-containing protein 11); 
IgH (immunoglobulin heavy chain); IgL (immunoglobulin light chain); IKK (inhibitor of NF-κB 
kinase); MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1); 
MAPK (mitogen-activated protein kinase); MAPKK, (MAPK kinase); MAPKKK (MAPK kinase 
kinase); mTOR (mammalian target of rapamycin); NFAT, (nuclear factor of activated T-cells); 
PKCβ (protein kinase Cβ). 
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1.2.2.3 B-cell Activation 
T-cell dependant B-cell activation 
When B-cells come in contact with antigen via the BCR, the antigen is internalised by 
endocytosis, processed and the resultant peptides presented to specific T-cells on class II 
major histocompatibility (MHC) molecules on its surface. This typically occurs in the T-cell 
zone of the primary lymph node follicle. This results in CD4+ T-helper (Th) and specifically T 
follicular helper (Tfh) cells, which have specificity for the same antigen, engaging with the 
peptide on MHC class II via its T-cell receptor (TCR). The engagement of the TCR by the 
MHC class II in turn leads to cytokine production, including IL-4 and IL-21, which stimulate the 
B-cell. As part of this process CD40, a member of the tumour necrosis factor (TNF) receptor 
family expressed on mature B-cells, is engaged by its ligand CD154 (also known as CD40L) 
on T-cells. CD40L activates the RelA dependant NF-kB canonical and the RelB non-canonical 
activation pathways. This interaction leads to activation of many signalling pathways which 
play a crucial role in inducing proliferation, antibody secretion, cytokine production, class 
switching (of the activated IgM+ B-cells to another isotype), germinal centre formation and 
ultimately producing long-lived memory B-cells.  
T-cell independent B-cell activation 
A T-cell independent B-cell response can also occur, but this does not allow efficient class 
switching or the generation of long-lived memory B-cells. This occurs when antigens, such as 
foreign polysaccharides, activate the B-cell but the co-stimulatory signals from the T-cell are 
absent. Therefore activation utilises alternative pathways such as binding of toll-like receptors 
(TLRS).   
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1.2.3 Normal T-cell Development 
T-cells are a crucial component of the adaptive immune system and cell mediated immunity. 
T-cell development is complex due to the functional diversity of mature T-cells. All T-cells 
originate from a lymphoid precursor in the bone marrow but there is subsequent migration to 
the thymus for further development. T-cell subsets are customarily subdivided according to 
their function and cytokine production, 
1.2.3.1 T-helper Cells 
T-helper cells are crucial for the maturation of B-cells into long-lived memory B-cells and 
plasma cells and are also required for the activation of cytotoxic T-cells. These cells express 
the glycoprotein CD4 on their surface. They are activated when they engage with peptide 
presented by MHC Class II molecules on APCs. Once activated, CD4+ Th cells predominantly 
differentiate into Th1 or Th2. There are also other subtypes including Th17, Th3, Th9 and Tfh 
cells. The differentiation process is complex and depends upon the cytokine stimulation the 
T-cell is receiving.  
Th1 
Th1 cells facilitates the proliferation and expansion of T-cells and plays a critical role in cell 
mediated immunity; particularly in the clearance of intracellular bacteria and protozoa. They 
specifically promote macrophages. They are triggered by IL-2 production. Th1 cells produce 
predominately IL-2, interferon gamma (IFN-γ), tumour necrosis factor beta (TNF-β) and 
granulocyte macrophage colony-stimulating factor (GM-CSF). Some Th1 cells have cytolytic 
capacity and can produce perforin, granzyme and express Fas ligand.  
Th2 
Th2 cells play a role in the host immunity against extracellular pathogens, particularly 
parasites. They are triggered by IL-4 secretion. They produce IL-4, IL-5, IL-6 and IL-10 and 
this cell type provides help to activate the B-cell to produce antibody, particularly IgE. They 
also specifically effect the function of eosinophils, basophils and mast cells.   
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Th17 
Th17 are a relatively recently discovered subset of Th cells which produce IL-17. They mainly 
produce IL-17, IL-21 and IL-22. They seem to play a critical role in autoimmunity, where Th17 
over activity is associated with diseases such as rheumatoid arthritis and psoriasis. Th17 cells 
expansion is mediated by IL-23 (Zambrano-Zaragoza, Romo-Martinez et al. 2014). 
Tfh 
Tfh cells are intrinsically involved in the formation of the germinal centre reaction. Defining Tfh 
cells has been controversial, but they express varying levels of CXC chemokine receptor 5 
(CXCR5) and Programmed Death-1 (PD-1) and facilitate the formation of a long-lived B-cell 
responses and immunoglobulin production (Dorfman, Brown et al. 2006).  
1.2.3.2 Regulatory T-cells 
Regulatory T-cell (Tregs) account for up to 5% of CD4+ T-cells and express high levels of 
CD25, forkhead box P3 (Foxp3), CD62 and IL-10. Tregs play an important part of maintaining 
peripheral T-cell tolerance to self-antigens and protection from autoimmunity. They suppress 
immune responses and have been correlated with poor prognosis in solid tumours (Wallace, 
Alcantara et al. 2015).  
1.2.3.3 Cytotoxic T-cells 
Cytotoxic T-cells express the CD8 glycoprotein on their surface and have a major role in 
eradicating viruses and tumours. They are activated when they bind antigen presented by 
MHC Class I molecules, which are present on all nucleated cells. The cytokine profile of CD8+ 
T-cells subdivides them into Tc1, Tc2 and Tc17 cells. All CD8+ T-cells are cytotoxic, and upon 
engagement with its target leads to cell death by releasing perforins and granzymes. CD8+ T-
cells can also lead to apoptosis via binding of Fas ligand. Cytotoxic T-cells can be subdivided 
according to their cytokine profile and function. Tc1 cells predominately secrete IFN-γ, Tc2 
cells predominately secrete IL-4 and Tc17 cells predominately secrete IL-17.  
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1.2.3.4 T-cell Receptor 
Just like the B-cell, T-cells have a receptor, which defines its specificity for antigen. The T-cell 
receptor is a heterodimer of either an alpha (α) and beta (β) chain or less commonly a gamma 
(γ) and delta (δ) chain. The TCR forms a transmembrane signalling complex in conjunction 
with CD3. The TCR specificity is altered, like the BCR, through random genetic rearrangement 
of constant and variable domains. The variable domains contain VDJ gene families and the 
linkage points are called hypervariable regions. The final rearranged segments of DNA, which 
encode for the antigen binding area is called the complementary-determining region (CDR). It 
is the third hypervariable region (CDR3), between the V and J region of the β chain, which 
mostly defines the specificity of the TCR. The differences between the sequence and length 
of the CDR3 define Vβ families. Some Vβ families are used more frequently than others. This 
process of TCR rearrangement occurs early in development of the T-cell, before it encounters 
antigen for the first time. The process was thought to lead to the production of over 106 TCRs, 
but new gene sequencing techniques has suggested this may be much larger (Robins, 
Campregher et al. 2009). Within the thymus it is estimated that over 95% of T-cells are deleted, 
some by failure to rearrange their TCR, some by active elimination and some by neglect. T-
cells undergo a process of positive and negative selection within the thymus, where T-cells 
with a high affinity for self-derived peptides die by apoptosis, and low affinity T-cells are 
released into the periphery.  
1.2.3.5 T-cell Activation 
Naïve T-cells circulate between the PB and secondary lymphoid tissues under the influence 
of homing receptors, such as CD62L and CC-chemokine receptor 7 (CCR7) looking for their 
cognate peptide on the MHC of antigen presenting cells. At this stage these T-cells usually 
already express either CD4 or CD8 on their surface. CD4+ Th-cells recognise antigenic 
peptides presented to them by MHC class II molecules found on the surface of APCs such as 
dendritic cells, B-cells and thymic epithelial cells. Cytotoxic CD8+ T-cells respond to peptides 
presented to them by Class I MHC molecules and it is by this mechanism that T-cells exert 
cytotoxicity.  
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Once the TCR engages its MHC-peptide complex, ligation of other co-stimulatory molecules 
is required for T-cell activation. The primed T-cell expresses CD28 on its surface which binds 
to its ligands which are members of the B7 family, including B7-1 (CD80) and B7-2 (CD86) on 
the surface of the antigen presenting cell. This ligation promotes T-cell IL-2 secretion, 
activation and survival. Without CD28 ligation the T-cell undergoes apoptosis or is anergic. 
Activated T-cells also upregulate CD25, which is the alpha chain of the high affinity IL-2 
receptor. Once T-cells are activated by antigen they proliferate, producing daughter effector 
T-cells of the same specificity, which are attracted by chemokines and adhesion molecules to 
migrate out of the lymph node to the required site of action.  
1.2.3.6 Negative regulators of T-cell activation 
T-cell activation must also be negatively regulated to attenuate and eventually terminate the 
T-cell response. Inhibitory T-cell receptors include Cytotoxic T-Lymphocyte Antigen 4 (CTLA-
4) and Programmed Death 1 (PD-1).  
CTLA-4 
CTLA-4 has very high homology with CD28. It is upregulated on activated T-cells and binds 
to the same B7 family members as CD28, but at a much higher affinity. It negatively regulates 
the T-cell by decreasing IL-2 production and therefore has a critical role in terminating the 
immune response (reviewed in (Alegre, Frauwirth et al. 2001, Sharma and Allison 2015). 
Clearly T-cell activation is in a delicate balance, and most surface CTLA-4 is rapidly 
endocytosed to prevent early termination of the immune response. Interestingly CTLA-4 
deficient mice develop an aggressive lymphoproliferative disorder, due to the lack of a “brake” 
on the immune system (Waterhouse, Penninger et al. 1995). These findings lead to the 
hypothesis that CTLA-4 blockade in cancers might allow T-cells to eradicate tumours. A series 
of murine studies over more than a decade lead to the development of Ipilimumab, a human 
anti-CTLA-4 antibody (Leach, Krummel et al. 1996, Hurwitz, Yu et al. 1998, van Elsas, Hurwitz 
et al. 1999, Waitz, Fasso et al. 2012, Zamarin, Holmgaard et al. 2014). This drug was 
approved by the FDA for treatment of metastatic melanoma in 2011 (Hodi, O'Day et al. 2010, 
Robert, Thomas et al. 2011).  
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PD-1 
PD-1 has been identified as a critical immune checkpoint regulator and limiter of T-cell 
responses (Freeman, Long et al. 2000). PD-1 is expressed on activated T-cells, B-cells and 
macrophages. PD-1 belongs to the immunoglobulin superfamily and has an extracellular IgV 
domain, a transmembrane region and an intracellular tail with 2 phosphorylation sites; one is 
an immunoreceptor tyrosine based inhibitory motif and the other an immunoreceptor tyrosine 
based switch motif (Freeman, Long et al. 2000). Both motifs are phosphorylated on PD-1 
ligation, which recruits SHP-2 (Src homology domain-containing tyrosine phosphatase 2) in 
B-cells and SHP-1 and SHP-2 in T-cells (Okazaki, Maeda et al. 2001, Riley 2009, Yokosuka, 
Takamatsu et al. 2012). In the B-cell SHP2 activation inhibits downstream BCR signalling by 
reducing phosphorylation of immunoglobulin β, SYK, PLC, ERK and PI3kinase (Maeda, 
Scharenberg et al. 1999). TCR signalling is inhibited by reduced phosphorylation of the ZAP-
70/CD3zeta signalsome and subsequently reduced downstream signalling to PKCtheta 
(Sheppard, Fitz et al. 2004).  
PD-1 has two known ligands PD-L1 (programmed death ligand 1 also known as B7-H1) and 
PD-L2. PD-L1 can be upregulated, as a result of IFN-γ secreted by activated T-cells, on 
tumour cells, epithelial cells B-cells and the T-cells themselves (Dong, Strome et al. 2002). 
A simplified schema of the crosstalk between T-cells and the B7-CD28 superfamily is shown 
in Figure 1-4, adapted from Sharpe et al (Sharpe and Freeman 2002).  
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Figure 1-4 B7-CD28 superfamily crosstalk between APC and T-cells. Adapted from Sharpe et 
al. 
 
1.2.3.7 Memory T-cells 
Following most infections, after T-cell activation and proliferation, the pathogen is cleared and 
the massive T-cell expansion is contracted by apoptosis. Some “memory T-cells” will remain 
in the lymph node awaiting re-exposure to the same antigen. Both CD4+ and CD8+ T-cells 
can form memory T-cells, which persist following antigen activation and expand upon re-
exposure to their cognate antigen. Memory cells are maintained in part by signalling from 
FDCs in germinal centres. It is thought memory cell can persist in the absence of the antigen, 
but it is likely they are periodically re-presented antigen by FDCs. Memory cells can affect a 
rapid response to re-infection in part through increased expression of accessory molecules 
such as LFA-1 (lymphocyte function associated antigen 1), LFA-3 and ICAM-1 (intercellular 
adhesion molecule 1) and by faster triggering into cell division and cytokine secretion. Naïve 
T-cells have a different phenotype from memory T-cells. In memory T-cells there is a change 
in isoform of the leukocyte common antigen CD45R, from CD45RA to CD45RO. Naïve T-cells 
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also express low levels of the adhesion molecule CD44 compared to high levels on memory 
T-cells. Generally memory T-cells are considered to be either central memory (TCM) or effector 
memory (TEM) (Sallusto, Lenig et al. 1999). Within these populations the expression levels of 
the co-stimulatory molecules CD27 and CD28 decrease with differentiation. There has been 
reported to be significant inter-individual variation in the frequencies of the individual CD4+ 
and CD8+ subsets, but specifically there are particularly marked differences with advancing 
age, notably with an overall decrease in the number of naïve cells in the CD8+ pool (Koch, 
Larbi et al. 2008).  
Central Memory T-cells (TCM) 
The TCM population are antigen primed T-cells, which when they re-encounter their cognate 
antigen offer B-cell help, stimulate DCs and generate effector T-cells. TCM cells express CCR7, 
which is the receptor for the chemokines CCL19 and CCL21, they also express CD62L. 
CD62L, also known as L-selectin, is a cell adhesion molecule whose role, at least in part, is 
to influence the cells to home to the secondary lymphoid tissue.  
Effector memory T-cells (TEM) 
The TEM population lack both CCR7 and CD62L, but they express CCR1, CCR3, CCR5 
receptors which respond to pro-inflammatory chemokines, and therefore mediate 
inflammatory reactions and cytotoxicity.  
The differential expression of CD62L and CCR7 therefore orchestrates the TCM to generally 
home to the lymph nodes, spleen and blood and TEM to the sites of inflammation and infection 
in the peripheral tissues.  
Terminal Effector memory T-cells (TEMRA) 
A small population of terminal differentiated effector memory (TEMRA) cells are defined as 
CD45RA+/CCR7- and expresses CD57. They are cytotoxic and express high levels of perforin 
and Fas ligand. As such they are highly susceptible to apoptosis. 
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Exhausted T-cells 
In persistent infections there may be eventual “exhaustion” of the effector function and 
substantial phenotypic and functional abnormalities of the memory T-cells. These memory 
cells are being continuously stimulated and in contrast to the usual slow turnover of a memory 
T-cell their proliferation is substantial. As a cell can only undergo a finite number of divisions 
eventually the telomeres become too short (the so called “Hayflick limit), these cells will 
eventually be eliminated.  
Chronically activated T-cells express PD-1 which has been referred to as a sign of exhaustion. 
The negative regulatory function of PD-1 suppresses the T-cell function and seems to maintain 
its dysfunction. If the PD-1 expression is reversed the T-cell function has been shown to be 
revived. A seminal experiment of mice infected with chronic cytomegalovirus (CMV) infections, 
showed an improvement in the functionality of memory CD8+ T-cells and clearance of the 
virus when PD-1 was blocked (Barber, Wherry et al. 2006).  PD-1 knockout C57BL/6 mice 
develop lupus-like autoimmune diseases due to the lack of this crucial negative regulator of 
the immune system (Nishimura, Nose et al. 1999).  Blockade of the PD-1 / PD-L1 axis has 
generated much interest recently. Anti PD-L1 antibodies have been shown to promote tumour 
regression in melanoma, bladder cancer, renal carcinoma and non-small cell lung cancer 
(Brahmer 2012, Powles, Eder et al. 2014). Several anti-PD-1 drugs have reached the clinic 
since the work in this thesis was undertaken. Pembrolizumab has shown up to a 38% 
response rate in advanced metastatic melanoma and was FDA approved in September 2014 
(Hamid, Robert et al. 2013, Robert, Ribas et al. 2014). Nivolumab showed similar success 
and was FDA approved in December 2014 for melanoma and March 2015 for lung cancer 
(Robert, Ribas et al. 2014). (Reviewed by (Sharma and Allison 2015)). 
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1.3 Pathology of CLL B-cells  
1.3.1 Introduction 
Malignant CLL B-cells have diverse cytogenetic abnormalities and show immunological 
heterogeneity. Historically CLL was thought to be a disease of quiescent B-cells and therefore 
a disease of accumulation, due to a defect in apoptosis, and not a disease of proliferation 
(Dameshek 1967). This hypothesis was informed by PB studies of circulating CLL cells that 
found the majority of them to be in the resting, G0 phase, of the cell cycle (Dighiero, Travade 
et al. 1991). However there is now good evidence that CLL is more dynamic than previously 
thought. One good piece of evidence that CLL cells have a replicative history comes from the 
discovery that CLL cells have short telomeres and that cases with the shortest telomeres have 
the most aggressive disease (Bechter, Eisterer et al. 1998). Single-molecule telomere length 
and telomere fusion analysis has now been undertaken and the shortest telomere length 
recorded in human tissue was reported in CLL (Lin, Letsolo et al. 2010).   
Additional evidence for proliferation in CLL was provided by the seminal study of Messmer et 
al, who performed in vivo labelling studies, of patients with CLL, using deuterated water (2H20). 
Deuterium (2H) becomes incorporated into the DNA of proliferating CLL cells, so that the 
degree of 2H enrichment measured by gas chromatography / mass spectrometry, reflects 
overall tumour proliferation. The study revealed that the CLL birth rate was up to 1% of the 
total clone per day (Messmer, Messmer et al. 2005).  
1.3.2 Cell of Origin 
The malignant transformation of B-cells can occur at any stage in B-cell development. In CLL 
however, unlike in some other B-cell malignancies, there is not a clear non-malignant B-cell 
counterpart. Some groups have postulated there may be a distinct CD5+ malignant B lineage 
cell (Caligaris-Cappio 1996, Dono, Burgio et al. 2007). Others have found there are phenotypic 
similarities between CLL cells and splenic marginal zone B-cells suggesting an alternative cell 
of origin (Chiorazzi and Ferrarini 2003). Gene expression profiling of CLL cells has given new 
insights; malignant CLL B-cells show marked similarities to that of a normal memory B-cells 
(Klein, Tu et al. 2001, Rosenwald, Alizadeh et al. 2001). In these studies both mutated and 
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unmutated cases had very similar gene profiles which seemed to dispute the theory that 
unmutated CLL originated from naïve B-cells as previously hypothesised (Forconi, Potter et 
al. 2010). Recent studies have found receptor tyrosine kinase-like orphan receptor 1 (ROR-1) 
on CLL B-cells, which is only usually found on haematogones, opening up an alternative 
theory of potential cell of origin (Zhang, Chen et al. 2012). More recent detailed flow cytometric 
studies have revealed that CLL most likely arises from a hitherto unrecognised post germinal 
centre CD5+ B-cell subset (Seifert, Sellmann et al. 2012). Chiorazzi reviewed the many 
models of either a single or multiple cell origins of CLL and although this question remains 
unanswered there is likely to be a multistep process of leukaemogenesis. (Chiorazzi and 
Ferrarini 2011).  
Although CLL cells were originally believed to be quiescent, their phenotype is consistent with 
ongoing antigenic stimulation as they express a number of markers of antigen exposure / 
activation, including CD23, CD25, CD69, CD71 and CD27; this is the case for both mutated 
and unmutated cases (Damle, Ghiotto et al. 2002).  
1.3.3 Immunoglobulin Repertoire 
Most CLL cells express surface IgM/IgD and this initially was taken as evidence that CLL is a 
disease of naïve B-cells which had not been exposed to antigen (Coffman and Cohn 1977), 
but there is now compelling evidence to the contrary. CLL cells show significant skewing in 
their VH gene usage and the VH genes used most frequently are VH1-69, VH3-07 and VH4-34 
(Schroeder and Dighiero 1994, Fais, Ghiotto et al. 1998, Hamblin, Davis et al. 1999). This bias 
would suggest that the B-cell is responding to antigen. Another piece of supportive evidence 
is that in approximately 50% of CLL cases the immunoglobulin heavy chain shows evidence 
of somatic hypermutation, as discussed previously this is a process which occurs following 
antigen exposure (Schroeder and Dighiero 1994, Hashimoto, Dono et al. 1995, Oscier, 
Thompsett et al. 1997, Fais, Ghiotto et al. 1998). Several studies have also revealed that in 
subsets of unrelated patients, CLL cells expressed BCRs with a striking homology to each 
other; so much so as to suggest specificity to the same antigen (Messmer, Albesiano et al. 
2004, Tobin, Thunberg et al. 2004, Widhopf, Rassenti et al. 2004, Ghia, Stamatopoulos et al. 
2005, Stamatopoulos, Belessi et al. 2007). Stereotyped BCRs occurs in up to a third of CLL 
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cases (Chiorazzi, Rai et al. 2005, Agathangelidis, Darzentas et al. 2012). This phenomenon 
could not possibly occur by random chance and the probability independent clones would 
carry the same BCR would be in the region 1 in 10-12.   
1.3.4 BCR Signalling and Antigen Drive 
The data discussed above suggests that both mutated and unmutated cases of CLL are both 
derived from B-cells which have been exposed to antigen and continue to signal through their 
BCRs by ligand dependant mechanisms and it is becoming increasingly apparent that 
signalling through the BCR is critical in the pathobiology of CLL (Stevenson, Krysov et al. 
2011, Woyach, Johnson et al. 2012). BCR signalling may be additionally enhanced by ZAP-
70 expression, which facilitates the recruitment of kinases to the BCR complex (Chen, Huynh 
et al. 2008). 
Unlike in diffuse large B-cell lymphoma (DLBCL), studies to date have not detected a high 
frequency of activating mutations in the BCR pathway that might lead to independence from 
antigen (Philippen, Diener et al. 2010). This has led investigators to try and identify putative 
antigens.  Many B-cell malignancies are known to be triggered by chronic stimulation from 
antigen such as Helicobacter pylori, EBV, hepatitis C. There is also an association with 
autoimmune disorders such as rheumatoid arthritis (RhA), systemic lupus erythematosus 
(SLE) and Sjörgren’s syndrome (Morse, Kearney et al. 2001, Kuppers 2005). Interestingly 
BCRs from unmutated CLL cases appear to be polyreactive but some BCRs show affinity for 
self-antigens (Herve, Xu et al. 2005). These self-antigens include cytoskeletal proteins, such 
as non-muscle myosin heavy chain IIA, vimentin and cofilin. Additional reactivity has been 
demonstrated by self-antigens such as the Fc immunoglobulin tail, single stranded DNA, 
double stranded DNA, lipopolysaccharide, insulin and oxidised low density lipoprotein (Catera, 
Silverman et al. 2008, Lanemo Myhrinder, Hellqvist et al. 2008, Binder, Lechenne et al. 2010, 
Chu, Catera et al. 2010).  
Other groups have found affinity of BCRs for a variety of non-self-antigens including bacteria, 
fungal elements and viruses including CMV (Landgren, Rapkin et al. 2007, Kostareli, 
Hadzidimitriou et al. 2009, Steininger, Rassenti et al. 2009). Hoogeboom et al published a 
stereotyped mutated BCR IGHV3-7 recognised the antigen beta-(1,6)-glucan (found in yeasts 
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and filamentous fungi) with high affinity and in fact lead to CLL cell proliferation (Hoogeboom, 
van Kessel et al. 2013). This gives further weight to the argument that antigen responsiveness 
in part drives CLL proliferation. Duhren-von Minden et al have fascinatingly published in 
Nature evidence for BCR activation by antigen independent cell autonomous signalling. They 
showed that, by binding the CLLs own CDR3 to an epitope in the second framework region, 
calcium signalling was induced; suggesting an auto-reactive BCR activation. Following on 
from this study a second group demonstrated CLL BCRs ability to recognise themselves via 
an epitope of the framework region 3 (Duhren-von Minden, Ubelhart et al. 2012).  
1.4 T-cells in CLL 
1.4.1 Introduction 
It is well established from numerous published studies going back to the 1970’s that there are 
both quantitative and qualitative abnormalities of PB T-cells in CLL. T-cell dysfunction plays a 
key role in the immunopathology in CLL. In health one role of the T-cells is to identify and 
eliminate emerging neoplastic clones, but in CLL there is direct evidence that dysregulated T-
cells may play a supportive role in sustaining the malignant B-cells. Early studies hypothesised 
that the expansion of T-cells in CLL was related to a specific anti-leukaemic effect; however 
the reality is far more complex and the T-cell dysfunction in CLL is manifold. In fact a myriad 
of T-cell abnormalities have been described in CLL and the precise role they play in the 
pathogenesis remains to be fully elucidated. Immune suppression is a typical finding in CLL, 
with an increased risk of infections and a predisposition to second malignancies (Rossi, De 
Paoli et al. 2008, Morrison 2010, Solomon, Rabe et al. 2013, Riches and Gribben 2014). 
Haematological autoimmune phenomenon are commonly observed, most frequently 
autoimmune haemolytic anaemia (Dearden 2008).  
T-cells in CLL are part of a complex balancing act. Some appear to be cytotoxic against the 
tumour and are in part being supressed by the CLL B-cells themselves, some appear to be 
actively supporting tumour proliferation whilst others are contributing to autoimmune 
phenomenon. I shall summarise the literature below.  
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1.4.2 T-cell Accumulation in CLL 
In 1973 Wybran et al first published in the Lancet that there was a low proportion of T-cells in 
CLL patients and that this was a “dilution” effect (Wybran, Chantler et al. 1973). Then in a 
follow up paper in 1974, Catovsky et al first made the observation that untreated patients with 
CLL had a markedly expanded T-cell compartment compared to healthy controls (Catovsky, 
Miliani et al. 1974). In this study, before the advent of flow cytometry, B-cells were identified 
by indirect immunofluorescence and T-cells by the spontaneous formation of sheep red cell 
rosettes. By the late 1970’s monoclonal antibodies allowed CD4+ and CD8+ T-cell 
subpopulations to be determined (Kung, Goldstein et al. 1979). One of the first papers utilising 
this technique to investigate CLL T-cells was Platsoucas et al, they studied 30 untreated CLL 
cases and found increased T-cell numbers, but a significantly decreased proportion of CD4+ 
T-cells and a subsequent increased proportion of CD8+ T-cells compared to normal controls. 
They concluded that the CD4/CD8 ratio was lower in CLL patients than normal controls 
(Platsoucas, Galinski et al. 1982). Many groups have since investigated the CD4/CD8 ratio in 
the PB of CLL patients. Kimby et al published a study of 48 untreated patients with CLL, and 
again found that the total T-cell count was high and the CD4/CD8 ratio was low compared to 
normal controls; they additionally found the total T-cell numbers were correlated with the size 
of the CLL clone and that the CD8+ numbers increased and CD4/CD8 ratio decreased with 
progressive advanced stage disease (Kimby, Mellstedt et al. 1987). Now, an overall increase 
in CD4 and CD8 numbers with a decreasing ratio with advancing disease has been 
consistently reported (Herrmann, Lochner et al. 1982, Mills and Cawley 1982, Gonzalez-
Rodriguez, Contesti et al. 2010). This mirrors the finding of a reduction in CD4/CD8 ratio found 
in chronic infections such as CMV. Palmer et al published a study, which showed the relative 
size of the T-cell component was highest in early stage and good prognosis patients, but 
nonetheless the total number of T-cells continued to increase with advancing stage (Palmer, 
Hanson et al. 2008). Nunes et al more recently undertook the largest comprehensive 
phenotypic analysis of 110 untreated CLL patients.  They also demonstrated an expansion of 
CD4+ and CD8+ T-cells and found that the inversion of the CD4:CD8 ratio was related to the 
comparatively larger expansion of CD8+ T-cells (Nunes, Wong et al. 2012). In general terms 
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the total T-cell compartment is reported to be 3 fold larger than in healthy controls, with CD8+ 
T-cells 4 fold increased and CD4+ T-cells 2.5 fold increased (Mellstedt and Choudhury 2006).  
The exact mechanism by which T-cells accumulate in CLL is not well defined. It is not fully 
known whether the accumulation is a specific TCR dependent response to antigen(s) or 
superantigen or if the T-cells are non-specifically expanded by chemokines.  
Some CLL cells have been shown to aberrantly express BAFF (B-cell activating factor) and in 
vitro studies have shown that BAFF can stimulate T-cells to proliferate (Huard, Schneider et 
al. 2001, Novak, Bram et al. 2002), by this means T-cells could be chronically stimulated and 
accumulate in CLL. Borge et al have reported T-cell responses to various chemokines and 
found that there was migration by CLL T-cells towards CXCL12 (also known as SDF-1; stromal 
derived growth factor). This migration was impaired in ZAP-70 negative CLL cases, 
hypothesising that T-cells are encouraged to accumulate in the microenvironment in poor risk 
ZAP-70 positive cases (Borge, Nannini et al. 2010). 
1.4.3 T-helper Perturbations in CLL 
Studies analysing CLL T-cell cytokine production have found several deviations from the 
normal pattern that is observed in healthy controls. Rossmann et al found levels of IL-2, IL-4, 
TNF-α and GM-CSF to be significantly increased in T-cells from CLL patients (Rossmann, 
Lewin et al. 2002). The cytokine profiles of T-cells between indolent and advanced disease 
also shows differences, with the highest levels of IL-2 and IL-4 being present in patients with 
advanced disease. In vitro studies of patients with early stage disease seem to show a bias 
towards Th1 (IL-2, IFN-γ, TNF-β, GM-CSF) cytokine production over Th2 (IL-4, IL-5, IL-6, IL-
10) production and conversely more Th2 in advanced cases (Podhorecka, Dmoszynska et al. 
2002). The shift from Th1 to Th2 with advanced disease may play a role in CLL cells escaping 
immune surveillance (Mellstedt and Choudhury 2006). Interestingly IL-2, IL-4 and TNF-α are 
thought to support CLL survival in vitro (Cordingley, Bianchi et al. 1988, Trentin, Zambello et 
al. 1994). IL-4 also may assist the transition of CLL cells from resting G0 to G1/S (Luo, Rubio 
et al. 1991, van Kooten, Rensink et al. 1992) and IFN-γ is reported to rescue CLL cells from 
apoptosis in vitro (Buschle, Campana et al. 1993). 
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This perturbation in Th polarisation may therefore be, in part, driven by the CLL cells 
themselves, as their prolife of cytokine expression includes IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, 
IL-10, IFN-α, IFN-γ, G-CSF, GM-CSF, TNF-α and TGF-β. Research from our group has 
previously shown that CLL cells secrete high levels of IL-6, and suggest its role in inhibiting T-
cell activation and inducing a Th2 response (Buggins, Patten et al. 2008).  
Th17 
Il-17 secreting Th17 helper cells have recently been studied by several groups. They have 
found higher levels of Th17 phenotype T-cells in CLL patients compared to normal controls 
but that lower numbers correlate with advancing disease (Tang, Niu et al. 2014). Th17 
numbers seem to correlate inversely with the proportion of Tregs (Jain, Javdan et al. 2012, 
Hus, Bojarska-Junak et al. 2013).  
Tfh 
Little work has focused on the T follicular helper cells in CLL to date. Cha et al defined Tfh as 
CD4+ CXCR5+ and found these cells to represent 25% of CD4+ T-cells in CLL compared to 
8% in normal controls suggesting a role in disease (Cha, Zang et al. 2013). However it must 
be taken into account that CXCR5 is also expressed on central memory T-cells. Ahearne et 
al concurred there were increased Tfh cells in CLL PB using a more robust CD4+ CXCR5+ 
ICOS+ phenotype although they found numbers did not correlate with stage. They went on to 
investigate their major cytokines produced by Tfh cells, IL-21 and IL-4, and found that these 
promote leukaemic proliferation (Ahearne, Willimott et al. 2013).  
Tregs 
Tregs maintain self-tolerance and have a significant role in many cancers. Treg numbers in 
the PB have been consistently shown to be increased in CLL and correlate with advanced 
stage disease (Beyer, Kochanek et al. 2005, Giannopoulos, Schmitt et al. 2008, Jak, Mous et 
al. 2009, Weiss, Melchardt et al. 2011, Biancotto, Dagur et al. 2012, D'Arena, D'Auria et al. 
2012, Lad, Varma et al. 2013). Treg numbers seem to predict time to first treatment in low risk 
patients (D'Arena, D'Auria et al. 2012). The complex T-cell immune deficiency means CLL T-
cells do not mount an effective anti-tumour effect may in part be assisted by the increased 
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Tregs which may exert their effect by downregulating tumour specific effector T-cells (D'Arena, 
Laurenti et al. 2011). The negative regulator CTLA-4 is expressed at high levels by Tregs and 
high levels of CTLA-4 was found to be correlated with aggressive disease. Recently an 
interesting paper by Jitschin et al suggested this may be as a result of an increased number 
of myeloid derived suppressor cells (MDSCs) which supress T-cell activation and induce 
Tregs (Jitschin, Braun et al. 2014). Another mechanism by which Tregs may be induced is via 
CD200. CD200 is an immunomodulatory molecule recently found to be expressed on CLL 
cells which down regulates Th1 responses and induces Tregs (Kretz-Rommel, Qin et al. 2007, 
Pallasch, Ulbrich et al. 2009). 
1.4.4 Evidence of T-cell Stimulation 
Phenotypically the T-cells derived from PB patients with CLL have marked differences from 
normal controls. These phenotypic changes support the hypothesis that the T-cells are 
undergoing chronic antigenic stimulation. Several groups have reported an increased TEM 
phenotype (CD45RA-/CCR7-) in the CD4+ T-cells of CLL patients compared to healthy 
controls and a relative decrease in naïve T-cells, data confirmed in this thesis (Motta, Chiarini 
et al. 2010, Walton, Lydyard et al. 2010, Nunes, Wong et al. 2012). By convention these CD4+ 
TEM cells develop post antigen exposure. Similar findings are reported in the CD8+ T-cells with 
less naïve subsets in CLL patients than healthy controls (Nunes, Wong et al. 2012). 
Many studies have found CD69, HLA-DR and CD95 to be higher on the CD4+ PB cells from 
CLL patients (Totterman, Carlsson et al. 1989, Scrivener, Kaminski et al. 2001, De Fanis, 
Dalla Mora et al. 2002). Serrano et al also reported that CD57 was significantly increased in 
both the CD8+ and CD4+ T-cell populations in CLL patients compared to normal controls 
(Serrano, Monteiro et al. 1997). CD57, as discussed earlier, is a marker of chronic activation, 
and is expressed on late effector T-cells, again following antigenic stimulation.  
Low expression of the co-stimulatory molecule CD28 in both CD4+ and CD8+ T-cells has 
been consistently reported and lower levels appear to correspond with more advanced 
disease (Rossi, Matutes et al. 1996, Rossmann, Jeddi-Tehrani et al. 2003). CTLA-4 is found 
at higher levels on CLL derived T-cells compared to normal controls and is hypothesised to 
be a mechanism by which T-cell function is impaired (Frydecka, Kosmaczewska et al. 2004). 
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Taken together these findings have led to the hypothesis that T-cells in CLL, just like the B-
cell have been activated and show features of exposure to antigen.  
1.4.5 Functional Abnormalities 
The functional T-cell abnormalities in CLL PB have long been appreciated (Chiorazzi, Fu et 
al. 1979). Much of the observed T-cell dysfunction is thought to be induced by the CLL cells 
themselves. The dysfunction is at least in part mediated by the cytokine production of the 
tumour cells such as TNF-β and IL-10 that supress T-cell activation and effector function. I 
shall outline some of the major abnormalities below. 
Exhausted T-cells 
More recent evidence, and presented here in this thesis, is that the T-cells appear to have 
markers of chronic exhaustion such as PD-1, CD244 and CD160 (Xerri, Chetaille et al. 2008, 
Nunes, Wong et al. 2012, Brusa, Serra et al. 2013, Riches, Davies et al. 2013, Novak, 
Prochazka et al. 2015, Rusak, Eljaszewicz et al. 2015). Ramsay et al reported PD-1 
expression on CD3+ T-cells of CLL patients to be higher than those from normal controls and 
correlated with poor prognosis (Ramsay, Clear et al. 2012). Brusa et al reported that the PD-
1 levels were higher on both the CD4+ and CD8+ PB T-cells than normal controls and that 
surprisingly all subsets could express PD-1 including naïve T-cells (Brusa, Serra et al. 2013). 
Nunes et al reported that the emergence of CD8+ PD-1+ T-cells at an early stage were 
associated with a more aggressive clinical disease (Nunes, Wong et al. 2012). Novak et al 
added that relapsed refractory patients had the highest number of CD4+ and CD8+ T-cells 
co-expressing PD-1 (Novak, Prochazka et al. 2015). Rusak et al found a higher frequency of 
CD4+ PD-1+ T-cells in more aggressive disease and suggested that the higher the numbers 
at diagnosis the shorter the time to first treatment (Rusak, Eljaszewicz et al. 2015). An 
apparently contradictory report from Tonino et al found decreased expression of PD-1 on 
effector CD8+ T-cells in CLL compared to normal controls, which was negatively correlated 
with absolute T-cell numbers, (Tonino, van de Berg et al. 2012). This result is in contrast to 
other reports and one explanation for this could be the population under study in this paper 
was the CMV specific CD8+ population, where they showed the largest T-cell effector 
expansion. 
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Riches et al found the “exhausted” CD8+ T-cells to have defective cytotoxicity in vitro related 
to impaired vesicle formation but found these T-cells retained the ability to produce cytokines. 
Unlike T-cells exhausted from viral infections, CLL derived CD8+ “exhausted” T-cells express 
high levels of IFN-γ, TNF-α and T-BET which may help protect the cells from apoptosis 
(Riches, Davies et al. 2013).  
Much work has now been focusing on the effects of rescuing PD-1+ T-cells from exhaustion. 
Gassner et al showed in the TCL-1 mouse model that PD-1 / PD-L1 blockade did aid tumour 
clearance in vivo. (Gassner, Zaborsky et al. 2015). Although this murine model may not reflect 
the situation in human CLL. Brusa et al reported, in primary CLL cells, that blocking the PD-1 
/ PD-L1 axis in vitro, with an anti-PD-L1 antibody, lead to increased CD8+ IFN-γ expression, 
and conversely co-culture with recombinant soluble PD-L1 decreased IFN-γ levels, a concept 
I shall discuss further in this thesis (Brusa, Serra et al. 2013). 
CD40:CD40L 
It is unknown what role CD40:CD40L interactions between CLL and T-cells occur in vivo and 
several groups have reported a defect in CD40L signalling when PB T-cells are cultured with 
CLL in vitro (Cantwell, Hua et al. 1997, Tretter, Schuler et al. 1998, Kneitz, Goller et al. 1999, 
Buggins, Patten et al. 2008). The overall T-cell immune deficiency in CLL has in fact been 
likened to those found in patients that genetically lack CD40L (CD154). Patients with genetic 
defects of CD40L have the phenotype of reduced secondary immunoglobulins and increased 
susceptibility to bacterial infection. They also fascinatingly, just like CLL patients, produce 
auto-antibodies against autoantigens for example those found on red cells and platelets 
(Hamblin, Oscier et al. 1986, Cantwell, Hua et al. 1997). In CLL there is not a lack of CD154 
mRNA; the deficiency has been shown to be secondary to receptor mediated down modulation 
by CD40 expressing CLL cells. This effect can be overcome by adding a CD40 blocker. Ghia 
et al suggested a role for the CD40/CD40L interaction by cross linking CD40 on CLL cells in 
vitro and observing an increase in CCL22 expression, which in turn was a chemoattractant to 
CD4+ CD40L+ CCR4+ T-cells (Ghia, Strola et al. 2002), but in this experiment the CD40 
crosslinking would have preventing the downregulation of T-cells. CD40 crosslinking has also 
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been demonstrated to upregulate anti-apoptotic genes such as survivin (Granziero, Ghia et 
al. 2001).  
Interestingly, when normal T-cells are co-cultured with CLL cells at a ratio of <1:33 (more than 
33 CLL cells per T-cell) then they too cannot upregulate CD40L. (Cantwell, Hua et al. 1997) 
Therefore CLL seems to be a model of acquired CD40L deficiency caused by the CLL cells 
themselves; reducing the ability of the T-cells to effectively activate and therefore helping the 
tumour itself to evade attack. In fact many solid tumours express CD40 and this is a postulated 
mechanism by which tumours regulate their microenvironment by reducing the upregulation 
of the tumour infiltrating lymphocytes. Examples include breast cancer (Hutchins and Steel 
1994), bladder cancer (Ben-Aissa, Paulie et al. 1988) and Kaposi’s sarcoma (Pammer, 
Plettenberg et al. 1996).  
Gene Expression 
Gene expression profiling studies have revealed additional major differences between T-cells 
derived from CLL patients and healthy aged matched controls. Gorgun et al found the majority 
of the differentially expressed genes in the CD4+ compartment to be involved in cell 
differentiation, and in the CD8+ population to be defects in cytoskeleton formation, vesicle 
trafficking and cytotoxicity. Interestingly they additionally noted that similar abnormalities could 
be induced in allogeneic T-cells when co-cultured with CLL cells in vitro. This again implicates 
the CLL cells themselves in dysregulating T-cells; leading to gene expression changes in 
otherwise healthy T-cells and rendering them functionally deficient (Gorgun, Holderried et al. 
2005). Rissiek et al came to the same conclusions; suggesting the CLL cells themselves are 
inducing T-cell dysfunction over time, by studying T-cell phenotypic changes in patients with 
all stages of disease from MBL to advanced CLL (Rissiek, Schulze et al. 2014).   
Defective Immunological Synapse 
Ramsay et al have examined the abnormalities in the physical associations between the T 
and B-cells in CLL. They have shown the formation of a defective “immunological synapse”, 
when CLL cells are incubated with allogeneic or CLL derived T-cells. There is suppressed 
actin polymerisation, and decreased recruitment of LFA-1 (Lymphocyte function associated 
- 73 - 
antigen 1), LCK (lymphocyte specific protein tyrosine kinase) and the TCR to the T-cell 
synapse. They suggest it is this cytoskeletal defect, which ultimately leads to a defective TCR 
signalling and therefore impaired downstream functional T-cell responses. They go on to show 
this defect can be repaired with the use of the immunomodulatory drug, lenalidomide 
(Ramsay, Johnson et al. 2008). The same group undertook functional assays and found that 
PD-L1, CD200, CD270 (Herpes virus entry mediator) and CD276 (B7-H3) could induce a 
similarly impaired immunological synapse formation in allogeneic T-cells (Ramsay, Clear et 
al. 2012) again suggesting the CLL cells themselves play a role in evading immune 
surveillance. 
1.4.6 CLL TCR Repertoire  
The T-cell accumulation in CLL may in part be dependent on TCR engagement but this in 
itself does not give definitive evidence of a specific response to antigen. Analysis of the TCR 
repertoire has provided direct evidence of oligoclonality in CLL. The overall TCR repertoire in 
CLL has marked skewing from normal controls (Forconi and Moss 2015). Wen et al were the 
first to identify the presence of T-cell clones in the PB of 3 out of 5 stage A CLL patients (Wen, 
Mellstedt et al. 1990). The presence of T-cells clones in CLL has since been replicated by 
many groups (Farace, Orlanducci et al. 1994, Serrano, Monteiro et al. 1997, Rezvany, Jeddi-
Tehrani et al. 1999, Goolsby, Kuchnio et al. 2000). Several groups have demonstrated a small, 
but definable population of postulated anti-leukaemic T-cells, these have been the subject of 
interest especially in the possibility of expanding them by vaccination (Rezvany, Jeddi-Tehrani 
et al. 2000, Goddard, Prentice et al. 2001, Gitelson, Hammond et al. 2003). Cytotoxic CD8+ 
T-cells have been reported at low frequency that respond to CLL idiotypic peptide (Trojan, 
Schultze et al. 2000). However CLL derived T-cells dysfunction seems to render them unable 
to mount an effective anti-leukaemic effect and they do not explain the marked repertoire 
skewing in CLL (Christopoulos, Pfeifer et al. 2011).  
Nunes et al have shown that in CLL, and other human cancers, there is abnormal degradation 
of BAX (Bcl-2 associated X protein) protein, and that the derived peptides can be presented 
to CD8+ T-cells on MHC Class I (Nunes, Miners et al. 2011). In vitro studies revealed that 
these antigen specific T-cells are capable of killing primary CLL cells. 
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These are several alternative potential mechanisms for driving a skewed T-cell repertoire in 
CLL. When investigating the overall T-cell repertoire of an elderly CLL patient population it 
must be remembered that there is known to be marked skewing of the TCR repertoire with 
normal ageing and as a response to chronic viral infections (Giannopoulos, Schmitt et al. 
2008). A full understanding of the aberrations in the TCR repertoire in CLL remains to be 
defined, but there is mounting evidence that CLL T-cells, just like the B-cells are antigen 
experienced and subject to chronic stimulation. I shall address this in detail in this thesis. 
1.4.7 Pro-tumour Role of T-cells in CLL 
Taken together, the above studies show that there is a major T-cell dysfunction in CLL which 
permits the tumour to evade the immune system and that the CLL cells themselves are in part 
orchestrating this dysfunction. There is evidence of marked skewing of the TCR repertoire and 
a small but definable number of CD8+ anti-CLL T-cells. However there is also substantial 
evidence that CD4+ T-cells are supportive of CLL in vitro. It is well established that co-culture 
of CLL cells with CD4+ T-cells promotes CLL cell survival (Tretter, Schuler et al. 1998, Patten, 
Devereux et al. 2005).  More compelling evidence that T-cell help is key in the development 
of CLL comes from the murine studies from the Chiorazzi group in New York. They found that 
CLL engraftment in an immunodeficient mouse was entirely dependent on the addition of 
activated autologous CD4+ T-cells; again inferring that T-cells are essential for in vivo 
proliferation of CLL cell (Bagnara, Kaufman et al. 2011).  
Zangani et al also reported a mouse model where B-cell lymphomas developed and were 
maintained by CD4+ T-cells with specificity for B-cell self-antigens. This is a very interesting 
concept. It has been previously shown that idiotypic peptides can be eluted from Class II MHC 
in B-cell lymphomas. The hypothesis is that B-cells constantly present their own 
immunoglobulin as unique variable region idiotypic peptides on class II MHC to idiotype 
specific T-cells to drive lymphomas (Bogen, Malissen et al. 1986). Bogen et al showed that 
the B-cells are chronically helped by these idiotype specific T-cells to develop into lymphomas. 
Therefore these idiotypic peptides from the immunoglobulin itself may represent a chronic 
antigen stimulus to Th cells which, in turn, promotes lymphogenesis (Zangani, Froyland et al. 
2007). This of course should not occur if the T-cells are universally tolerant to self-antigens; 
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but it is known that self T-cells can respond to rarer idiotype peptides from unique N regions 
or somatic mutations (Bogen, Dembic et al. 1993, Eyerman, Zhang et al. 1996). These self-
reactive T-cells are found at low frequency (Snodgrass, Fisher et al. 1992).  
Os et al looked further at the role of self-reactive T-cells in CLL. Firstly they showed that resting 
CLL cells could endocytose, process and present self-antigens on Class II MHC and could 
receive help from specific CD4+ T-cells. Next they generated T-cell lines by stimulating T-cells 
with autologous CLL cells. They found these T-cell lines to have specificity for endogenous 
CLL derived antigens and could support CLL proliferation in vitro and in a mouse model. The 
T-cells had a Th1 phenotype and secreted IFN-γ (Os, Burgler et al. 2013).  
Therefore the CD4+ T-cells in CLL are activated and can respond to antigen presented to 
them by the CLL cells. The actual antigenic stimulus remains unknown and, just like the BCR, 
several candidates have been put forward. Hall et al suggested, like Os et al, that the CD4+ 
T-cells were autoreactive, as shown in autoimmune haemolytic anaemia (Hall, Vickers et al. 
2005). Alternative theories are that the T-cells are responding to exogenous antigen such as 
fungal elements, like has been described in the BCR (Hoogeboom, van Kessel et al. 2013).  
1.4.8 CMV and CLL 
Several groups have investigated the complexity that arises in patients with CLL and co-
existing cytomegalovirus (CMV) seropositivity and hypothesised a role for CMV for the CLL T-
cell aberrations. CMV is a very common virus, which is known to cause marked perturbation 
of the normal T-cell pool of otherwise healthy individuals. In a healthy elderly population CMV 
specific CD8+ T-cells can account for up to half the T-cell repertoire (Khan, Shariff et al. 2002). 
Mackus et al identified the presence of CD8+ T-cell clones reactive against CMV with a 
CD45RA+ CD27- cytotoxic phenotype in previously infected CLL patients (Mackus, Frakking 
et al. 2003). These findings lead to the hypothesis that CMV could be in part responsible for 
the global T-cell expansion and dysfunction in CLL (Akbar 2010). However it has been 
acknowledged that the T-cell abnormalities in CLL are not just restricted to CMV seropositive 
individuals and that there is still a vast T-cell expansion of dysregulated T-cells with abnormal 
phenotype even in CMV seronegative individuals (Nunes, Wong et al. 2012, Riches, Davies 
et al. 2013). It is also observed that CMV reactivation is rare in untreated CLL individuals 
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suggesting an intact T-cell response to the virus. To investigate this in detail, te Raa et al 
designed a series of experiments to assess the function of T-cells from CMV seropositive CLL 
patients (te Raa, Pascutti et al. 2014). Firstly, they confirmed the global T- cell dysfunction of 
the total T-cell pool, as evidenced by finding increased levels of expression of inhibitory 
markers such as PD-1, CD244 and CD160 on CLL CD8+ T-cells. This was associated with 
increased levels of IFN-γ and TNF-α, in concordance with previous studies. They then 
selected CLL CMV specific T-cells using CMV tetramers and found no increase in the 
inhibitory markers and an intact cytokine production. Additionally, in functional assays using 
CMV peptide loaded target cells,  they found CLL derived CD8+ T-cells to be just as effective 
at killing as those derived from age matched normal controls and they formed an effective 
immunological synapse. They concluded there was a preserved CD8+ CMV specific T-cell 
function on a background of global T-cell dysfunction.  
The next question is whether there is any perturbation of CD4+ T-cells as a result of CMV 
seropositivity. 1 et al initially identified a population of CD4+ CD57+ T-cells in CLL patients 
which were mainly CD45RO+ CD28- and expressed perforin; suggesting a possible cytolytic 
function. (Porakishvili, Roschupkina et al. 2001). These CD4+ cells lacked CD69 or HLA-DR. 
They subsequently published evidence that the CD4+ perforin producing T-cells they identified 
appear to be CMV specific effector / memory T-cells (Walton, Lydyard et al. 2010). 
Pourgheysari et al further investigated the CD4+ expansion in CLL patients and found the 
absolute CD4+ T-cell count in CLL was not influenced by CMV serostatus, but found on 
average 11% of the CD4+ T-cell pool was CMV specific in previously infected individuals 
(Pourgheysari, Bruton et al. 2010). They reported, like Porakishvili, that there were more CD4+ 
CD28- T-cells in CMV seropositive compared to seronegative individuals, but these account 
for a small proportion of the total CD4+ pool.  
Taken together, these studies seem to suggest that CMV is not the reason for the global T-
cell dysfunction in CLL; in fact CMV responses may be a remaining intact immunological 
function in the midst of T-cell dysfunction. This could point to the hypothesis that there is a 
specific suppression of only certain subpopulations of T-cells by CLL. It is not clear whether 
there could be other subpopulations of T-cells whose function is unaffected by the CLL clone, 
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as no other viral response is so immuno-dominant and overrepresented in the T-cell 
repertoire. 
1.4.9 Telomeres 
Indirect evidence that the T-cells have a specific active role in CLL comes from studies of 
telomere length. Just like in CLL cells, T-cells from CLL PB have shorter telomeres than 
healthy matched controls, indicating that these T-cells have a replicative history. This suggests 
that the T-cells are proliferating, and not merely bystanders (Roth, de Beer et al. 2008). The 
shortest T-cells telomeres are also correlated with advanced disease.  
1.5 NK Cells 
Quantitative and qualitative abnormalities in natural killer (NK) cells seem to be relevant in 
CLL pathology. A higher NK to CLL B-cell ratio is predictive of longer time to treatment as 
higher numbers were found in early stage disease and mutated cases (Palmer, Hanson et al. 
2008). NK cells derived from CLL patients have long been known to have a lower cytolytic 
capacity than those found in healthy controls (Kay and Zarling 1987), which could be restored 
by the addition of IL-2 in vitro (Kay and Zarling 1987). More recently CLL derived NK cells 
have been shown to have defective actin polymerisation and impaired immunological synapse 
formation (Xing, Ramsay et al. 2010).  
1.6 Lymph Node Microenvironment in CLL 
1.6.1 Introduction 
When PB CLL cells are cultured in vitro they die rapidly by apoptosis, even when cultured in 
media which is usually supportive to human B-cell lines (Collins, Verschuer et al. 1989). This 
is in contrast to the in vivo situation where CLL cells are long-lived. From this it can be inferred 
that the resistance to apoptosis in vivo is not intrinsic to CLL cells, but is dependent on external 
factors (Ghia, Circosta et al. 2005). It has been shown that co-culture of PB CLL cells with 
CD4+ T-cells and other components of the tumour microenvironment increases CLL cell 
survival in vitro (Ghia and Caligaris-Cappio 2005, Patten, Devereux et al. 2005). It is also now 
appreciated that the major site of CLL proliferation is not within the PB but within the secondary 
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lymphoid organs (Ghia and Caligaris-Cappio 2000, Granziero, Ghia et al. 2001). As the 
proliferating component of CLL is essentially within secondary lymphoid tissue, it is reasonable 
to propose that the tumour microenvironment niche here provides a supportive environment 
for the CLL clone where CLL cells are in close communion with other non-malignant cells such 
as T-cells, stromal cells and vascular endothelium. It is here that the CLL cells can send and 
receive signals either via cell to cell contact or by soluble factors with T-cells, dendritic cells 
and stromal cells. 
1.6.2 CLL Cells in the Lymph Node Microenvironment 
Investigators have long been asking the question whether CLL cells within the LN are 
intrinsically different from those of the PB. Several studies have identified differences between 
the CLL cells derived from the PB compared to those from within the microenvironment. 
Proliferation and Anti-apoptosis 
Histological studies of CLL lymph nodes have identified pale staining “proliferation centres” or 
“pseudofollicles”; which some have been likened to malignant germinal centres (Stein, Bonk 
et al. 1980). Proliferation centres contain large prolymphocytes and paraimmunoblasts, 
surrounded by smaller lymphocytes. The number and size of these proliferation centres may 
correlate with aggressive disease, but this has not been a reproducible finding (Bonato, 
Pittaluga et al. 1998, Asplund, McKenna et al. 2002). Within the proliferation centre there is a 
higher concentration of Ki-67 positive proliferating cells.  
CLL cells derived from lymph nodes express higher levels of E2F1 (E2F Transcription Factor 
1), which is a transcription factor that drives cell cycle transition from G1/S. There is also an 
increase expression of c-MYC target genes compared to the peripheral blood, which drive cell 
proliferation (Herishanu, Perez-Galan et al. 2011). Proliferating CLL cells express higher 
levels of survivin (Granziero, Ghia et al. 2001); survivin, or BIRC5, is an inhibitor of apoptosis. 
There is also upregulation of the anti-apoptotic regulators BCL-XL (B-cell lymphoma extra 
large) and MCL-1 (myeloid cell leukaemia 1) in the LN compared to PB (Smit, Hallaert et al. 
2007). 
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Mittal et al simultaneously studied gene expression profiles of CLL cells from LN, BM and PB 
and also found signatures that promote pathways of tumour survival and proliferation within 
the microenvironment (Mittal, Chaturvedi et al. 2014).  There were increased levels of BAFF 
and APRIL (a proliferation inducing ligand) within the LN and evidence of increased NF-kB 
activation (Mittal, Chaturvedi et al. 2014). Levels of BAFF and APRIL are postulated to support 
CLL survival through activation of the NF-kB pathway and patients expressing lower levels 
have a longer survival (Endo, Nishio et al. 2007, Bojarska-Junak, Hus et al. 2009). BAFF has 
3 receptors; TACI (transmembrane activator and calcium modulator and cyclophilin ligand 
interactor), BCMA (B-cell maturation antigen) and BAFF-R (B-cell activating factor receptor) 
all of which are activated in CLL lymph nodes.  
Gilling et al also examined the differing gene signatures in LN and PB compartments and 
chose a few genes for further examination. These included Caveolin-1 (CAV1) which was 
found to be expressed seven fold higher in CLL LNs compared to PB. When they knocked 
down CAV1 in CLL cells, they demonstrated decreased CLL migration and proliferation. In 
CAV1 cell line knockdowns the immunological synapse was also impaired implying CAV1 can 
help the CLL cell escape immune-surveillance (Gilling, Mittal et al. 2012).  
Adhesion Molecules and Chemokine Receptors 
CLL cells from the lymph node also have differential expression of adhesion molecules and 
chemokine receptors (Burger 2010). This is thought to be a mechanism by which CLL cells 
are trafficked into, and remain in lymph nodes; leading to lymphadenopathy in more 
aggressive disease phenotypes.  
CD49d, which enhances cell to cell adhesion via VCAM-1 (vascular cell adhesion molecule 1) 
and fibronectin on stromal cells is expressed at higher levels in lymph nodes (Ghia, Guida et 
al. 2003, Jaksic, Paro et al. 2004). Levels of CD49d on CLL cells of the PB are known to 
correlate with poor prognosis. They also found that CD38, another poor prognostic marker, 
which forms a macromolecular complex with CD49d, is found at higher levels in LN than PB.  
There is also an increase in the lymphocyte homing chemokine CXCL13 on the LN CLL cells 
(Burkle, Niedermeier et al. 2007). CXCR5 is the receptor for CXCL13 (also known as B-
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lymphocyte chemoattractant) and this interaction is another postulated mechanism for 
attracting CLL cells into the LN.  CLL cells directly isolated from the LN also appear to express 
higher levels of CCL3 and CCL4. CCL3 and CCL4 are cytokines involved in inflammation and 
chemoattractant to immune cells (Herishanu, Perez-Galan et al. 2011). This data implies the 
CLL cells are creating their own supportive microenvironment. 
CXCL12 (SDF-1), is a chemokine that is chemoattractant to lymphocytes via its ligand 
CXCR4. CXCR4 has been shown to be expressed at relatively lower levels on proliferating 
LN CLL cells than PB, which is thought to be due to down-modulation as a result of CXCL12 
ligation (Bennett, Rawstron et al. 2007).  CXCR4 levels are also known to be downregulated 
as a result of BCR signalling (Quiroga, Balakrishnan et al. 2009, Vlad, Deglesne et al. 2009).  
In vivo deuterium heavy water labelling studies have now shown a higher uptake in the CLL 
cells with lower levels of CXCR4 and higher CD38 (Calissano, Damle et al. 2009). This model 
suggests chemokine attraction, followed by BCR ligation by antigen drives proliferation within 
the PC of the lymph node.  
BCR Signalling and Antigen Drive 
Herishanu et al performed gene expression studies on CLL cells from 24 untreated patients 
taken simultaneously from blood, bone marrow and lymph nodes. They found that the CLL 
cells within the LN have upregulation of genes associated with BCR signalling and increased 
NF-kB activation. There was also increased SYK phosphorylation, consistent with antigen 
dependant BCR signalling within the lymph node (Herishanu, Perez-Galan et al. 2011). In a 
similar study Mittal et al found in the LN CLL cells there were genetic signatures associated 
with chronic activation of the BCR (Mittal, Chaturvedi et al. 2014). LN CLL cells have also 
been shown to have increased levels of the interferon regulatory factor 4 (IRF-4 or MUM-1), 
which is expressed following somatic hypermutation (Ito, Iida et al. 2002, Soma, Craig et al. 
2006).  
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Clonal Diversity 
Several groups have tried to address the question of whether phenotypically different LN and 
circulating B CLL cells were clonally similar. An early study from Bonato et el, showed there 
was similar light and heavy chain expression between LN sections and PB (Bonato, Pittaluga 
et al. 1998). Isobe et al went further and dissected proliferation centres from lymph node 
sections from 4 patients. They extracted the DNA and showed the clonal diversity was very 
similar in the LN to the PB (Isobe, Tamaru et al. 2001). Vandewoestyne et al raised the 
question that not all CLL cells within the PC are in fact proliferating and therefore used laser 
capture to dissect out proliferation centres and then isolated the specific Ki67+ CD79a+ cells 
to ask the same question.  They compared the IGHV of cells from 7 patients’ lymph nodes 
and compared them to matching PB. They found the overrepresented IGHV clones in the LN 
mirrored the PB providing evidence the proliferating CLL cells in the LN are clonally related to 
the PB compartment (Vandewoestyne, Pede et al. 2011).   
1.6.3 CLL Cells Sustained by the Microenvironment 
Much work has focused on which elements within the LN microenvironment are enabling CLL 
cells to proliferate and offer protection from apoptosis. Studies by our group and others have 
shown proliferating CLL cells are in close contact with CD4+ T-cells (Ghia, Strola et al. 2002, 
Patten, Buggins et al. 2008) and stromal cells (Ruan, Hyjek et al. 2006) within the LN 
microenvironment. The protective advantage given by co-culture of CLL with CD4+ T-cells 
has already been discussed. In addition in vitro culture models have shown that CLL survival 
can be prolonged by co-culture with several of the elements found within the CLL 
microenvironment niche.  
Stromal Cells 
Stromal cells derived from the bone marrow have been consistently shown to support CLL 
survival in vitro (Panayiotidis, Jones et al. 1996, Lagneaux, Delforge et al. 1999, Kay, 
Shanafelt et al. 2007). Bone marrow stromal cells appear to activate CLL cells and are 
themselves activated (Ding, Nowakowski et al. 2009, Lutzny, Kocher et al. 2013). Stromal 
cells interact with CLL cells through receptors for CXCR4 and CXCR5. CLL cells expressing 
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CXCR4 are attracted to migrate beneath cells that express its ligand CXCL12 (such as stromal 
cells) by pseudo-emperipolesis (Burger, Burger et al. 1999). CXCL12 ligation in return induces 
pro-survival signals and downregulates CXCR4 which is associated with the Ki67+ 
proliferative CLL pool found in the PC (Burger, Hartmann et al. 2005). Vaisitti et al found that 
CXCL12 induced migration of CLL cells correlated with higher levels of CD38 (Vaisitti, Aydin 
et al. 2010). These results suggest that CXCL12 secretion within the microenvironment 
promotes the accumulation of CLL cells.  
Bone marrow stromal cells also express Wnt5a which signals though ROR-1. ROR-1 has 
recently described to be expressed by CLL cells, suggesting another mechanism by which 
stromal cells may assist CLL cells survival (Fukuda, Chen et al. 2008). Recently abnormalities 
of the bone marrow derived stromal cells in CLL patients has also been described 
(Pontikoglou, Kastrinaki et al. 2013) 
Vascular Endothelium 
The vascular component of lymph nodes has been reported to be increased in CLL compared 
to normal nodes (Chen, Treweeke et al. 2000). Our group additionally reported that increased 
expression of CD31 (PECAM-1 (platelet endothelial cell adhesion molecule) expressed on 
vascular endothelium) in CLL lymph nodes correlated with CD38 levels and therefore poor 
prognosis (Patten, Buggins et al. 2008). CD31 is the only known ligand of CD38 and it has 
been shown that ligation of CD38 with CD31 decreases CLL apoptosis in vitro (Deaglio, Aydin 
et al. 2010, Poggi, Prevosto et al. 2010). These results suggest that CLL cases with poor 
prognosis, as evidenced by high levels of CD38, are more vascular and provide a more 
supportive environment to CLL cells. Our group has also directly shown that co-culture of CLL 
cells and endothelial cells promotes CLL cell survival in vitro (Buggins, Pepper et al. 2010).  
Follicular Dendritic Cells 
There has been some controversy regarding the presence of FDCs within involved CLL lymph 
nodes, with some studies reporting their occasional presence and others concluding they are 
absent (Stein, Gerdes et al. 1982, Swerdlow, Murray et al. 1984, Chilosi, Pizzolo et al. 1985, 
Greil, Gattringer et al. 1986, Ratech, Sheibani et al. 1988). However, co-culture of CLL cells 
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with immortalised FDCs prolongs CLL survival through CD44 ligation and upregulation of the 
anti-apoptotic protein MCL-1. (Pedersen, Kitada et al. 2002). CD44 is a receptor for hyaluronic 
acid that interacts with CD38, CD49d, MMP-9 and ZAP-70 (Zhang, Wu et al. 2013) . It is now 
known that CD44 forms a macromolecular complex with CD38 CD49d and MMP9 which may 
influence CLL cell  migration, invasion and homing (Buggins, Levi et al. 2011). 
Nurse-Like Cells 
In an in vitro system devised by Burger et al, CLL PB cells were co-cultured for 7-14 days with 
CD14+ monocytes and they observed monocyte differentiation into large so called “Nurse-like 
cells” (NLCs). These cells are reported to protect CLL cells from apoptosis (Burger, Tsukada 
et al. 2000). NLCs, similarly to stromal cells derived from the BM, appear to interact with CLL 
cells through secretion of CXCL12. Co-culture of CLL cells with NLCs increases the CLL 
expression of CCL3 and CCL4 which consequently attracts supportive cells such as regulatory 
T-cells (Burger, Quiroga et al. 2009). These NLCs express also high levels of BAFF and APRIL 
(Nishio, Endo et al. 2005). The presence, or not, of these cells in vivo is controversial. 
Cytokines 
Other mechanisms by which CLL cells can be sustained in vitro include co-incubation with a 
vast array of cytokines, some of which may be produced by cells of the microenvironment. 
These include IL-4 (Panayiotidis, Ganeshaguru et al. 1993), IL-6 (Reittie, Yong et al. 1996), 
IL-8 (Francia di Celle, Mariani et al. 1996), IL-10 (Jurlander, Lai et al. 1997), IL-13 (Chaouchi, 
Wallon et al. 1996), IFN-α (Chaouchi, Wallon et al. 1994), IFN-γ (Buschle, Campana et al. 
1993), VEGF (Pepper, Ward et al. 2007) and CXCL12 (O'Hayre, Salanga et al. 2010). 
Interestingly all of these cytokines have also been shown to be intrinsically produced by CLL 
cells.  
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1.6.4 T-Cells Derived from the CLL Microenvironment 
There has been extensive research into T-cells found in the PB of CLL patients, however very 
little research has focused on the T-cells from other compartments which may be distinct.  
T-cells in CLL Bone Marrow 
Immunohistochemistry studies in the 1980’s of found the number of T-cells in the CLL bone 
marrow to be increased compared to normal controls, and that the T-cells were primarily of 
the Th-cell phenotype (Pizzolo, Chilosi et al. 1983). Bojarska-Junak looked specifically at the 
levels of TNF in the PB and BM of CLL patients and found higher levels from the BM 
compartment than the PB, and levels correlated with poor prognostic factors (Bojarska-Junak, 
Hus et al. 2008).  
T-cells in CLL Lymph Nodes 
Swerdlow et al published a series of 9 CLL lymph node biopsies and showed the T-cell 
component to be up to 15% of the total cell numbers with a preponderance of Th T-cells 
(Swerdlow, Murray et al. 1984). Another small series have reported up to 35% of lymphocytes 
being T-cells within CLL lymph nodes, with predominately a Th phenotype (Schmid and 
Isaacson 1994, Bonato, Pittaluga et al. 1998, Granziero, Ghia et al. 2001). Ghia et al 
suggested between 5-30% of these CD4+ T-cells expressed CD40L, but this has not been 
consistently reproduced (Ghia, Strola et al. 2002). Our group have previously published, using 
multiparameter immunofluorescence microscopy, that within the CLL lymph node 
microenvironment, proliferating CLL cells are in cellular contact with CD4+ Foxp3- T-cells 
(Patten, Buggins et al. 2008). These T-cells were CD25+ suggesting an activated phenotype. 
Lad et al have very recently reported that the number of Tregs in the LN microenvironment is 
higher than in the PB , data confirmed by this thesis (Lad, Varma et al. 2015). Conversely they 
found fewer Th17 cells. Their hypothesis is that IL-10 excreting Tregs supress the Th17 cells 
in this compartment allowing CLL to escape immune surveillance. Brusa et al have also 
recently published a study of CLL lymph nodes and find the presence of CD4+ PD-1+ T-cells 
in contact with PD-L1+ CLL cells, data I shall discuss further in this thesis (Brusa, Serra et al. 
2013). 
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1.7 Aim of Thesis 
The aim of this thesis is to further characterise the T-cell component of the CLL lymph node 
microenvironment. Although much is known of the PB T-cells in CLL the specific phenotype 
of the lymph node infiltrating T-cells has not been fully elucidated. Taken together there is 
strong evidence that T-cells in CLL, just like the B-cell, have been activated and show features 
of post antigen exposure. The role of T-cells in CLL is clearly complex, with apparently 
opposing roles; with CD4+ T-cells supporting the tumour whilst CD8+ T-cells are trying to 
eliminate the tumour but are hampered by their dysfunction. The CLL cells themselves seem 
to play a critical role in maintaining the T-cell help and dysfunction simultaneously. Our 
hypothesis is that the critical interaction between T-cells and CLL are taking place within the 
supportive LN microenvironment. Therefore the investigation of the specific T-cells found 
within the lymph node microenvironment forms the basis of this research.  
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Chapter 2 General Materials and Methods 
2.1 Ethics 
Peripheral blood (PB) was collected from patients under national research ethics NREC: 
08/H0906/94 and from healthy controls under LREC: 02-044. Ethical approval was obtained 
to perform lymph node fine needle aspirations (LN FNA) on CLL patients for research 
purposes from the research ethics committee REC: 09/H0805/5. Written informed consent 
was gained according to the Declaration of Helsinki, 2008. Ethical approval for was obtained 
for use of surplus anonymous lymph node (LN) biopsy samples for research from the national 
research ethics service (NRES 08/H0906/94) and local research ethics committee (LREC 02-
044).  
2.2 Primary Patient Material 
2.2.1 Peripheral Blood Sample Collection 
Patients with a diagnosis of CLL and healthy controls were invited to take part in the study. 
They were given a patient information sheet and given adequate time to consider their entry 
into the study. Written consent was obtained and samples pseudo-anonymised. Up to 40mls 
PB was collected from CLL patients and healthy controls directly into CLL media (See 2.4.5) 
and EDTA.   
2.2.2 Isolating PB Mononuclear Cells (PBMCs) 
CLL PBMCs were isolated from PB using Ficoll Histopaque® (Sigma Aldrich) density 
centrifugation. 10mls anticoagulated whole blood in CLL media was layered onto 10mls of 
Histopaque in a 50ml FalconTM tube (Fisher Scientific) and centrifuged at 400g for 25 minutes 
at room temperature (RT). The opaque layer at the interface was carefully pipetted into a fresh 
tube. Cells were washed in PBS and centrifuged 250g for 15 minutes. The cell pellet was 
resuspended in CLL media. Manual cell counting was performed using a counting chamber 
(Hawksley), with trypan blue solution as a viability stain. 
2.2.3 Cryopreservation of Cells 
CLL PBMCs were centrifuged at 200g for 5 minutes and resuspended in a 50% solution (v/v) 
with RPMI-1640, 40% FCS, 10% DMSO. The cells were aliquoted into 1ml cryovials (Nalgene) 
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at a concentration of CLL cells 1x107-108/ml and frozen overnight in a Mr. Frosty™ Freezing 
Container (Nalgene) at -80°C; which optimally cools by -1°C per minute. The cryovials were 
then transferred to liquid nitrogen storage tanks within the King’s College London (KCL) 
haemato-oncology tissue bank under the license of the Human Tissue Authority (HTA) 
(licence 12223, awarded 1st September 2006, unconditional status)  
2.2.4 Defrosting Cells 
Frozen cryovials were thawed in water bath at 37°C. The cells were added to 10mls of pre-
warmed CLL media and pelleted by centrifugation at 200g for 5 minutes, before washing and 
resuspending in CLL media at desired concentration.  
2.2.5 Negative B-cell Isolation 
The EasySep® negative selection human B-cell enrichment kit without CD43 depletion 
(StemCell Technologies) was used to isolate CLL B-cells. The magnetic dextran bioparticles 
form tetrameric antibody complexes with an anti-dextran antibody and antibodies against CD2, 
CD3, CD14, CD16, CD56 and glycophorin A on the cells to be removed. This leaves behind 
the B-cells of interest. CLL PBMCs were resuspended in CLL media at a concentration of 5 x 
107/ml in a 5ml tube. 50µl of EasySep® negative selection human B-cell enrichment cocktail 
was added per ml. The mix was incubated for 10 minutes at RT. The EasySep® nanoparticles 
were mixed by pipetting up and down (not vortexed). 50µl of nanoparticles were added per ml 
of cells and well mixed. The mix was incubated for 10 minutes at RT. The total volume of cells 
was made up to 2.5mls with PBS and 2% FCS (magnesium and calcium free). The tube was 
then inserted into the proprietary magnet for 5 minutes. The negatively selected cells that had 
not bound to the nanoparticles and been removed by the magnet were then harvested from 
the tube by inversion.  
2.2.6 LN FNA Sample Collection 
Patients with a diagnosis of CLL and an easily palpable lymph node were invited to take part 
in the study. They were given a patient information sheet and given adequate time to consider 
their entry into the study. Written consent was obtained and samples pseudo-anonymised. 
The LN FNA was performed by a trained clinician using a 23 gauge needle attached to 10ml 
syringe. Once the sample was aspirated the needle was washed in CLL media. This was 
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repeated on average 4 times per patient. The LN FNA was sample centrifuged at 200g for 5 
minutes and resuspended in CLL media to a final volume depending on the cell count. Manual 
cell counting was performed using a counting chamber (Hawksley), with trypan blue solution 
(Fluka Analytical) as a viability stain.  
2.2.7 Lymph Node Sections 
Lymph node excision biopsies were performed on CLL patients as part of their routine clinical 
care. These samples were anonymised before release. FFPE blocks were cut into 3 micron 
sections and mounted onto glass microscope slides by the Department of Histopathology, 
King’s College Hospital NHS Foundation Trust (KCHFT). 
2.3 Reagents 
2.3.1 General Chemicals, Consumables and Kits 
A list of consumables and manufacturers is provided in Table 2-1. 
Table 2-1 General chemicals, consumables and kits 
Consumable Manufacturer 
0.1M Dithiothreitol (DTT) Invitrogen 
0.5% Triton Sigma 
10nM dNTP Mix Invitrogen 
10X AccuPrime™ PCR Buffer I (600mM Tris-
SO4 (pH 8.9), 180mM (NH4)2SO4, 20mM 
MgSO4, 2mM dGTP, 2mM dATP, 2mM dTTP, 
2mm dCCT, thermostable AccuPrime™ protein 
and 10% glycerol), 
Invitrogen 
5% Donkey Serum Stratech 
5X DNA Loading Buffer Blue (bromophenol blue) Bioline 
5X VILO™ Reaction Mix (random primers, MgCl2 
and dNTPs in a proprietary buffer formulation), 
10X SuperScript® enzyme mix 
Invitrogen 
7-Amino-Actinomycin (7-AAD) BD Biosciences 
- 89 - 
AccuPrime™ Taq DNA Polymerase High Fidelity Invitrogen 
AccuPrime™ Taq DNA Polymerase High Fidelity Invitrogen 
Agarose  Bioline 
Annexin V – FITC BD Biosciences 
Annexin V Binding Buffer BD Biosciences 
BD Cytofix/CytopermTM BD Biosciences 
BD GolgiPlugTM BD Biosciences 
BD Perm/Wash BufferTM BD Biosciences 
BD™ CompBeads Anti-Mouse Igk BD Biosciences 
BD™ CompBeads Negative Control BD Biosciences 
Boric Acid Sigma 
Buffer PE (10mM TrisCl, pH 8.5) Qiagen 
Buffer QG (5.5 M guanidine thiocyanate; 20 mM 
Tris HCl pH 6.6.) 
Qiagen 
cDNA Buffer (250mM Tris acetate (ph 8.4), 
375mM potassium acetate, 40mM magnesium 
acetate and stabilizer), 
Invitrogen 
cDNA Synthesis mix Invitrogen 
DAPI Sigma 
DEPC Treated Water Invitrogen 
Dimethyl Sulphoxide (DMSO)  Sigma 
Dulbecco’s Modified Eagle Medium Sigma 
Dynabeads® Human T-Activator CD3/CD28 Thermo Fisher Scientific 
EasyLadder I Bioline 
Ethanol Fisher Scientific 
Ethidium Bromide Invitrogen 
Fixable Viability Dye eFluor® 780  eBioscience  
Foetal Calf Serum (FCS) Sigma 
Formamide Promega 
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Foxp3 Fixation/Permeabilisation Working 
Solution  
eBioscience 
Heparin Leo Laboratories 
Histopaque 1077 Sigma Aldrich 
HyperLadder I Bioline 
HyperLadder V  Bioline 
ILS-600 (Internal Lane Standard 600) Promega 
L-Glutamine Sigma 
MgSO4 (50mM) Invitrogen 
MinElute Gel Extraction Kit Qiagen 
PEG 8000 Sigma 
Penicillin Sigma 
Permeabilisation Buffer eBioscience 
Phase Lock Gel Heavy 5 Prime  
Phosphate Buffered Saline (PBS) Sigma 
ProLong® Gold Antifade Reagent  Invitrogen 
Random Hexamers (50ng/µl) Invitrogen 
Red Cell Lysis Buffer  eBioscience 
RNase H Invitrogen 
RNaseOUT™ Invitrogen 
RNeasy® Mini Kit Qiagen 
RPE Buffer Qiagen 
RPMI 1640 Gibco 




SuperScript® VILO™ cDNA Synthesis Kit Invitrogen 
ThermoScript™  Invitrogen 
Tris Base Sigma 
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Trisodium Citrate Sigma 
TRIzol Invitrogen 
Trypan Blue Fluka Analytical 
Tween-20 Sigma 
Xylene  Fisher Scientific 
 
2.4 Media / Buffers / Solutions 
2.4.1 Phosphate Buffered Saline (PBS) 
1 PBS tablet (Sigma) (phosphate buffer, 0.02% (w/v) potassium chloride, 0.8% (w/v) sodium 
chloride) was dissolved per 200ml of deionised H2O. PBS was autoclaved prior to storage. 
2.4.2 TBE 
For 1 litre of 5X stock solution. 54g of Tris base (Sigma), 27.5g of boric acid (Sigma) and 
20mls of 0.5M EDTA (pH 8.0) was made up to 1 litre with H2O.  
2.4.3 Citrate Buffer  
0.001M citrate buffer was made with 2.94g of trisodium citrate (Sigma) dissolved in 150µl HCL 
(Fisher Scientific), 1 litre of distilled H2O and 0.5ml Tween 20 (Sigma) to pH 6.1.   
2.4.4 Paraformaldehyde Fixation Buffer (4%) 
0.375g paraformaldehyde (Sigma) was dissolved in 1ml distilled water with 10µl 10M KOH in 
a boiling water bath and diluted in 4mls distilled water and 5mls x2 PHEMS buffer. 
2.4.5 CLL Media 
1 litre RPMI 1640 + L-glutamine (Sigma) + 100 IU heparin (Leo Laboratories) + 5% FCS 
(Sigma) 
2.4.6 Jurkat Culture Media 
1 litre RPMI 1640 + 10% FCS + 100µg/ml penicillin + 100µg/ml streptomycin.  
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2.5 Cell Culture 
2.5.1 CLL PBMC Culture 
Frozen cryovials were thawed as in 2.2.4. PBMCs were resuspended at a density of 2x106 
cells/ml in CLL media. Cells were incubated in a 5% CO2 37°C humidified incubator.  
For T-cell stimulation experiments cells were cultured in 24 well plates at 1x106 cells per well, 
resuspended in 500µl of CLL media. 
2.5.2 Jurkat Cell Culture 
Frozen cryovials were thawed as in 2.2.4. Cells were resuspended in Jurkat media at 1 x 
105/ml. 5mls was transferred to a 25ml tissue culture flask (Sigma). Cells were cultured at 5% 
CO2 at 37°C in a humidified incubator. The cell culture was split in fresh media every 2 days 
or when cells >1 x106/ml. 
 
2.6 Antibodies 
2.6.1 Flow Cytometry Antibodies 
The flow cytometry antibodies and their dilutions are detailed in Table 2-2.  
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Table 2-2 Flow cytometry antibodies 
Antigen Clone Conjugation Volume Company 
CD3 SP34-2 APC-Cy7® 2.5µl BD Biosciences 
CD3 UCHT1 APC-Alexa Fluor® 750 10µl eBioscience 
CD3 UCHT1 V500  5µl BD Biosciences  
CD4 RPA-T4 PE 10µl AbD Serotec 
CD4 RPA-T4 PerCp-Cy5.5 2.5µl eBioscience 
CD5 UCHT2 Pe-Cy7 10µl BioLegend 
CD5 MF7-14.5 APC  5µl AbD Serotec 
CD8 SK1 PE 10µl BD Biosciences 
CD8 OKT8 Pacific Blue™ 10µl eBioscience 
CD8 OKT8 eFluor® 450 2.5µl eBioscience 
CD19 SJ25-C1 Pacific Blue™ 2.5µl Invitrogen 
CD19 HIB19 eFluor® 450 2.5µl eBioscience 
CD25 BC96 PE 2.5µl eBioscience 
CD25  MEM-181 FITC 5µl AbD Serotec 
CD28 CD28.2 APC 10µl eBioscience 
CD38 HB7 PE 2.5µl eBioscience 
CD45RA H100 Biotin 1µl eBioscience 
CD49d 44H6 FITC 5µl AbD Serotec 
CD49d 44H6 Biotin 5µl AbD Serotec 
CD62L DREG-56 APC-Alexa Fluor® 750 10µl eBioscience 
CD68 eBioY1/82A Biotin 1µl eBioscience 
CD69 FN50 PE 10µl BioLegend 
CD80 2D10 FITC 10µl BioLegend 
CD80 2D10 PE 10µl BioLegend 
CD86 IT2.2 APC 10µl BioLegend 
CD86 IT2.2 PE 10µl BioLegend 
CD127 (IL-7Ra) eBioRDR5 FITC 2.5µl eBioscience 
CD152 (CTLA-4) 14D3 Biotin 1µl eBioscience 
CD154 (CD40L) 24-31 PE 10µl eBioscience 
CD185 (CXCR5) 51505 Biotin 5µl R&D Systems 
CD197 (CCR7) 3D12 PE 10µl eBioscience 
CD273 (PD-L2) MIH18 PE 10µl BD Biosciences 
CD274 (PD-L1) MIH1 FITC 10µl BD Biosciences 
CD279 (PD-1) MIH4 Alexa Fluor® 647 5µl AbD Serotec 
Foxp3 PCH101 APC 2.5µl eBioscience 
Streptavidin N/A FITC 2.5µl eBioscience 
Streptavidin N/A PE-Cy7 1µl eBioscience 
 
- 94 - 
2.6.2 Indirect Immunofluorescence Antibodies 
Primary antibodies for immunofluorescence microscopy are shown in Table 2-3. Secondary 
fluorescently conjugated antibodies for immunofluorescence microscopy in Table 2-4. 
Table 2-3 Primary antibodies for immunofluorescence microscopy 
Antigen Species Clone Dilution Manufacturer 
CD3 Rabbit Polyclonal IgG 1 in 40 Abcam 
CD4 Mouse IgG1: 4B12 1 in 10 Novocastra 
CD4 Rabbit Polyclonal IgG 1 in 40 Abcam 
CD5 Mouse Monoclonal IgG 1 in 40 Abcam 
CD8 Mouse  IgG3: FK18 1 in 30 Thermoscientific 
CD23 Goat  Polyclonal IgG 1 in 30 R&D Systems 
CD38 Mouse IgG1 1 in 100 AbD Serotec 
CD49d Rabbit Polyclonal IgG 1 in 40 AbD Serotec 
CD79a Goat Polyclonal IgG 1 in 40 Santa Cruz 
Ki67 Mouse IgG1: MM1 1 in 100 Novocastra 
Ki67 Rabbit Polyclonal IgG 1 in 100 Abcam 
PD-1 Goat Polyclonal IgG 1 in 30 R&D Systems 
CXCR5 Rat IgG2: RF8B2 1 in 40 BD Biosciences 
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Table 2-4 Secondary fluorescently conjugated antibodies for immunofluorescence microscopy 
Target Species Conjugate Dilution Manufacturer 
Goat IgG (H+L) Donkey Cy™5 1 in 100 Jackson ImmunoResearch 
Goat IgG (H+L) Donkey FITC 1 in 100 Jackson ImmunoResearch 
Mouse IgG (H+L) Donkey Cy™3 1 in 100 Jackson ImmunoResearch 
Mouse IgG (H+L) Donkey DyLight™ 488 1 in 100 Jackson ImmunoResearch 
Mouse IgG (H+L) Donkey Alexa Fluor® 555 1in 100 Invitrogen  
Rabbit IgG (H+L) Donkey FITC 1 in 50 Jackson ImmunoResearch 
Rabbit IgG (H+L) Donkey Cy™3 1 in 100 Jackson ImmunoResearch 
Rabbit IgG (H+L) Donkey Cy™5 1 in 100 Jackson ImmunoResearch 
Rat IgG (H+L) Donkey FITC 1 in 50 Jackson ImmunoResearch 
Rat IgG (H+L) Donkey DyLight™ 549 1 in 100 Jackson ImmunoResearch 
Rat IgG (H+L) Donkey AMCA 1 in 100 Jackson ImmunoResearch 
 
2.7 Flow Cytometry 
2.7.1 Staining Cell Surface Antigens for Flow Cytometry 
100µl LN FNA, whole PB or PBMCs were aliquoted into the required 12x75mm round bottom 
test tubes (BD Falcon, BD Biosciences). Directly conjugated +/- biotinylated antibodies were 
added at appropriate titrated volume as outlined in Table 2-2. Cells were incubated with the 
required antibodies for 20-30 minutes at 4°C in the dark. Following this 2mls of ammonium 
chloride 1X red cell lysis buffer (eBioscience) was added to appropriate tubes and the sample 
incubated at 4°C for 30 minutes in the dark. Cells were then centrifuged at 200g for 5 minutes 
at 4°C and washed twice in PBS. If all samples used directly conjugated antibodies, the cells 
were resuspended in PBS for analysis on BD FACSCanto II. For biotinylated antibodies the 
appropriate streptavidin-conjugate was added and incubated for a further 10-20 minutes at 
4°C in the dark. The cells were then pelleted at 200g for 5 minutes at 4°C and then washed 
twice in PBS prior to resuspension for analysis. 
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2.7.2 Foxp3 Intracellular Cell Staining Protocol 
Cells were stained for surface antigens according to the staining cell surface antigens protocol 
above. Following the last wash 1ml of 1X Foxp3 Fixation/Permeabilisation working solution 
(eBioscience) was added to appropriate tubes and the sample incubated at 4C for 30 minutes 
in the dark. The 1X permeabilisation buffer (eBioscience) was added to each tube.  Tubes 
were centrifuged at 200g for 5 minutes at room temperature (RT). The cell pellet was 
resuspended in 100µl 1X permeabilisation buffer and the directly conjugated antibody added 
at appropriate volume. The tube was again incubated in the dark at RT for 30 minutes. The 
cells were then washed and pelleted twice in 1X Permeabilisation buffer and centrifuged at 
200g for 5 minutes at RT. The final cell pellet was resuspended in PBS for analysis on the BD 
FACSCanto II. 
2.7.3 Intracellular Cytokine Staining Protocol 
Cells were washed twice and resuspended in PBS. 1µl fixable viability dye was added and 
cells were incubated for 10 minutes at RT.  Cells were washed twice and then stained for cell 
surface antigens as described. Following the last wash cells were resuspended in 250µl BD 
Cytofix/CytopermTM fixation buffer (BD Biosciences) for 20 mins at 4C. 1ml BD Perm/Wash 
buffer (x10 perm wash diluted in distilled water) was added and left for 15 min in the dark. 
Cells were then washed and resuspended in 50µl Perm/Wash buffer. Intracellular antibodies 
were added at the appropriate volume and incubated for 20 minutes at RT in the dark. Then 
cells were washed twice in 1ml BD Perm/Wash and resuspended for flow cytometry.  
2.7.4 Flow Cytometry Viability Assay 
Cell viability was assessed by flow cytometry using Annexin V, conjugated to FITC and 7-AAD 
(BD Biosciences). Annexin V binds to phosphatidyl serine which moves from the intracellular 
to extracellular leaflet early in apoptosis. 7-AAD is a DNA dye and therefore binds when the 
cytoplasm is compromised later in apoptosis. 100µl of Annexin V binding buffer was added to 
the cells of interest with 2.5µl Annexin V +/- 1µl 7-AAD.  Samples were incubated for 15 
minutes in the dark. 400µl Annexin V binding buffer is then added prior to analysis by flow 
cytometry.  
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For the intracellular cytokine staining panels a viability dye was used to ensure the integrity of 
the cells under investigation. Fixable viability dye eFluor® 780 (eBioscience) is a viability dye 
that irreversibly labels dead cells. Unlike 7-AAD, cells can then go on to be washed, fixed, 
permeabilised, and stained for intracellular antigens. 
2.7.5 Compensation Matrix 
Either cells or compensation beads were used to create the compensation matrix. The staining 
protocol was as follows. The beads were vortexed and 60µl of positive and 60µl of negative 
beads added to each tube. The required volume of antibody was added and the tube incubated 
at RT for 30 minutes in the dark. The beads were washed in PBS and then centrifuged at 200g 
for 10 minutes twice. The singly stained beads were then resuspended in PBS and analysed 
on the BD FACSCanto II to create a compensation matrix.  
2.7.6 BD FACSCanto II (BD Biosciences) 
The BD FACSCanto II configuration 4-2-2 has 3 lasers allowing 8 colour flow cytometry. The 
cytometer is set up as shown in Table 2-5. BD Cytometer Set up and Tracking beads (BD 
Biosciences) were used to validate the cytometers performance. The beads contain equal 
concentrations of dim, mid-range and bright fluorescent intensities and are used to determine 
baseline PMT gains and allow performance quality control.     
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Table 2-5 FACSCanto II configuration 
Lasers Violet 405nm solid state diode, 30mW fibre power 
output 
Argon (Blue) 488nm solid state, 20mW laser output 
Red 633-nm HeNe, 17Mw laser output 
Fluorescence 
Detectors 
8 PMTs in 4-2-2 configuration 
















Detector Bands Violet 450/50; 502-525nm 
Blue 530/30; 585/42; >670; 780/60nm 
Red 660/20; 780/60 nm 
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2.7.7 Flow Cytometry Data and Statistical Analysis 
Samples were collected and analysed using FACSDiva software (BD Biosciences) and 
FlowJo (TreeStar). Percentage positivity and/or mean fluorescence intensity (MFI) values 
were obtained as appropriate. Statistical analysis was performed using GraphPad Prism® 
(Graph Pad Inc.). For comparisons to be made between paired samples, first a D’Agostino 
and Pearson omnibus normality test was performed on the whole sample group and then 
paired t-tests for those that passed and a Wilcoxon matched pairs test for those that did not. 
A p-value of <0.05 was considered statistically significant. For unpaired comparisons an un-
paired t-test was used and again a p-value of <0.05 was considered statistically significant. 
Results are expressed +/- standard error of the mean. 
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Chapter 3 Characterisation of the T-cell Component of the CLL 
Tumour Microenvironment by Immunophenotyping 
3.1 Introduction 
It is well described that in CLL the malignant B-cell proliferation occurs primarily within the 
secondary lymphoid tissues, and not in the PB (Ghia and Caligaris-Cappio 2000, Granziero, 
Ghia et al. 2001). It is here where the CLL cells are in close contact with T-cells and other 
elements of the supportive microenvironment (Ghia and Caligaris-Cappio 2005, Patten, 
Buggins et al. 2008) . As outlined in the introductory chapter, PB CLL cells die rapidly when 
cultured alone in vitro, but they can be rescued from apoptosis when co-cultured with cells or 
cytokines found from within the microenvironmental niche (Collins, Verschuer et al. 1989, 
Ghia, Circosta et al. 2005).  Studies of the T-cell component in CLL have been performed 
almost exclusively on T-cells derived from the PB and not the actual T-cells that are in close 
contact with the proliferating cells. It is well described that T-cells from CLL PB show numerous 
quantitative and qualitative abnormalities with many phenotypic and functional perturbations 
from T-cells form age matched normals. These have been reviewed in detail in the introductory 
chapter. Such studies have many, potentially major, limitations and one specific question that 
has never been answered is: are the CLL PB T-cells the same population of T-cells that are 
found within the lymph node? It could be speculated T-cells within the lymph node are the CLL 
specific population, and may be quite different from the PB, or that only a proportion of these 
T-cells are present in the PB. The aim of this chapter is to phenotype the T-cell component of 
the lymph node microenvironment and to compare them to the PB T-cells of the same patient 
taken at the same time using multi-parameter flow cytometry. This will ascertain whether the 
T-cell populations from these two compartments are phenotypically similar or have a different 
profile. 
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3.1.1 Experimental Approach 
The first hurdle is to obtain T-cells from the lymph node. The limited work that has been 
performed to date on this compartment is mainly on surgical lymph node biopsy specimens 
and this has some specific limitations (Swerdlow, Murray et al. 1984, Schmid and Isaacson 
1994, Patten, Buggins et al. 2008). The patients who undergo lymph node biopsies in CLL are 
by definition a select group. CLL can usually be diagnosed from the PB and this obviates the 
need for removing lymph node tissue to make a diagnosis. Routinely a lymph node biopsy 
adds little or nothing that would influence the treatment pathway for an individual patient and 
therefore is rarely performed. When lymph node biopsies are performed for diagnostic 
purposes there are usually in specific and unusual circumstances; such when there is 
lymphadenopathy which is “out of proportion” compared to the PB picture or when there is a 
solitary large node and a high grade transformation needs to be excluded. Almost exclusively 
these highly selected patients are of an advanced stage disease and usual require immediate 
therapy, therefore it can be seen that this group do not reflect the heterogeneity of the CLL 
population as a whole. In order to address this issue a study could be undertaken where lymph 
nodes are surgically resected, for research purposes, on an unselected group of CLL patients. 
The LN in this scenario would have to be disaggregated to allow multiparameter flow 
cytometry; this process in itself may change the phenotype of the cells of interest. Indeed the 
most significant limitations remain as the potential ethical and financial barriers of a patient 
undergoing a surgical procedure solely for research purposes. We therefore decided not to 
pursue this approach. An alternative and much less invasive method of obtaining cells from a 
lymph node uses the technique of lymph node fine needle aspiration (LN FNA). This 
overcomes the problem of patient selection as any CLL patient with an enlarged LN could 
undergo the procedure. The cells would be fresh, unfixed and potentially could be cell sorted 
by flow cytometry. The advantages and disadvantages of the source material are outlined in 
Table 3-1. 
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Table 3-1 Lymph node source material 
T-cell source Advantages Disadvantages 
Fresh Lymph Node 
(Disaggregated) 
Unfixed tissue 
Large cell numbers 
Ability to sort T-cells  
Matched PB 
Very low availability 
Highly selected population 
No normal controls 
Sample processing required 
FNA Lymph Node Better Availability  
Unfixed tissue 
Unselected population 
Ability to sort T-cells 
Matched PB 
Small cell numbers 
Difficult to extract RNA 
No normal controls 
 
Initially we embarked on a study to assess the feasibility of performing LN FNA to access and 
investigate the T-cell component of the lymph node microenvironment. This is a novel 
approach to obtaining cells from the tumour microenvironment in CLL, which to our knowledge 
has not been previously reported in the literature. We first undertook a pilot study of settling 
small numbers of cells onto poly-L-lysine coated slides and then analysing cell types by 
immunofluorescence microscopy and whilst this was feasible, as will be outlined in chapter 4, 
the method was considered superfluous when it became evident that sufficient cells would be 
available to use the more powerful technique of flow cytometry. Another method we 
considered was to perform a LN FNA cytospin and to then embed the sample in paraffin for 
sectioning and analysis however this had no advantage over flow cytometry and was not 
pursued. 
3.1.2 Principles of Multiparameter Flow Cytometry 
Flow cytometry allows the identification of cells according to their light scatter and by the 
surface labelling of known antigens on the cell surface with specific antibodies conjugated to 
a known fluorochrome (Hulett, Bonner et al. 1973). The fundamental principles of the process 
can be broken down into fluidics, optics, detection and signal processing. The fluidics system 
takes up the sample into a central channel, which is surrounded by an outer sheath containing 
fluid moving at a much faster velocity. The velocity differentials allow cells to move though the 
chamber in single file, this is called hydrodynamic focusing. Each cell is then interrogated by 
a beam of light or a laser. Light that is scattered forward (forward scatter channel; FSC) gives 
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information about the cells size. Light scattered sideways (side scatter channel; SSC) gives 
information regarding the cells granularity. When a cell is labelled with a fluorochrome the light 
properties of that specific fluorochrome can be exploited. The fluorochrome is excited by a 
known specific wavelength and then emits light predictably at another known longer 
wavelength; the excitation and emission spectra. A flow cytometer can be installed with one 
or several lasers that emit at a known wavelength, to excite a wide variety of fluorochromes in 
a predictable way. The flow cytometer then detects the signals with a photomultiplier tube 
(PMT). The detection specificity is controlled by optical filters/dichroic mirror; this allows 
specified wavelengths of light to pass through to the sample and then another back to the 
detector. When the emitted light hits a photodetector a small current is generated, with a 
voltage proportional to the number of photons received by the detector. This can then be 
graphically represented as a histogram. Detailed post acquisition analysis can then be 
performed using proprietary software, such FACSDiva (BD Biosciences) or FlowJo (TreeStar). 
3.1.2.1 Flow Cytometry Compensation 
Appropriate selection of fluorochrome combinations is critical in the design of multiparameter 
flow cytometry panels (Mahnke and Roederer 2007). The most crucial element to take into 
consideration when performing multi-colour fluorescence immunophenotyping is spectral 
overlap (Kalina, Flores-Montero et al. 2012). When a fluorochrome is excited the emission 
spectra may be detected not only in the primary channel but also by the other detectors, or 
secondary channels (Baumgarth and Roederer 2000). If not taken into account, this “spillover” 
would lead to a false positive signal. An example of commonly used fluorochromes excitation 
and emission spectra and spectral overlap is shown in Figure 3-1. 
 
Figure 3-1 Fluorochrome spectral overlaps (Ref: BD Biosciences) 
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Ideally when choosing fluorochrome combinations for an experiment they would be well apart 
on the light spectrum and this can be achieved with 2 or 3 colour cytometry. However, in 
reality, multi-colour experiments give far more powerful data and are thus more commonly 
undertaken, so overlap is inevitable. Fluorescence compensation applies a mathematical 
algorithm which calculates how much fluorescence detected in a channel is from the desired 
fluorochrome and how much is detection is as a result of emission from another unrelated 
fluorochrome (Tung, Parks et al. 2004). This calculation is possible because the spillover is 
predictable and therefore can be subtracted after acquisition. The compensation matrix 
depends on the fluorochrome used, the filters and mirrors of the cytometer, the intensity of the 
measured signal and the PMT voltages (Kalina, Flores-Montero et al. 2012). Correct 
compensation is crucial and incorrect compensation, both over- and under- compensation can 
lead to dramatic errors in results interpretation (Roederer 2001).  Compensation is more open 
to errors when using tandem dyes where one fluorochrome is excited and then transfers the 
energy across to the coupled dye by fluorescence resonance energy transfer (FRET) as there 
is more variable spillover (Kalina, Flores-Montero et al. 2012).  
3.1.2.2 Designing Multiparameter Flow Cytometry Panels 
When designing multi-colour immunophenotyping cytometry panels consideration must be 
made to the fluorochrome, the cytometer, the antibody and the starting material (Kalina, 
Flores-Montero et al. 2012). These are summarised in Table 3-2. 
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Table 3-2 Considerations when designing multiparameter flow cytometry panels 
Fluorochrome  
(Maecker, Frey et al. 2004)  










(McLaughlin, Baumgarth et al. 2008) 




Cell of interest 
Expected antigen expression levels 
 
3.1.3 Multiparameter Flow Cytometry of Lymph Node Fine Needle Aspirates 
Immunophenotyping of LN FNA samples has been extensively used by many institutions for 
the diagnosis of lymphoproliferative disorders and although not universally adopted, it has 
been validated by many centres, who have found high sensitivity and specificity allowing for  
identification of the neoplastic clone (Jeffers, Milton et al. 1998, Young, Al-Saleem et al. 1998, 
Ravinsky, Morales et al. 1999, Meda, Buss et al. 2000, Nicol, Silberman et al. 2000, Sandhaus 
2000, Dong, Harris et al. 2001, Kaleem, White et al. 2001, Liu, Stern et al. 2001, Saboorian 
and Ashfaq 2001, Gong, Williams et al. 2002, Zeppa, Marino et al. 2004, Bangerter, Brudler 
et al. 2007, Schmid, Tinguely et al. 2010). However, of note, The British Committee for 
Standards in Haematology (BSCH) guidance entitled the “Best Practice in Lymphoma 
Diagnosis and Reporting” recommends that “FNA samples should not normally be used as 
the sole tissue for diagnosis” (Grade B: evidence level III).   
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3.2 Aim 
The aim of this chapter is first to assess the feasibility of performing LN FNAs to obtain T-cells 
from the CLL tumour microenvironment for analysis.  We then plan to undertake multi-
parameter flow cytometry on the cells obtained; which allows for a detailed phenotypic 
analysis on small numbers of cells. We aim to perform a direct comparisons of the phenotype 
of PB T-cells with the T-cells derived from the LN of the same patient. We additionally aim to 
compare the phenotype of PB CLL T-cells with those from age matched normal controls.     
3.3 Materials and Methods 
3.3.1 Ethics 
Ethical approval was obtained to perform LN FNAs on CLL patients for research purposes 
from the research ethics committee REC: 09/H0805/5. PB was collected from patients under 
national research ethics NREC: 08/H0906/94 and healthy controls under LREC: 02-044. 
Written informed consent was gained according to the Declaration of Helsinki, 2008. 
3.3.2 Primary Patient Material 
3.3.2.1 PB Sample Collection 
Patients with a diagnosis of CLL and an easily palpable lymph node were invited to take part 
in the study. Healthy controls were invited to take part in the control arm of the study. They 
were given a patient information sheet and given adequate time to consider their entry into 
the study. Written consent was obtained and samples pseudo-anonymised. PB was collected 
from CLL patients and healthy controls directly into CLL media.   
3.3.2.2 LN FNA Sample Collection 
CLL patients consenting to the study underwent a LN FNA. The LN FNA was performed by a 
trained clinician using a 23 gauge needle attached to 10ml syringe. The sample was aspirated 
and the needle was washed directly into CLL media. This was repeated on average 4 times 
per patient. The LN FNA was sample centrifuged at 200g for 5 minutes and resuspended in 
CLL media to a final volume depending on the cell count. 
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3.3.3 Flow Cytometry Panels 
As described the appropriate selection of fluorochrome combinations is critical in the design 
of multiparameter flow cytometry panels (Mahnke and Roederer 2007). The following panels 
were developed for the work presented here. 
Panel A: T-cell Stimulation and Immune Checkpoint Inhibition.  








CD25 CD40L CD4 CTLA-4 PD-1 CD3 CD8 
 
Panel B: CLL Prognostic Factors. 
Fluorochrome 
 




CD25 CD38 CD49d CD5 CD19 
 
Panel C: Cell Viability.  






 CD5 CD19 
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CXCR5 CD4 PD-1 CD8 
 









CXCR5 CD4 CD3 CD8 
 
Panel G: T-cell Memory Subsets 1. 






Antigen CD25 CCR7 CD4 
 
CD45RA CD28 CD62L CD8 
 
Panel H: T-cell Memory Subsets 2. 




Antigen CD45RA CCR7 CD4 CD28 CD8 
 
 
Panel I: Immune Checkpoint Inhibitors and Ligands 1. 
Fluorochrome FITC PE PerCP-
Cy5 
Pe-Cy7 APC Pacific 
Blue 
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Panel J: Immune Checkpoint Inhibitors and Ligands 2. 
Fluorochrome FITC PE PerCP-
Cy5 
Pe-Cy7 APC Pacific 
Blue 
Antigen PD-L1 PD-L2 CD4 CD5 PD-1 CD8 
 
 
Panel K: T Regulatory Cells 1. 






Antigen CD127 CD25 CD4 FOXP3 CD3 CD8 
 
 
Panel L: T Regulatory Cells 2. 






CD127 CD25 CD4 CD8 
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3.3.4 Flow Cytometry Antibodies 
The flow cytometry antibodies used in this chapter and the volumes per test are detailed in  
Table 3-3. 
Table 3-3 Flow cytometry antibodies 
Antigen Clone Conjugation Volume Company 
CD3 SP34-2 APC-Cy7® 2.5µl BD Biosciences 
CD3 UCHT1 APC-Alexa Fluor® 750 10µl eBioscience 
CD4 RPA-T4 PE 10µl AbD Serotec 
CD4 RPA-T4 PerCp-Cy5.5 2.5µl eBioscience 
CD5 UCHT2 Pe-Cy7 10µl BioLegend 
CD5 MF7-14.5 APC  5µl AbD Serotec 
CD8 SK1 PE 10µl BD Biosciences 
CD8 OKT8 Pacific Blue™ 10µl eBioscience 
CD8 OKT8 eFluor® 450 2.5µl eBioscience 
CD19 SJ25-C1 Pacific Blue™ 2.5µl Invitrogen 
CD19 HIB19 eFluor® 450 2.5µl eBioscience 
CD25 BC96 PE 2.5µl eBioscience 
CD25  MEM-181 FITC 5µl AbD Serotec 
CD28 CD28.2 APC 10µl eBioscience 
CD38 HB7 PE 2.5µl eBioscience 
CD45 HI30 APC-Alexa Fluor® 750 10µl eBioscience 
CD45RA H100 Biotin 1µl eBioscience 
CD49d 44H6 FITC 5µl AbD Serotec 
CD49d 44H6 Biotin 5µl AbD Serotec 
CD62L DREG-56 APC-Alexa Fluor® 750 10µl eBioscience 
CD127 (IL-7Ra) eBioRDR5 FITC 2.5µl eBioscience 
CD152 (CTLA-4) 14D3 Biotin 1µl eBioscience 
CD154 (CD40L) 24-31 PE 10µl eBioscience 
CD185 (CXCR5) 51505 Biotin 5µl R&D Systems 
CD197 (CCR7) 3D12 PE 10µl eBioscience 
CD273 (PD-L2) MIH18 PE 10µl BD Biosciences 
CD274 (PD-L1) MIH1 FITC 10µl BD Biosciences 
CD279 (PD-1) MIH4 Alexa Fluor® 647 5µl AbD Serotec 
FOXP3 PCH101 APC 2.5µl eBioscience 
Streptavidin N/A FITC 2.5µl eBioscience 
Streptavidin N/A PE-Cy7 1µl eBioscience 
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3.3.5 Staining Cell Surface Antigens for Flow Cytometry 
Cells were resuspended in 100µl CLL media and labelled for flow cytometry according to 2.7.1. 
Directly conjugated +/- biotinylated antibodies were added at appropriate titrated volume as 
described in Table 3-3  according to the panels outlined in 3.3.3.  
3.3.6 Compensation Matrix 
Either cells or compensation beads were used to create the compensation matrix. BD™ 
CompBeads (BD Biosciences) are polystyrene microparticles which are either negative (BD™ 
CompBeads negative control), and bind nothing, or are anti-mouse Igk (BD™ CompBeads 
anti-mouse Igk), which will bind any antibody that was raised in a mouse (providing it has an 
Igk specificity). By this means distinct positive and negative fluorescence can be obtained 
from the actual fluorochrome used in each experiment to create the compensation matrix. The 
compensation bead staining protocol is outlined in 2.7.5. 
3.3.7 BD FACSCanto II (BD Biosciences) 
The BD FACSCanto II configuration 4-2-2 has 3 lasers allowing 8 colour flow cytometry. The 
cytometer setup is shown in 2.7.6. 
3.3.8 Flow Cytometry Data and Statistical Analysis 
Samples were collected and analysed using FACSDiva software (BD Biosciences) and 
FlowJo (TreeStar). Percentage positivity and/or mean fluorescence intensity (MFI) values 
were obtained as appropriate. Statistical analysis was performed using GraphPad Prism® 
(Graph Pad Inc.). For comparisons to be made between LN FNA and PB populations, first a 
D’Agostino and Pearson omnibus normality test was performed on the whole sample group 
and then paired t-tests for those that passed and a Wilcoxon matched pairs test for those that 
did not. A p-value of <0.05 was considered statistically significant. For comparison between 
CLL PB and PB of normal controls an un-paired t-test was used and again a p-value of <0.05 
was considered statistically significant. Results are expressed +/- standard error of the mean. 
Box and whiskers plots show the median and minimum and maximum values. 
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3.4 Patient Material 
3.4.1 Demographics of Patients and Normal Controls 
LN FNA and PB sampling was undertaken on 28 patients with a diagnosis of CLL and palpable 
cervical lymph nodes. The demographics of the patient group are outlined in Table 3-4. An 
unselected group of serial CLL patients from King’s College Hospital Foundation Trust 
(KCHFT) were invited to take part in the study. Eligibility criteria was a diagnosis of CLL, 
palpable lymphadenopathy and no treatment within the prior 3 months. Exclusion criteria were 
anti-coagulated patients, known bleeding disorders and/or evidence of previous or current 
infection with hepatitis B, C, HIV and/or HTLV-1. Due to the local demographics of CLL 
patients at KCHFT many patients were excluded due to prior exposure to hepatitis B. This 
may in part explain the apparent lower incidence of CMV IgG positive individuals as viral 
infections are often co-existent. PB was additionally sampled from 16 age matched normal 
controls.  
There was no difference in the age of the CLL patients and the normal controls.  The median 
age of patients was 63.5 +/- 11.01 and the median age of controls was 60 +/- 7.90 (p=0.27) 
see Figure 3-2. 
 
Figure 3-2 CLL patients and healthy control volunteers are age matched 
The age of CLL patients (n=28) and healthy controls (n=16) were not statistically different. A 
D’Agostino and Pearson omnibus normality test was applied prior to un-paired t-test using 
GraphPad Prism® (Graph Pad Inc.). 
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Table 3-4 Demographics of CLL patients 
Patient Demographics  n = 28 
Age  Years  (38-80) 64 
Sex  Male  17 61% 
Female  11 39% 
CMV Status IgG Pos 11 39% 
IgG Neg 15 54% 
Indeterminate 2 7% 
Binet Stage  A  10 36% 
B  12 43% 
C  6 21% 
Cytogenetics / FISH  Normal  3 11% 
13q-  9 32% 
11q-  3 11% 
17p-  3 11% 
Trisomy 12  4 14% 
Complex  6 21% 
CD38 status <30% 16 57% 
>30% 12 43% 













Unknown  3 11% 
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3.5 Results 
3.5.1 LN FNA feasibility 
A total of 45 LN FNAs were performed on 28 CLL patients. The procedure was well tolerated 
and was feasible if the palpable lymph node exceeded 1cm. An additional 6 patient samples 
were unsuitable for processing/analysis; 2 were found to have a high grade transformation, in 
2 the total cell count was too low to proceed, in 1 the patient was subsequently found to have 
co-existing hepatitis infection and in 1 the sample was lost in processing. Cell counting was 
performed manually using a counting chamber (Hawksley), with trypan blue solution as a 
viability stain. On average the total cell count was 4.1x106 (1-13x106). Because of the limited 
number of cells available in a LN FNA, not every panel was performed on every sample. 
3.5.2 There is marked T-cell expansion in the PB of CLL patients compared to healthy 
controls  
Initial experiments investigated the T-cell component of CLL PB compared to healthy age 
matched controls. As a total proportion of PB lymphocytes, the T-cells make up a small 
percentage in CLL; 3.67% +/- 3.54 (n=15) compared to 75.9% +/- 2.70 in the control population 
(n=11); p=<0.0001, see Figure 3-3. However the absolute T-cell numbers is statistically much 
higher in the CLL population compared to normal controls, with the mean total T-lymphocyte 
count in the CLL group of 4.97x109/l +/- 2.16 (n=13) versus 1.47x109/l +/-0.57 in the normal 
controls (n=11), see Figure 3-4. The expansion is in both the CD4 and CD8 compartment. 
See Figure 3-5 and Figure 3-6. This confirms the findings of many previous studies (Catovsky, 
Miliani et al. 1974, Herrmann, Lochner et al. 1982, Mills and Cawley 1982, Platsoucas, 
Galinski et al. 1982, Kimby, Mellstedt et al. 1987, Palmer, Hanson et al. 2008, Gonzalez-
Rodriguez, Contesti et al. 2010, Nunes, Wong et al. 2012).  
The CD4/CD8 ratio in our CLL patient cohort had a median value of 1.75 +/- 1.982 (n=14), 
with a wide range (0.59-6.87).  The ratio in the normal control group was 2.52 +/- 1.36 (n=11), 
which was not statistically different from the CLL cohort; p=0.698, see Figure 3-7.  
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We next investigated whether within the CLL cohort there was a correlation between the 
CD4/CD8 ratio and the total lymphocyte count, which was not the case; see Figure 3-8. 
 
Figure 3-3 Increased percentage of CD3+ T-cells in the lymphocyte gate of normal controls 
compared to CLL cohort 
CD3+ T-cells from the PB of CLL patients (n=15) and normal aged matched controls (n=11) 
was determined by flow cytometry using the FACSCantoII (BD Biosciences). The lymphocyte 
gate was based upon the forward and side scatter profile of the sample and then the CD3+ 
events gated. CD3+ events are presented as a percentage of the lymphocyte gate. Samples 
were analysed using FACSDiva software (BD Biosciences). A statistical D’Agostino and 
Pearson omnibus normality test and un-paired t-test was applied using GraphPad Prism® 
(Graph Pad Inc.). The box and whiskers plots; the box shows the median and 25th to 75th 
percentile and the whiskers show the minimum to maximum values. 
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Figure 3-4 Increase in the total CD3+ T-cell count in CLL patients compared to normal controls 
The absolute CD3 count was determined from the total lymphocyte count using the ADVIA® 
2120i analyzer (Siemens). The total PB CD3+ T-cell count in the CLL cohort (n=13) was 
statistically higher than in the normal control cohort (n=11), p=<0.0001. 
 
                 
Figure 3-5 The absolute CD4+ count is higher in CLL patients PB than normal controls 
The absolute CD4 count was determined from the total lymphocyte count using the ADVIA® 
2120i analyzer (Siemens). The total PB CD4+ T-cell count in the CLL cohort (n=13) was 
statistically higher than in the normal control cohort (n=11), p=0.0036. 
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Figure 3-6 There is an expansion in the absolute CD8+ T-cell count in CLL patients compared 
to normal controls 
The absolute CD8 count was determined from the total lymphocyte count using the ADVIA® 
2120i analyzer (Siemens). The total PB CD8+ T-cell count in the CLL cohort (n=13) was 
statistically higher than in the normal control cohort (n=11), p=0.0004. 
 
 
Figure 3-7 There was no difference in PB CD4/CD8 ratio between CLL cohort and healthy 
controls 
PB CD4/CD8 ratios were calculated for normal controls (n=11) and CLL patients (n=14). The 
median ratio for the cohort of normal controls was 2.52 and for the CLL patients 1.75. There 
was no difference between the two by an un-paired t-test (p=0.698). 
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Figure 3-8 There is no correlation between the total WCC and CD4/CD8 ratio in CLL PB 
The total WCC was determined using the ADVIA® 2120i analyzer (Siemens). The correlation 
between the CD4/CD8 ratio and WCC of CLL patients (n=14) was determined by calculating 
the Pearson correlation coefficient and no correlation was found; Pearson’s r=0.2. 
 
3.5.3 CLL LN FNA and PB samples show differences in forward and side scatter 
reflecting their compartment 
Having confirmed the presence of a T-cell expansion in CLL PB, which has been well 
documented, we next undertook comparative studies of the phenotype of the T-cells taken 
simultaneously from the PB and LN of CLL patients.  
An example forward scatter (FSC) and side scatter (SSC) dot plot from a PB sample is shown 
in Figure 3-9. There are distinct lymphocyte, monocyte and granulocytic “clouds”. 
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Figure 3-9 Forward and side scatter dot plot of CLL PB 
A representative flow cytometry scatter dot plot (FACSDiva) demonstrating the forward (FSC-
A) and side scatter (SSC-A) obtained from the PB of a CLL patient. The lymphocyte, monocyte 
and granulocyte clouds are labelled. 
  
A representative FSC and SSC dot plot of CLL PB and LN FNA sample is shown in Figure 
3-10. It can be seen that the scatter plot of the LN FNA lacks the prominent granulocyte and 
monocyte cloud, giving evidence that the sample is from the LN, which predominately contains 
lymphocytes. 
 
Figure 3-10 Differences in the SSC versus FSC dot plots comparing PB and LN FNA 
A representative flow cytometry scatter dot plot demonstrating the forward (FSC-A) and side 
scatter (SSC-A) obtained from the PB of a CLL patient  is shown on the left and on the right 
the scatter plot obtained from the LN FNA of the same patient. The lack of granulocyte and 
monocyte cloud can be appreciated in the LN FNA.  
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3.5.4 There is a higher percentage of CD3+ T-cells in CLL LN FNA samples than the PB 
Data from the flow cytometry panels shown in 3.3.3 were used to identify the relative numbers 
of CD3 (APC-Cy7), CD4 (PerCp-Cy5.5) and CD8 (Pacific Blue) T-cells in the lymphocyte gate 
of the LN FNA versus PB.  
First the CD3+ T-cells were calculated as a percentage of total cells within the lymphocyte 
gate, see Figure 3-11. 
 
Figure 3-11 Gating of CD3+ T-cells from the lymphocyte gate 
Flow cytometry dot plots from PB (left panel) and LN FNA (right panel), from an example CLL 
patient. The acquisition was gated first on the lymphocyte gate (from the side and forward 
scatter pattern as described in Figure 3-9) and then on side scatter and CD3+ (APC-CY7). In 
this example the CD3+ T-cells in the PB account for 3.73% of the lymphocyte gate, and in the 
LN FNA for 14.23% of the lymphocyte gate.  
 
We found high numbers of CD3+ T-cells within the lymphocyte gate of LN FNAs, which was 
up to 43% of the total lymphocyte population. This was highly statistically significant compared 
to the PB, with a mean percentage of CD3+ T-cells in the lymphocyte gate of CLL LN FNAs 
17.10% +/- 2.08 compared to 5.51% +/- 1.10 in the PB; p=<0.0001. See Figure 3-12. 
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Figure 3-12 The lymphocyte gate contains more CD3+ T-cells in the LN FNA compared to PB 
The gating strategy is as described in Figure 3-13. The paired PB and LN FNA data is 
presented for each CLL patient (n=24). Statistical analysis of all paired PB and LN FNA 
samples was performed on GraphPad Prism, first with a D’Agostino and Pearson omnibus 
normality test followed by paired t-test. 
 
3.5.5 The CLL LN FNA has a higher proportion of CD4+ T-cells than the PB 
Next we wanted to identify whether these CD3+ T-cells were CD4+ or CD8+. We therefore 
gated on the lymphocyte population, CD3+ and then the CD4+ and CD8+ populations. A 
typical density flow cytometry dot plot is shown in Figure 3-13. 
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Figure 3-13 Gating strategy for CD4+ and CD8+ T-cells from the CD3+ T-cells in lymphocyte 
gate 
Flow cytometry dot plots from PB (left panel) and LN FNA (right panel), taken from an example 
CLL patient. The sample was gated first on the lymphocyte gate from the side and forward 
scatter acquisition plots and then on side scatter and CD3+ (as described in Figure 3-11). This 
was followed by gating on CD4 (PerCP-Cy5.5) and CD8 (Pacific Blue) subsets. In this 
example the CD4+ T-cells in the PB account for 64.65% of the CD3+ T-cells, and in the LN 
FNA for 75.41% of the CD3+ T-cells. Conversely the CD8+ T-cells in the PB account for 
34.31% of the CD3+ T-cells and in the LN FNA for 19.80% of the CD3+ T-cells. 
 
We found a much higher percentage of the CD3+ T-cells to be CD4+ in the LN FNA compared 
to the PB. Within the LN a mean 71.9% +/- 2.08 of the CD3+ cells were CD4+ compared to 
60.83% +/- 2.90 in the PB.  This was highly statistically significant with a p-value of <0.0001. 
See Figure 3-14 
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Figure 3-14 CD4+ T-cells were found at relatively higher frequency in the LN FNA compared 
to PB 
The gating strategy is described in Figure 3-13. The paired PB and LN FNA data is presented 
for each CLL patient (n=25) and statistical analysis as in Figure 3-12.  
Conversely, there was a higher proportion of CD8+ cells in the PB compared to the LN; 
36.51% +/- 3.07 vs 23.04% +/- 2.08; p=0.0002. See 
Figure 3-15. 
 
Figure 3-15 CD8+ T-cells were less abundant in lymphocyte gate of the LN FNA compared to 
PB 
The gating strategy is described in Figure 3-13. The paired PB and LN FNA data is presented 
for each CLL patient (n=24) and statistical analysis as in Figure 3-12.   
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3.5.6 There is a higher proportion of T-cells in CLL LN FNA compared to PB, biased 
towards CD4+ effector memory phenotype 
Once we established that there is a high proportion of T-cells within the lymphocyte gate of 
the CLL LN we wanted to investigate their phenotype in more detail. Several groups have 
reported an increased CD4+ TEM phenotype (CD45RA-/CCR7-) in the PB of CLL patients 
compared to healthy controls and a relative decrease in naïve T-cells (Motta, Chiarini et al. 
2010, Walton, Lydyard et al. 2010, Nunes, Wong et al. 2012). To further delineate the CD4+ 
phenotype in the CLL LN microenvironment we developed a flow cytometry panel consisting 
of CD4 (PerCP-Cy5.5), CD8 (Pacific Blue), CD45RA (Pe-Cy7), CD62L (APC-Cy7), CCR7 
(PE), CD28 (APC) and CD25 (FITC). This allowed us to differentiate between naïve, TEM, 
TCM, TEMRA subpopulations. See 3.3.3 Flow Cytometry Panels.  
Figure 3-16 shows an example dot plot gating T-cell memory subsets using the following 
gating strategy: naïve (CD4+/CD45RA+/CCR7+), TCM (CD4+/CD45RA-/CCR7+), TEM 
(CD4+/CD45RA-/CCR7-), TEMRA (CD4+/CD45RA+/CCR7-). 
 
Figure 3-16 Gating strategy for T-cell memory subsets 
Flow cytometry dot plots from PB taken from an example CLL patient. The sample was gated 
first on the lymphocyte gate from the side and forward scatter acquisition plots and then on 
side scatter, CD3+ followed by CD4 as described in Figure 3-13. CD4+ T-cell memory subsets 
were then defined according to the expression of CCR7 and CD45RA as follows; naïve 
(CD4+/CD45RA+/CCR7+), TCM (CD4+/CD45RA-/CCR7+), TEM (CD4+/CD45RA-/CCR7-) and 
TEMRA (CD4+/CD45RA+/CCR7-). 
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There was a reduction in the proportion of naïve CD4+ T-cells in the LN compared to PB; LN 
FNA 9.41% +/- 3.30 vs PB 24.16% +/- 6.10; p=0.002. See Figure 3-17. 
 
 
Figure 3-17 There are fewer naïve CD4+ cells in the LN FNA than the PB of the same patient 
The gating strategy is as described in Figure 3-16. The paired PB and LN FNA data is 
presented for each CLL patient (n=14). Statistical analysis as Figure 3-12. 
  
There was also a reduction in the TCM compartment overall in the LN compared to PN; LN 
FNA 6.79% +/- 3.50 vs PB 11.74% +/- 1.81; p=0.044. See Figure 3-18. 
 
Figure 3-18 There are fewer CD4+ TCM cells in the LN FNA than the PB of the same patient 
The gating strategy is as described in Figure 3-16. The paired PB and LN FNA data is 
presented for each CLL patient (n=14). Statistical analysis as Figure 3-12. 
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Conversely there was a higher percentage of TEM CD4+ T-cells in the LN compared to PB; 
LNA FNA 60.35% +/- 4.30 vs PB 48.41 +/- 5.39; p=0.035. See Figure 3-19. 
 
Figure 3-19 There are more CD4+ TEM cells in the LN FNA compared to the PB of the same 
patient 
The gating strategy is as described in Figure 3-16. The paired PB and LN FNA data is 
presented for each CLL patient (n=14). Statistical analysis as Figure 3-12. 
 
There was also an increased number of TEMRA CD4+ T-cells in the LN compared to PB; LN 
FNA 23.41% +/- 3.26 vs PB 15.75 +/- 2.77; p=0.022. See Figure 3-20.  
 
Figure 3-20 There are more CD4+ TEMRA cells in the LN FNA than the PB of the same patients 
The gating strategy is as described in Figure 3-16. The paired PB and LN FNA data is 
presented for each CLL patient (n=14). Statistical analysis as Figure 3-12. 
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Table 3-5 summarises the results with the mean percentage of CD4+ T-cells that fall into each 
of these subsets and the differences found between the LN and PB compartments.  
Table 3-5 The CD4+ T-cell subsets in CLL PB and LN FNA 
Data shows the mean percentage of CD4+ T-cells +/- standard error of the mean that are  
naïve (CD45RA+/CCR7+), TCM (CD45RA-/CCR7+), TEM (CD45RA-/CCR7-) and TEMRA 
(CD45RA+/CCR7-). Statistical analysis as in Figure 3-12. 
N=14  PB LN FNA P Value 
Naïve  24.16% +/- 6.10 9.41% +/- 3.30 p=0.002 
TCM  11.74% +/- 1.81 6.79% +/- 3.50 p=0.044 
TEM  48.41 +/- 5.39 60.35% +/- 4.30 p=0.035 
TEMRA  15.75 +/- 2.77 23.41% +/- 3.26 p=0.022 
 
3.5.7 CLL LNs contain relatively higher proportion of Tregs than the PB 
After establishing that there were more effector T-cells in the CLL LN FNA than in the PB of 
the same patient we wanted to look at the Treg subset. Tregs maintain self-tolerance and 
have a significant role in many cancers. Tregs have been consistently shown to be increased 
in CLL PB and correlate with advanced stage disease (Beyer, Kochanek et al. 2005, 
Giannopoulos, Schmitt et al. 2008, Jak, Mous et al. 2009, Weiss, Melchardt et al. 2011, 
Biancotto, Dagur et al. 2012, D'Arena, D'Auria et al. 2012, Lad, Varma et al. 2013). The initial 
strategy was to label the cells for Foxp3, which is an intracellular marker. The method is 
outlined in 2.7.2. This proved to be unfeasible as many more cells were required for the 
staining controls and as a result this approach substantially limited how many flow cytometric 
panels could be undertaken on one LN FNA sample. Therefore we switched to a cytoplasmic 
staining panel where Tregs were defined as CD4+, CD25bright, and CD127dim (Liu, Putnam 
et al. 2006, Seddiki, Santner-Nanan et al. 2006). This resulted the requirement of many fewer 
cells and enabled the sample to be effectively split between more panels.  
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We found that the percentage of the CD4+ T-cells that are Tregs to be significantly increased 
in the LN compared to the PB; LN FNA 9.51% +/- 1.95 vs PB 5.62% +/- 1.26; p=0.0135. See 
Figure 3-21 
 
Figure 3-21 There were more Tregs in the CLL LN compared to the PB taken simultaneously 
The sample was gated on CD4+ T-cells as described in Figure 3-13. Tregs were defined as 
CD4+/CD25bright/CD127dim. The paired PB and LN FNA data is presented for each CLL 
patient (n=6). Statistical analysis as Figure 3-12 
 
3.5.8 CLL LN derived T-cells show similar levels of CD25 expression as those from the 
PB 
Our hypothesis was that T-cells from within the tumour microenvironment would be activated, 
but there is little evidence of this from cells taken directly from the LN. Activated T-cells 
upregulate CD25, which is the alpha chain of the high affinity IL-2 receptor. Patten et al had 
described proliferating CLL cells to be in close contact with activated CD4+ CD25+ T-cells in 
LN biopsy sections (Patten, Buggins et al. 2008), so this marker was preferentially 
incorporated into the flow panels. We devised a series of panels to investigate activation 
(CD25, CD40L), co-stimulation (CD28), negative regulation (CTLA-4) and exhaustion (PD-1) 
on CLL T-cells. The flow cytometry panels used are shown in 3.3.3.  
Although there was a surprisingly slight downwards trend, there was no statistically significant 
difference in the proportion of CD4+ T-cells expressing CD25 in the PB or LN; PB CD4+ T-
cells 38.86% +/- 5.65 vs LN 31.17% +/- 3.38; p=0.090. See Figure 3-22. 
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Figure 3-22 There is no difference in the percentage of CD4+ T-cells expressing CD25 in LN 
FNA or PB 
The sample was gated on CD4+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD4+/CD25+. The paired PB and LN FNA data is presented for each CLL patient 
(n=17). Statistical analysis as Figure 3-12. 
 
The same held true for the CD8+ T-cells where the CD25 expression level was the same 
between compartments: PB CD8+ CD25+ 8.11% +/- 1.83 vs LN CD8+ CD25+ 8.95% +/- 1.39; 
p=0.600. Figure 3-23.  
 
Figure 3-23 There is no difference in the percentage of CD8+ T-cells expressing CD25 
between the LN FNA and PB 
The sample was gated on CD8+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD8+/CD25+. The paired PB and LN FNA data is presented for each CLL patient 
(n=16). Statistical analysis as Figure 3-12. 
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3.5.9 CD40L expression cannot be detected on resting CLL cells from the PB or LN FNA  
Next we looked for evidence of CD40L on the CD4+ T-cells. In the normal human immune 
response the engagement of the TCR by the MHC class II in turn leads to cytokine production, 
including IL-4 and IL-21 which stimulate the B-cell. As part of this process CD40 is engaged 
by its ligand CD40L (CD154) on T-cells. CD40L activates the RelA dependant NF-kB 
canonical and the RelB non canonical activation pathways. As discussed, in the introductory 
chapter, there is thought to be an acquired CD40L defect in CLL and the levels of expression 
in LN derived T-cells is debated. Ghia et al suggested between 5-30% of these CD4+ T-cells 
expressed CD40L, but this has not been consistently reproduced (Ghia, Strola et al. 2002). 
We found that levels of CD40L on CLL derived CD4+ T-cells was very low or absent in both 
the PB and LN FNA. A representative dot plot is shown in Figure 3-24. 
To investigate this small shift we analysed the mean fluorescent intensity (MFI) of the CD40L 
fluorochrome instead of using a more crude percentage value to identify if there was any small 
difference in expression between compartments.  
The MFI CD40L PB CD4+ T-cells was PB CD4+ CD40L 226 +/- 38.32 vs LN CD4+ CD40L 
352 +/- 67.1 in the LN; p=0.103. Therefore no difference was demonstrated. See Figure 3-25.  
 
 
Figure 3-24 CD40L expression in CD4+ T-cells of LN FNA compared to negative control 
LN FNA from an example CLL patient. The left panel is a LN FNA labelled with CD3 (APC-
Cy7), CD4 (PerCp-Cy5), CD8 (Pacific Blue) excluding the antibody conjugate directed against 
CD40L (PE). The right panel is labelled in addition with CD40L (PE). The gating strategy for 
CD4+ T-cells is as in Figure 3-13. The CD4+ CD40L+ gate has very few positive events. 
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Figure 3-25 There was no upregulation of CD40L in the CLL LN 
The sample was gated on CD4+ T-cells as described in Figure 3-13. The MFI of CD40L (PE) 
was acquired for the total CD4+ T-cell gate. The paired PB and LN FNA data is presented for 
each CLL patient (n=13). Statistical analysis as Figure 3-12. 
 
3.5.10 Co-stimulatory molecules show differential expression between LN FNA and PB 
in CLL 
Once the TCR engages with the MHC-peptide complex, co-stimulatory molecule ligation is 
required for T-cell activation. The primed T-cell expresses CD28 on its surface which binds to 
members of the B7 family, such as CD80 and CD86, on the antigen presenting cell. Lower 
expression of the co-stimulatory molecule CD28 on both CD4+ and CD8+ PB CLL T-cells has 
been consistently reported and lower levels appear to correspond with more advanced 
disease (Rossi, Matutes et al. 1996, Rossmann, Jeddi-Tehrani et al. 2003). Interestingly we 
found here was higher expression of the co-stimulatory molecule CD28 on both CD4+ and 
CD8+ T-cells of the LN compared to PB; CD4+ T-cells LN 95.66% +/- 1.47 vs PB 88.97% +/- 
3.10; p=0.049. See Figure 3-26. CD8+ T-cells LN 79.81% +/- 3.46 vs 39.64% +/- 6.04; 
p<0.0001. See Figure 3-27. 
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Figure 3-26 There was higher levels of CD28 on CD4+ T-cells in the LN compared to PB 
The sample was gated on CD4+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD4+/CD28+. The paired PB and LN FNA data is presented for each CLL patient 
(n=13). Statistical analysis as Figure 3-12. 
 
 
Figure 3-27 There was higher levels of CD28 on CD8+ T-cells in the LN compared to PB 
The sample was gated on CD8+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD8+/CD25+. The paired PB and LN FNA data is presented for each CLL patient 
(n=13). Statistical analysis as Figure 3-12. 
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3.5.11 Assessment of negative regulators of T-cells 
CTLA-4 is a negative T-cell regulator expressed on activated T-cells and binds to the same 
ligands as CD28. It negatively regulates the T-cell by decreasing IL-2 production and therefore 
has a critical role in terminating the immune response (Alegre, Frauwirth et al. 2001). We 
measured CTLA-4 in both CD4+ and CD8+ subpopulations. In the CD4+ population there was 
a trend toward increased CTLA-4 expression in the LN compartment compared to PB but this 
was not statistically significant; LN CD4+ CTLA-4 5.40% +/- 2.01 vs PB CD4+ CTLA-4 1.78% 
+/- 0.46; p=0.076. See Figure 3-28.  
There was, however, significantly more expression of CTLA-4 on the CD8+ T-cells in the LN 
compared to PB; LN CD8+ CTLA-4 21.80% +/- 4.36 vs PB CD8+ CTLA-4 13.05 +/- 3.67; 
p=0.010. See Figure 3-29.  
The increased levels of CTLA-4 in the CLL LN compared to PB are an indication the T-cells 
are activated in the LN.  
 
 
Figure 3-28 There was a trend toward an increase in CTLA-4+ expression on CD4+ T-cells 
derived from the  LN FNA compared to PB 
The sample was gated on CD4+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD4+/CTLA4+. The paired PB and LN FNA data is presented for each CLL patient 
(n=13). Statistical analysis as Figure 3-12. 
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Figure 3-29 There was a statistically higher percentage of CD8+ T-cells that expressed CTLA-
4+ in the LN FNA compared to PB 
The sample was gated on CD8+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD8+/CTLA4+. The paired PB and LN FNA data is presented for each CLL patient 
(n=12). Statistical analysis as Figure 3-12. 
 
3.5.12 PD-1 expression is higher on the PB T-cells of CLL patients than normal controls  
Chronically activated T-cells, express the “exhaustion” marker PD-1, whose negative 
regulatory functions suppresses the T-cell receptor activation. Since the work in this thesis 
was completed several groups have published that CLL PB T-cells express high levels of PD-
1 (Nunes, Wong et al. 2012, Ramsay, Clear et al. 2012, Brusa, Serra et al. 2013, Riches, 
Davies et al. 2013, Novak, Prochazka et al. 2015, Rusak, Eljaszewicz et al. 2015). We confirm 
that finding here. There was significantly higher PD-1 expression observed in both CD4+ and 
CD8+ PB T-cells from CLL PB compared to normals. CLL PB (n=21) CD4+ PD-1+ 31.12% +/- 
3.60 vs CD4+ PD-1+ normals (n=11) 17.74% +/- 3.25; p=0.022. See Figure 3-30.  
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Figure 3-30 There is a higher percentage of PD-1+ CD4+ T-cells in CLL PB compared to 
healthy controls 
The sample was gated on CD4+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD4+/PD-1+. The unpaired PB data is presented, PB from normal aged matched 
controls (n=11) and CLL patients (n=21). Statistical analysis as Figure 3-3. 
 
The same was true for the CD8+ component, where higher levels of PD-1 were found on CLL 
PB derived CD8+ T-cells than normal PB CD8+ T-cells: CLL PB (n=21) CD8+ PD-1+ 41.44% 
+/- 3.94 vs normal PB (n=11) CD8+ PD-1+ 23.37% +/- 3.81;  p=0.006. See Figure 3-31. 
 
Figure 3-31 There is a higher percentage of PD-1+ CD8+ T-cells in CLL PB compared to 
healthy controls 
The sample was gated on CD8+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD8+/PD-1+. The unpaired PB data is presented, PB from normal aged matched 
controls (n=11) and CLL patients (n=21). Statistical analysis as Figure 3-3.   
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3.5.13 PD-1 expression levels are markedly increased on T-cells derived from the CLL 
LN compared to PB of the same patient 
One of the most striking and previously unreported observations of this study was the 
significantly increased PD-1 on CLL T-cells of the LN. We found that the level of PD-1 
expression on T-cells was much higher in the CLL LN FNA than the corresponding cells of the 
PB in both the CD4+ and CD8+ T-cells.  
Figure 3-32 shows a representative flow cytometry dot plot, showing the shift in MFI of PD-1 
on the LN FNA CD4+ T-cells compared to those of the PB.  
The MFI of PD-1 in CD4+ T-cells was significantly higher in the CLL LN than the PB; 1272 +/- 
180.2 vs 514 +/- 62.2; p<0.0001. See Figure 3-33. Also the overall percentage of CD4+ T-
cells expressing PD-1 was much higher in the LN than PB; CLL LN CD4+ PD-1+ 56.42% +/- 
4.02 vs CLL PB CD4+ PD-1+ 31.12% +/- 3.60; p<0.0001. See Figure 3-34. 
 
 
Figure 3-32 Representative dot plot of PD-1+ / CD4+ T-cells of PB compared to LN FNA 
Paired PB (left panel) and LN FNA (right panel) from an example CLL patient. The gating 
strategy for CD4+ T-cells is as in Figure 3-13. The CD4+ PD-1+ gate has more positive events 
in the LN FNA than the PB and it can be appreciated the PD-1 shifts towards positive in the 
LN FNA as opposed to a discrete bimodal population of CD4 PD-1+ and PD-1- 
subpopulations. 
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Figure 3-33 The MFI of PD-1 was higher in the LN FNA CD4+ T-cells compared to PB 
The sample was gated on CD4+ T-cells as described in Figure 3-13. The MFI of PD-1 was 
acquired for the total CD4+ T-cell gate. The paired PB and LN FNA data is presented for each 




Figure 3-34 There is more PD-1 expressed on the CD4+ T-cells of the LN compared to PB 
The sample was gated on CD4+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD4+/PD-1+. The paired PB and LN FNA data is presented for each CLL patient 
(n=21). Statistical analysis as Figure 3-12. 
 
This finding was also mirrored in the CD8+ cells where the PD-1 MFI in the LN FNA was much 
higher than the same cells in the PB; 1615 +/- 218.4 vs 44 +/- 80.9 p<0.0001. See Figure 
3-35.  
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Figure 3-35 The MFI of PD-1 was higher in the LN FNA CD8+ T-cells compared to PB 
The sample was gated on CD8+ T-cells as described in Figure 3-13. The MFI of PD-1 was 
acquired for the total CD8+ T-cell gate. The paired PB and LN FNA data is presented for each 
CLL patient (n=20). Statistical analysis as Figure 3-12. 
 
There was also an overall increased percentage of PD-1+ CD8 T-cells in the LN vs PB; CLL 




Figure 3-36 There is more PD-1 expressed on the CD8+ T-cells of the LN compared to PB 
The sample was gated on CD8+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD8+/PD-1+. The paired PB and LN FNA data is presented for each CLL patient 
(n=20). Statistical analysis as Figure 3-12. 
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3.5.14 The known PD-1 ligands PDL1 and PDL2 are not expressed on resting CLL cells 
from the PB or LN 
PD-L1 and PD-L2 are the known ligands of PD-1, as discussed in the introductory chapter. 
Therefore we looked for evidence of the PD-L1 and PD-L2 expression on the CLL cells of the 
PB and LN. The level of expression of PD-L1 was very low in both compartments, with no 
significant difference between the two. PD-L1 on PB CLL cells vs LN CLL cells: 1.03% +/- 
0.59 vs 0.85% +/- 0.69; p=0.78. See Figure 3-37. The positive control experiments for PD-L1 
will be discussed in chapter 6 of this thesis.  
 
Figure 3-37 No difference in the level of expression of PD-L1 in the CLL PB or LN FNA 
The acquisition was gated first on the lymphocyte gate (from the side and forward scatter 
pattern as described in Figure 3-9) and then CLL cell population defined as dual CD5+ and 
CD19+. The CD5+/CD19+/PD-L1+ events were acquired. The PB and LN FNA data is 
presented for each CLL patient (n=8) and the mean shown. Statistical analysis as Figure 3-12. 
     
PD-L2 expression was not detected at a significant level on CLL cells derived from the PB or 
the LN. PB CLL cells 0.21% +/- 0.14 compared to LN CLL cells 0.18% +/- 0.10; p=0.74.  
3.5.15 PD-1 expression is also identified to be present on CLL cells 
Although the primary objective of this work was to study the T-cell compartment in LN and PB, 
as reported by others, we did detect PD-1 expression by CLL PB B-cells in this study (Xerri, 
Chetaille et al. 2008, Grzywnowicz, Zaleska et al. 2012, Brusa, Serra et al. 2013). We 
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therefore went on to study the differential expression of PD-1 on CLL cells of the PB and LN. 
As was the case for CLL LN derived T-cells, LN CLL B-cells also expressed higher levels of 
PD-1 compared to the PB; LN CLL PD-1+ 44.68 +/- 4.9 vs PB CLL PD-1+ 32.37 +/- 5.58; 
p=0.025. See Figure 3-38.  
This is of interest because Grzywnowicz et al have previously reported that although there 
was a higher level of PD-1 transcripts from CLL B-cells compared to normal, they found there 
was no difference between the CLL PB and BM, confirming again that the LN compartment is 
a distinct niche (Grzywnowicz, Karabon et al. 2015). 
 
Figure 3-38 Higher frequency of PD-1+ CLL cells in the LN FNA than PB 
The sample was gated on CLL cells as described in Figure 3-37 and then sequentially gated 
on PD-1+. The paired PB and LN FNA data is presented for each CLL patient (n=13). 
Statistical analysis as Figure 3-12. 
 
3.5.16 There is no difference in T follicular helper cell numbers between CLL PB and LN 
samples  
Little work has focused on the Tfh cells in CLL. Cha et al defined Tfh as CD4+ CXCR5+ and 
found these cells to represent 25% of CD4+ T-cells in CLL PB compared to 8% in normal 
controls suggesting a role in disease (Cha, Zang et al. 2013). We also found an increased 
number of CD4+ CXCR5+ T-cells in the PB of CLL patients (n=12) compared to healthy 
controls (n=6); 57.9% +/-15.27 vs 8.58% +/-4.20; p=0.0009.  See Figure 3-39.  
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Figure 3-39 Increased CXCR5+ CD4+ cells in CLL PB vs healthy PB 
The sample was gated on CD4+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD4+/CXCR5+. The unpaired PB data is presented, PB from normal aged matched 
controls (n=6) and CLL patients (n=12). Statistical analysis as Figure 3-3. 
When we investigated the same population in the CLL LN FNA we found no difference in the 
relative numbers of CXCR5+ CD4+ T-cells whether derived from the PB or LN; 57.90% +/- 
15.27 vs 61.30% +/- 25.86; p=1.00. Figure 3-40. 
 
Figure 3-40 There was no difference in the frequency of CD4+ / CXCR5+ T-cells found in the 
PB or LN FNA in CLL 
The sample was gated on CD4+ T-cells as described in Figure 3-13 and then sequentially 
gated on CD4+/CXCR5+. The paired PB and LN FNA data is presented for each CLL patient 
(n=5). Statistical analysis as Figure 3-12. 
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As this was a surprising finding, we questioned whether CD4+ CXCR5+ is a good method of 
describing Tfh cells. An alternative definition is CD4+ CXCR5+ ICOS+. We did not have 
access to sufficient LN FNA samples to perform this work by flow cytometry and instead 
investigated this question using FFPE lymph node biopsy samples, which will be addressed 
in the next chapter of this thesis. Tfh cells also express PD-1. However if the PD-1 positive 
cells identified in the study here were all Tfh cells we would be expected to see a differential 
expression of CXCR5 mirroring the PD-1 results which is not evident. 
3.5.17 The impact of CMV seropositivity  
Several groups have investigated the PB T-cells of CLL patients with co-existent CMV 
seropositivity. In a healthy elderly population CMV specific CD8+ T-cells can account for up 
to half the total T-cell repertoire (Khan, Shariff et al. 2002). As discussed in the introduction of 
this thesis it has been hypothesised that CMV could be, at least in part, responsible for the 
global T-cell expansion and dysfunction in CLL (Akbar 2010). However it has been 
acknowledged that the T-cell abnormalities in CLL are not just restricted to CMV positive 
individuals and that there is still a vast T-cell expansion of dysregulated T-cells with abnormal 
phenotype even in CMV seronegative individuals (Riches, Davies et al. 2013). A comparison 
between the PB and LN T-cell compartments of CLL patients with or without evidence of 
previous CMV exposure has not been undertaken before.  
We wanted to address whether CMV seropositivity influences the T-cell phenotype of the CLL 
LN microenvironment and whether the “antigen experienced” T-cell phenotype in the LN was 
restricted to CMV seropositive patients. Firstly we found there was no statistical difference in 
the size of the T-cell expansion (as a percentage of the total lymphocyte gate) in the CMV 
seropositive (n=9) or seronegative (n=15) populations: 4.3% +/- 1.2 vs 6.1% +/- 1.8; p=0.696. 
Figure 3-41. 
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Figure 3-41 The size of the CLL PB CD3+ expansion is not influenced by CMV serostatus 
The gating strategy is as in Figure 3-3. The unpaired data of PB CD3+ T-cells are presented 
as a percentage of the total lymphocyte gate in the CMV seropositive (n=9) and seronegative 
(n=15) CLL cohorts. Statistical analysis is as Figure 3-3.  
The relative size of the CD4 and CD8 expansion in the CLL PB was also the same regardless 
of CMV seropositivity: CD4+ CMV seropositive vs CMV seronegative: 58.7% +/- 5.0 vs 64.1% 
+/- 4.04; p=0.463. See Figure 3-42. CD8+ CMV seropositive vs seronegative: 36.97% +/- 6.18 
vs 34.78% +/- 4.04 p=0.739. See Figure 3-43. 
         
Figure 3-42 The percentage of CD4+ T-cells in CLL PB is not influenced by CMV serostatus 
The gating strategy is described in Figure 3-13. The unpaired data of PB CD4+ T-cells are 
presented as a percentage of the CD3+ T-cells in the lymphocyte gate in CMV seropositive 
(n=9) and seronegative (n=15) CLL cohorts. Statistical analysis is as Figure 3-3.  
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CD8+ CMV seropositive vs seronegative: 36.97% +/- 6.18 vs 34.78% +/- 4.04 p=0.739. See 
Figure 3-43. 
 
Figure 3-43 The percentage of CD8+ T-cells in CLL PB is not influenced by CMV serostatus 
The gating strategy is described in Figure 3-13. The unpaired data of PB CD8+ T-cells are 
presented as a percentage of the CD3+ T-cells in the lymphocyte gate in CMV seropositive 
(n=9) and seronegative (n=15) CLL cohorts. Statistical analysis is as Figure 3-3.   
 
To determine if there was a relationship between the extended CD4+ T-cell phenotype and 
CMV serostatus we compared the number of naïve, TCM, TEM and TEMRA cells between those 
subpopulations where the CMV status was known. There was no difference between the 
relative percentage of each subpopulation between CMV positive and CMV negative 
individuals regardless of whether the T-cells were derived from the PB or LN. See Figure 3-44, 
Figure 3-45, Figure 3-46 and Figure 3-47. 
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Figure 3-44 CMV serostatus does not influence the percentage of naïve CD4+ T-cells found 
in the PB or LN of CLL patients 
The gating strategy is as described in Figure 3-16. The unpaired data of PB and LN FNA naïve 
CD4+ T-cells in CMV seropositive (n=5) and seronegative (n=8) CLL cohorts. Statistical 




Figure 3-45 CMV serostatus does not influence the percentage of TCM CD4+ T-cells found in 
the PB or LN of CLL patients 
The gating strategy is as described in Figure 3-16. The unpaired data of PB and LN FNA CM 
CD4+ T-cells in CMV seropositive (n=5) and seronegative (n=8) CLL cohorts. Statistical 
analysis is as Figure 3-3.  
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Figure 3-46 CMV serostatus does not influence the percentage of TEM CD4+ T-cells found in 
the PB or LN of CLL patients 
The gating strategy is as described in Figure 3-16. The unpaired data of PB and LN FNA EM 
CD4+ T-cells in CMV seropositive (n=5) and seronegative (n=8) CLL cohorts. Statistical 
analysis is as Figure 3-3. 
 
Figure 3-47 CMV serostatus does not influence the percentage of TEMRA CD4+ T-cells found 
in the PB or LN of CLL patients 
The gating strategy is as described in Figure 3-16. The unpaired data of PB and LN FNA 
TEMRA CD4+ T-cells in CMV seropositive (n=5) and seronegative (n=8) CLL cohorts. 
Statistical analysis is as Figure 3-3. 
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There was a possible trend toward more CD4+ TEMRA cells in the PB of previously CMV 
infected individuals but this did not reach statistical significance; 22.0% +/- 5.15 vs 12.3% +/-
3.16; p=0.124, which may be due small numbers when the subpopulations are divided. 
Regardless of CMV serostatus there were statistically more effector CD4+ T-cells and fewer 
naïve in the LN compartment compared to PB across the patients. CMV seronegative patients: 
Naïve CD4+ T-cells PB vs LN: 26.8% +/- 9.5 vs 10.5% +/- 5.331; p=0.0268.  CMV seropositive 
patients: Naïve CD4+ T-cells PB vs LN: 24.0% +/- 7.8 vs 8.7% +/- 4.2; p=0.0347. Therefore 
the increased effectors in the LN of CLL patients cannot be explained by previous exposure 
to CMV.  
3.5.18 CMV serostatus did not influence levels of T-cell PD-1 expression 
Next we investigated whether the increased number of CD4+ T-cells expressing PD-1 in the 
LN held true regardless of the CMV serostatus and found that it did. CMV seronegative 
patients: CD4+ PD-1+ PB vs LN: 26.15% +/- 4.01 vs 55.53% +/- 6.00; p=0.0001. See Figure 
3-48. CMV seropositive patients: CD4+ PD-1+ PB vs LN: 36.89% +/- 7.25 vs 55.30% +/- 7.65; 
p=0.012. See Figure 3-49.  
 
Figure 3-48 PD-1 expression is higher on LN CD4+ T-cells than PB CD4+ T-cells in CMV 
seronegative CLL patients 
The sample was gated as described in Figure 3-30. The paired PB and LN FNA data is 
presented for each CLL CMV seronegative patient (n=10). Statistical analysis as Figure 3-12.  
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Figure 3-49 PD-1 expression is higher on LN CD4+ T-cells than PB CD4+ T-cells in CMV 
seropositive CLL patients 
The sample was gated as described in Figure 3-30. The paired PB and LN FNA data is 
presented for each CLL CMV seropositive patient (n=8). Statistical analysis as Figure 3-12.  
 
The same was true for CD8+ T-cells: CMV seronegative patients: CD8+ PD-1+ PB vs LN: 
47.65% +/- 4.65 vs 72.32% +/- 5.24; p=0.001. See Figure 3-50. CMV seropositive patients: 
CD8+ PD-1+ PB vs LN: 39.41% +/- 6.62 vs 73.49% +/- 5.40; p=0.013. See Figure 3-51. 
 
Figure 3-50 PD-1 expression is higher on LN CD8+ T-cells than PB CD8+ T-cells in CMV 
seronegative CLL patients 
The sample was gated as described in Figure 3-31. The paired PB and LN FNA data is 
presented for each CLL CMV seronegative patient (n=10). Statistical analysis as Figure 3-12.  
- 149 - 
 
 
Figure 3-51 PD-1 expression is higher on LN CD8+ T-cells than PB CD8+ T-cells in CMV 
seropositive CLL patients 
The sample was gated as described in Figure 3-31. The paired PB and LN FNA data is 
presented for each CLL CMV seropositive patient (n=8). Statistical analysis as Figure 3-12. 
 
CMV serostatus made no difference to the percentage of CD4+ PD-1+ cells in the PB of CLL 
patients: CD4+ PD-1+ CMV seronegative vs seropositive: 26.15% +/- 4.01 vs 36.89% +/- 7.25; 
p=0.190. The same was true in the LN where there were CMV serostatus made no impact in 
the size of the CD4+ PD-1+ expansion: CD4+ PD-1+ CMV seronegative vs seropositive: 
55.53% +/- 6.00 vs 55.30% +/- 7.65; p=0.981. See Figure 3-52. 
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Figure 3-52 CMV serostatus does not impact on levels of PD-1 on CD4+ T-cells in PB or LN 
The sample was gated as described in Figure 3-30. The figure shows the unpaired analysis 
of the data from PB and LN FNA CD4+ PD-1+ T-cells in CMV seropositive (n=8) and 
seronegative (n=10) CLL cohorts. Statistical analysis is as Figure 3-3.  
 
The same was true for CD8+ T-cells where there was no difference in the percentage of CD8+ 
PD-1+ cells in the PB of CMV seronegative or seropositive individuals: CD8+ PD-1+ CMV 
seronegative vs seropositive: 47.65% +/- 4.65 vs 39.41% +/- 6.62; p=0.311.  
Again CMV serostatus had no impact on the expansion of CD8+ T-cells expressing PD-1 in 
the CLL LN: LN CD8+ PD-1+ CMV seronegative vs seropositive: 72.32% +/- 5.24 vs 73.49% 
+/- 5.40; p=0.880. See Figure 3-53. 
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Figure 3-53 CMV serostatus does not impact on levels of PD-1 on CD8+ T-cells in PB or LN 
compartment 
The sample was gated as described in Figure 3-31. The figure shows the unpaired analysis 
of the data from PB and LN FNA CD8+ PD-1+ T-cells in CMV seropositive (n=8) and 
seronegative (n=10) CLL cohorts. Statistical analysis is as Figure 3-3. 
 
3.6 Discussion 
The work outlined in this chapter has validated the feasibility of the use of LN FNAs to obtain 
access to the cells of the CLL microenvironment. We were initially anticipating a very low cell 
yield from this technique and therefore prior to commencing this approach we considered 
several other methods of analysing small cell numbers. On average the total cell count was 
4.1x106 which was higher than we anticipated. However, clearly still the majority of these cells 
were malignant CLL B-cells and there was also some cell loss in processing (cell washing) so 
not every analysis could be performed on every sample. On reflection some of the initial 
experiments were too ambitious with the sample being split between too many panels with 
tubes containing insufficient T-cells for accurate analysis. Therefore this compromised some 
early analysis, especially when looking to identify infrequent populations, and some of the 
initial samples were not used optimally.  
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The aim of this study was to investigate T-cells in an unselected group of CLL patients. As 
outlined in the introduction, the study of LN biopsy samples generally favours a more 
advanced and atypical group of CLL patients and we were hoping to avoid this with a LN FNA 
approach. The demographics of the LN FNA patient group was shown in Table 3-4. The 
clinical and biological features of our group reflect the heterogeneity of CLL. By definition, 
there was a slight bias towards patients in the Binet stages B and C groups, as these are the 
patients with palpable lymphadenopathy. The distribution of cytogenetic abnormalities and 
mutation status, however, is quite representative of those found in the CLL population as a 
whole. Of note there is no excess of patients with 11q-, which is most often associated with 
bulky lymphadenopathy. Therefore we propose a cross section of CLL patients was under 
evaluation in this study. Of note the CMV IgG positive cohort accounted for only 39% of 
patients. This might seem low for an elderly unselected CLL population. An explanation for 
this may be that an exclusion criteria to undergoing a LN FNA included seropositivity for 
hepatitis B, C or HIV. Due to the local demographics of CLL patients at King’s College Hospital 
many patients were excluded due to prior exposure to hepatitis B, where infection rates 
amongst our clinical CLL cohort approach 30% (personal correspondence Professor Stephen 
Devereux) and viral infections are often co-existent. An exclusion criteria to the study was 
previous treatment for CLL in the past 3 months, unfortunately further details of prior treatment 
history are unknown and this is a recognised as a limitation.   
Firstly we confirmed the findings of many groups that there is an expansion in the T-cell 
compartment in the CLL PB compared to normal controls (Mellstedt and Choudhury 2006); 
with a greater than 3 fold expansion in the total lymphocyte count in the CLL group. An overall 
increase in CD4+ and CD8+ T-cell numbers in CLL PB with a decreasing ratio with advancing 
disease has been consistently reported (Herrmann, Lochner et al. 1982, Mills and Cawley 
1982, Gonzalez-Rodriguez, Contesti et al. 2010, Nunes, Wong et al. 2012). We did not find a 
difference in the CD4/CD8 ratio between the CLL and the control group; in fact there were 
some CLL patients with a reversed low ratio and some with a relatively high ratio. Both high 
and low CD4/CD8 ratios have been previously described in CLL patients. Nunes et al recently 
reported CD4/CD8 ratios on a cohort of 110 patients and found an inverted ratio in 47%, where 
a marked CD8+ expansion had a shorter time to first treatment (Nunes, Wong et al. 2012). It 
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might seem counter intuitive that an increase in CD8+ T-cells associates with a poor 
prognosis, although it is hypothesised that the decrease in naïve subsets plays a role in 
rendering the patient immuno-incompetent, unable to mount an effective response to 
pathogens and new tumour antigens. These T-cells also have markers of “exhaustion”, which 
is discussed below.  
Some groups have related the variation in CD4/CD8 ratios to lymphocyte count. We did not 
find a clear correlation with lymphocyte count. Analysis by stage may only be informative with 
a larger cohort size. We did not pursue a larger cohort analysis of PB T-cells in CLL as our 
study was focused on identifying T-cell phenotype changes between the PB and LN 
compartments in the same patient, it is not a cohort study of the CLL population as a whole, 
which has been well documented by others.  
The first comparative observation between the LN FNA and PB in the CLL cohort was the 
finding that there was a much higher percentage of CD3+ T-cells found within the lymphocyte 
gate of the LN FNA compared to PB; on average 18% and up to 43% of the total lymphocyte 
population were CD3+ T-cells compared to 4% in the PB of the same patients. Of these CD3+ 
T-cells there was a significant bias towards CD4+ T-cells in the LN FNA compared to PB. 
These results concurred with the few small histopathology series that have reported the T-cell 
component of a CLL lymph node to be up to 35% and show bias towards a CD4+ subset 
(Swerdlow, Murray et al. 1984, Schmid and Isaacson 1994, Bonato, Pittaluga et al. 1998, 
Granziero, Ghia et al. 2001). Very limited amounts of additional phenotyping has ever been 
performed on the T-cell compartment of the CLL lymph node and the differences we show 
here between the PB and LN FNA are being reported for the first time.  
We have shown on subset analysis of the CD4+ T-cells that there is a statistically significant 
increase in number of CD4+ TEM in the LN FNA compared to the PB; 68% versus 44%. The 
increase in the number of TEM cells is a very significant finding. Other groups have reported 
that there is an increased number of effector CD4+ and CD8+ T-cells in the PB CLL patients 
compared to normal controls (Platsoucas, Galinski et al. 1982, Vuillier, Tortevoye et al. 1988, 
Totterman, Carlsson et al. 1989, Goolsby, Kuchnio et al. 2000, Nunes, Wong et al. 2012), but 
this has not been reported in the LN. TEM cells lack markers such as CCR7 and CD62L, which 
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are usually required for efficient trafficking into the lymph node. Therefore CCR7- CD62L- TEM 
cells, in a normal immune response to an infection, would not gain access and reside in the 
lymph node, but be directed to the site of infection or inflammation. It could be speculated that 
these TEM cells are in the lymph node, because it is the lymph node itself that is the site of 
ongoing antigenic stimulation. There is supportive evidence of this theory from lymph node 
metastases in solid tumours. In melanoma it has been shown there is an increase in TEM CD8+ 
T-cells in involved lymph nodes compared to non-involved nodes (Anichini, Scarito et al. 2003) 
and many groups have shown that in melanoma the T-cell response has specificity for tumour 
associated antigens (Lee, Yee et al. 1999). So these results support the hypothesis that in 
CLL the T-cells are responding to antigen within the lymph node. What is not known is the 
nature of the antigen; whether this is a tumour associated antigen, an autoantigen or an 
infectious agent remains to be elucidated and is beyond the scope of this study.  
Several studies have shown that in otherwise healthy individuals those with CMV seropositivity 
have a decrease in CD4 and CD8 naïve T-cells and an increase in CD4 and CD8 memory T-
cells, and this holds true in both the young and old (Looney, Falsey et al. 1999, Wikby, 
Johansson et al. 2002, Chidrawar, Khan et al. 2009, Litjens, de Wit et al. 2011). Pourgheysari 
et al have previously published that the absolute CD4+ T-cell numbers in CLL PB are the 
same regardless of CMV seropositivity (Pourgheysari, Bruton et al. 2010) and Nunes et al 
found the CD8+ expansion was not explained by CMV alone (Nunes, Wong et al. 2012). To 
identify if the skewing of the repertoire towards the TEMRA subset was simply an effect of CMV 
in our study we compared the relative proportion of these cells in the CMV seropositive and 
seronegative individuals and found no difference in the relative proportion of CD4+ Tnaïve, TCM, 
TEM and TEMRA between CMV seropositive or negative patients in any compartment. There 
may be a trend towards more CD4+ TEMRA in the PB of CMV positive individuals and this would 
need further investigation in a larger patient cohort. The observation of increased effector cell 
proportions vs naïve in our study remained between the LN and PB respectively irrespective 
of CMV serostatus. This gives further evidence that CMV in CLL is not responsible for all the 
T-cell perturbations. 
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Next we looked at the Treg subset and found they were significantly over-represented in the 
LN compared to the PB. Tregs are known to be increased in CLL PB and accumulate as 
disease progresses although the mechanism is not well understood (Beyer, Kochanek et al. 
2005, Giannopoulos, Schmitt et al. 2008, Deutsch, Perry et al. 2009, Jak, Mous et al. 2009, 
D'Arena, Laurenti et al. 2011, Biancotto, Dagur et al. 2012, Nunes, Wong et al. 2012, D'Arena, 
Simeon et al. 2013, Lad, Varma et al. 2013). It could be that Treg numbers simply reflect 
disease burden or that they play a part in its progression. Some groups have suggested they 
can be used as a prognostic marker; although this doesn’t help answer whether they are just 
innocent bystanders or involved in CLL pathogenesis (D'Arena, Simeon et al. 2013). Our 
results show they are found a higher frequencies in the LN than the PB. This raises the 
question what role are they playing in within the LN? Have they merely accumulated as a 
result of tumour or are they promoting the tumour by dampening down the immune response 
and allowing tolerance? As they have accumulated within the LN it is suggesting they are 
playing an active role and are thus a target for future study. A recent publication by Lad et al 
concurs with the results presented here. They also found a higher proportion of Tregs in the 
LN of CLL patients compared to the PB (Lad, Varma et al. 2015). They hypothesise that Tregs 
excrete IL-10 which in turn supress the Th17 cells allowing CLL to escape immune 
surveillance Some groups have used CD4+ CD25+ alone as a definition of Tregs which is an 
oversimplification. CD25 is upregulated on activated cells, a report by Jackson et al, has 
shown that up to 25% of CD4+ T-cells express CD25 in the PB of normal healthy controls 
(Jackson, Matsumoto et al. 1990). Patten et al previously reported, by immunofluorescence 
of lymph node sections, that the proliferating CLL cells are in close contact with CD4+ CD25+ 
but Foxp3-, activated T-cells (Patten, Buggins et al. 2008). Here no difference in the level of 
CD25+ expression on CD4+ T-cells of the LN FNA compared to PB was identified; 21% versus 
18%.  
Next we looked for evidence of CD40L on the CD4+ T-cells and almost no expression was 
seen. As previously discussed, the role of the CD40:CD40L interaction between T and CLL 
cells in vivo is not clear but it is well described that there is a defect in CD40L signalling in 
CLL. Cantwell et al investigated both PB and splenic CD4+ CLL T-cells and found, following 
CD3 ligation, no expression of CD40L by flow cytometry. Normal CD4+ T-cells produce CD40L 
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quickly and transiently upon stimulation. (Castle, Kishimoto et al. 1993, Roy, Waldschmidt et 
al. 1993). However Cantwell also reported that normal T-cells can acquire a defect in CD40L 
upregulation in the presence of CLL cells when cultured at ratios of >1:33. This is thought to 
be due to the expression of CD40 on CLL cells as blocking CD40 reversed the effect. 
Therefore there is an acquired CD40L defect in CLL (Cantwell, Hua et al. 1997). Our results 
concur with this finding and call into question the widespread use of CD40L transfected 
fibroblasts as an in vitro “model” of the CLL LN microenvironment. 
The next step in this study was to investigate other markers of T-cell activation. Once the TCR 
engages its MHC-peptide complex, ligation of co-stimulatory molecules is required for T-cell 
activation. These primed T-cells express CD28 which bind to CD80 and CD86 on the antigen 
presenting cell which in turn promotes T-cell IL-2 secretion, activation and survival. Without 
CD28 ligation the T-cell undergoes apoptosis or is anergic. Repeated chronic antigenic 
stimulation eventually leads to CD28 downregulation and replicative senescence. Many 
studies have reported that there are increased CD28 negative T-cells in the PB of advanced 
CLL (Rossi, Matutes et al. 1996, Rossmann, Jeddi-Tehrani et al. 2003). In our study, when 
the total pool of CLL patients is examined, it appears there are more CD28 negative T-cells in 
the CLL PB compared to LN, albeit at low frequencies. This was of particular interest because 
CD28 negative T-cells are known to accumulate in the PB of patients with CMV seropositivity, 
although not exclusively (Walton, Lydyard et al. 2010, Nunes, Wong et al. 2012).  
The next aim of this study was to investigate further the negative T-cell regulators. Following 
TCR engagement with antigen, T-cells require co-stimulatory signalling through CD28 and 
CTLA-4 is the negative counter-balance in this system. CTLA-4 also binds to CD80 and CD86 
and downregulates the T-cell response. Several groups have reported that CTLA-4 levels 
were markedly increased on both CD4+, CD8+ T-cells and Tregs in CLL PB compared to 
healthy controls (Rossmann, Jeddi-Tehrani et al. 2003, Motta, Rassenti et al. 2005). We 
additionally show here that the cell surface expression of CTLA-4 is found at statistically higher 
levels in the LN FNA compared to the PB in the CD8+ T-cell subsets. There was also a trend 
toward increased levels in the CD4+ LN T-cells. The overall level of surface CTLA-4 on the 
CD4+ population was modest, but this may be a reflection of the fact that the majority of CTLA-
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4 is cytoplasmic as it is rapidly endocytosed. Our results suggest that the T-cells are being 
stimulated in a TCR dependent manner within the LN. Higher levels of CTLA-4 in the LN would 
suggest that T-cells are being specifically inhibited in this compartment and which would be 
predicted to lead to T-cell anergy. Of note it has been observed by others that cytoplasmic 
CTLA-4 is also constitutively activated on Tregs and its expression can be further induced 
upon T-cell activation (Jonuleit, Schmitt et al. 2001). We did not specifically look at CTLA-4 on 
Tregs, nonetheless it can be hypothesised that CTLA upregulation on Tregs in the LN may 
further help CLL evade the immune system. These results would concur with other clinical 
scenarios where high levels of CTLA-4 have been reported on T-cells, for example in germinal 
centres, in the skin of patients with graft versus host disease and in the milieu of Hodgkin 
lymphoma (Vandenborre, Delabie et al. 1998), downregulating T-cell responses. Motta 
reported, as would be predicted, that blocking CTLA-4 using a monoclonal antibody on CLL 
derived T-cells resulted in T-cell proliferation (Motta, Rassenti et al. 2005). Therefore this axis 
has been considered for exploitation for therapeutic purposes. The challenge is manipulating 
this pathway could lead to unregulated CD4+ and CD8+ T-cell expansions which might be a 
double edged sword in CLL. 
Another important negative T-cell regulator and a marker of T-cell exhaustion is PD-1. PD-1 
has been shown to be upregulated in T-cells in response to chronic viral infections including 
CMV, HIV, adenovirus, hepatitis B and C (Yi, Cox et al. 2010). The theory of T-cell exhaustion, 
in an intact immune system, is that the T-cell eventually terminates its effective immune 
response towards the infected cell when it is stimulated over a long period of time and the 
pathogen is not effectively eradicated. This occurs by PD-1 interaction with its ligands PD-L1 
or PD-L2, which leads to reduced signalling through ZAP-70 and PI3k leading to decreased 
sensitivity to antigenic stimulation (Baitsch, Legat et al. 2012). The PD-1 / PD-L1 axis is 
thought to be the major T-cell inhibitory pathway (Schietinger and Greenberg 2014). In our 
study PD-1 expression was significantly increased in both the CD4+ and CD8+ T-cells of LN 
FNA compared to the PB. This differential expression between the PB and the LN FNA would 
suggest that the major site where PD-1 is up-regulated is within the lymph node. This result 
was independent of CMV seropositivity, in keeping with previous reports from the PB (Nunes, 
Wong et al. 2012). These PD-1+ effector T-cells are then senescent and have low replicative 
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potential.  Very interestingly in viral infections the PD-1 downregulation of the T-cell response 
can be reversed by blocking PD-1. This has been shown in both CMV and HIV infections 
where PD-1 blockade effectively leads to reversal of the T-cell exhaustion and allows the T-
cell to reinitiate an effective immune response (Trautmann, Janbazian et al. 2006). There is 
now increasing evidence PD-L1 and PD-L2 is expressed on a variety of solid tumours and this 
axis can be targeted. PD-L1 / PD-L2 expression correlates with a negative prognosis in 
several of these malignancies including in ovarian, pancreas and renal cell carcinoma 
(Okazaki and Honjo 2007). We looked for evidence of PD-L1 or PD-L2 expression on CLL 
cells but only found very low levels and no difference between compartments. Grzywnowicz 
et al looked for evidence of PD-L1 on CLL surface and found it to be no different from normal 
controls although there was a shift in the MFI (Grzywnowicz, Zaleska et al. 2012). Interestingly 
they found no difference in the quantification of PD-L1 transcripts between CLL and normal 
B-cells, nor between CLL B-cells from the PB or BM. Our result concurs with the findings 
published by Xerri at el who found no evidence of PD-L1 on 18 LN sections of CLL/SLL 
patients (Xerri, Chetaille et al. 2008). A conflicting study has been published by Brusa et al 
which reported PD-L1 expression on LN CLL sections, where expression was localised in 
proliferating paraimmunoblasts (Brusa, Serra et al. 2013). Ramsay et al also report expression 
of PD-L1 by PB CLL cells and that the expression is higher in CLL LNs compared to reactive 
normal LNs (Ramsay, Clear et al. 2012). The reasons for these conflicting results are unclear 
but may relate to technical factors, such as cell preparation and antibody specificity. 
Since the work on this thesis was completed there has been a huge amount of interest 
focusing on exploiting the PD-1 / PD-L1 axis in cancers. PD-1 expression has been identified 
by tumour infiltrating T-cells of many solid tumours. PD-1 blockade was first shown to expand 
the effector T-cell population and suppress the tumour cells in melanoma and colon cancer 
cell lines (Iwai, Terawaki et al. 2005, Curran, Montalvo et al. 2010). Since then there have 
been several clinical trials showing efficacy in, for example, melanoma (Wolchok, Hodi et al. 
2013), Hodgkin lymphoma (Ansell, Lesokhin et al. 2015), non-small cell lung cancer and renal 
cancers (Brahmer 2012).  So encouraging have been the results that the PD-1 blocker, 
Pembrolizumab, has been given advanced FDA approval in melanoma, giving it “breakthrough 
therapy designation” (Momtaz and Postow 2014). This is a fascinating concept in the context 
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of CLL, and begs the question what would happens if the CLL PD-1 axis is blocked. Recently 
a study has reported that the exhausted T-cells can be mimicked in the TCL1 mouse model 
of CLL and that this phenotype is induced by the tumour cells. They went on to show blockade 
of the PD-1 / PD-L1 axis can increase the cytotoxic potential of those T-cells (Gassner, 
Zaborsky et al. 2015). Brusa et al reported, in primary CLL cells, that blocking the PD-1 / PD-
L1 axis in vitro with an anti-PD-L1 antibody lead to increased CD8+ IFN-γ expression, and 
conversely co-culture with recombinant soluble PD-L1 decreased IFN-γ levels (Brusa, Serra 
et al. 2013). This will be addressed further in chapter 6 of this thesis.  
One interpretation of the results presented in this chapter is that the PD-1+ T-cells seen are 
exhausted antigen-stimulated T-cells, it must however also be remembered that PD-1 
expression is  found at high levels on Tfh cells (Dorfman, Brown et al. 2006). Little work has 
focused on the Tfh cells in CLL, although Ahearne et al reported increased numbers in CLL 
PB compared to normal controls (Ahearne, Willimott et al. 2013). The study presented here 
concurs with this finding where we identify higher levels of CD4+ CXCR5+ T-cells in the PB 
of CLL patients compared to healthy controls. Ahearne et al went on to investigate their major 
cytokines produced by Tfh cells, IL21 and IL4, and found that these promote leukaemic 
proliferation. We further investigated the CD4+ CXCR5+ phenotype by looking in the LN and 
found no difference between the LN and PB compartment. However we accept that dual 
positivity of CD4+ and CXCR5+ is an oversimplification of the definition of Tfh cells and that 
CXCR5 is also expressed on TCM cells. Tfh cells are probably more accurately defined as 
CD4+ CXCR5+ ICOS+ PD-1hi. We found approximately 60% of CLL PB CD4+ T-cells were 
CXCR5+ compared to only 30% that were PD-1+.  Therefore, by inference, the PD-1+ CD4+ 
T-cells we have described cannot all be Tfh cells. In the next chapter we study Tfh cells further 
by analysis on FFPE lymph node sections. 
Taken together our results support the hypothesis that in CLL there is a T-cell population that 
is chronically stimulated by antigen within the lymph node which leads to an accumulation of 
effector T-cells. Furthermore, the data suggests that in the face of ongoing TCR stimulation 
there is upregulation of negative T-cell regulators including CTLA-4 and PD-1 which leads to 
termination of the immune response and renders the T-cell into a state of exhaustion. This 
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finding was independent of CMV seropositivity. To confirm these findings we sought to validate 
our results using multi-parameter staining of lymph node sections, which are detailed in the 
next chapter.  
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Chapter 4 Investigation of the T-cells in CLL Lymph Nodes by 
Multi-parameter Immunofluorescence Microscopy 
4.1 Introduction  
The lymph node fine needle aspirate study outlined in the previous chapter has provided new 
information on the phenotype of T-cells infiltrating the CLL LN microenvironment. To confirm 
these findings and to take this work further this chapter investigates a complimentary method 
of phenotyping the T-cells, and additionally looks for spatial relationships between T-cells and 
CLL cells within the lymph node microenvironment niche. This work develops the technique 
of multi-parameter immunofluorescence microscopy on formalin fixed, paraffin embedded 
(FFPE) lymph node sections. Microscopy on tissue sections has the major advantage that 
information can be gained regarding the in vivo architecture of the lymph node 
microenvironment and enables the visualisation of and spatial relationships of more than one 
cell type on a section simultaneously. This can help inform which cell types of interest should 
be studied further. Additionally it can be possible to locate an antigens cellular localisation. It 
is well established that cells within the microenvironment promote CLL survival and 
proliferation including T-cells (Patten, Devereux et al. 2005, Kiaii, Kokhaei et al. 2013). In vitro 
co-culture models attempt to recapitulate the microenvironment but few studies have 
investigated the in vivo architecture of lymph nodes. Previous work from our group provides 
evidence that proliferating CLL cells are in close contact with CD4+ CD25+ T-cells in vivo 
(Patten, Buggins et al. 2008). The aim of this chapter is to further characterise the LN T-cells 
and specifically to look for evidence of antigen exposure in these cells and investigate their 
interaction with proliferating CLL cells.  
4.1.1 Experimental Approach 
The aim of this chapter is to optimise the technique of multiparameter immunofluorescence 
microscopy on lymph node sections and then further phenotype the infiltrating T-cells. As the 
work in chapter 3 identified PD-1 expression to be differentially expressed in CLL PB and LN 
FNA samples, an overall aim was to confirm the presence of this antigen on the T-cells found 
within LN biopsy specimens. This would also enable us to identify if there was any spatial 
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proximity between proliferating Ki67+ CLL cells and PD-1+ T-cells. A supplementary aim was 
to look for any evidence that these T-cells were infiltrating follicular T-helper (Tfh) cells, which 
are known to express high levels of PD-1 in normal germinal centres (Dorfman, Brown et al. 
2006, Wang, Hillsamer et al. 2011).  
The disadvantages of studying FFPE lymph node biopsy sections have been detailed in 
chapter 3. In summary, access to lymph node excision biopsy specimens is limited as lymph 
nodes are now rarely removed diagnostically and CLL can usually be diagnosed from the PB 
obviating the need for removing lymph node tissue. Additionally when lymph nodes are 
excised it is usually in specific circumstances, such as when a patient presents with out of 
proportion lymphadenopathy to the WCC or when there is a solitarily large node and a high 
grade (Richter’s) transformation needs to be excluded; which makes this a highly selected 
population. As a tissue biopsy usually does not alter treatment decisions for an individual 
patient, it can usually be avoided and therefore access to CLL lymph nodes is limited.  In order 
to overcome this problem we considered the possibility of removing lymph nodes from patients 
for research purposes only. We did not pursue obtaining ethical approval for such a study as, 
although there is precedent from other groups, we felt it was inappropriate for patients to 
undergo such an invasive procedure for the purposes of research alone.  
A second option was to prospectively tissue bank fresh frozen lymph nodes removed from 
patients for diagnostic purposes with matched PB, bearing in mind this only happened in 
specific circumstances. We have successfully obtained ethical permission for this study 
although eligible patient numbers are small. Therefore we chose to proceed with utilising the 
CLL lymph nodes archived by the KCHFT histopathology department, for which we had ethical 
approval to use surplus material from, in an anonymised fashion. These specimens were all 
FFPE, which limits the range of investigations that can be performed and we do not have 
matched PB for comparison, nonetheless the material is still valuable to study.  
The archived lymph node tissue sections are a scarce resource and therefore the initial 
optimisation of cell staining was undertaken using B-cells, selected from previously 
cryopreserved PBMCs from CLL patients, settled onto slides. This approach enabled the 
gaining of invaluable experience in the cell staining techniques without wasting primary lymph 
- 163 - 
node material. This technique, described below, involved settling CLL cells onto poly-lysine 
slides and indirectly labelling with antibodies conjugated to fluorochromes, allowing for 
immunofluorescence microscopy.  
4.1.2 Immunofluorescence Microscopy 
Microscopy has made huge advances from its origins as a simple magnifier to the confocal 
imaging that can be performed today. Originally it was a single lens system with a fixed tube 
length; now multiple lenses are configured to provide what is known as “infinity optics”. 
Conventional light microscopy and standard tissue staining techniques allow excellent 
visualisation of tissues but are limited in that morphology alone is used to distinguish between 
different cell types. Immunohistochemistry revolutionised light microscopy, allowing specific 
cell types to be identified by the use of antibodies. However, this still has major limitations in 
that only one specific marker can be identified at a time on an individual tissue section. 
Immunofluorescence microscopy allows the visualisation of more than one antigen on the 
same section by taking advantage of the different light properties of the secondary fluorescent 
antibodies and the development of filter sets within microscopes. In fluorescence microscopy 
the target antigen is labelled with a primary antibody which is in turn targeted by a secondary 
antibody (with specificity to the species of the first), conjugated to a fluorochrome. Specific 
fluorochromes predictably absorb light and emit light at known wavelengths. Good 
fluorochromes have a high “quantum yield”, meaning that there is a favourable ratio of the 
emitted light versus absorbed photons, and a barrier filter is used when viewing the specimen 
so that only the emission spectra is transmitted back to the eyepiece/camera. This allows cells 
with the attached fluorescent molecules to be visualised against a black background. The 
principle of immunofluorescence has been discussed in chapter 2.  
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The ultimate aim of this chapter is to optimise a method of immunofluorescence staining and 
systematic analysis of FFPE LN sections, in order to assess the phenotype of the infiltrating 
T-cells and to examine the spatial organisation of these cells in relation to the proliferating 
tumour cells in CLL.   
4.3 Materials and Methods 
4.3.1 Ethics 
PB was collected from CLL patients with ethical approval NREC: 08/H0906/94 044. Written 
informed consent was gained according to the Declaration of Helsinki, 2008. Ethical approval 
was obtained for use of surplus anonymous lymph node biopsy samples for research from the 
national research ethics service (NRES 08/H0906/94) and local research ethics committee 
(LREC 02-044).  
4.3.2 Patient Material 
CLL PBMCs were isolated from PB using Ficoll Histopaque® (Sigma Aldrich) density 
centrifugation and aliquots were stored frozen in liquid nitrogen as described in 2.2.2. Lymph 
node excision biopsies were performed on CLL patients as part of their routine clinical care. 
FFPE blocks were cut into 3 micron sections and mounted onto glass microscope slides by 
the Department of Histopathology, King’s College Hospital NHS Foundation Trust (KCHFT). 
A total of 15 LN biopsy samples were available in an anonymous fashion. 
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4.3.3 PBMC Slide Preparation 
CLL PBMCs were cultured, after defrosting, in CLL medium at a concentration of 1x106/ml as 
previously described in 2.5.1. B-cells were selected as in 2.2.5. 2 x106 B-cells were 
resuspended in 400µl CLL media and dropped onto poly-l-lysine coated slides (Polysine, 
Menzel-Glaser) within an area bounded by an ImmEdge™ pen (Vector laboratories, Inc.) and 
allowed to settle for 24 hours at 37°C. Excess media was removed under suction. Cells were 
fixed with paraformaldehyde for 2 hours. Slides were then washed x3 with PBS. For 
permeabilisation Triton 0.5% was added for 10 minutes per slide. Slides were then again 
washed x3 PBS. 
4.3.4 FFPE Antigen Retrieval 
FFPE sections were dewaxed in xylene (Fisher Scientific) twice for 5 minutes. The slides were 
then rehydrated in ethanol-water of decreasing grades (100%, 96%, 96%, 70% and 50%) for 
10 minutes each. The slides were subsequently washed with water. Antigen retrieval was 
performed using citrate buffer pH 6.0 in a pressure cooker. Slides were pressure cooked at 
15 pounds per square inch for 3 minutes and subsequently cooled in water. This was 
performed in the KCHFT department of histopathology. 
4.3.5  Immunofluorescence Antibodies   
The primary antibodies used are listed in Table 4-1. All primary antibodies used on the same 
section must be raised in a different species to allow detection by species specific secondary 
conjugates. The secondary fluorescently conjugated antibodies were all raised in donkey and 
are listed in Table 4-2. The excitation and emission spectra of the secondary antibodies are 
listed in Figure 3-1. The concentration of antibody that yielded the best signal with the least 
background fluorescence was determined by serial dilution; these are shown below.  
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Table 4-1 Primary antibodies for immunofluorescence microscopy 
Antigen Species Clone Dilution Manufacturer 
CD3 Rabbit Polyclonal IgG 1 in 40 Abcam 
CD4 Mouse IgG1: 4B12 1 in 10 Novocastra 
CD4 Rabbit Polyclonal IgG 1 in 40 Abcam 
CD23 Goat  Polyclonal IgG 1 in 30 R&D Systems 
CD38 Mouse IgG1 1 in 100 AbD Serotec 
CD49d Rabbit Polyclonal IgG 1 in 40 AbD Serotec 
CD79a Goat Polyclonal IgG 1 in 40 Santa Cruz 
Ki67 Mouse IgG1: MM1 1 in 100 Novocastra 
Ki67 Rabbit Polyclonal IgG 1 in 100 Abcam 
PD-1 Goat Polyclonal IgG 1 in 30 R&D Systems 
CXCR5 Rat IgG2: RF8B2 1 in 40 BD Biosciences 
 
Table 4-2 Secondary fluorescently conjugated antibodies for immunofluorescence microscopy 
Target Species Conjugate Dilution Manufacturer 
Goat IgG (H+L) Donkey Cy™5 1 in 100 Jackson ImmunoResearch 
Goat IgG (H+L) Donkey FITC 1 in 100 Jackson ImmunoResearch 
Mouse IgG (H+L) Donkey Cy™3 1 in 100 Jackson ImmunoResearch 
Mouse IgG (H+L) Donkey DyLight™ 488 1 in 100 Jackson ImmunoResearch 
Mouse IgG (H+L) Donkey Alexa Fluor® 555 1in 100 Invitrogen  
Rabbit IgG (H+L) Donkey FITC 1 in 50 Jackson ImmunoResearch 
Rabbit IgG (H+L) Donkey Cy™3 1 in 100 Jackson ImmunoResearch 
Rabbit IgG (H+L) Donkey Cy™5 1 in 100 Jackson ImmunoResearch 
Rat IgG (H+L) Donkey FITC 1 in 50 Jackson ImmunoResearch 
Rat IgG (H+L) Donkey DyLight™ 549 1 in 100 Jackson ImmunoResearch 
Rat IgG (H+L) Donkey AMCA 1 in 100 Jackson ImmunoResearch 
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4.3.6 Immunofluorescence Labelling 
Following optimisation the final method for immunofluorescence staining of settled PBMCs 
and antigen retrieved FFPE lymph node sections is described below.  
A circle was drawn onto the slide around the visible specimen with ImmEdge™ pen (Vector 
laboratories Inc.). The sections were next pre-hydrated in PBS for 30 minutes. The PBS was 
removed and 5% donkey serum (Jackson ImmunoResearch) added for 1 hour at 4°C to block 
non-specific antibody binding. Primary antibodies were diluted in PBS as listed in Table 4-1. 
A final volume of 400µl was added to each slide, which was incubated for 2 hours at RT. 
Primary antibodies were removed by washing the slide for 10 minutes in PBS 3 times. The 
secondary antibodies were diluted according to Table 4-2 and 400µl of final solution was 
added to each slide, which was incubated for 2 hours at RT in the dark. Samples were again 
washed for 10 minutes in PBS 3 times. Slides were carefully dried and a mounted with a 
coverslip using ProLong® gold antifade reagent (Invitrogen). Negative, single and multiply 
stained slides were prepared for each sample. For the multi-parameter staining experiments, 
all secondary antibodies were added to the negative and single labelled controls to control for 
non-specific binding. 
4.3.7 Microscopy and Image Acquisition 
Multi-parameter fluorescence microscopy was performed using the Zeiss Axiovert 200 
inverted microscope system (Carl Zeiss MicroImaging). The microscope is fitted with the 
following objectives; LD Plan-NeoFluor 20x/0.4, Plan-Apochromat 40x/1.0 oil iris, Plan-
Apochromat 100x/1.0 oil iris. The microscope is fitted with four filter cube sets allowing a 
maximum of four colour visualisation, the set up allows for visualisation with DAPI, FITC, Cy3 
and Cy5. Therefore a single slide can be labelled with a maximum of four fluorochromes 
(antigens). The filter cubes must be manually put in place to acquire the image produced by 
the associated fluorochrome. There will be some spectral overlap as other fluorochromes 
present on the slide may also be excited / visualised to some extent depending on the 
wavelength. A single image is captured for each fluorochrome through the appropriate filter 
and then the final image is constructed by overlaying the images generated from each 
fluorochrome. The exposure times were optimised for minimal autofluorescence and then 
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consistently applied across the sections. Random microscope fields for each slide were 
chosen for image capture, avoiding areas of haemorrhage. Images were captured using 
AxioCam MRm high resolution microscopy camera (Carl Zeiss MicroImaging) and image 
analysis was performed on AxioVisonLE software (Carl Zeiss MicroImaging) and NIS 
Elements AR Microscope Imaging Software (Nikon Corporation, Tokyo, Japan).  
4.4 Results 1 – Optimisation Experiments 
4.4.1 Immunofluorescence labelling of settled cells 
Due the limited availability of the primary lymph node tissue samples we first undertook 
optimisation experiments by indirect immunofluorescence labelling of CLL cells settled on 
poly-lysine slides. Initially we opted to use directly conjugated antibodies but this method did 
not provide an adequate fluorescent signal for detection (data not shown).  A combination of 
CD5, CD79a, CD38, CD49d and Ki67 primary antibodies were used to optimise the technique 
as these antibodies have been successfully used previously in our laboratory. The major 
technical challenges of this pilot was ensuring that the immunofluorescence staining was 
specific, with positive and negative controls showing no non-specific binding. An example 
matrix of controls is shown in Table 4-3 below. This shows that for dual antigen staining on a 
single specimen an additional 4 control slides were required. 
Table 4-3 Immunofluorescence control slide matrix 
Five slides are required for adequate positive and negative controls of two colour 
immunofluorescence staining on slides. Matrix is as follows: A1 (negative control), A2 (DAPI 
and both secondary antibodies), A3 (DAPI and primary 1 and both secondary antibodies), A4 
(DAPI, primary 2 and both secondary antibodies), A5 (DAPI, primary 1 and 2 and both 
secondary antibodies). 
 
Slide DAPI Primary 1 Primary 2 Secondary 
to Primary 1 
Secondary 
to Primary 2 
A1 - - - - - 
A2 ✓ - - ✓ ✓ 
A3 ✓ ✓ - ✓ ✓ 
A4 ✓ - ✓ ✓ ✓ 
A5 ✓ ✓ ✓ ✓ ✓ 
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Images were captured for each of the control slides separately, using all the filters of the 
microscope with the exposure time optimised and then consistently applied. The manual 
nature of the specific microscope set-up in our laboratory made controlling the exposure times 
a critical step in the image acquisition. Initially optimising controls and non-specific binding of 
secondary antibodies to cells in the absence of a primary antibody was problematic. This was 
overcome by a series of stepwise experiments changing incubation times, adding an 
additional blocking step with donkey serum and from gaining technical expertise with the 
microscope. An example of the acquired images from the matrix in above Table 4-3 is shown 
in Table 4-4 below, showing successful staining of settled PBMCs. 
Table 4-4 Staining matrix of settled CLL B-cells on slides 
Selected CLL B-cells were allowed to settle for 24 hours and labelled as described. Positive 
and negative control slides are stained as per the matrix outlined in Table 4-3. Multi-parameter 
fluorescence microscopy was performed using the Zeiss Axiovert 200 inverted microscope 
system (Carl Zeiss MicroImaging). A single image is captured for each fluorochrome through 
the appropriate filter and then the final overlay image is constructed by overlaying the images 
generated from each fluorochrome channel. The exposure times were optimised for minimal 
autofluorescence and then consistently applied across the sections. Images were captured 
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4.4.2 Fluorescence labelling of lymph node sections 
Once the technical skills of slide labelling were achieved the next step was to successfully 
singly label FFPE lymph node sections with fluorescence markers. The multiparameter 
immunofluorescence staining of FFPE lymph node posed many technical challenges that were 
not experienced to such a degree with settled cells on slides. The first issue encountered was 
that of autofluorescence. Autofluorescence is well known to create significant issues in 
fluorescence microscopy and is based on the fact that many biological molecules have 
inherent fluorescent properties and the emission spectra tends to wide compared to the 
narrow spectra of fluorescence probes (Van de Lest, Versteeg et al. 1995). Significant 
molecules in human tissues exhibit this phenomenon including elastin, collagen, fibronectin 
and lipofuscin; this is natural fluorescence. Formaldehyde has properties of fixative-induced 
fluorescence, this is caused when aldehydes react with amines and proteins resulting in a 
fluorescent product which is seen in the green (FITC) channel (Billinton and Knight 2001). The 
best ways of minimising this issue is by carefully choosing the excitation wavelength, 
excitation power and microscope aperture, fluorochrome and to perform filtering during image 
acquisition. If a weak fluorochrome is used or an antigen expressed at low density it can be 
difficult to visualise on a background of autofluorescence. If these considerations are not taken 
into account misinterpretation of results can result. FFPE lymph node samples exhibit high 
levels of autofluorescence, which is most significantly related to formaldehyde and also elastin 
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Figure 4-2 is a cautionary example, where a slide section image is captured with no primary 
or secondary fluorescence antibody present at all. This image is obtainable simply by 
increasing the cameras exposure time in the FITC channel.  
 
Figure 4-2 Autofluorescence in unstained CLL lymph node in FITC channel, magnification x10 
This example FFPE section of a CLL lymph node was dewaxed, rehydrated and antigen 
retrieved using a citrate buffer as described. Multi-parameter fluorescence microscopy was 
performed directly using the Zeiss Axiovert 200 inverted microscope system (Carl Zeiss 
MicroImaging). No primary of secondary antibodies are present. This image was captured in 
the FITC channel using the AxioCam MRm high resolution microscopy camera (Carl Zeiss 
MicroImaging) demonstrating autofluorescence.   
 
This highlights the need for strict negative controls in all fluorescence experiments. Several 
technical protocols are available to try and reduce the fixative induced fluorescence, for 
example using sodium borohydride or trypan blue.  During this period of initial optimisation 
experiments CLL lymph node sections and normal reactive lymph nodes were labelled with 
antibody combinations previously used in our laboratory.  
Figure 4-3 shows the successful labelling of CLL B-cells with CD23 using a donkey anti-goat 
Cy5 secondary antibody. The negative controls showed no background fluorescence.  
Following considerable optimisation, single immunofluorescence staining of CD4 in a CLL LN 
is shown in Figure 4-4 using the Cy3 channel.  
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Figure 4-3 CD23+ CLL cells labelled with Cy5 (red), magnification x10 
This example CLL LN FFPE section was processed as described in Figure 4-2. The sample 
was labelled with the primary antibody CD23 (goat) and the secondary antibody conjugated 
to Cy5 (donkey anti-goat IgG). This image was captured in the Cy5 channel using the AxioCam 





Figure 4-4 CD4 labelled with Cy3 (blue) in a CLL lymph node, magnification x10  
This example CLL LN FFPE was labelled with the primary antibody CD4 (mouse) and the 
secondary antibody conjugated to Cy3 (donkey anti-mouse IgG). This image was captured in 
the Cy3 channel using the AxioCam MRm high resolution microscopy camera. The negative 
controls showed no background fluorescence. 
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In order to validate the findings from the LN FNA analysis in chapter 3, we next sought to 
optimise PD-1 labelling. Successful staining with PD-1 in the Cy5 channel is shown in a normal 
lymph node in Figure 4-5 and a CLL lymph node section is shown in Figure 4-6. 
 
Figure 4-5 PD-1 labelled with Cy5 (red) in a normal reactive lymph node, magnification x10 
This example normal reactive LN FFPE was labelled with the primary antibody PD-1 (goat) 
and the secondary antibody conjugated to Cy5 (donkey anti-goat IgG). This image was 
captured in the Cy5 channel using the AxioCam MRm high resolution microscopy camera. 
The negative controls showed no background fluorescence. 
 
Figure 4-6 PD-1 labelled with Cy5 (red) in a CLL lymph node, magnification x10 
This example CLL LN FFPE was labelled with the primary antibody PD-1 (goat) and the 
secondary antibody conjugated to Cy5 (donkey anti-goat IgG). This image was captured in 
the Cy5 channel using the AxioCam MRm high resolution microscopy camera. The negative 
controls showed no background fluorescence. 
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The most striking visual observation of the PD-1 fluorescence pattern in CLL was the 
apparently random, less bright and diffuse expression in CLL compared to the bright and 
organised pattern in the normal reactive node, where the structure of a reactive germinal 
centre can be observed.  
As the ultimate aim of this study was to examine the relationship between proliferating CLL 
cells and T-cells we decided to utilise Ki67 as a marker of proliferation. Ki67 was first optimised 
using the secondary donkey anti-rabbit antibody conjugated to Cy3. However this was 
subsequently substituted by donkey anti-rabbit FITC secondary antibody. As discussed 
autofluorescence is most marked in the FITC channel, therefore as Ki67 has a very specific 
nuclear staining pattern it was much easier to identify genuinely positive cells from the 
background of autofluorescence than when FITC was used for a cytoplasmic antigen. Post-
acquisition image analysis was made much less complicated following this change. 
 A normal reactive lymph node, shown in Figure 4-7, is labelled with Ki67 in (FITC). This image 
clearly shows the architecture of a normal germinal centre. Figure 4-8 and Figure 4-9 shows 
the Ki67+ distribution in a representative CLL sample.  
 
 
Figure 4-7 Ki67 green labelled with FITC (green) in a normal germinal centre, magnification 
x10 
This example normal reactive LN FFPE was labelled with the primary antibody Ki67 (rabbit) 
and the secondary antibody conjugated to FITC (donkey anti-rabbit IgG). This image was 
captured in the FITC channel using the AxioCam MRm high resolution microscopy camera. 
The negative controls showed minimal background autofluorescence. 
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 A 
Figure 4-8  Ki67 cells labelled with FITC (green) in a CLL lymph node, magnification x10  
This example CLL LN FFPE was labelled with the primary antibody Ki67 (rabbit) and the 
secondary antibody conjugated to FITC (donkey anti-rabbit IgG). This image was captured in 
the FITC channel using the AxioCam MRm high resolution microscopy camera. The negative 




Figure 4-9 The nuclear staining of Ki67 can be appreciated at high power, magnification x 40 
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The normal reactive lymph node, shown in Figure 4-7, labelled with Ki67, shows the 
architecture of a normal reactive germinal centre. This pattern was in stark contrast to the 
diffuse fluorescence pattern seen in CLL in Figure 4-8 and Figure 4-9. In all the cases 
examined the pattern was visually comparable between lymph nodes of different patients. No 
residual normal germinal centres were seen in any of the CLL cases in this study. Additionally 
there was no clear evidence of areas with a higher concentration of Ki67 cells, which may 
have been anticipated to correlate with “proliferation centres”, which can be identifiable as 
pale staining areas by conventional immunohistochemistry using Haematoxylin and Eosin 
(H&E).  
4.4.3 Multiparameter immunofluorescence of lymph node sections 
Following on from the single labelling studies, we proceeded to dual and triple labelling of the 
tissue sections. Figure 4-10 and Figure 4-11 shows the successful staining of CLL LNs with 
CD23+ and proliferating Ki67+ cells in the same section.  
 
Figure 4-10 CD23 labelled with Cy5 (red) and Ki67 labelled with Cy3 (green) in a CLL lymph 
node, magnification x10  
This example CLL LN FFPE was labelled with two primary antibodies; CD23 (goat) and Ki67 
(rabbit) and both secondary antibodies, one conjugated to Cy5 (donkey anti-goat IgG) and the 
other to FITC (donkey anti-rabbit IgG). Images were captured in the Cy5 and FITC channels 
using the AxioCam MRm high resolution microscopy camera. The negative controls showed 
minimal background autofluorescence. The Image shown is the overlay from the two images 
acquired and visualised using AxioVisonLE software. 
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Figure 4-11 CD23 labelled with Cy5 (red) and Ki67 labelled with Cy3 (green) in a CLL lymph 
node, magnification x40  
High power visualisation of the CLL LN shown in Figure 4-10. 
Next we performed dual labelling of CD4+ cells and Ki67. A normal reactive lymph node is 
shown in Figure 4-12 and a CLL lymph node in Figure 4-13.  
  
Figure 4-12 Ki67 labelled with FITC (green) and CD4 with Cy3 (blue) in a normal lymph node, 
magnification x10 
This example normal reactive LN FFPE was labelled with two primary antibodies; Ki67 (rabbit) 
and CD4 (mouse) and both secondary antibodies, one conjugated to FITC (donkey anti-rabbit 
IgG) and the other to Cy3 (donkey anti-mouse IgG). Images were captured in the FITC and 
Cy3 channels using the AxioCam MRm high resolution microscopy camera. The negative 
controls showed minimal background autofluorescence. The Image shown is the overlay from 
the two images acquired and visualised using AxioVisonLE software. 
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Figure 4-13 Ki67 labelled with FITC (green) and CD4 with Cy3 (blue) in a CLL lymph node, 
magnification x10  
This example CLL LN FFPE was labelled with two primary antibodies; Ki67 (rabbit) and CD4 
(mouse) and two secondary antibodies, one conjugated to FITC (donkey anti-rabbit IgG) and 
the other to Cy3 (donkey anti-mouse IgG). Images were captured in the FITC and Cy3 
channels using the AxioCam MRm high resolution microscopy camera. The negative controls 
showed minimal background autofluorescence. The Image shown is the overlay from the two 
images acquired and visualised using AxioVisonLE software. 
 
Following this, CLL lymph node sections were successfully labelled with 3 markers. First 
CD23, CD4 and Ki67, see Figure 4-14. This shows the close proximity of Ki67+ CLL cells with 
CD4+ T-cells, as previously reported by our group (Patten, Buggins et al. 2008).  
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Figure 4-14 CLL lymph node triple labelled with CD23 (red), CD4 (blue) and Ki67 (green), 
magnification x40 
This example CLL LN FFPE was labelled with three primary antibodies; CD23 (goat), Ki67 
(rabbit) and CD4 (mouse) and three secondary antibodies, one conjugated to Cy5 (donkey 
anti-goat IgG), one to FITC (donkey anti-rabbit IgG) and the other to Cy3 (donkey anti-mouse 
IgG). Images were captured in the Cy5, FITC and Cy3 channels using the AxioCam MRm high 
resolution microscopy camera. The negative controls showed minimal background 
autofluorescence. The Image shown is the overlay from the three images acquired and 
visualised using AxioVisonLE software. 
  
As the main purpose of this work was to investigate PD-1hi T-cells we next optimised the 
multicolour staining with PD-1. PD-1 and Ki67 dual labelling in a normal germinal centre is 
shown in Figure 4-15 and a representative CLL lymph node in Figure 4-16. 
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Figure 4-15 Ki67 labelled with FITC (green) and PD-1 labelled with Cy5 (red) in a germinal 
centre of a normal lymph node, magnification x10 
This example normal reactive LN FFPE was labelled with two primary antibodies; Ki67 (rabbit) 
and PD-1 (goat) and two secondary antibodies, one conjugated to FITC (donkey anti-rabbit 
IgG) and the other to Cy5 (donkey anti-goat IgG). Images were captured in the FITC and Cy5 
channels using the AxioCam MRm high resolution microscopy camera. The negative controls 
showed minimal background autofluorescence. The Image shown is the overlay from the two 
images acquired and visualised using AxioVisonLE software. 
 
 
Figure 4-16 Ki67 labelled with FITC (green) and PD-1 labelled with Cy5 (red) in a CLL lymph 
node, magnification x40 
High power visualisation of the CLL LN shown in Figure 4-15. 
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Finally we successfully simultaneously stained CD4, PD-1 and Ki67 on the same slide. All the 
appropriate positive and negative controls were performed for each channel (data not shown). 
Figure 4-17 and Figure 4-18 shows a normal germinal centre and the relationship between T-
cells, PD-1+ cells and Ki67 cells can be readily appreciated. Interestingly a distinct pattern of 
cellular distribution can be seen in the normal germinal centre. The germinal centre itself 
shows polarity, with the Ki67 (green) cells localised in the dark zone and the PD-1hi (red) T-
cells (blue) are localised in the light zone, consistent with previous publications (De Silva and 
Klein 2015). 
 
Figure 4-17 Normal germinal centre in a reactive lymph node. Ki67 (green), CD4 (blue) and 
PD-1 (red), magnification x10 
This example reactive normal LN FFPE was labelled with three primary antibodies; Ki67 
(rabbit), CD4 (mouse) and PD-1 (goat) and three secondary antibodies, one conjugated to 
FITC (donkey anti-rabbit IgG), one to Cy3 (donkey anti-rabbit IgG) and the other to Cy5 
(donkey anti-goat IgG). Images were captured in the FITC, Cy3 and Cy5 channels using the 
AxioCam MRm high resolution microscopy camera. The negative controls showed minimal 
background autofluorescence. The Image shown is the overlay from the three images 
acquired and visualised using AxioVisonLE software. 
 
 
- 182 - 
 
Figure 4-18 Normal germinal centre in a reactive lymph node. Ki67 (green), CD4 (blue) and 
PD-1 (red), magnification x40. The blue and red positive cells (CD4 and PD-1) are pink/purple. 
High power visualisation of the germinal centre of the normal reactive LN shown in Figure 
4-17. The overlay image in higher magnification shows clearly the cells that are CD4+ and 
PD-1+ are pink/purple.  
The ultimate aim of this work was to stain a CLL lymph node with CD4, PD-1 and Ki67, this 
would enable analysis of the spatial interactions between these cell types.  
Figure 4-19 and Figure 4-20 show a representative example of the staining pattern in a CLL 
lymph node. Here the distinct normal germinal centre pattern cannot be appreciated. Once 
this technical method was optimised, it enabled the successful staining of multiple CLL LN 
samples from different patients to be undertaken. 
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Figure 4-19 CLL lymph node stained for Ki67 labelled with FITC (green), CD4 with Cy3 (blue) 
and PD-1 with Cy5 (red), magnification x10.  
This example CLL LN FFPE was labelled with three primary antibodies; Ki67 (rabbit), CD4 
(mouse) and PD-1 (goat) and three secondary antibodies; conjugated to FITC (donkey anti-
rabbit IgG), Cy3 (donkey anti-rabbit IgG) and Cy5 (donkey anti-goat IgG). Images were 
captured in the FITC, Cy3 and Cy5 channels using the AxioCam MRm high resolution 
microscopy camera. The blue and red positive cells (CD4 and PD-1) are pink/purple. The 
negative controls showed minimal background autofluorescence. The Image shown is the 
overlay from the three images acquired and visualised using AxioVisonLE software.  
 
 
Figure 4-20 CLL lymph node stained for Ki67 labelled with FITC (green), CD4 with Cy3 (blue) 
and PD-1 with Cy5 (red), magnification x40.  
High power visualisation of the CLL LN shown in Figure 4-19. The overlay image in higher 
magnification shows clearly the cells that are CD4+ and PD-1+ are pink/purple. 
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4.5 Results 2 - Image Analysis 
4.5.1 Analysing co-expression of CD4 and PD-1 on FFPE LN samples 
Once the technique of antibody staining method on FFPE lymph node samples was optimised, 
patient samples were processed in a consistent manner going forward. The first question we 
wanted to answer was identify whether the CD4+ T-cells in the lymph node biopsy sections 
also expressed PD-1 as found in the LN FNA samples. To address this we had to adopt a 
robust method of analysing the immunofluorescence images. The methods for approaching 
this type of study are not uniform and extreme caution must be adopted when analysing 
images. Images from unselected fields were captured, excluding areas with extensive 
haemorrhage and therefore high background autofluorescence. The images were acquired 
from the microscope camera and stored as proprietary Zeiss “zvi” files, these were then 
exported as uncompressed lossless Tagged Image File Format (tiff) files. It must be realised 
that if any compressed format of image is used data from the image is lost and integrity of 
analysis compromised. “Lossy” compression is a feature of many file formats including “Jpeg” 
(Joint Photographic Experts Group) and these should not be used (Kabachinski 2007).  It is 
also important to remember that the actual images are black and white and that the 
red/blue/green channels are entirely artificial overlays on the image for visualisation purposes. 
Therefore these potential pitfalls must be guarded against when analysis is undertaken. 
Identifying and mastering a method to analyse the images to answer specific questions was 
technically challenging. The AxioVisonLE software (Carl Zeiss MicroImaging) did not have 
adequate functionality to enable this work.  Therefore we decided to proceed with initial 
analysis using visual inspection of the image and manual counting of positive cells as 
previously published (Patten, Buggins et al. 2008). This proved to be very time consuming 
and difficult to validate. Subsequently we had access to use the facilities at the Nikon Imaging 
Centre at King’s College London (KCL). The NIS Elements AR Microscope Imaging Suite 
offered the best software solution for our needs.  
Here I shall summarise the image analysis technique we employed. Initially the “threshold” of 
the image needs setting; put simply this step informs the software which area of the image is 
“positive” (i.e. antigen present) and which is “negative” (antigen absent). The thresholding can 
be set to inform the software when the image intensity is too bright or too dim to be considered 
- 185 - 
positive; thus demarcating the image assigned as “positive” and defining an area of interest. 
Where there are two fluorochromes on a slide there will be two associated image layers; one 
for fluorochrome/antigen 1 and one for fluorochrome/antigen 2. Thresholding is performed 
separately for each layer of an image and in the NIS software these images are called “binary 
layers”. Each thresholded binary layer can be assigned a colour for convenience and for ease 
of visualisation; these layers can then be saved for later analysis. The binary layers can be 
converted to “regions of interest” or “objects”. The region of interest can be refined 
mathematically to exclude areas that are judged too big or too small according to the users 
own defined parameters. Objects can be assigned an individual number to “tag” them, which 
enables cell counting and for individual cells to be analysed, this can then be manually verified 
on the image.  
Once the user has defined two binary layers (regions of interest or objects) the software can 
compare the two layers to look for overlap and therefore infers the presence of two antigens 
on same cell. The software generates the Boolean “AND”; forming a new layer of the 
intersection from the two layers. It can also generate the Boolean “OR”; and a new layer is 
formed where either of the two layers are present. If individual cells on a slide have been 
defined as objects the thresholded region of interest of the second or third layer can be 
overlaid and the software can then calculate the number of objects (cells) that intersect with 
defined regions of interest. This quantitates whether two or three fluorochromes do or do not 
overlap on a cell of interest. Figure 4-21 shows the stepwise approach. 
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Figure 4-21 Thresholding and Overlap 
 The original image is first split into its image layers from the time of acquisition. The image 
layers are converted to binary layers by thresholding the images. The two binary layers are 
combined and an overlap is produced (visualised in yellow). 
 
4.5.2 CD4+ and PD-1+ co-expression on FFPE LN samples mirrors the findings of the 
LN FNA 
The first analysis we performed was to confirm whether the CD4+ T-cells in the LN biopsy 
sample co-expressed PD-1. Nine individual CLL lymph nodes from different patients were 
examined. A median of 7 different fields were analysed per patient (range 4-15). Each 
experiment was repeated on average twice.  
The data for each patient analysed is shown in Figure 4-22. Every dot represents an individual 
field in that patient. 
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Figure 4-22 Percentage of CD4+ T-cells expressing PD-1 across the 9 CLL samples.  
Slides were labelled for CD4 and PD-1 as described in Figure 4-19. Nine individual CLL lymph 
nodes were examined (CLL LN sample ID 1-9). Binary layers of CD4+ and PD-1+ were 
constructed as described in Figure 4-21 and analysed using NIS Elements AR Microscope 
Imaging Suite. A median of 7 random fields were analysed per sample (range 4-15). Each 
experiment was repeated on average twice. Each data point represents the percentage of 
CD4+ T-cells that are also PD-1+ in each individual field. The number of CD4+ PD-1+ T-cells 
per image was normally distributed both within patient samples and between patients by a 
D’Agostino and Pearson omnibus normality test. 
 
The number of CD4+ PD-1+ T-cells per image was normally distributed both within patient 
samples and between patients by D’Agostino and Pearson omnibus normality test.  
Overall a median of 49.77% +/- 4.99 of the CD4+ T-cells were PD-1 positive. This compared 
to 56.42% +/- 4.02 in the fresh LN FNA sample data presented in chapter 3. An unpaired t-
test was used to compare the number of CD4+ PD-1hi T-cells observed in the LN FNA study 
from chapter 3 and the LN FFPE samples presented here. There was no statistical difference 
between the median number of CD4+ PD-1+ T-cells found in the LN FNA study (n=21) 
compared to the FFPE (n=9); p=0.40), confirming the validity of the FNA results. See Figure 
4-23.  
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Figure 4-23 Comparison between percentage CD4+ T-cells expressing PD-1 in fresh LN FNA 
samples and FFPE LN biopsy sections.  
By flow cytometry, 56.42% +/- 4.02 of LN FNA CD4+ T-cells were also PD-1+ (n=21) (data 
set presented in Chapter 3, Figure 3-34). This compares to 49.77% +/- 4.99 in the FFPE LN 
samples (n=9), data set presented in Figure 4-22. There was no difference between these two 
methods; p=0.40. Statistical analysis was with a D’Agostino and Pearson omnibus normality 
test and unpaired t-test. 
 
4.5.3 The majority of Ki67+ cells in CLL lymph node are contacting a CD4+ PD-1+ T-cell   
The next question was whether the CD4+ PD-1+ T-cells were in close contact with Ki67+ 
proliferating CLL cells. To address this a binary layer was made for the intersection of CD4+ 
AND (Boolean) PD-1+ areas as above. Then a binary layer was made of the Ki67+ cells. 
Several algorithms were tried to make the Ki67 binary layer, before an optimal method was 
devised.  
As stated previously Ki67 was visualised in the FITC channel, and images in this channel have 
the disadvantage of unavoidable background autofluorescence. This can be manually visually 
overcome, as the Ki67 is a very specific staining pattern; but the software cannot easily make 
this distinction. Therefore when the FITC positivity was assigned by thresholding alone then 
the background autofluorescence was also included in the binary layer. Therefore, two 
methods of analysis had to be employed. Firstly the image was thresholded and then the 
“region of interest” identified manually. There needed to be a stringent deletion of thresholded 
areas inappropriately assigned as a region of interest. The software can be programmed to 
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ignore regions of interest below and above a defined size, which are deemed too small or too 
big to represent a cell, although this did not negate the requirement of a manual sense check. 
As all the individual Ki67+ cells can be identified as distinct objects by eye, we therefore 
manually assigned the genuine individual cells onto the thresholded layer. The objects were 
then dilated to increase the size of the region of interest to that of the whole cell. At the end of 
this process a layer was formed with multiple cells identified as Ki67+. The software then 
tagged the cells and assigned each individual Ki67+ cell a cumulative number and a new 
image layer is formed. The Boolean AND / OR script can then be applied to this layer and 
another layer with a defined region of interest. We therefore asked whether there was any 
overlap with the Ki67 layer and the CD4+ PD-1+ binary layers. Figure 4-24 shows the stepwise 
process in undertaking this analysis.  
 
Figure 4-24 Objects and Regions of interest 
The original image is split into its original layers and thresholded to produce binary layers as 
before. The Ki67 layer is converted to numeric objects. The overlapping binary of CD4 AND 
PD-1 is defined as the region of interest. Then the number of objects (Ki67 cells) that overlap 
with the region of interest (CD4+/PD-1+ cells) can be calculated.   
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The software generates a spreadsheet of all Ki67+ cells overlapping with cells that are CD4+ 
AND PD-1. We can therefore calculate the median percentage of the total number of Ki67+ 
cells that were touching a CD4+ / PD-1+ T-cells per field.  
Six individual patients lymph node samples were examined, once again on average on two 
separate occasions, with a median of number of fields analysed per sample being 6 (range 4-
10). The data derived from the 6 patients is shown in Table 4-5 and Figure 4-25. 
Table 4-5 Analysis of Ki67 on CLL FFPE sections  
FFPE CLL lymph node sections from 6 individual patients (CLL1-6) were analysed. Slides 
were labelled as described in Figure 4-19. Binary layers were made and overlapping objects 
(Ki67+ cells) and regions of interest (CD4+ AND PD-1+ cells) were calculated as described in 
Figure 4-24 using NIS Elements AR Microscope Imaging Suite. A median of 6 random fields 
were analysed per sample.  
Sample  Mean number  
 of Ki67+ cells 
 per field 
Mean number 










percentage of  
Ki67 touching 
CD4+/PD-1+   
CLL1   53.6 34.8 18.8 63.4% 
CLL2  62.7 36.7 26.0 61.7% 
CLL3  19.5 14.5 5 66.7% 
CLL4  111.7 101.4 10.3 91.1% 
CLL5  47.7 37.7 10 77.2% 
CLL6  18.3 15.8 2.5 85.0% 
 
There was a median of 50.65 Ki67+ cells per field (range 18-111). The mean percentage of 
Ki67+ cells overlapping with a CD4+ / PD-1+ T-cell in the whole population was 74.18% +/- 
14.01. See Figure 4-25. 
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Figure 4-25 Percentage of Ki67+ cells overlapping with a CD4+ PD-1+ T-cell  
Experimental details as described in Table 4-5. This data here shows a mean percentage of 
74.18% of Ki67+ cells overlap with a CD4+ / PD-1+ T-cell across all fields examined (n= 40) 
from the total patient cohort (n=6).  
The range of Ki67+ cells per field was large but there was no correlation between number of 
Ki67+ cells per field and likelihood of touching a CD4+ PD-1+ T-cell (r=0.259) see Figure 4-26.  
 
Figure 4-26 No correlation between number of Ki67+ cells per field and the likelihood of 
touching a CD4+ PD-1+ T-cell 
The correlation between the number of Ki67+ cells per field and the percentage of Ki67+ 
touching a CD4+ PD-1+ T-cell across all 40 fields was determined by calculating the Pearson 
correlation coefficient, no correlation was found; Pearson’s r=0.259. 
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4.5.4 The majority of PD-1+ T-cells in CLL LN samples do not have a Tfh phenotype 
The normal germinal centre is shown in Figure 4-17. It can be seen that the distribution of the 
CD4+ PD-1+ T-cells in the normal reactive lymph node is vastly different to that in the CLL 
lymph node shown in Figure 4-19. In the reactive lymph nodes germinal centres Ki67+ 
proliferating cells can be clearly visualised organised into a distinct structure with a 
surrounding polar halo of CD4+ PD-1+ T-cells; conversely there is no such clear 
organisational structure to the CLL lymph node. It can also be readily appreciated that the 
intensity of PD-1 fluorescence in the normal germinal centre appears much higher than that 
seen in the CLL lymph node. The PD-1 very bright T-cells in the light zone of a normal germinal 
centre are the Tfh cells. Wang et al designated these cells as PD-1+++ memory T-cells; they 
localise to the rim of the germinal centre and co-express CXCR5 and CXCR4 (Wang, 
Hillsamer et al. 2011).  These Tfh cells produce IL-21 and CXCL13 and offer B-cell help. Tfh 
cells are critical in the normal B-cells development as discussed in the introductory chapter. 
They provide differentiation signals to germinal centre B-cells and mediate the selection of 
high affinity B-cell clones allowing them to become mature plasma cells (Linterman 2014).  Tfh 
cells have recently been reported to be found at in increased numbers in the PB of CLL 
patients compared to healthy controls (Ahearne, Willimott et al. 2013), data we confirmed in 
the previous chapter.  
To confirm the presence of CD4+ cells with the phenotype of the Tfh in normal lymph nodes, 
and to look for evidence of Tfh cells in CLL lymph nodes we initially chose to use the marker 
CXCR5 in combination with PD-1 (Schaerli, Willimann et al. 2000, Haynes, Allen et al. 2007, 
Wang, Hillsamer et al. 2011). We quickly ran into problems as CLL cells also express CXCR5 
making the image analysis technically very difficult, see Figure 4-27.  
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Figure 4-27 CXCR5 staining of a CLL LN with DyLight™ 549 (red) reveals all cells to be 
positive  
This example CLL LN FFPE was labelled with the primary antibody CXCR5 (rat) and the 
secondary antibody conjugated to DyLight™ 549 (donkey anti-rat IgG). This image was 
captured in the Cy3 channel using the AxioCam MRm high resolution microscopy camera, 
magnification x10. All cells appear red. The negative controls showed no background 
fluorescence.  
Therefore to move this work forward we chose to substitute CXCR5 with ICOS which is also 
a marker of Tfh cells (Schaerli, Willimann et al. 2000, Akiba, Takeda et al. 2005).  
This labelling was conducted by Dr William Townsend, a Clinical Research Fellow in our 
group. A comparison was made between the percentages of CD4+ PD-1hi T-cells which co-
express ICOS in normal germinal centres and CLL patients. Lymph nodes from 6 CLL patients 
were labelled with CD4, PD-1 and ICOS. A median of 5 fields were examined per patient 
(range 4-5). The analysis was undertaken by creating binary layers of the individual markers 
and looking for overlap as described. In CLL PD-1 positivity was observed in 54.17% +/- 4.26 
of the CD4+ T-cells, confirming the results reported above on separate cohort of CLL LN 
samples.  
This also adds further validation to the results already presented, as these experiments were 
performed and analysed by a different operator.  ICOS+ was present on 9.0% +/-2.33 of the 
CLL CD4+ PD-1+ cells (range 2-16%). Therefore 91% of the CD4+ PD-1+ T-cells are not 
ICOS+ and therefore do not represent Tfh cells in the CLL LN.  
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In the normal reactive lymph nodes microscopy fields from the germinal centre and non-
germinal centre were analysed (n=6). PD-1 was expressed on 49% +/- 5.26 of the CD4+ T-
cells of the normal germinal centre. Of the CD4+ T-cells 33.0% +/-5.24 were dual PD-1+ and 
ICOS+ and therefore these are Tfh cells. In the non-germinal centre areas only 0.46% +/- 0.23 
CD4+ cells also co-expressed PD-1+ and ICOS+.  
These results confirm that in the normal germinal centre there is a high number of Tfh cells 
which is in contrast to CLL where the PD-1+ CD4+ T-cells more closely resemble the T-cells 
of the normal inter-follicular areas. See Figure 4-28.  
 
Figure 4-28 The majority of CD4+ T-cells in the CLL LN are not Tfh cells  
FFPE CLL LN sections from 6 individual patients and 6 normal reactive LN were analysed. 
Slides were labelled with CD4, PD-1 and ICOS. Binary layers of CD4+, PD-1+ and ICOS were 
constructed as described in Figure 4-21 and analysed using NIS Elements AR Microscope 
Imaging Suite. Tfh cells are defined here as CD4+/PD-1+/ICOS+. A median of 5 fields were 
examined per slide. In the normal reactive LN, fields were assigned visually to be germinal 
centres (GC) and non-germinal centres (Non GC). In the normal GC 33.0% +/-5.24 of CD4+ 
T-cells are Tfh cells whereas in the non-germinal centre areas they account for only 0.46% +/- 
0.23 (p=0.08). In the CLL sample Tfh cells accounted for 9.0% +/-2.33 of the CD4+ T-cells. 
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4.6 Discussion 
The aim of the work outlined in this chapter was to complement the findings described in 
chapter 3. The results from the lymph node FNA phenotyping informed the choice of antigens 
investigated here. Firstly, the aim was to confirm the presence of CD4+ PD-1+ T-cells in the 
CLL lymph node and to investigate the spatial relationship between the different cell types. 
CD4+ T-cells are known to be in close contact with proliferating B-cells but little more is known 
of the phenotype of these T-cells (Patten, Buggins et al. 2008). Since the flow cytometry 
studies described in chapter 3 indicated that CLL LNs contain numerous CD4+ PD-1hi T-cells, 
we investigated whether it was these cells that contact proliferating CLL cells. In a normal 
germinal centre, antigen responsive helper T-cells supply growth promoting signals to B-cells, 
so in this study we sought to determine whether the same process might occur in CLL LNs.  
Multiparameter immunofluorescence microscopy of FFPE lymph nodes sections is technically 
challenging, however we were able to develop a robust method of immunostaining, image 
acquisition and systematic analysis of the resulting data.  
This work confirmed that there is a high level of PD-1 expression on CD4+ T-cells in CLL 
lymph nodes. This confirms the results presented in chapter 3 and the study by Xerri et al who 
previously demonstrated PD-1 to be present on CLL LN sections. It also complements the 
data presented here and from recent studies which have found PD-1 to be expressed at higher 
levels on the T-cells of the PB in CLL patients compared to normal controls (Nunes, Wong et 
al. 2012, Ramsay, Clear et al. 2012, Brusa, Serra et al. 2013, Riches, Davies et al. 2013, 
Novak, Prochazka et al. 2015, Rusak, Eljaszewicz et al. 2015).   
Our group had previously reported that the T-cells within the CLL LN express the activation 
marker CD25 and these results give further evidence of T-cell activation. Brusa et al recently 
published that levels of PD-1 increase with T-cell activation with CD3/CD28 beads, data which 
is confirmed in chapter 6 of this thesis. Our data shows that PD-1 is increased in CLL CD4+ 
T-cells of the LN and this suggests that there is in vivo T-cell activation ongoing in the LN.   
Brusa also showed that the PD-1 T-cells within the lymph node are in contact with PD-L1+ 
CLL cells (Brusa, Serra et al. 2013). We have additionally demonstrated that the CD4+ PD-
1+ T-cells are not simply in contact with CLL B-cells but they contact the proliferating 
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component of the CLL lymph node microenvironment. We have specifically shown that the 
CD4+ PD-1+ T-cells are in contact with Ki67+ B-cells, suggesting a specific recruitment to the 
tumour. Two groups have reported that PD-1 positivity in CLL lymph nodes has two patterns 
diffusely positivity or locally concentrated within proliferation centres in CLL when using 
standard immunohistochemistry techniques (Ahearne, Willimott et al. 2013, Brusa, Serra et 
al. 2013). These patterns could not be demonstrated by immunofluorescence in our study or 
in the Brusa paper. This may be in part because immunofluorescence is technically not 
feasible at the low power magnifications that are required to visualise proliferation centres. To 
try and overcome this we hypothesised that fields with a relatively higher number of Ki67 
positive events per field may represent a proliferation centre. Therefore we looked to identify 
whether in fields with a low number of Ki67+ cells they were less likely to be in contact with 
CD4+ PD-1+ T-cells compared to areas which were presumed to be proliferation centres with 
a higher number of Ki67+ cells. We found there was no correlation between number of Ki67+ 
cells per field and the likelihood that the Ki67+ cells were in contact with a CD4+ PD-1+ T-cell.  
The next question we asked was whether the CLL CD4+ PD-1+ T-cells were Tfh cells like 
those of the normal germinal centre reaction. Wang et al reported, in normal lymph nodes that 
there was heterogeneous expression of PD-1+ T-cells (Wang, Hillsamer et al. 2011).  They 
described the very bright PD-1+ T-cells of the germinal centre as PD-1+++. Wang identified 
these germinal centres PD-1+++ cells to be Tfh cells. In addition they identified PD-1dim T-cells 
which they designated as PD-1low(+) and PD-1medium(+). Whilst the PD-1+++ Tfh cells stimulated 
the germinal centre B-cells, the PD-1dim population were Th1 and Th17 cells which were 
located in the mantle zone and appear to restrains the B-cell helper function to prevent an 
excessive antibody response.  In our study we also observed that the PD-1+ T-cells of the 
CLL lymph node were visually much less bright than the PD-1+++ cells of the normal germinal 
centre. Therefore this suggests that the CLL PD-1+ T-cells are not Tfh but may reflect the PD-
1dim population of the normal lymph node.  With this knowledge we perhaps could have 
designed experiments to assess the relative brightness of the PD-1 in normal and CLL lymph 
nodes for an accurate comparison. This was not feasible retrospectively, at least in our study, 
as the image acquisition was not set up for inter-sample comparisons. The sections were of 
slightly variable thickness and the samples acquired at different times so although internal 
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controls were strict, direct comparison between slides of fluorescence intensity would not be 
scrupulously robust. A future direction would be to design the experiments to allow a 
comparison of the relative pixel intensity of the PD-1+ cells.  Nevertheless the visually lower 
intensity of the PD-1+ T-cells in CLL lymph nodes gives a clue that the CLL PD-1+ T-cells are 
probably not predominately Tfh. We confirmed this assumption with immunofluorescence 
experiments incorporating co-staining with ICOS. We found that only a small proportion of the 
PD-1+ CD4+ cells co-expressed ICOS and therefore the majority of these cells were not Tfh 
cells. A median of 9% of the cells had the phenotype of Tfh cells. The significance of this is 
not clear and a direct comparison with a normal lymph node is difficult, where the PD-1+++ Tfh 
cells reside in discrete germinal centres. As discussed, Ahearne et al have reported an 
increased number of circulating CD4+ CXCR5+ ICOS+ Tfh cells in CLL patients compared to 
normal controls. They also demonstrated that IL-21 and IL-4, which are the major cytokines 
secreted by Tfh cells, promote CLL proliferation in vitro (Ahearne, Willimott et al. 2013). We 
have also shown in the proceeding chapter evidence of increased CD4+ CXCR5+ T-cells in 
CLL PB compared to age matched controls. The mechanism for the Tfh accumulation is 
unknown but may be as a result of the CLL cell secreting favourable cytokines into the tumour 
microenvironment. We have previously reported that CLL cells secrete high levels of IL-6 
which is required for Tfh cell development (Buggins, Patten et al. 2008, Eto, Lao et al. 2011). 
Clearly the field of research of Tfh cells in CLL requires further study. 
This chapter has confirmed the presence of CD4+ / PD-1+ cells residing in the CLL lymph 
node and in contact with proliferating Ki67+ CLL cells. It has also shown that the majority of 
these CD4+ T-cells do not have the phenotype of Tfh cells. PD-1 is known to be upregulated 
on T-cells in response to TCR stimulation and our results therefore suggest this stimulation is 
ongoing in the LN. In the next chapter we address whether we can provide any direct evidence 
that the PD-1+ CD4+ T-cells have an antigen specific response by studying their T-cell 
receptor repertoire.  
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Chapter 5 Investigating the T-cell Receptor Repertoire in CLL 
Lymph Nodes 
5.1 Introduction  
The work outlined in chapters 3 and 4 suggests that CLL lymph node T-cells are phenotypically 
different from those in normal LNs and the CLL PB compartment. The observation that there 
is a high proportion of effector memory T-cells that express markers of chronic activation, such 
as PD-1 further suggests that these cells may have undergone an antigen specific response. 
As discussed earlier, there is evidence that just like the BCR the TCR in CLL shows evidence 
of an antigenic response; as CLL PB derived T-cells show a skewed TCR repertoire. 
The BCRs in CLL are generally polyreactive and some show affinity for self-antigens; including 
antigens derived from apoptosis, such as cytoskeletal proteins, non-muscle myosin heavy 
chain IIA and vimentin (Herve, Xu et al. 2005). BCR reactivity has also been identified to the 
Fc immunoglobulin tail, single stranded DNA, double stranded DNA, lipopolysaccharide, 
insulin and oxidised low density lipoprotein (Catera, Silverman et al. 2008, Lanemo Myhrinder, 
Hellqvist et al. 2008, Binder, Lechenne et al. 2010, Chu, Catera et al. 2010). Other groups 
have found affinity of BCRs for a variety of non-self-antigens including bacteria, fungal 
elements and viruses including CMV (Landgren, Rapkin et al. 2007, Kostareli, Hadzidimitriou 
et al. 2009, Steininger, Rassenti et al. 2009). In regard to the TCR it has been exclusively 
studied within the PB compartment, where there are major perturbations in the TCR repertoire 
of CLL patients compared to healthy controls. Oligoclonality has been identified in both the 
CD4+ and CD8+ compartments. The presence of T-cells clones in CLL has been reported by 
many groups (Wen, Mellstedt et al. 1990, Farace, Orlanducci et al. 1994, Serrano, Monteiro 
et al. 1997, Rezvany, Jeddi-Tehrani et al. 1999, Goolsby, Kuchnio et al. 2000). A 
comprehensive explanation for this remains to be fully elucidated and although several groups 
have identified putative candidates the issue is still hotly debated and the mechanisms of 
antigenic drive remains elusive.  
Several groups have demonstrated a small, but definable population of postulated anti-
leukaemic T-cells with a measurable specific tumour driven antigen response (Rezvany, 
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Jeddi-Tehrani et al. 2000, Goddard, Prentice et al. 2001, Gitelson, Hammond et al. 2003). 
These CD8+ cytotoxic T-cells have been the subject of interest especially with regard to the 
possibility of expanding them by vaccination. The repertoire of the CD4+ T-cells has been the 
subject of limited study, but is of interest due to the observation that these T-cells are 
supportive in vitro to the CLL clone (Patten, Buggins et al. 2008).  
As previously noted, CLL is generally a disease of the elderly and when investigating the T-
cell repertoire of an elderly patient population it must be remembered that there is known to 
be marked skewing of the TCR repertoire as a consequence of normal ageing and previous 
exposure to common viral infections. CMV is a ubiquitous beta herpes virus that has a 
prevalence of approximately 70% of 70 year olds and is known be very immuno-dominant on 
the normal immune system (Savva, Pachnio et al. 2013). In a healthy elderly population CMV 
specific CD8+ T-cells can account for up to half the T-cell repertoire (Khan, Shariff et al. 2002). 
As discussed in the introduction chapter several groups have investigated the hypothesis that 
CMV could be in part responsible for the global T-cell expansion and dysfunction in CLL (Akbar 
2010). However, it has been acknowledged that the T-cell abnormalities in CLL are not just 
restricted to CMV seropositive individuals and that there is still a vast T-cell expansion of 
dysregulated T-cells with abnormal phenotype even in CMV seronegative individuals (Riches, 
Davies et al. 2013). te Raa et al recently published a study whereby they selected CMV 
specific T-cells from CLL patients, using CMV tetramers, and found a preserved CD8+ CMV 
specific T-cell function on a background of T-cell dysfunction. Therefore they hypothesised 
that the CLL cell induced T-cell suppression is not global and there may be specific 
suppression of T-cell subsets by the CLL within the microenvironment (te Raa, Pascutti et al. 
2014). We have shown in chapter 3 that the phenotypic changes in CLL T-cells are not 
restricted to CMV seropositive individuals.  
Research has not focused on the TCR repertoire from T-cells from with lymph nodes due to 
the lack of availability of material; however there is evidence from some solid cancers that T-
cells derived from within the tumour microenvironment have a more skewed TCR repertoire 
compared to the PB. For example, Sfanos et al, have published that CD8+ T-cells obtained 
from prostate glands infiltrated with prostatic cancer have an oligoclonal repertoire, to an as 
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yet unknown antigen (Sfanos, Bruno et al. 2009). Moreover the CD8+ T-cells expressed high 
levels of PD-1, suggesting a chronically antigen stimulated phenotype. Similarly, tumour 
infiltrating oligoclonal T-cells have been found in ovarian cancer (Pappas, Jung et al. 2005), 
gastric and colorectal patients (Matsutani, Shiiba et al. 2004, Sherwood, Emerson et al. 2013). 
A meta-analysis of 126 studies has been published which reviewed the literature of the impact 
of tumour infiltrating T-cells, B-cells, NK cells and macrophages in a variety of cancers 
(Fridman, Pages et al. 2012). In the solid tumour setting, high levels of infiltrating cytotoxic T-
cells, Th1 and memory T-cells have a positive impact on patient survival. Although the 
scenario is not directly comparable to CLL where the immune system is itself the tumour, host, 
defender and supportive microenvironment, nonetheless we can learn from these studies in 
terms of experimental approach and technical application.  
Several studies are now incorporating the utility of high throughput sequencing (HTS) to 
investigate the TCR repertoire in health and disease; and this emergent technology has given 
in further insights into the vast TCR diversity, which in the PB of healthy subjects is estimated 
to be in the order of 20-100 million clonotypes (Arstila, Casrouge et al. 1999, Robins, 
Campregher et al. 2009). Our collaborators at Adaptive Biotechnologies® have published 
several recent studies and proposed new methods for the quantification and analysis of the 
TCR repertoire of tumour immune infiltrates in a variety of cancers (Robins, Ericson et al. 
2013).  
A full understanding of the aberrations in the TCR repertoire in CLL remains to be defined, but 
there is mounting evidence that CLL T-cells, just like the B-cells are antigen experienced. In 
this chapter the aim is to analyse the TCR repertoire of CD4+ T-cells derived from the CLL LN 
microenvironment and compare it to the repertoire found in the PB. Our hypothesis is that the 
TCR repertoire of the high frequency PD-1hi LN and PB T-cells will show evidence of greater 
antigen specificity than the PD-1lo counterparts and that they are therefore antigen driven 
within the lymph node.   
This hypothesis could be addressed by a variety of different experimental approaches. 
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5.2 Experimental Approach 
5.2.1 TCRV Repertoire Assessment 
Before proceeding with the analysis of the LN TCR repertoire we assessed the various 
methods. These are reviewed below (Six, Mariotti-Ferrandiz et al. 2013). 
1. Flow Cytometry  
Monoclonal antibodies are available to some of the TCRV subgroups and have been used 
to study the TCR repertoire (Faint, Pilling et al. 1999). The TCR repertoire can then be 
expressed in terms of family usage. This approach is limited by the availability of antibodies 
and the inability to detect junctional diversity. One publication has suggested that just 364 T-
cell events need to be captured to calculate divergence by this method (Ciupe, Devlin et al. 
2013). 
2. Micro-array 
The micro-array method is a direct method of assessing the repertoire without PCR. RNA is 
isolated and cDNA constructed. The double stranded cDNA is biotinylated and the in vitro 
transcription product cRNA isolated. The cRNA is then hybridised to a gene chip of random 
oligonucleotides. The diversity of the TCR can then be inferred from the number of hybridised 
oligonucleotides (Ogle, Cascalho et al. 2003, Bonarius, Baas et al. 2006) 
3. Quantitative Reverse Transcriptase Polymerase Chain Reaction  
Many PCR methods have been employed to try and assess TCR repertoire. Constant and 
variable family-specific primers can be used to amplify the CDR3, as it is the CDR3 region of 
the β chain defines the specificity of the TCR. One of the limitations of this approach is the 
potential for amplification bias with multiple primer sets.  
Ligation anchored PCR is a method of amplifying cDNA with an unknown 5’ sequence. An 
oligonucleotide (the anchor), which has no sequence homology to the gene of interest, is 
ligated to the first strand cDNA using RNA T4 ligase. The anchor oligonucleotide has a 5’ 
phosphorylation and a 3’ ddC, to ensure the ligation can only occur in one direction. Next a 
PCR can be performed using two primers – one to the anchor and the other to the sequence 
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of interest (Troutt, McHeyzer-Williams et al. 1992). In this scenario one primer is to the anchor 
oligonucleotide and the other to the constant region of the TCRVβ.  
Matsutami et al described a cDNA restriction digest and an adapter ligated PCR with one set 
of primers, where one primer is 32P labelled. The PCR products are fractionated by agarose 
gel electrophoresis and the size of each fragment is compared to known lengths for each 
TCRV family and densiometric quantification of signal intensity used to quantify the product. 
This is technically difficult and the use of radiolabelled primers reduces the general utility of 
this method (Matsutani, Oishi et al. 1994).  
To try and remove the need for a radiolabelled primer Matsutami et al developed a microplate 
based assay. First RNA is extracted and transcribed into cDNA. Then a universal adapter is 
ligated onto the 5’ end of the resultant cDNA. The adapter allows for a universal PCR 
amplification of all the TCRVs. The PCR products are then biotinylated. Microplate wells are 
coated with TCRV specific oligonucleotide probes in water soluble carbodiimide. The PCR 
products are allowed to hybridise to the plate and the amount can be measured by a 
quantitative ELISA and automated colorimetric methods (Matsutani, Yoshioka et al. 1997) 
4. Spectratyping 
At the time of this study spectratyping (also known as Immunoscope technology), was the 
most common method of assessing the TCRVβ repertoire (Cochet, Pannetier et al. 1992, 
Pannetier, Cochet et al. 1993). DNA or cDNA is used as a PCR template where primers cross 
the V, D, J and C regions of the TCRVβ chain and encompass the CDR3. One primer is to the 
constant region and the other to one of the Vβ families. As the TCR gene size varies according 
to its mutated sequences different length PCR products will result. As the genetic 
rearrangement is random, the PCR product lengths should fall into a Gaussian distribution 
and should differ from each other by 3 nucleotides. PCR fragment length distribution analysis 
measures the CDR3 length of each TCR within V families. Fragment length distribution 
analysis can assess the normal distribution of the repertoire. Any over represented lengths in 
a population will deviate the eight peak bell-shaped distribution curve which suggests skewing 
in the repertoire, due to an over represented TCR in the population. Both oligoclonal or clonal 
expansions of T-cells disrupts the bell shape curve (Cochet, Pannetier et al. 1992). This 
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method is not quantitative but allows for assessment of diversity. Analysis of spectratype data 
is typically judged subjectively and although statistical analysis tools have been developed, 
they have not been widely adopted (Wu, Chillemi et al. 2000, Lu, Basu et al. 2004, He, 
Tomfohr et al. 2005). Clearly primer design is a key issue in spectratyping studies. Primers 
need to encompass the VDJ gene segments, the number of primers pairs should be as 
minimal as possible and the resultant PCR product be of a reasonable size. The European 
BIOMED-2 collaborative group have published a standardised Vβ primer set which it 
recommends for assessing T-cell clonality; see Table 5-6. The conventional PCR 
methodology uses 24 Vβ family forward primers and one common Cβ reverse primer. In order 
that the resultant fragments can be sized, the Cβ primer is conjugated to a FAM reporter 
molecule, and an analysing platform, such as Genetic Analyser (Applied Biosystems), is used 
to size the resultant products by fluorescence-based capillary electrophoresis. In order to size 
the fragments a fluorescently labelled size standard ladder (such as ILS-600, Promega) is 
added to the amplified PCR product mix; this enables the software to size the fragments 
against the known lengths in the ladder. The ILS-600 (Internal Lane Standard 600) is a double 
stranded DNA ladder consists of 22 fragments between 60bp and 600bp asymmetrically 
labelled with carboxy-X-rhodamine. Formamide is used as a denaturing agent in the mix. The 
mix is moved through a polymer filled capillary (multiple capillaries per machine) by 
electrophoresis. The Genetic Analyser then records the fluorescent intensity as a function of 
time and wavelength and can size fragments up to 12000bp. Enumeration and sizing of the 
individual fragments is then analysed on software program such as GeneMapper (Applied 
Biosystems) allowing graphical and statistical analysis. 
5. Sanger Sequencing 
Capillary based Sanger sequencing individually sequences each TCR present in a sample. 
The Sanger method first requires a sequence amplification step where the input DNA is 
fragmented and cloned into bacterial vectors. Then a reverse strand synthesis is undertaken 
with DNA polymerase using a known priming sequence. The sequence can be elucidated by 
the combining deoxy-nucleotides (dNTPs) and modified and labelled dideoxy-nucleotides 
(ddNTPs). Sequencing reactions utilise three of the four dNTPs (combination of dATP, dGTP, 
dCTP, dTTP) and one of four is a labelled ddNTPs (ddATP, ddGTP, ddCTP or ddTTP). The 
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addition of the ddNTP to the sequence causes a non–reversible termination of the sequence 
as it does not have the 3’ hydroxyl group which is needed to form a phosphodiester bond. The 
resulting DNA fragments are heat denatured and separated by electrophoresis (Sanger, 
Nicklen et al. 1977). This fundamental method has been enhanced and adapted allowing a 
PCR amplification and a single tube reaction with automated capillary based electrophoresis 
technology. This method, called dye-terminator sequencing, uses different fluorescent labels 
for each of the four ddNTPs; which can be detected by the emission of light at different 
wavelengths (Smith, Sanders et al. 1986). Fully automated methods have subsequently been 
developed and several methods now do not require prior amplification. The main limitation 
continues to be the size limit and insufficient power to sequence fragments that alter by just 
one nucleotide. It is only possible to sequence up to 384 sequences of between 600-1000bp 
in parallel and the error rate is between 1 in 104 and 1 in 105 (Kircher and Kelso 2010). 
Therefore its utility in assessing the whole TCR repertoire is limited and it can only be 
effectively used to selectively characterise the TCR sequence of clones identified by other 
techniques such as flow cytometry or spectratyping. Direct sequencing of 102-103 TCRs has 
been undertaken by this method but is not routinely a useful approach due to cost and time 
(Six, Mariotti-Ferrandiz et al. 2013).  
6. High Throughput Sequencing 
High throughput sequencing is an emerging technology to investigate the TCR repertoire. This 
PCR based technology allows the parallel direct sequencing of the total TCR repertoire, which 
may be up to 106-107 clonotypes (Arstila, Casrouge et al. 1999). Unlike Sanger sequencing, 
HTS can sequences millions of TCRs simultaneously, from which the diversity of the CDR3 
can be assessed as well as the relative frequency within a population. Whereas spectratyping 
looks for overrepresented TCR clones by virtue of the size of the PCR product, HTS can 
sequence each and every individual receptor. Comparative studies of spectratyping and HTS 
show very similar CDR3 distributions (Ademokun, Wu et al. 2011, Six, Mariotti-Ferrandiz et 
al. 2013). This new technology still requires validation and is not universally accepted 
technology for accurate TCR repertoire assessment due to high rates of sequencing error and 
complex bioinformatics (Bolotin, Mamedov et al. 2012).  Robins et al first published an 
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assessment of the TCR repertoire in healthy subjects using the Illumina Genome Analyser 
platform whilst our studies were underway (Robins, Campregher et al. 2009).  
There are three main technologies currently leading the field to sequence the TCR repertoire: 
454 (Roche), MiSeq/HiSeq (Illumina) and Ion Torrent (Life Technologies). Figure 5-1, adapted 
from Baum et al and Bolotin et al, is an illustrative schema of the different technologies (Baum, 
Venturi et al. 2012, Bolotin, Mamedov et al. 2012).   
The first step in the process is TCR cDNA amplification (A); the 454 and Illumina use a 
universal 5’ primer (M1) whereas Ion Torrent requires a multiplex V and J primer set because 
the fragments need to be short (150-200 base pairs (bp)) for the Ion Torrent platforms bead 
based PCR. Next the resultant fragments are immobilised prior to amplification (B). The 454 
and Illumina can immobilise larger fragments than the Ion Torrent. The 454 and Ion Torrent 
use a bead technology and emulsion PCR, whereas Illumina uses a cluster on a glass slide 
and bridge PCR. The 454 and Ion Torrent elongates the sequence using one nucleotide (nt) 
at a time (dATP, dCTP, cTTP or dGTP) and every time a new nucleotide is incorporated a 
pyrophosphate (PPi) and a proton (H+) is released (C). The 454 detects the pyrophosphate 
by using sulfurylase and luciferase enzymes which emit light which is then detected on a bead 
array. The Ion Torrent detects the proton by measuring a resultant change in pH on a transistor 
chip (D). The Illumina platform adds in all of the nucleotides simultaneously but as they are 
fluorescently labelled and irreversibly blocked, only one nucleotide can be added per cycle 
(C), the fluorescence from the specific nucleotide that was incorporated can then be detected 
on the slide.  
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Figure 5-1 Methods of analysing the TCR by HTS. Adapted from Baum et al and Bolotin et al. 
 
Because a direct comparison was needed in our study, the method of assessing the TCR 
repertoire needed to be able to be comparative but not necessarily quantitative. Our initial 
approach was that of a cDNA ligation technique with a single primer set PCR to avoid any 
PCR bias, but this proved to be unreliable (discussed below). Subsequently we decided to 
undertake conventional TCRV spectratyping, as this was the gold standard validated 
technique for assessing the TCR at the time of study. HTS was subsequently undertaken in a 
pilot study as the technology became available to us. 
5.2.2 Starting Material 
Following identification of the most appropriate methodology for assessing the TCR repertoire, 
the next step was to choose the best primary starting material. The major advantages and 
disadvantages of each tissue have been previously discussed and are reviewed again in Table 
5-1.  
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Table 5-1 Starting material 
T-cell source Advantages Disadvantages 
FFPE lymph Node Samples available 
Normal controls available 
Ability to laser dissect PCs 
Anonymous samples   
No matched PB  
Highly selected population  
Fixed sample 
Unable to extract RNA 
Difficulty sorting T-cells 
Fresh Lymph Node Unfixed tissue 
Large cell numbers 
Ability to sort T-cells  
Ease of RNA extraction 
Matched PB 
Low availability 
Highly selected population 
No normal controls 
FNA Lymph Node Better availability  
Unfixed tissue 
Unselected population 
Ability to sort T-cells 
Matched PB 
Small cell numbers 
Difficult to extract RNA 
No normal controls 
 
The most straightforward approach would have been to have paired fresh lymph node biopsy 
samples and peripheral blood, but the lack of availability was a major stumbling block and the 
highly selected population that undergo lymph node biopsy could bias the study. FFPE LN 
samples were already available, but only available to us in an anonymised fashion without 
clinical details or paired PB. Additionally sorting cells and extracting quality RNA from FFPE, 
although not impossible, is technically difficult. Laser dissection microscopy can be employed 
on FFPE sections although very small numbers of cells are extracted.  
Vandewoestyne et al dissected out proliferation centres in CLL by laser pressure catapulting 
and sorted the Ki67+ subset in order to sequence the IgVH (Vandewoestyne, Pede et al. 
2011). This group stated that extracting genomic DNA (gDNA) from 2000 cells gave a 
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Gaussian distribution of the IGHV, however using gDNA as a template to assess the TCR 
repertoire has flaws. The rearranged TCR are of course structurally different from the genomic 
template and even though there is not the added complexity of affinity maturation as seen in 
the BCR, using DNA as a templates does not exclude the TCRs that are rearranged but not 
expressed. Nonsense mRNA molecules, on the other hand, are quickly degraded (Wang, 
Vock et al. 2002, Bhalla, Gudikote et al. 2009). Recent evidence from HTS reveals marked 
differences in the reported TCR repertoire depending on whether cDNA or gDNA were used 
as starting material; with under and over representation of transcripts (Desmarais 2012). 
Hedegaard et al have also recently published their experience of HTS using DNA and RNA 
extracted from FFPE compared to fresh frozen samples. They compared several methods of 
DNA and RNA extraction and outline the inaccuracies in sequencing that can arise from the 
fragmentation and chemical modifications that can occur to nucleic acids post fixation. They 
found, by pairwise analysis, that whole exome sequencing of extracted DNA showed only a 
70-80% concordance between fresh and FFPE samples. The concordance was superior when 
RNA was used as a template but they recognise RNA extraction from FFPE is more 
challenging (Hedegaard, Thorsen et al. 2014). Despite the technical challenges, RNA 
extraction from FFPE for TCR repertoire analysis has been reported as feasible by several 
groups (O'Shea, Hollowood et al. 1996, Le Gal, Widmer et al. 2007).  
Weighing up the advantages and disadvantages we decided to use RNA as a starting material. 
Despite the potential ability to extract RNA from FFPE we decided that as the studies main 
aim was to be comparative between compartments, the lack of matched PB and the difficulties 
in extracting RNA from paraffin made the utility of this approach less attractive. We therefore 
made the decision to use fresh LN FNA and PB as starting material. This had the major 
advantage of matched fresh samples allowing for RNA extraction. There was also the ability 
to control cell numbers, samples could be obtained from an unselected CLL population and 
this study was ethically approved. The strongest power of this approach was the potential to 
be able to sort T-cells in a comparable way between sample types; we could also utilise flow 
sorting to look at subpopulations of T-cells and compare them between compartments. In 
addition, results could be compared to those from normal PB. The disadvantage of small 
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amounts of starting material would need to be overcome, especially when sorting cells and 
extracting RNA. 
5.2.3 Flow Cytometric Cell Sorting 
Flow cytometric cell sorting allows the isolation and collection of fluorescently labelled cells. 
The basic principles of flow cytometry principles have been reviewed in chapter 3. Flow 
cytometric cell sorters differentiate cell populations by exactly the same principle. In addition, 
this system allows subpopulations of cells to be defined and then collected according to their 
fluorescent cell surface labelling. The cells are first immunofluorescently labelled by the 
conventional method. The properties of the cell population of interest are inputted into the 
software to define which populations are to be collected. The BD FACSAria (BD Biosciences) 
sorter can simultaneously sort 4 defined populations, assuming there is no conflicting overlap 
between collection subsets. The sample is loaded onto the FACSAria and the fluidics system 
moves cells from the sample injection chamber into the cuvette flow cell where the stream is 
hydrodynamically focused and the cell within it is interrogated and subsequently either 
collected or sent to waste, depending on the parameters that have been defined for the sort. 
For the collection or “sort” to take place so called “drop drive” energy is applied to the flow 
stream to split it into highly uniform droplets containing a cell. When a cell is detected, and it 
meets the criteria for collection, an electrical charge is applied to the stream at exactly the 
moment the droplet is about to break off. The resultant droplet, containing only the cell, has 
then gained a charge. The droplet then passes between two strongly charged deflection plates 
and depending on the droplets charge polarity it is attracted or repelled left or right by different 
degrees into a waiting collection tube. The FACSAria allows a differential charge to be applied 
to each droplet containing the specified cell population to be collected. A non-charged droplet 
passes into the central waste collector. By this method, four populations of cell can be 
simultaneously collected and the remaining cells discarded. 
5.3 Aim 
The major question we wanted to answer in this study was whether the high frequency PD-1+ 
T-cells found in the lymph node had a skewed TCR repertoire and therefore evidence of a 
specific antigen driven response. In order to elucidate this we chose to undertake TCRVβ 
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repertoire analysis on the PD-1hi and PD-1lo CD4+ subsets of the LN and PB and look for 
skewing of the repertoire in each subset by conventional spectratyping. We were specifically 
interested in the CD4+ T-cells as these T-cells are supportive of CLL in vitro. The CD8+ T-
cells were also selected for future work. We also sought to identify whether the PD-1hi T-cells 
were a different population from the PD-1lo T-cells and whether the T-cells within the PB were 
the same or a distinct population from the LN. In order to perform TCR analysis on a subset 
of T-cells the individual populations were first sorted by flow cytometry.  
5.4 Materials and Methods 
5.4.1 Ethics 
Ethical approval was obtained to perform LN FNAs on CLL patients for research purposes 
from the research ethics committee REC: 09/H0805/5. PB was collected from patients under 
national research ethics NREC: 08/H0906/94. PB was collected from healthy controls under 
LREC: 02-044. Written informed consent was gained according to the Declaration of Helsinki, 
2008. 
5.4.2 Primary Patient Material 
5.4.2.1 Peripheral Blood  
PB was collected from CLL patients undergoing LN FNA and from healthy controls directly 
into CLL media or EDTA as described in 2.2.1. 
5.4.2.2 LN FNA 
Patients with a diagnosis of CLL and an easily palpable lymph node were invited to take part 
in the study. They were given a patient information sheet and given adequate time to consider 
their entry into the study. Written consent was obtained and samples pseudo-anonymised. 
The LN FNA was performed using a 23 gauge needle attached to 10ml syringe. Once the 
sample was aspirated and the needle washed directly into CLL media. This was repeated on 
average 4 times per patient.  
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5.4.3 Jurkat Cells 
Jurkat cells were donated by Dr Shahram Kordasti and cultured as in 2.5.2. Cells were 
resuspended in Jurkat media at 1 x 105/ml. 5mls was transferred to a 25ml tissue culture flask 
(Sigma). Cells were cultured at 5% CO2 at 37°C in a humidified incubator. The cell culture was 
split in fresh media every 2 days or when cells >1 x106/ml. 
5.4.4 Antibodies for FACS Cell Sorting 
The antibodies used for cell sorting were are shown in Table 5-2. 
Table 5-2 Antibodies for flow cytometric sorting 
Antigen Clone Conjugation Volume Company 
CD4 RPA-T4 PE 10µl AbD Serotec 
CD8 OKT8 Pacific Blue™ 10µl eBioscience 
CD279 (PD-1) MIH4 Alexa Fluor® 647 5µl AbD Serotec 
  
5.4.5 Staining Cell Surface Antigens for Flow Cytometry 
Cells were resuspended in 100µl PBS and labelled for flow cytometry according to 2.7.1. 
Directly conjugated antibodies were added at appropriate titrated volume as described in 
Table 5-2. 
5.4.6 FACS Sorting 
Cells were sorted using the BD FACSAria flow cytometer with technical assistance from 
Winston Vetharoy. Cells were sorted from the lymphocyte gate. Cells were defined as 
CD4+/PD-1hi, CD4+/PD-1lo. CD8+/PD-1hi, CD8+/PD-1lo. Sorted cells were collected directly 
into CLL media and their post purity was checked by flow cytometry. The cells were 
subsequently centrifuged at 200g for 5 minutes and the cell pellet resuspended in 0.5ml 
TRIzol® for subsequent RNA extraction. 
5.4.7 RNA Extraction 
Several methods of RNA extraction were optimised. Initially mRNA was extracted using a 
direct method and subsequently a total RNA extraction; described below. 
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5.4.7.1 Direct mRNA Isolation Protocol 
1. Preparation of Lysate from Cell Suspension 
Cells were pelleted by microcentrifugation at 200g for 5 minutes. Cells were then washed in 
PBS and re-pelleted by microcentrifugation 200g 5 minutes. 300µl Invitrogen Dynabeads 
lysis/binding buffer (Invitrogen) was added to the cell pellet. The solution was repeatedly 
passed through an RNAse free plugged pipette tip until the solution became viscous which 
confirmed complete lysis.  
2. Preparation of Dynabeads Oligo(dT)25 
Dynabeads Oligo(dT)25 (Invitrogen) were prepared before use. First they were vortexed to 
resuspend them and then 20µl was transferred to a RNase free 1.5 ml microcentrifuge tube. 
This was placed on the proprietary magnet and when suspension was clear (about 30 
seconds), the supernatant was removed. The beads were washed by resuspending in 50µl 
lysis/binding buffer and then replaced on the magnet ready for use.  
3. Direct mRNA Isolation  
The sample lysate was added to the prepared Dynabeads Oligo(dT)25 and resuspended by 
pipetting. The tube was then continuously mixed on rotating mixer for 5 minutes at RT to allow 
the polyA tail of the mRNA to hybridize to the oligo(dT)25 on the beads. Beads were 
magnetically removed and then the bead/mRNA complex were washed twice with 600µl 
Washing Buffer A and twice with 300µl Washing Buffer B (Invitrogen) at RT. The magnet was 
used to separate the beads from the solution between each washing step. Finally the beads 
were washed and resuspended in 50µl cDNA synthesis buffer ready for cDNA first strand 
synthesis. 
5.4.7.2 Total RNA Extraction  
A method for total RNA extraction was optimised for the FACS sorted samples stored in 
TRIzol® (Invitrogen) (Chomczynski and Sacchi 1987). A combined TRIzol®/RNeasy® 
Extraction Protocol was developed and described here. 
Two different hybrid methods utilising the RNeasy® Micro kit (Qiagen) were used. The first 
method utilised the Phase Lock Gel Heavy (5 Prime) product to ensure no contamination of 
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the organic phase and the aqueous phase, the second method did not use the gel tubes and 
prove to be robust.   
The following procedure was performed in a fume hood where no post PCR products were 
handled. Samples in TRIzol® were either used directly or thawed from -80oC. 0.2ml of 
chloroform was added per 1ml TRIzol® homogenate. The sample in TRIzol® was shaken 
vigorously for approximately 15 seconds and then left to stand at RT for 3 minutes.  
For the samples extracted using the Phase Lock Heavy Gel tube (5-Prime), the gel tube was 
first prepared by pre-centrifugation at 12000g for 3 minutes at RT. Then the sample was 
loaded into the Phase Lock tube.  Whether the Phase Lock tube was used or not the extraction 
continued as per the RNeasy® Mini Kit (Qiagen) protocol as follows. 
Samples were centrifuged at 12000g for 15 minutes at 4C. The aqueous phase was then 
removed carefully by aspiration and transferred to a new RNAse free tube. The sample volume 
was noted and an equal volume of 70% ethanol was added slowly. The sample, including any 
precipitation that had occurred, was loaded into an RNeasy® column on a collection tube and 
centrifuged at 8000g for 30 seconds. The flow-through was discarded and the sample sat on 
a new collection tube. 700µl RW1 buffer (2.5-10% guanidine thiocyanate, 2.5-10% ethanol) 
was added to the column and centrifuged again for 30 seconds at 8000g. The flow-though 
was discarded and the column seated on a new collection tube. Ethanol was added to the 
RPE buffer and 500µl was added to the column which was again centrifuged for 30 seconds 
at 8000g. This was repeated but with a 2 minute centrifugation, discarding the flow-through 
between steps. The tube was then centrifuged empty in a new collection tube for a further 1 
minute to remove any remaining buffer in the column. The column was transferred to the final 
collection tube and 30µl of RNase-free water added to the column membrane. The sample 
was left for 2 minutes at RT before a final centrifuge of 1 minute at 8000g to elute the RNA. 
1µl of RNA was used to quantify the product using a spectrophotometer (NanoDrop, Thermo 
Scientific) and the remainder was stored at -80C or used immediately for downstream 
applications. 
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5.4.8 RNA Quantification 
The NanoDrop spectrophotometer was used to quantify the RNA concentration and measure 
its purity and integrity. First the upper and lower optical surfaces were cleaned. The NanoDrop 
was initialised and a blank measurement performed on 1 µl of deionised water pipetted onto 
the lower optical surface. 1µl of the RNA was then pipetted onto the lower surface and 
measurement performed using the NanoDrop propriety software in nucleic acid mode. This 
calculates the nucleic acid concentration (Gallagher and Desjardins 2006).  
5.4.9 First Strand cDNA Synthesis 
First strand cDNA synthesis was performed originally using ThermoScript™ (Invitrogen) and 
subsequently by SuperScript® VILO™ cDNA synthesis kit (Invitrogen) due to the improved 
yields obtained using this protocol. 
1. ThermoScript™ cDNA synthesis 
In an RNase-free 0.2ml thin walled tube (StarLab) the RNA was added to 1µl random 
hexamers (50ng/µl) and 2µl 10nM dNTP mix and made up to 12µl with DEPC treated water. 
This was incubated at 65oC for 5 minutes then transferred onto ice. 8µl of cDNA synthesis mix 
was added which is made up of 4µl 5X cDNA buffer (250mM Tris acetate (ph 8.4), 375mM 
potassium acetate, 40mM magnesium acetate and stabilizer), 1µl 0.1M DTT, 1µl 
RNaseOUT™(40U/µl), 1µl DEPC water and 1µl ThermoScript™ RT. The tube was incubated 
for 25C for 10 minutes, then 50C for 45 minutes and finally the reaction was terminated by 
incubation at 85C for 5 minutes. 1µl of RNase H was added and incubated for 20 minutes at 
37C. The resultant cDNA was subsequently used immediately for downstream reactions or 
stored at -20C. 
2. SuperScript® VILO™ cDNA synthesis 
In an RNase-free 0.2ml thin walled tube (StarLab) the RNA was added to 4µl 5X VILO™ 
reaction mix (random primers, MgCl2 and dNTPs in a proprietary buffer formulation), 2µl 10X 
SuperScript® enzyme mix and made up to 20µl with DEPC treated water. The contents were 
gently mixed and incubated at 25C for 10 minutes, then at 42C for 60 minutes. The reaction 
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was terminated by incubating at 85C for 5 minutes. The resultant cDNA was subsequently 
used immediately for downstream reactions or stored at -20C. 
5.4.10 Ligation of Novel Oligonucleotide to Single Stranded cDNA 
For the ligation anchored PCR experiments the following optimised method was used. The 
cDNA was washed and then resuspended in x1 NEB reaction buffer (50 mM Tris-HCl, pH 7.8, 
10 mM MgCl2, 10 mM DTT, 1 mM ATP). 10µl of 100pmol oligonucleotide for ligation was 
added with 25% (w/v) PEG 8000 and 1µl T4 RNA ligase (NEB). The oligo for ligation was 
phosphorylated at the 5’end and 3’ddC and is shown in Table 5-3.  
The ligation mix was incubated at 22oC for 72 hours.  
Table 5-3 Ligation PCR oligonucleotide and primer design 
 Sequence 
Oligonucleotide for ligation 5' (PHO)TAGGATCTGGGACGGATGGC(3'ddC) 3' 
TCR Forward Primer 5' CTCAAACACAGCGACCTCGG 3'   
Oligo Reverse Primer 5' GCCATCCGTCCCAGATCCTA 3'      
5.4.11 Polymerase Chain Reaction Methods 
The PCR methodologies were subject to numerous modifications and optimisation steps and 
the final methods are presented below. The final method used for TCR Vβ TCR repertoire 
spectratyping is method 4.  
1.   Ligation Anchored PCR 
cDNA was washed in x1 PCR buffer and was added to 5µl 10x PCR buffer (without Mg), 1.5µl 
50Mm MgCl, 1µl 10mM dNTP mix, 0.4µl and Platinum Taq DNA polymerase (5U/µL). Forward 
and reverse primers were added. Primers used are detailed in Table 5-3. DEPC treated water 
was added to make up to final volume 50µl.  
The PCR was undertaken using a Veriti® 96-well thermal cycler (Applied Biosystems) 
according to the following program:  
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1. Hot start: 94C 2 minutes 
2. Denaturation: 94C 30 seconds 
3. Annealing: 55C 30 seconds             X30 cycles 
4. Elongation: 72C 108 seconds 
5. Final elongation 72C 5 minutes 
6. Hold 4C 
 
2. PCR Housekeeping Gene (Beta Actin)  
The beta actin primer set is shown in Table 5-4. The PCR was undertaken in 0.2ml thin walled 
tubes (StarLab). To each tube 2 µl of cDNA was mixed with 12.5µl TaqMan® Gene Expression 
Master Mix (AmpliTaq Gold® DNA Polymerase, Uracil-DNA glycosylase, dNTPs (with dUTP), 
ROX™ Passive Reference, and optimized buffer components), 2.5µl β actin forward primer, 
2.5µl β actin reverse primer and the final volume was made up to 25µl with water.  
The PCR was undertaken using a Veriti® 96-well thermal cycler (Applied Biosystems) 
according to the following program:  
1. 94C 30 seconds 
2. 55C 30 seconds 
3. 72C 108 seconds                               
4. Hold 4C 
 
Table 5-4 Beta actin primer set 
β actin Primers Sequence 
Forward 5’ TGGCGCTTTTGACTCAGGAT 3’   
Reverse 5’ GGGATGTTTGCTCCAACCAA 3’ 
 
3. PCR Housekeeping Gene (Abl)  
The Abl (Abelson murine leukaemia viral oncogene homolog 1) primer set is shown in Table 
5-5. The PCR was undertaken in 0.2ml thin walled tubes (StarLab). To each tube 2µl of cDNA 
was mixed with 12.5µl TaqMan® Gene Expression Master Mix (AmpliTaq Gold® DNA 
X 40 Cycles 
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Polymerase, Uracil-DNA glycosylase, dNTPs (with dUTP), ROX™ Passive Reference, and 
optimized buffer components), 2.5µl Abl forward primer, 2.5µl Abl reverse primer and the final 
volume was made up to 25µl with water.  
The PCR was undertaken using a Veriti® 96-well thermal cycler (Applied Biosystems) 
according to the following program:  
1. 50C 2 minutes 
2. 95C 10 minutes 
3. 95C 15 seconds         
4. 60C 1 minute 
5. Hold 4C 
 
Table 5-5 Abl primer set 
Abl Primers Sequence 
Forward 5’ GATACGAAGGGAGGGTGTACC A 3’ 
Reverse 5’ CTCGGCCAGGGTGTTGAA 3’ 
 
4. PCR TCRVβ Repertoire  
The final method for assessing the TCRVβ repertoire by PCR using AccuPrime™ Taq DNA 
Polymerase High Fidelity (Invitrogen) is outlined below.  
The 24 forward Vβ primer and Cβ reverse primer sequences are detailed in Table 5-6. The 
Cβ primer was FAM labelled for subsequent analysis. 
The PCR was undertaken in a 96 well plate (Applied Biosystems). To each well the cDNA was 
mixed with 2.5µl of 10X AccuPrime™ PCR Buffer I (600mM Tris-SO4 (pH 8.9), 180mM 
(NH4)2SO4, 20mM MgSO4, 2mM dGTP, 2mM dATP, 2mM dTTP, 2mm dCCT, thermostable 
AccuPrime™ protein and 10% glycerol), 2µl forward primer, 2µl reverse primer, 0.2µl 
AccuPrime™ Taq DNA Polymerase High Fidelity (5U/µl), 1µl MgSO4 (50mM) and the final 
volume was made up to 25µl with water.  
X 40 Cycles 
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The PCR was undertaken using a Veriti® 96-well thermal cycler (Applied Biosystems) 
according to the following program:  
1. Hot start: 95C 5 minutes 
2. Denaturation: 94C 45 seconds 
3. Annealing: 60C 45 seconds             X40 cycles 
4. Elongation: 72C 90 seconds 
5. Final elongation 72C 5 minutes 
6. Hold 4C 
 
Table 5-6 Vβ primer set for TCR sequencing 
Primer Sequence 
Vβ1 5′ GTAGTGCGATGGCCAGTCCGCACAACAGTTCCCTGACTTGC 3′ 
Vβ2 5′ GTAGTGCGATGGCCAGTGGCCACATACGAGCAAGGCGTCGA 3′ 
Vβ3 5′ GTAGTGCGATGGCCAGTCGCTTCTCCCGGATTCTGGAGTCC 3′ 
Vβ4 5′ GTAGTGCGATGGCCAGTTTCCCATCAGCCGCCCAAACCTAA 3′ 
Vβ5 5′ GTAGTGCGATGGCCAGTAGCTCTGAGCTGAATGTGAACGCC 3′ 
Vβ6 5′ GTAGTGCGATGGCCAGTTCTCAGGTGTGATCCAAATTCGGG 3′ 
Vβ7 5′ GTAGTGCGATGGCCAGTCCTGAATGCCCCAACAGCTCTCTC 3′ 
Vβ8 5′ GTAGTGCGATGGCCAGTCCATGATGCGGGGACTGGAGTTGC 3′ 
Vβ9 5′ GTAGTGCGATGGCCAGTTTCCCTGGAGCTTGGTGACTCTGC 3′ 
Vβ10 5′ GTAGTGCGATGGCCAGTCCACGGAGTCAGGGGACACAGCAC 3′ 
Vβ11 5′ GTAGTGCGATGGCCAGTTGCCAGGCCCTCACATACCTCTCA 3′ 
Vβ12 5′ GTAGTGCGATGGCCAGTTGTCACCAGACTGGGAACCACCAC 3′ 
Vβ13 5′ GTAGTGCGATGGCCAGTCACTGCGGTGTACCCAGGATATGA 3′ 
Vβ14 5′ GTAGTGCGATGGCCAGTGGGCTCGGCTTAAGGCAGACCTAC 3′ 
Vβ15 5′ GTAGTGCGATGGCCAGTCAGGCACAGGCTAAATTCTCCCTG 3′ 
Vβ16 5′ GTAGTGCGATGGCCAGTGCCTGCAGAACTGGAGGATTCTGG 3′ 
Vβ17 5′ GTAGTGCGATGGCCAGTCTGCTGAATTTCCCAAAGAGGGCC 3′ 
Vβ18 5′ GTAGTGCGATGGCCAGTTGCCCCAGAATCTCTCAGCCTCCA 3′ 
Vβ19 5′ GTAGTGCGATGGCCAGTTCCTCTCACTGTGACATCGGCCCA 3′ 
Vβ20 5′ GTAGTGCGATGGCCAGTTCTCAATGCCCCAAGAACGCACCC 3′ 
Vβ21 5′ GTAGTGCGATGGCCAGTTCCAACCTGCAAGGCTTGACGACT 3′ 
Vβ22 5′ GTAGTGCGATGGCCAGTAAGTGATCTTGCGCTGTGTCCCCA 3′ 
Vβ23 5′ GTAGTGCGATGGCCAGTGCAGGGTCCAGGTCAGGACCCCCA 3′ 
Vβ24 5′ GTAGTGCGATGGCCAGTCCCAGTTTGGAAAGCCAGTGACCC 3′ 
Cβ 5′ CAGTGTGCAGCGATGACCGGGCTGCTCCTTGAGGGGCTGCG 3′ 
 
5.4.12 TBE Agarose Gel 
PCR products were run on a 2% TBE (Tris/Borate/EDTA) agarose gel to ensure successful 
amplification prior to running on the Genetic Analyser (Applied Biosystems). The gel was 
made up with 150ml 1X TBE (5-Prime) and 3g agarose (Bioline), which was microwaved for 
3 minutes, left to cool and then 10µl ethidium bromide (10µl/ml) was added. The gel was run 
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at 150V for 1-2 hours. 5X DNA loading buffer blue (bromophenol blue) (Bioline) and 
HyperLadder I or V (Bioline) were used for visualisation and product sizing.  
5.4.13 DNA Gel Extraction 
MinElute Gel Extraction Kit (Qiagen) was used to extract DNA from the gel. The PCR product 
of interest on the gel was excised using a scalpel.  The gel was weighed and 3 volumes of 
Buffer QG (Qiagen) was added per 1 volume of 2% gel (100mg gel = 100µl). This was 
incubated for 10minutes at 50°C to dissolve the gel. pH was corrected with 3M sodium acetate 
as required. Isopropanol was added at equivalent gel volume. The sample was added to the 
MinElute spin column, inside a collection tube and centrifuged for 1 minute. The flow through 
was discarded and 500µl of Buffer QG was added and the tube centrifuged again. Then 750µl 
of Buffer PE (Qiagen) was added and centrifuged again. To elute the DNA 10µl of Buffer EB 
(10nM TrisCl, pH 8.5) was added and the tube was left to stand for 1 minute before centrifuging 
for 1 minute. The eluted DNA was collected for downstream applications. 
5.4.14 PCR Product Sequencing 
The cleaned PCR products were sent to GeneserviceTM (Source Bioscience) for Sanger 
sequencing. They undertake a plasmid based protocol using the primers we provided. 
5.4.15 TCRVβ Spectratyping Fragment Analysis    
The Genetic Analyser 3130XL (Applied Biosystems) was used to size PCR products. To each 
well of a 96 well plate (Applied Biosystems) 1µl of the FAM labelled PCR product was added 
to 0.8µl ILS-600 (Internal Lane Standard 600, Promega) and 8.8µl formamide. The plate was 
incubated at 95C for 3 minutes before being run on the Genetic Analyser; a fluorescence-
based capillary electrophoresis system, as described above. 
5.4.16 TCRVβ Spectratyping Profile Analysis 
Once the CDR3 amplicons were sized using the Genetic Analyser, the data was analysed 
using the GeneMapper Software (Applied Biosystems). The software generates a graphical 
spectratyping prolife usually consisting of 8 (5-10) major peaks each representing a CDR3 
length differing from the next by 3 nucleotides. The fluorescence intensity is representative of 
the frequency of the CDR3.  A spectratyping profile is produced for each of the 24 TCRVβ 
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families. An example of a spectratype prolife for one Vβ family from one sample is shown in 
Figure 5-2 below. The Bell shaped curve represents the normal distribution.  
 
Figure 5-2 Typical TCRVβ spectratype profile 
This is an example spectratype profile from one TCRVβ family visually represented using 
GeneMapper Software (Applied Biosystems). A normal TCRVβ spectratype prolife consists of 
8 (5-10) major peaks each representing a CDR3 length (fragment size) differing from the next 
by 3 nucleotides. The fluorescence intensity is representative of the frequency of the CDR3. 
The Bell shaped curve confirms the normal distribution.    
 
There is no universally accepted method of spectratyping profile analysis and a range of 
methods have been employed. Some groups have used visual assessment (Ferrand, Robinet 
et al. 2000, Kook, Risitano et al. 2002), whilst others have adopted scoring methods 
(Bomberger, Singh-Jairam et al. 1998, Wu, Chillemi et al. 2000, Peggs, Verfuerth et al. 2003). 
Ciupe et al in the department of mathematics at Virginia Tech have described a mathematical 
method of assessing the deviance of spectratypes form the normal repertoire. They used 
computational mathematics to calculate the Kullback-Leibler divergence to ascertain the 
difference of the TCRVβ profile from a normal reference (Ciupe, Devlin et al. 2013). We 
employed two complementary scoring methods adapted from the published literature (Wu, 
Chillemi et al. 2000, Lu, Basu et al. 2004, Le, Melenhorst et al. 2011). Spectratype profiles 
were compared for their complexity (number of discrete peaks) and diversity (skewing of the 
distribution) (Ciupe, Devlin et al. 2013). A complexity score was derived by assigning the 
spectratype of each subfamily a score of 0-5, dependent on the number of discrete peaks, 
and then multiplying by the number of TCRVβ families. Spectratypes with >5 peaks were given 
the maximum score of 5 and no peaks 0. The total complexity score is out of 120 (24x5) (Wu, 
Chillemi et al. 2000, Lu, Basu et al. 2004). A diversity score was used to ascertain skewed 
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profiles and a score of 1 given for a single peak being >x2 the height of the next second 
highest peak. The total diversity score was calculated by summating the scores for all the 
TCRVβ families, with 24 being the most skewed profile and 0 the least. An example of the 
scoring is shown in Figure 5-3.  
 
Figure 5-3 Spectratype scoring system 
Spectratype profiles are visually assessed for their complexity (number of discrete peaks) and 
diversity (skewing). The complexity of a TCRVβ spectratype is derived by assigning a score 
of 0-5, dependent on the number of discrete peaks in the profile. Spectratypes with >5 peaks 
are given the maximum score of 5 and no peaks 0. The maximum complexity score across 
the 24 TCRVβ families is 120 (24x5). A diversity score of 1 is assigned to a skewed 
spectratype profile when a single peak is >x2 the height of the next second highest peak. A 
total diversity score is calculated by summating the scores for all the TCRVβ families, with 24 
being the most skewed profile and 0 the least. The panels above show four examples of 
differing spectratype profiles and the associated complexity and diversity scoring. 
 
5.4.17 Statistical Analysis 
Statistical analysis of the diversity or complexity scores was performed using GraphPad 
Prism® (Graph Pad Inc.). For paired comparisons to be made between LN FNA and PB 
populations a paired t-tests was performed and a p-value of <0.05 was considered statistically 
significant. For comparison between un-paired sample an unpaired t-test was used and again 
a p-value of <0.05 was considered statistically significant. Results are expressed +/- standard 
error of the mean. Box and whiskers plots show the median and minimum and maximum 
values. The statistical analysis used for HTS data is described in the text. 
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5.4.18 High Throughput Sequencing Analysis 
cDNA samples were sent to Adaptive Biotechnologies® using propriety plates. Amplification 
and sequencing of TCRVβ CDR3 was performed using the immunoSEQ Platform (Adaptive 
Biotechnologies®, Seattle, WA). TCRVβ CDR3 regions were amplified using a bias controlled 
high throughput multiplex PCR on the Illumina platform. TCRVβ CDR3 sequences from 
Adaptive Biotechnologies are defined according to the International ImMunoGeneTics (IMGT) 
collaboration nomenclature (Yousfi Monod, Giudicelli et al. 2004).  Results were made 
available through the ImmunoSEQ analyser software. The immunoSEQ Platform combines 
multiplex PCR with high throughput sequencing and a sophisticated bioinformatics pipeline 
for TCRVβ CDR3 analysis (Robins, Campregher et al. 2009, Carlson, Emerson et al. 2013). 
The software allows repertoire characterisation, clone tracking and clone identification.  
5.5 Results 
5.5.1 Demographics of patients and normal controls for spectratyping 
The demographics of the CLL patients studied for TCRVβ repertoire by spectratyping is shown 
in Table 5-7.  An additional patient consented to this study and underwent FNA and cell sorting 
but was subsequently identified to be hepatitis B positive and were therefore excluded. PB 
from six aged matched normal controls was also taken. The mean age for CLL patients was 
61 years +/- 2.07 compared to 58 years +/- 5.05 for healthy controls. There was no statistical 
difference between the ages p= 1.00, see Figure 5-4. 
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Table 5-7 Demographics of CLL patients for spectratyping 




38 F NEG POS C 98 17p- Mutated 
CLL2  
 
64 M POS POS C 87 Trisomy 
12 
Unmutated 
CLL3  64 M NEG POS 
 
B 57 17p- Unmutated 
CLL5  
 
74 M POS POS C 62 13q- Unmutated 
CLL6  
 
57 M NEG POS A 0 13q- Mutated 
CLL 7  
 
52 M NEG POS A 0 13q- Mutated 
 
 
Figure 5-4 Age demographics of patients and normal controls 
Age of CLL patients (n=6) and healthy controls (n=6). A D’Agostino and Pearson omnibus 
normality test was applied prior to un-paired t-test using GraphPad Prism® (Graph Pad Inc.). 
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5.5.2 Ligation anchored PCR  
Our initial experimental approach to sequencing the TCR was to undertake the ligation 
anchored PCR method. The design was to ligate a unique oligonucleotide sequence to the 
single stranded cDNA with a 5’ phosphorylation and a 3’ ddC, to ensure the ligation can only 
occur in a one direction. We designed a unique oligonucleotide which had no sequence 
homology to the TCRVβ in the human genome using NCBI BLAST (Basic Local Alignment 
Search Tool). Next we chose a primer for the constant region of the CDR3 of the TCR and a 
complimentary primer to the bespoke oligonucleotide. The oligonucleotide and primer design 
is shown in Table 5-3. 
As a proof of principle we used the Jurkat cell line for initial ligation experiments. Jurkat cells 
are an immortalized human T-cell line from a patient with T lineage acute lymphoblastic 
leukaemia. Jurkat cells were grown in cell culture as described in 2.5.2. The mRNA was 
directly isolated according to the Dynabeads® mRNA Direct™ protocol from 1x106 cells 
described in 5.4.7.1. First strand cDNA synthesis was then undertaken according to the 
ThermoScript™ cDNA synthesis protocol described in 5.4.9.  A control PCR of a 
housekeeping gene was undertaken using beta actin (primers kindly donated by Dr Costas 
Chronis) as described in 5.4.11. This required several optimisation steps. A successful 
amplification of actin is shown in Figure 5-5. 
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Figure 5-5 Actin in successfully amplified in Jurkat cell line  
mRNA was directly isolated from 1x106 cells Jurkat cells, then first strand cDNA was 
synthesised and a PCR of the actin gene was undertaken as described. The PCR products 
were run on a TBE gel with ethidium bromide. The gel was run at 150V for 2 hours. Lanes 
1&6 show the sizing ladder (HyperLadder I, Bioline), lane 2 is a negative control (no cDNA), 
lanes 3&4 show the PCR product (actin) in Jurkat cDNA, lane 5 is a negative control (Jurkat 
RNA).  
 
The Oligonucleotide ligation took many optimisation steps before a PCR product was 
successfully amplified using the novel TCR primers. A literature review was undertaken to find 
ways to optimise the ligation. Table 5-8 summarises the published methods. We repeated a 
series of experiments altering the amount of oligo, total volume, buffer, concentrations of 
magnesium, PEG, BSA and T4 ligase. We additionally undertook a series of temperature 
gradient modifications. The successfully optimised ligation method is described in 5.4.10. 




Volume  Buffer Constituents 
Tris-
HCL 
pH MgCl2 BSA PEG Hexamine 
Colbat 
Chloride 








10pM 10µl 50Mm 8.0 10mM 10µg/ml 8000 
25% 
(wt/vol) 




Jones et al. 
1996) 
 
100pM 10µl 50mM 8.0 10mM 10µg/ml 8000 
25% 
(wt/vol) 




Kaur et al. 
2002) 
 








1mM 1mM 10mM 20U  
(1 µl) 
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The negative control for the ligation TCR PCR was cDNA made from selected CLL B-cells. B-
cell selection method is described in 2.2.5. Clearly B-cells should not amplify a TCR even after 
a successful anchor ligation. A control PCR using actin was undertaken to prove cDNA was 
extracted successfully from the B-cells. A successful amplification of the Jurkat TCR and the 
positive and negative controls are shown in Figure 5-6. 
 
Figure 5-6 Successful TCR amplification in Jurkat cell line (lane 6) 
RNA was isolated from 1x106 cells Jurkat cells and selected CLL B-cells. First strand cDNA 
was synthesised and the oligonucleotide ligation undertaken as described. PCR was 
undertaken to control gene actin and to the TCR (using the TCR forward primer and the ligated 
oligonucleotide as a reverse primer). The PCR products were run on a TBE gel with ethidium 
bromide. The gel was run at 150V for 2 hours. Lanes 1&8 are the sizing ladder (HyperLadder 
I, Bioline), lane 2 is the actin PCR negative control (no cDNA), lane 3 is the actin PCR product 
in Jurkat cDNA, lane 4 is the actin PCR product in CLL B-cells cDNA, lane 5 is the TCR PCR 
negative control (no cDNA), lane 6 is the TCR PCR product in Jurkat cDNA, lane 7 is a TCR 
negative control (CLL B-cells).  
 
The band presumed to be representing the TCR of the Jurkat in lane 6 was cut out of the gel 
and cleaned up as in 5.4.13. In order to optimise the yield the cleaned up PCR product was 
amplified with a further 20 PCR cycles.  The band was then cut out and cleaned up again. The 
result PCR product is shown on the gel photo in Figure 5-7. 
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Figure 5-7 Lane 2 shows the cleaned up Jurkat TCR PCR product 
The TCR PCR product in Figure 5-6 was excised from the gel and cleaned up using the 
MinElute Gel Extraction Kit (Qiagen) as described. The cleaned up PCR product was amplified 
with a further 20 PCR cycles.  The resultant PCR products were run on a TBE gel with ethidium 
bromide. The gel was run at 150V for 2 hours. Lanes 1 is the sizing ladder (HyperLadder I, 
Bioline), lane 2 is the TCR PCR product. 
 
5.5.3 Gene sequencing of TCRV 
The cleaned PCR product was sent to GeneserviceTM (Source Bioscience) for Sanger 
sequencing as described in 5.4.14. They undertake a plasmid based protocol using the 
primers we provided. The sequence was returned as 503bp. A snapshot of the sequence is 
shown in Figure 5-8.  
 
Figure 5-8 Snapshot of sequencing data of PCR product  
The TCR PCR product from the Jurkat cell line from Figure 5-7 was sent to GeneserviceTM 
(Source Bioscience) for Sanger sequencing using a plasmid based protocol. The sequence 
was returned was 503bp.  
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The full sequence is shown in Figure 5-9. We used the sequence identification tool NCBI 
BLAST to find matching sequences in the human genome database (RefSeq Genome). The 
database identified the sequence as Homo sapiens T-cell receptor beta locus (TRB) on 
chromosome 7 family TCRVβ 12. This confirms that the oligo ligation PCR worked and the 
TCR could be successfully amplified.    
 
Figure 5-9 BLAST search  
The Jurkat TCR PCR product sequence obtained from GeneserviceTM was searched for 
homology to known sequences in the human genome database (RefSeq Genome) using the 
NCBI BLAST sequence identification tool NCBI BLAST. The database identified the sequence 
as Homo sapiens T-cell receptor beta locus (TRB) on chromosome 7 family TCRVβ 12.  
 
Despite the ultimately successful ligation of an oligo to the single stranded cDNA for TCR 
amplification the technique was time consuming, inconsistent and required a large amount of 
starting cDNA. The ligation was never successfully undertaken in primary patient material from 
normal controls or CLL patients (data not shown). The fundamental unanswered question 
remained - how efficiently was the cDNA being ligated? It follows that even if a very small 
percentage of the total Jurkat cDNA was successfully ligated this could enable amplification 
of the single clonal TCR.  In contrast if only a proportion of the cDNA was ligated in a primary 
patient sample, with a diverse repertoire, then the whole TCR would not be represented. The 
question of ligation efficiency could potentially be answered by undertaking Jurkat cDNA 
spiking experiments. Nevertheless even if we did manage to construct a complete TCRV 
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library, a method for repertoire analysis would still need to be devised. Therefore we did not 
pursue this experimental approach any further for our study and instead proceeded with 
standard TCRV spectratyping. 
5.5.4 TCRV spectratyping in primary patient material 
TCRVβ spectratyping is the gold standard technique for assessing the TCR repertoire. We 
chose to assess the TCRVβ repertoire in CD4+ T-cells from the PD-1hi and PD-1lo 
populations from the PB and LN to look for inter-patient variations. This would be achieved by 
flow sorting the desired subpopulations, extracting total RNA and undertaking a PCR 
amplification of the 24 TCRV families before assessing the resultant fragment sizes on the 
Genetic Analyser. Initial experiments were again focused on optimising the method. 
5.5.5 Jurkat cell TCRV spectratyping  
As the ligation experiments and gene sequencing had confirmed the clonal TCR expression 
in the Jurkat cells we decided to use this cell line for initial TCRV spectratyping. This would 
provide a positive control for the presence of a clonal TCR and a negative control for the 
remaining V families. We could also identify the cell number of Jurkats required to extract 
RNA and make cDNA successfully. cDNA was made from 5 x 105, 5 x 104, 1 x 104 and 1 x 103 
Jurkat cells as described in 5.4.9. Abl was used as a housekeeping gene and PCR was 
undertaken as outlined in 5.4.11. Abl was successfully amplified in all 4 dilutions. A caveat is 
this experiment could not prove that 1000 cells would be adequate for successful amplification 
in primary patient material as cell lines do not express the same amount of RNA as primary 
patient T-cells.  
Next we undertook the TCRV PCR using the 24 family specific primers as described in 
5.4.11. As would be predicted, only one lane revealed an amplified product; which confirmed 
the clonal TCR production of the Jurkat cell line. We ran the samples on the Genetic Analyser 
and generated a dominant peak in one family confirming the clonal TCR.  Figure 5-10 shows 
the presence of a dominant clonal peak. The two smaller peaks are likely PCR artefacts.  
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Figure 5-10 Dominant peak in Jurkat V spectratype profile 
mRNA was isolated from Jurkat cells and TCRV spectratyping was performed as described. 
The FAM labelled CDR3 PCR products were sized using the Genetic Analyser 3130XL 
(Applied Biosystems), and the data was visualised using the GeneMapper Software (Applied 
Biosystems). The PCR product size and fluorescence intensity is displayed, representative of 
the frequency of the CDR3. The dominant peak here represents the Jurkat TCR.  
 
5.5.6 Cell sorting for TCRV spectratyping of primary patient T-cells 
Subsets of CD4+ and CD8+ PD-1hi and PD-1lo T-cells were sorted from PB and LN FNA by 
FACS as described in 5.4.6. Table 5-9 shows the total numbers of cells of each subpopulation 
collected in the sort for each CLL patient.  
Table 5-9 Total cell numbers of T-cell sub-populations collected in FACS sort 
Subsets of CD4+ and CD8+ PD-1hi and PD-1lo T-cells were sorted from PB and LN as 
described using the BD FACSAria (BD Biosciences). Cells were sorted from the lymphocyte 
gate and populations defined as CD4+/PD-1hi, CD4+/PD-1lo, CD8+/PD-1hi, CD8+/PD-1lo.  
 
Sample CLL 1 CLL 2 CLL 3 CLL 5 CLL 6 CLL 7 
 
PB FNA PB FNA PB FNA PB FNA PB FNA PB FNA 
CD4+ 
PD-1hi 
10000 63427 42082 36276 36900 14612 21959 25409 4130 28299 15860 23595 
CD4+ 
PD-1lo 
10000 38179 31072 10535 54400 12797 31037 9425 8999 32595 36600 13446 
CD8+ 
PD-1hi 
10000 19810 10011 5643 10060 3348 6158 3559 4215 16364 24611 8221 
CD8+ 
PD-1lo 
10000 4787 18083 628 18200 1461 56982 2700 4166 3165 13924 1982 
 
Statistical analysis using GraphPad showed a normal distribution of cells collected of each 
CD4+ T-cell subpopulation within and between patients. The mean number of PB CD4+ PD-
1hi cells was 21822 +/- 6127. The mean number of PB CD4+ PD-1lo cells was 28685 +/- 
7004. The mean number of LN CD4+ PD-1hi was 31936 +/- 6919. The mean number of LN 
CD4+ PD-1lo was 19496 +/- 5112. There was no statistical difference in the number of cells 
in each subpopulation. See Figure 5-11 and Figure 5-12 




























































Figure 5-11 Number of each CD4+ T-cell subset in CLL FACS sort 
CD4+ T-cells were sorted from PB and LN as described in Table 5-9. A statistical D’Agostino 
and Pearson omnibus normality test and un-paired t-test was applied using GraphPad Prism®. 




























































Figure 5-12 No difference in the number of cells sorted of each subpopulation 
CD4+ T-cells were sorted from PB and LN as described in Table 5-9. A statistical D’Agostino 
and Pearson omnibus normality test and un-paired t-test was applied using GraphPad Prism®. 
There was no statistical difference in the number of cells sorted from each subset. 
 
The total cell numbers collected from the PB of normal controls is shown in Table 5-10.  
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Table 5-10 Number of sorted cells from healthy control PB 
Subsets of CD4+ and CD8+ PD-1hi and PD-1lo T-cells were sorted from PB of normal controls 
as described using the BD FACSAria (BD Biosciences). Cells were sorted from the 
lymphocyte gate and populations defined as CD4+/PD-1hi, CD4+/PD-1lo, CD8+/PD-1hi, 
CD8+/PD-1lo.  












10000 5547 3110 13000 18000 10000 
CD4+  
PD-1lo 
10000 59732 80216 86000 88462 10000 
CD8+ 
PD-1hi 
6129 2279 5376 19500 6600 n/a 
CD8+ 
PD-1lo 
12572 13388 40702 13700 64000 n/a 
There was no statistical difference between the number of cells collected from the PB of CLL 






























































Figure 5-13 Number of sorted CD4+ PB cells normal vs CLL 
CD4+ T-cells were sorted from PB from normal controls and CLL patients as described in 
Table 5-9. A statistical D’Agostino and Pearson omnibus normality test and un-paired t-test 
was applied using GraphPad Prism®. There was no statistical difference in the number of 
cells sorted from the PB of normal controls and CLL patients of any CD4+ subset. 
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5.5.7 RNA quantification 
The amount of RNA was quantified using the NanoDrop as described in 5.4.8. The amount of 
RNA extracted from the flow sorted cells is shown in Table 5-11.  
Table 5-11 Quantity of RNA extracted  
CD4+ T-cells were sorted from PB and LN as described in Table 5-9. The number of cells 
sorted from each subset (CD4+/PD-1hi or CD4+/P1-lo) from both PB and LN is shown, with 
the corresponding quantity of RNA extracted in ng, as recorded using the NanoDrop (Thermo 
Scientific). 
 
Sample PB CD4 PD-1hi PB CD4 PD-1lo LN CD4 PD-1hi LN CD4 PD-1lo 
Cells RNA ng Cells RNA ng Cells RNA ng Cells RNA ng 
CLL1 10000 118 10000 448 63427 121 39179 157 
CLL2  42082 78 31072 60 36276 47 10535 42.3 
CLL3  36900 57 54400 444 14612 n/a 12797 57 
CLL5 21959 199 31037 n/a 25409 504 9425 144 
CLL6  4130 406 8999 261 28299 173 32595 280 
CLL7 15860 102 36600 87 23595 113 13446 115 
 
The technology relies on the surface tension of the drop forming a liquid column between the 
upper and lower optical measurement surfaces. The NanoDrop then measures the 
absorbance between 200nm and 350nm. The concentration of RNA can then be determined 
by the Beer-Lambert Law of the linear change in absorbance and concentration. The 
absorbance ratio at 260nm and 280nm is then quantified. RNA has maximal absorbance at 
260nm and proteins, particularly aromatic amino acids absorb light at 280nm. Therefore the 
260/280 ratio can be used to assess purity; where a ratio of 2 indicate pure RNA (Desjardins 
and Conklin 2010). There were some quality assurance issues with the NanoDrop machine in 
our laboratory at the time of measurement. Detergent cleaning which interferes with the liquid 
column formation, may have been the cause of the problem (Desjardins and Conklin 2010).  
With this caveat I present the data recorded.  
The mean RNA quantity from each subpopulation of CD4+ T-Cells was as follows: PB CD4+ 
PD-1hi 160ng +/- 53; PB CD4+ PD-1lo 260ng +/- 84; LN CD4+ PD-1hi 191ng +/- 81; LN CD4+ 
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PD-1lo 132.6ng +/- 35. There was no statistical difference between these amounts. See Figure 
5-14.  
The mean quantity of RNA extracted from normal control PB CD4+ PD-1hi was 356ng +/- 237 
and PB CD4+ PD-1lo 192ng +/- 61. There was no statistical difference between these values 
p=1.00. There was also no statistical difference between the amount of RNA extracted from 
the PB subpopulations of CLL and normal controls: CD4+ PD-1hi PB CLL 160ng +/- 53 vs 















































Figure 5-14 Quantity of RNA extracted from each CD4+ T-cell subpopulation in CLL patients 
CD4+ T-cells were sorted from PB and LN as described in Table 5-9. The quantity of RNA 
from each subset (CD4+/PD-1hi or CD4+/P1-lo) from both PB and LN is shown, as recorded 
using the NanoDrop (Thermo Scientific). A statistical D’Agostino and Pearson omnibus 
normality test and un-paired t-test was applied using GraphPad Prism®. There was no 
statistical difference in the quantity of RNA from any of the sorted CD4+ populations. 
 
5.5.8 PCR of control housekeeping genes from sorted subpopulations 
cDNA was synthesised from the RNA from each CD4+ T-cell subpopulation. Every cDNA 
sample was checked for integrity with the amplification of a housekeeping gene prior to the 
TCRVβ PCR as outlined in 5.4.11. The PCR underwent multiple optimisation steps and the 
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experiments were repeated with stepwise changes in the protocol due to the inability to 
consistently amplify PCR products. Whilst attempting to ascertain the reasons for the technical 
failures we used the human immortalized myeloid leukaemia cell line K562 as a positive 
control (donated by Dr Shahram Kordasti). Several issues were uncovered and it was finally 
determined the most significant problem was the intermittent use of a specific PCR thermal 
cycler in our laboratory which was not performing optimally. Figure 5-15 shows a 
representative example of the gel electrophoresis of successfully amplified Abl in all four CLL 
PB and LN CD4+ subpopulations from one patient. 
 
Figure 5-15 Abl amplification in PB and LN sorted CD4+ cell populations 
RNA was extracted, first strand cDNA was synthesised and a PCR of the control gene abl was 
undertaken, as described, from the sorted CD4+ PD-1hi and PD-1lo populations from the PB 
and LN. The PCR products were run on a TBE gel with ethidium bromide. The gel was run at 
150V for 1 hour. Lanes 1&7 show the sizing ladder (HyperLadder II, Bioline), lane 2 is an 
internal abl control with K562 (a non T-cell cell line), lanes 3-6 show the abl PCR product in 
all 4 sorted CD4+ populations (CLL PB CD4+/PD-1hi, CLL PBCD4+/PD-1lo, CLL LN 
CD4+/PD-1hi, CLL LN CD4+/PD-1lo).  
5.5.9 TCRV PCR products were successfully amplified from the sorted cell 
populations 
Following successful Abl amplification, the cDNA from each subpopulation was used to 
undertake the 24 individual PCR reactions, one for each TCRVβ family. The products of every 
individual population (24 families x4 sorted populations x6 patients) were ran on a gel prior to 
analysis in the Genetic Analyser. A representative gel electrophoresis of the resultant 24 
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TCRVβ family products from the CD4+ PD-1hi and PD-1lo subpopulations from the PB and 
LN of one patient is shown in Figure 5-16. 
 
Figure 5-16 Representative figure from one patient showing 24 TCRVβ families amplification 
in the 4 sorted CD4+ T-cell populations 
In this example RNA was extracted from the sorted CD4+ subpopulations from the CLL PB 
and LN as described. Then first strand cDNA was synthesised and TCRV PCR performed 
using 24 V family specific forward primers and a constant FAM labelled reverse Cβ primer. 
The PCR products were run on a TBE gel with ethidium bromide. The gel was run at 150V for 
1 hour. The photograph of the gels show the PCR products from the 24 V family primers (1-
24 left to right). The top panel (Gel 1) shows PCR products from the CLL PB CD4+/PD-1hi 
samples, the second row shows CLL PB CD4+ PD-1lo. The bottom panel (Gel 2) shows, in 
the first row, CLL LN CD4+/PD-1hi, and in the second row CLL LN PD-1lo. PCR products can 
be appreciated in all rows. 
 
5.5.10 TCRVβ spectratyping 
The resultant PCR products were subsequently run on the Genetic Analyser as described in 
5.4.15. Initially not every Vβ family produced a spectratype profile and the technique required 
considerable optimisation. In some instances this was secondary to sample overload in the 
capillary electrophoresis and selected samples were re-run at a lower dilution. For some 
samples not every Vβ family generated a spectratype profile; this may be due to differences 
in Vβ usage. An example spectratyping profile from CLL PB is shown in Figure 5-17 and a 
normal PB in Figure 5-18. 
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Figure 5-17 Example Vβ spectratype profile from CLL PB.  
This is an example Vβ spectratype profile, from each of the 24 Vβ families (labelled Vβ1-24), 
from a sorted CD4+ population from the PB of a CLL patient. The GeneMapper Software 
generates a graphical spectratyping prolife usually consisting of 8 (5-10) major peaks each 
representing a CDR3 length differing from the next by 3 nucleotides. The fluorescence 
intensity is representative of the frequency of the CDR3.  A spectratyping profile is produced 
for each of the 24 TCRVβ families. As described previously a bell shaped curve represents a 
normal distribution.  
 
Figure 5-18 Example Vβ spectratype profile from normal PB. 
This is an example Vβ spectratype profile, from each of the 24 Vβ families (labelled Vβ1-24), 
from a sorted CD4+ population from the PB of a normal control generated as described in 
Figure 5-17. 
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5.5.11 Diversity and complexity scores 
The diversity and complexity scores for each TCRV spectratype were calculated for each 
subpopulation as outlined in 5.4.16. In summary, a complexity score was derived by assigning 
the spectratype of each Vβ family a score of 0-5, depending on the number of discrete peaks, 
and then multiplying by the number of Vβ families (n=24). Spectratypes with >5 peaks were 
given the maximum score of 5 and those with no peaks scored 0, giving a maximum score for 
the most complex repertoire of 120 (5x24). A diversity score was used to quantify the degree 
of skewing within the repertoire. A score of 1 was given for a peak that was more than twice 
the height of the second next highest peak and overall diversity calculated by adding the 
scores for all the Vβ families, therefore a score of 24 is highly skewed and 0 not skewed.           
A higher diversity score thus signifies a less diverse repertoire. The calculated scores 
for the 4 CD4+ subpopulations of the 6 CLL patients PB and LN samples is shown in Table 
5-12. 
Table 5-12 Diversity and complexity scores from CD4+ PD-1hi and PD-1lo populations from 
CLL PB and LN 
CD4+/PD-1hi and CD4+/PD-1lo T-cells were FACS sorted from 6 CLL patients PB and LN as 
described in Table 5-9. TCRVβ spectratyping was performed as described and spectratype 
profiles generated as in Figure 5-17. Diversity and complexity scores for each TCRV 
spectratype from all the subpopulations from each patient are shown below. The complexity 
score was derived by assigning the spectratype of each Vβ family a score of 0-5, depending 
on the number of discrete peaks, and then multiplying by the number of Vβ families (n=24, 
maximum score 120). The diversity scoring system assigns a score of 1 for a peak that is 
more than twice the height of the second next highest peak. The overall diversity score 
calculated by adding the scores for all the Vβ families (n=24, maximum score 24). 



























10000 79 23 10000 77 16 10000 76 20 10000 92 12 
Patient 
2 
4130 39 24 8999 68 20 28299 71 21 13446 74 11 
Patient 
3 
21959 39 23 31037 62 22 25409 70 23 9425 62 22 
Patient 
4 
15860 67 16 36600 87 9 23595 49 21 13446 59 15 
Patient 
5 
36900 95 15 54400 93 7 14612 95 20 12797 70 20 
Patient 
6 
42082 91 18 31072 102 14 36276 78 23 10535 89 16 
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The diversity results for each individual is easier to interpret when displayed graphically. The 
data can be shown for each individual patient as a “spectratype heat map”.  
In Figure 5-19 each individual CLL patient is represented by a chart of 24x4 boxes; where the 
4 rows represent the 4 sorted CD4+ T-cell populations: PB PD-1hi, PB PD-1lo, LN PD-1hi and 
LN PD-1lo and the 24 columns are the 24 TCRV families. The individual boxes represent the 
diversity (or skewing) of each TCRV family repertoire. A black box represents a skewed 
repertoire, a grey box a non-skewed repertoire and a white box represents no spectratype 
profile for that V family. The calculated complexity score (x/120) is displayed in the final 
column.  
Figure 5-20 shows the same data but divided by the sorted CD4+ population of interest. Each 
chart represents a population of interest; PB PD-1hi, LN PD-1hi, PB PD-1lo and LN PD-1lo 
from top to bottom. The 6 rows of each chart are the 6 individual patients and the 24 columns 
are the TCRV families.  
Figure 5-21 compares the skewing of the repertoire of the CLL PB and normal PB in the CD4+ 
PD-1hi and CD4+ PD-1lo populations. The populations of interest are CLL PB PD-1hi, Normal 
PB PD-1hi, CLL PB PD-1lo and Normal PB PD-1lo from top to bottom. The 6 rows of each 
chart are the 6 individual patients and the 24 columns are the V families. 
 
- 240 - 
 
Figure 5-19 The overall diversity of the TCRV families from PD-1hi and PD-1lo PB and LN 
subpopulations in 6 CLL patients 
Each individual CLL patient’s complete spectratype scoring data (Patient 1-6, top to bottom) 
is represented by 24x4 boxes; where the 4 rows represent the 4 sorted CD4+ T-cell 
populations: PB PD-1hi, PB PD-1lo, LN PD-1hi and LN PD-1lo and the 24 columns are the 24 
TCRV families. The individual boxes represent the diversity (or skewing) of each TCRV 
family repertoire. A black box represents a skewed repertoire, a grey box a non-skewed 
repertoire and a white box represents no spectratype profile for that V family. The calculated 
complexity score (x/120) is displayed in the final column.  
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Figure 5-20 The diversity of the TCRV from PD-1hi and PD-1lo PB and LN subpopulations 
in 6 CLL patients 
This figure shows the same complete spectratyping data of the cohort as presented in Figure 
5-19 but each panel represents the sorted CD4+ population of interest; PB PD-1hi, LN PD-
1hi, PB PD-1lo and LN PD-1lo from top to bottom. The 6 rows of each chart are the 6 individual 
patients and the 24 columns are the TCRV families. The individual boxes represent the 
diversity (or skewing) of each TCRV family repertoire. A black box represents a skewed 
repertoire, a grey box a non-skewed repertoire and a white box represents no spectratype 
profile for that V family. The calculated complexity score (x/120) is displayed in the final 
column.  
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Figure 5-21 A comparison of the overall TCRV diversity in the PB PD-1hi and PD-1lo 
subpopulations of 6 CLL patients and normal controls 
This figure shows the complete spectratyping data of the CD4+ sorted subpopulations from 
the PB of CLL patients and normal controls. Each panel represents the sorted CD4+ 
population of interest; CLL PB PD-1hi, Normal PB PD-1hi, CLL PB PD-1lo and Normal PB 
PD-1lo from top to bottom. The 6 rows of each chart are the 6 individual patients and the 24 
columns are the V families. The individual boxes represent the diversity (or skewing) of each 
TCRV family repertoire. A black box represents a skewed repertoire, a grey box a non-
skewed repertoire and a white box represents no spectratype profile for that V family. The 
calculated complexity score (x/120) is displayed in the final column.  
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5.5.12 There is increased skewing of the TCRV spectratype in PD-1hi T-cells compared 
to PD-1lo T-cells in both LN and PB compartments in CLL 
Analysis of this data showed there was a significant reduction in overall TCR diversity (i.e. the 
diversity score is higher and repertoire is more skewed) in the PD-1hi subset in both CLL 
compartments compared to PD-1lo T-cells; PB PD-1hi vs PD-1lo (19.83+/-1.62 vs 14.67+/-





















































Figure 5-22 There is more skewing in the CD4+ PD-1hi T-cells than CD4+ PD-1lo T-cells of 
both PB and LN in CLL 
A total TCRV spectratype diversity score was calculated for each sorted CD4+ subpopulation 
(CLL PB PD-1lo, CLL PB PD-1hi, CLL LN PD-1lo and CLL LN PD-1hi) from all 6 CLL patients, 
as in Table 5-12. Statistical analysis was performed with a D’Agostino and Pearson omnibus 
normality test and a paired t-test using GraphPad Prism®. There was a significant reduction 
in overall TCR diversity (i.e. the diversity score is higher and repertoire is more skewed) in the 
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There was no difference between the diversity in CLL PB PD-1hi T-cells and LN PD-1hi T-
cells; PB PD-1hi vs LN PD-1hi (19.83+/-1.62 vs 21.33+/-0.56; p=0.39) or CLL PB PD-1lo T-
cells and LN PD-1lo T-cells; PB PD-1lo vs LN PD-1lo (14.67+/-2.42 vs 16.00+/-1.77; p=0.69). 




















































Figure 5-23 The CLL CD4+/PD-1hi population are skewed whether derived from the PB or LN 
The total TCRV spectratype diversity score for each sorted CD4+ subpopulation (CLL PB 
PD-1lo, CLL PB PD-1hi, CLL LN PD-1lo and CLL LN PD-1hi) from all 6 CLL patients, was 
calculated and analysed as in Figure 5-22. There was no difference in the overall TCR diversity 
score for the CD4+/PD-1hi subset whether the cells were derived from the CLL PB or LN 
(p0.39).  
 
This demonstrates that the PD-1hi T-cells have a more skewed TCRV spectratype than PD-
1lo T-cells whether they are in the LN or PB. However we know from our data in chapter 3, 
there is a significantly larger proportion of PD-1hi T-cells in the LN compared to PB, and 
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No significant differences in TCR complexity score was observed between the PD-1hi and 
PD-1lo populations; PB PD-1hi vs PB PD-1-lo (68.33+/-10.10 vs 81.50+/-6.23; p=0.057); LN 























































Figure 5-24 The complexity score was the same in all subpopulations of CLL 
A total TCRV spectratype complexity score was calculated for each sorted CD4+ 
subpopulation (CLL PB PD-1lo, CLL PB PD-1hi, CLL LN PD-1lo and CLL LN PD-1hi) from all 
6 CLL patients, as in Table 5-12. Statistical analysis was performed with a D’Agostino and 
Pearson omnibus normality test and a paired t-test using GraphPad Prism®. No significant 
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5.5.13 There is skewing of the TCRV spectratype in PD-1hi CD4+ T-cells compared to 
PD-1lo CD4+ T-cells in normal PB 
In order to see whether it held true that PD-1hi T-cells are skewed in the normal controls we 
compared the diversity and complexity scores of PB CD4+ PD-1hi and PB CD4+ PD-1lo 
subsets in the normal controls. There was a higher diversity score, and therefore less diversity, 
in the PB CD4+ PD-1hi T-cells than the PB CD4+ PD-1lo T-cells. Mean diversity scores PB 








































Figure 5-25 Decreased diversity score in the PD-1lo CD4+ T-cells in normal PB 
A total TCRV spectratype diversity score was calculated for each sorted PB CD4+ 
subpopulation, (PD-1lo and PB PD-1hi) from the cohort of normal controls (n=6). Statistical 
analysis was performed with a D’Agostino and Pearson omnibus normality test and a paired 
t-test using GraphPad Prism®. There was a significant reduction in overall TCR diversity (i.e. 
the diversity score is higher and repertoire is more skewed) in the PD-1hi subset compared to 
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There was also a trend towards, but not statistically significant, less complexity in the PB CD+ 
PD-1hi T-cells than the PB CD4+ PD-1lo: PB CD4+ PD-1hi vs PB CD4+ PD-1lo: 96.67 +/- 
7.75 vs 109.3 +/- 2.73; p=0.063. See Figure 5-26.  
This demonstrates that there is evidence of skewing in the PD-1hi, antigen experienced CD4+ 











































Figure 5-26 Complexity is preserved in the PD-1hi CD4+ T-cells of normal PB 
A total TCRV spectratype complexity score was calculated for each sorted PB CD4+ 
subpopulation, (PD-1lo and PB PD-1hi) from the cohort of normal controls (n=6). Statistical 
analysis was performed with a D’Agostino and Pearson omnibus normality test and a paired 
t-test using GraphPad Prism®. There was a trend towards less complexity in the PB CD+ PD-
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5.5.14 There is increased skewing of the CLL PB TCRV spectratype compared to age 
matched normal controls in both PD-1hi and PD-1lo CD4+ T-cell subsets 
From the normal control data presented above we demonstrate that there was a higher 
diversity score and thus more skewing in the TCRV repertoire of PB CD4+ PD-1hi T-cell 
subsets compared to CD4+ PD-1lo T-cells in normal individuals. Next we wanted to ascertain 
whether the degree of skewing of the PB TCRV repertoire in PD-1hi CD4+ subset of CLL 
patients and normal controls was the same.  
We found the diversity of the TCRV to be even more skewed in CLL PB PD-1hi CD4+ T-cells 
than in the equivalent PD-1hi cells in normal PB. CLL PB CD4+ PD-1hi vs normal PB CD4+ 
PD-1hi: 19.83 +/- 1.62 vs 12.67 +/- 2.54; p=0.039). Additionally the CLL PB PD-1lo CD4+ T-
cell population was more skewed than the normal counterpart. CLL PB CD4+ PD-1lo vs 
























































Figure 5-27 CLL CD4+ T-cells have more skewing than normal PB 
A total TCRV spectratype diversity score was calculated for each sorted PB CD4+ 
subpopulation, (PD-1lo and PB PD-1hi) from the cohort of CLL patients (n=6) and normal 
controls (n=6). Statistical analysis was performed with a D’Agostino and Pearson omnibus 
normality test and an un-paired t-test using GraphPad Prism®. The diversity of the TCRV 
was more skewed in CLL PB PD-1hi CD4+ T-cells than in the equivalent PD-1hi cells in normal 
PB; p=0.039. Additionally the CLL PB PD-1lo CD4+ T-cell population was more skewed than 
the normal counterpart; p=0.019. 
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This confirms more skewing of the CD4+ TCRV repertoire overall in CLL compared to age 
matched normal controls, with evidence in both the CD4+ PD-1hi and PD-1lo T-cells. 
There was also less complexity in the TCRV repertoire of CLL PD-1hi CD4+ T-cells 
compared to normal controls. Normal PB CD4+ PD-1hi vs CLL PB CD4+ PD-1hi: 96.67 +/- 
7.75 vs 68.33 +/- 10.10; p=0.05. The same was true for the PD-1lo subset; where there was 
more complexity in the TCRV repertoire of normal PD-1lo CD4+ T-cells compared to the 
same population in CLL. Normal PB CD4+ PD-1lo vs CLL PB CD4+ PD-1lo: 109.30 +/- 2.73 
vs 81.50 +/- 6.23; p=0.02. See Figure 5-28.  
This is in keeping with the published data that there is oligoclonality of the CLL PB TCR 


























































Figure 5-28 TCRV repertoire in normal PB is more complex than in CLL 
A total TCRV spectratype complexity score was calculated for each sorted PB CD4+ 
subpopulation, (PD-1lo and PB PD-1hi) from the cohort of CLL patients (n=6) and normal 
controls (n=6). Statistical analysis was performed with a D’Agostino and Pearson omnibus 
normality test and an un-paired t-test using GraphPad Prism®. The complexity of the TCRV 
was less in CLL PB PD-1lo CD4+ T-cells than in the equivalent PD-1lo cells in normal PB; 
p=0.002. The same was true between CD4+ PD-1hi T-cells; p=0.05.  
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5.5.15 TCRVβ family skewing  
It has been shown here that the CD4+ TCR Vβ repertoire in the PD-1hi subset of CLL is more 
skewed than the PD-1lo subset in both PB and LN and that the PD-1hi subset of normal 
controls is more skewed than the PD-1lo population. In addition, the overall PB CD4+ TCRVβ 
repertoire of patients with CLL is less complex than normal controls. A graphical 
representation of the frequency of PB CD4+ TCRV family skewing across the CLL and 
normal control cohorts is shown in Figure 5-29. It can be seen that across the CLL cohort 
there is an increased frequency of TCRV family skewing in both the PD-1hi and PD-1lo 
subpopulations compared to normal controls with no clear pattern. 
 
Figure 5-29 The frequency of TCRV family skewing of PB CD4+ T-cells across the cohort is 
greater in CLL patients (n=6) than in normal controls (n=6) in both PD-1hi and PD-1lo 
subpopulations 
In this graphical representation of the total PB cohort of 6 CLL patients and 6 normal controls, 
each TCRV family in a subpopulation (normal PB CD4+ PD-1lo (green), normal PB CD4+ 
PD-1hi (purple), CLL PB CD4+ PD-1lo (blue) or CLL PB CD4+ PD-1hi (grey)) can be skewed 
to a maximum score of 6 (representing the cohort of 6 individuals under study). As an example, 
the green bars above represent the CD4+ PD-1lo samples from the normal PB (n=6). If, as 
shown here, the TCRV family vb1 was skewed in one sample out of the total 6 it scores 1. 
However if the same family was skewed in 2 out of 6 samples it would have scored 2 (as in 
vb12) and if every sample skewed that TCRV family then it would have scored 6 out of 6. 
The height of the bar therefore represents the number of individuals in the cohort of 6 that 
skewed that TCRV family. Visually it can be seen that the CLL PB samples have a higher 
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In this study we are primarily interested in the CLL cohort. A graphical representation of the 
frequency of TCRV family skewing across the CD4+ PD-1hi and PD-1lo subpopulations from 
the LN and PB CLL cohort is shown in Figure 5-30. Each column represents the frequency of 
skewing of the CD4+ TCRV family across all 6 CLL patients in the PB and LN PD-1hi and 
PD-1lo compartments. It can be seen that all families show a degree of skewing across the 
cohort and no families are unaffected. 
 
 
Figure 5-30 Frequency of skewing of the TCRV families in CLL CD4+ PB and LN 
subpopulations; n=6 
The frequency of skewing is as described in Figure 5-29. Here it can be seen that there is 
skewing across all TCRV families in all 4 CLL CD4+ subpopulations, PB PD-1lo (blue), LN 
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For clarity this data is split into 3 comparisons of interests, looking specifically at comparisons 
with the CD4+ PD-1hi population. Figure 5-31 shows just the frequency of TCRV skewing for 
the LN PD-1hi and PD-1lo CD4+ T-cells subpopulations. Figure 5-32 shows the CLL PB CD4+ 
PD-1hi and PB PD-1lo subpopulations. Figure 5-33 shows the CLL LN CD4+ PD-1hi and PB 
PD-1hi subpopulations.  
 
Figure 5-31 Frequency of skewing of the TCRV families in LN PD-1hi compared to PD-1lo 
subpopulations; n=6 
The frequency of skewing is as described in Figure 5-29. Here it can be seen that there is 
skewing across all TCRV families in both CLL LN CD4+ subpopulations, LN PD-lo (orange), 




Figure 5-32 Frequency of skewing of the TCRV families in CLL PB PD-1hi vs PD-1lo 
subpopulations; n=6 
The frequency of skewing is as described in Figure 5-29. Here it can be seen that there is 
skewing across all TCRV families in both CLL PB CD4+ subpopulations, PB PD-1lo (blue) 
and PB PD-1hi (grey). 
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Figure 5-33 Frequency of skewing of the TCRV families in CLL LN CD4+ PD-1-hi vs CLL PB 
CD4+ PD-1hi subpopulations; n=6. 
The frequency of skewing is as described in Figure 5-29. Here it can be seen that there is 
skewing across all TCRV families in both CLL CD4+ PD-1hi subpopulations, PB PD-1hi 
(grey) and LN PD-1hi (yellow). 
 
This data shows that in this cohort of 6 patients, any of the TCRVβ families can be skewed, 
but gives no further information. We wanted to know whether the TCRVβ family skewing was 
concordant in the different populations and compartments within an individual patient.  
5.5.16 Concordance of skewing 
In order to determine whether the events causing skewing of the TCRVβ repertoire were 
specific to the LN, or part of a more general process in a patient, we estimated the 
“concordance of skewing” in the PB and LN subpopulations for each individual patient.  
To calculate the concordance of skewing we constructed an algorithm that asked if the 
spectratype profile is skewed in “population 1” of an individual was it also skewed in the same 
way, (i.e. with the same peaks), in “population 2” of the same individual.  
Specifically the first analysis sought to determine if a TCRVβ family was skewed in LN CD4+ 
PD-1hi population was it also skewed in the same way for LN CD4+ PD-1lo population?  
This required visualisation of each spectratype profile and scoring “yes” or “no” if the 
spectratype profile was skewed in the same way. From this, an overall “concordance of 
skewing” can be calculated a percentage across the repertoire.  
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The scoring system is shown in Figure 5-34.  
 
Figure 5-34 Scoring the concordance of skewing 
Concordance of skewing is scored by visually assessing if two spectratype profiles are skewed 
in the same way or not and scoring “yes” or “no”. All example pairs shown above are a 
comparison of the spectratype profiles from the same TCRVβ family from matched samples 
from the same patient. In the top and bottom panels the concordance of skewing is “yes” as 
both paired spectratype profiles are skewed in the same way. In the middle panel, the 
concordance of skewing is “no” as although both spectratypes are skewed, the same peak is 
not skewed and therefore they are not concordant. 
 
First we compared the CD4+ PD-1hi and PD-1lo populations of the LN, and found the 
concordance of skewing for the cohort to be 59.8% +/- 4.09.  Next we asked if the spectratype 
profile was skewed in the same way between the PB CD4+ PD-1hi and PB CD4+ PD-1lo T-
cell subpopulations. The concordance of skewing was 71.5% +/- 4.96 for the cohort. Finally 
we wanted to compare the profile skewing of the CD4+ PD-1hi populations of the LN and PB. 
The concordance of skewing for the cohort was the lowest at 49.5% +/- 10.47.  
This would suggest different families are being used in the PB and LN. Additionally there is 
less concordance of skewing between the PD-1hi and PD-1lo subsets of the LN than the same 
comparison in the PB; p=0.039.  
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Figure 5-35 shows the overall concordance of skewing for these 3 comparisons 
 
Figure 5-35 Concordance of skewing of TCRVβ spectratyping profiles of CLL CD4+ PD-1+ T-
cells from different compartments 
Concordance of skewing for each spectratype was calculated according to Figure 5-34. From 
this a percentage of concordance of skewing was calculated for all TCRVβ families in a 
sample. The concordance of skewing was highest between the CLL PB CD4+ PD-1hi and PD-




This analysis strongly suggests that the TCR repertoire of the PD-1hi population in the LN and 
PB are distinct and likely originate through interaction with different antigens.  
5.5.17 High throughput TCRVβ sequencing 
Our spectratyping results have shown that the CD4+ TCRVβ repertoire is skewed in the PB 
and LN in CLL, and for the first time we have shown that the diversity was even more skewed 
within the PD-1hi population. The PD-1hi population of T-cells predominate in the LN and 
therefore the TCR diversity was most skewed in this compartment. The skewing occurred 
across all TCRVβ families and although the concordance of skewing strongly suggested 
differences between the PB and LN, the resolution of spectratype analysis means that we 
were unable to make a definitive statement about this. In order to further address this point 
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we employed the emerging technology of high throughput sequencing of the TCR CDR3. 
Using this technique we could ascertain commonality in the TCRVβ repertoire of the CD4+ T-
cells derived from the PB and LN at the level of the individual TCRVβ CDR3. Additionally, we 
sought to compare the TCRVβ repertoire of a patients PB and 2 separate lymph nodes taken 
from the same patient at the same time. From this we could identify whether there is any 
commonality in the TCRVβ repertoire between two different LNs and the LN and PB. 
Identification of T-cell clonality within the LN would provide evidence that the T-cells are 
specially proliferating within the LN in response to cognate antigen in a TCR specific manner.  
This work was undertaken in partnership with Dr Marta Pasikowska, a post-doctoral scientist 
in our laboratory and our collaborators at Adaptive Biotechnologies. 
Note the TCRVβ nomenclature from Adaptive Biotechnologies is IMGT (Robins, Campregher 
et al. 2009, Yassai, Naumov et al. 2009).  
5.5.18 Demographics of patients and normal controls for HTS 
HTS of the TCRVβ was performed on FACS sorted CD4+ T-cells from a separate cohort of 6 
patients paired LN and PB. The Demographics of the patients is shown in Table 5-13. 
Table 5-13 Demographics of CLL patients for HTS 
 Age Sex CMV Binet CD38% Cyto/FISH Mutational 
Status 
CLL8 75 F POS B 0 Normal Unmutated 
CLL9  66 M NEG C 3 Normal Unmutated 
CLL10  72 M POS B 18 11q- Unmutated 
CLL11 53 F NEG A 0 Normal Mutated 
CLL12 46 M UNK B 5 Normal Unmutated 
CLL 13 74 M UNK A 13 13q- Mutated 
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5.5.19 Average Vβ gene usage differs between CLL and normal PB 
The first analysis used the HTS technology to look at the total CD4+ TCRVβ repertoire in CLL 
and normal PB, to validate the technology. We wanted to look for evidence of over or 
underused TCRVβ families in the CD4+ T-cells of CLL PB compared to normal controls. The 
results are graphically represented in Figure 5-36. The orange bars are selected CD4+ T-cells 
from normal controls, the blue bars PB from CLL patients. Figure 5-36 shows the frequency 
of usage of an individual TCRVβ as a percentage of the total TCRV usage. It can be seen 
that the CLL cases appear to have a different pattern of TCRV usage than the wild type TCR, 
with over and under used TCRV families.  
 
 
Figure 5-36 Frequency of TCRVβ family usage in normal CD4+ PB T-cells (n=6) and CLL PB 
T-cells (n=6)  
cDNA from flow sorted CD4+ T-cells from 6 PB normal controls (orange bars), and 6 CLL 
patients (blue bars) were sent to Adaptive Biotechnologies® for amplification and sequencing 
of TCRVβ CDR3 using the immunoSEQ Platform. TCRVβ CDR3 regions were amplified using 
a bias controlled high throughput multiplex PCR. TCRVβ CDR3 sequences are defined 
according to the IMGT collaboration nomenclature. Data was analysed through the 
ImmunoSEQ analyser software. The bars show the frequency of usage of an individual 
TCRVβ as a percentage of the total TCRV usage. It can be seen that the CLL cases appear 
to have a different pattern of TCRV usage than the wild type TCR, with over and under used 
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This data shows there is divergence of the CD4+ TCRVβ repertoire in the PB CLL compared 
to normals in this cohort. This is fascinating and potentially a very significant result, however 
as the cohort size is small, this requires further study in a larger cohort analysis.  
This set of experiments has provided evidence that the HTS method worked and allowed us 
to go on to perform comparative experiments in individual patients to assess differences in 
the TCRVβ usage between the CD4+ PB and LN. 
5.5.20 There is commonality of TCRVβ family usage between CD4+ T-cells from CLL PB 
and LNs 
We next directly compared the overall CD4+ TCRVβ family usage between CLL patients PB 
and LN, shown graphically in Figure 5-37. The blue bars are the TCRVβ families from the 
CD4+ T-cells derived from PB and the green bars are the CD4+ TCRVβ families from the LN. 
This shows a commonality in the frequency of TCRVβ family usage between the PB and LNs 
across the cohort. 
 
Figure 5-37 Frequency of sorted CD4+ T-cells TCRVβ family usage in matched CLL PB and 
LN (n=6)  
HTS of the TCRVβ was undertaken on matched flow sorted CD4+ T-cells from CLL PB and 
LN (n=6) and analysed as described in Figure 5-36. The blue bars represent the frequency of 
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These results tell us which families are used and gives quantitative data of the frequency of 
usage. However, it does not tell us about the complexity i.e. number of unique sequences 
within the family. In order to assess the complexity of the repertoire we assessed the number 
of individual productive unique sequences across all TCRVβ families from CLL patients PB 
and LN.   
We found the median number of unique sequences in the CD4+ cells from CLL PB was no 

























Figure 5-38 No difference in the number of unique sequences (complexity) of the CD4+ TCR 
repertoire in CLL PB and LN by HTS  
HTS of the TCRVβ was undertaken on matched flow sorted CD4+ T-cells from CLL PB and 
LN (n=6) and analysed as described in Figure 5-36. The number of unique sequences 
identified in the CD4+ sample from the CLL PB was no different to that in the LN; p=0.834. 
Therefore the number of unique sequences was the same whether the CD4+ T-cells were 
derived from the PB or the LN. This confirms that the CLL repertoire complexity is maintained 
between the PB and LN, supporting the data from the spectratyping.  
5.5.21 The starting number of T-cells is proportionate to the number of unique 
sequences derived 
It would be expected that the number of unique sequences would be less with fewer cell 
numbers. To confirm this PB CD4+ T-cells were sorted in different quantities prior to HTS 
TCRVβ sequencing. The starting number of T-cells positively correlated the number of unique 
sequences identified; shown in Figure 5-39. This analysis was kindly provided by Adaptive 
Biotechnologies. Therefore to mitigate for this bias in this study we sorted equal number of 
CD4+ T-cells from PB and LN.  
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Figure 5-39 Number of unique sequences correlates with starting CD4+ cell number.  
HTS of the TCRVβ was undertaken on flow sorted CD4+ T-cells from normal control PB (n=25) 
and analysed as described in Figure 5-36. The number of unique sequences correlates with 
the number of sorted CD4+ T-cells. Analysis courtesy of Adaptive Biotechnologies. 
 
5.5.22 There is more clonality of the CD4+ T-cells from the LN FNA than the PB 
The advantage of HTS over spectratyping is that the frequency of each of the unique 
sequences can be determined. This gives direct evidence of clonality. The spectratyping data 
found more skewing in the LN compared to PB; which is a presumed surrogate for clonality. 
Therefore, using HTS, we investigated the skewing of the TCRVβ repertoire by quantifying 
the actual number of over-represented individual sequences, i.e. identifying clonotypes. 
The mathematical techniques underlying this analysis are complex and beyond the scope of 
this thesis. In brief, this involves the assessment of entropy, a technique derived from 
information theory, which quantifies the predictability of information. When assessing immune 
repertoires Shannon entropy is a measure of diversity within a complex data set. Samples 
with high entropy have a greater diversity of sequence, conversely samples with low entropy 
have sequences that share nucleotide homology. Entropy is calculated by summing the 
frequency of each clone, multiplied by the log of the same frequency of all productive reads of 
the sequence. This value is normalised based on the total number of productive sequences 
and subtracted from 1. Therefore entropy takes into account the variation of clone frequency. 
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The resultant equation to calculate clonality is 1-(entropy)/log2(number of productive unique 
reads). This generates a relative “clonality” value (Robins, Campregher et al. 2009).  A value 
of 1 is a clonal repertoire and a value of 0 completely random.  Values approaching 1 have a 
few predominant clones or are more oligoclonal. Adaptive Biotechnologies report a median 
clonality score of adult TCR repertoire as 0.075. The analysis of clonality in our samples was 
performed by Dr David Hamm at Adaptive Biotechnologies.  
Both the CD4+ T-cells derived from the PB and LN in our study have median clonality values 
>0.075, confirming they are more oligoclonal than normal PB. Our results additionally reveal 
a higher clonality score in the LN than the PB, revealing for the first time the CD4+ TCRVβ 
repertoire is more oligoclonal in the LN than PB in CLL. See Figure 5-40. We repeated the LN 
and PB sampling on two occasions for the 6 patients. This data further supports the hypothesis 
that there is antigen driven expansion of T-cells within the LN. 
                              
Figure 5-40 The CLL LN CD4+ T-cells are more clonal than those derived from the PB 
HTS of the TCRVβ was undertaken on matched flow sorted CD4+ T-cells from CLL PB and 
LN (n=6) and analysed as described in Figure 5-36. The experiment was repeated on 2 
separate occasions. A clonality score was calculated by Adaptive Biotechnologies with the 
following equation; 1-(entropy)/log2(number of productive unique reads). A value of 1 is a 
clonal repertoire and a value of 0 completely random. Adaptive Biotechnologies report a 
median clonality score of an adult TCR repertoire as 0.075. Data shown here shows a higher 
clonality score in the CLL CD4+ T-cells derived from the LN than the PB. Analysis courtesy of 
Adaptive Biotechnologies. 
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5.5.23 CLL CD4+ T-cells derived from LNs have more commonality of TCR usage with 
each other than with matched PB 
To identify whether the CD4+ T-cell clones in the CLL LN showed commonality between LNs 
of the same patient, we sampled 2 separate LNs from the same patient at the same time. We 
then looked for overlapping sequences between the 2 LNs. In addition we compared the CD4+ 
LN derived clones with matched PB, to identify whether the same clones were present in the 
LN and PB. This enabled the analysis of the frequency of overlapping sequences between the 
two compartments and to identify whether the same clones are present in the LN and PB.  
A representative example is graphically illustrated in Figure 5-41. Each dot represents a TCR 
clonotype. It can be seen visually that there appears to be more common T-cell clones 
between the 2 LNs than either LN with the PB. 
 
Figure 5-41 More commonality of TCR usage between two separate LNs from same patient 
than between the LN and matched PB 
HTS of the TCRVβ was undertaken on matched flow sorted CD4+ T-cells from CLL PB and 2 
separate LNs taken at the same time. Analysis was as described in Figure 5-36. Data shown 
here is a graphical comparison of TCR usage of the CD4+ T-cells from the PB and 2 LNs (LN1 
and LN2) of a single individual. Each dot represents the frequency of a TCR clonotype. It can 
be seen visually that there appears to be more common T-cell clones between the 2 LNs than 
between either LN with the PB. 
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Statistical analysis showed the mean “overlap score” between the sequences in LN1 and LN2 
was 0.331 and between LN1 and PB was 0.151; p=0.0064.  
The overlap score in immunoSEQ analyser, defines the extent to which clonotypes are 
observed to be shared between two samples. It is a sum of the counts for all shared sequences 
observed in sample A and sample B (in our first example LN1 and LN2) divided by the total 
number of counts of all sequences in both samples.  
We went on to repeat this experiment with 4 more patients on up to two occasions. The results 
confirm there is more commonality of TCRVβ usage between two LNs in the same patient 
than between LNs and PB, as the overlap score is higher in the LN-LN comparison than LN-
PB of the same patient. See Figure 5-42 
   
Figure 5-42 More overlapping TCR sequences (a higher overlap score) between two LNs than 
between LN and PB  
Comparison of TCRVβ usage from CD4+ T-cells from CLL PB and 2 separate LNs taken at 
the same time from 4 individuals. Experimental detail as in Figure 5-41. An overlap score is 
derived using the immunoSEQ analyser, which defines the extent to which clonotypes are 
observed to be shared between two samples. This is calculated as a sum of the counts for all 
shared sequences observed in sample A and sample B divided by the total number of counts 
of all sequences in both samples. The overlap score is higher in the LN-LN comparison than 
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5.6 Discussion 
There is compelling evidence for an antigenic drive in CLL and the preceding chapters have 
presented indirect phenotypic evidence for antigenic stimulation of the CD4+ T-cells within the 
lymph node CLL microenvironment. As discussed in chapter 1, there are postulated 
mechanisms by which T-cells could accumulate in CLL and we have speculated that T-cells 
could be attracted into the microenvironment by both TCR dependant and independent 
means. The observation of high frequency PD-1hi T-cells in the LN supports the theory that 
there is an antigen drive of T-cells within the lymph node; which operates via a TCR dependant 
mechanism. The aim of the work in this chapter was to find direct evidence of specific T-cell 
accumulation in the lymph node by investigating the T-cell receptor repertoire. We approached 
this problem in several ways. The initial approach was using a ligation oligo PCR method. This 
method would allow the variable CDR3 to be amplified using a single primer pair. It is well 
established that different PCR primer pairs have differential amplification efficiency, which can 
introduce bias and therefore this method would potentially reduce this. The technique however 
was technically challenging and successful ligation was difficult to replicate consistently.  
Several methods of optimising the ligation were undertaken as reviewed in Table 5-8 and 
evidence for successful ligation and amplification of the TCR in the Jurkat cell line is presented 
here. A potential shortcoming in this method is that the ligation efficiency was unknown and 
therefore there may be significant bias introduced if only a small percentage of the cDNAs are 
ligated to the oligo. In the Jurkat experiment this would be unknown as there was only one 
TCR mRNA as starting material, therefore even if only a relatively small percentage of 
resultant cDNA molecules were ligated the PCR would still amplify the solitary TCR. In primary 
patient material, where there are many thousands of potential T-cell receptors, if the efficiency 
of ligation was not 100% then the whole repertoire could be non-specifically, randomly 
skewed. This could make comparisons between samples impossible. To assess the ligation 
efficiency we could have ligated a “wild type” TCRVβ repertoire to look for diversity. 
Alternatively Jurkat spiking experiments with known amounts of starting RNA could have been 
tried.   
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To determine the best method to adopt we clarified exactly the question we were addressing. 
In this case we wanted to examine the TCR repertoire of CD4+ PD-1hi and PD-1lo cells 
between different compartments within the same patients. Therefore the fundamental analysis 
was a paired comparison. By choosing conventional spectratyping we would utilise multiple 
primers pairs, which may amplify variably, and this is only of concern in a quantitative study. 
However our primary analyses were comparative and therefore the relative inefficiency of one 
pair of PCR primers versus another would, in the end, be applied consistently across all groups 
and therefore the bias would not favour one group. This would lead to a specific and constant 
bias and not non-specific random bias as may have occurred with the inefficient oligo ligation 
method. Therefore we felt this potential limitation was acceptable. The potential impact of 
primer bias in the HTS setting is discussed later.  
An unavoidable limitation with any pooled cDNA PCR method is that the starting quantity of 
mRNA molecules may not be consistent, even with the same number of starting T-cells. Some 
T-cell subsets have different amounts of mRNA which can be up or down-regulated by 
microenvironmental factors (Paillard, Sterkers et al. 1988), therefore if one of our sorted 
subsets of T-cells had a higher level of mRNA TCR expression than another the relative 
proportion of cDNA entering the PCR reaction from those cells could bias the result. To identify 
the amount of starting material we measured the total RNA extracted, which may not reflect 
the TCR mRNA. This limitation could potentially be overcome by single cell PCR or by using 
gDNA. The disadvantage of using gDNA has already been discussed, but the major 
disadvantage is that this method takes no account of whether there is a resultant functional 
rearranged TCR expressed by the T-cell (Desmarais 2012).   
As our study was not designed to compare quantitative information about the frequency of a 
TCRVβ family usage, but was simply looking for diversity of the repertoire, the impact of these 
potential PCR biases were considered acceptable. Therefore we decided to proceed with 
TCRVβ spectratyping using RNA as the starting material. This technique was well validated 
in the literature and the resultant PCR fragments could be analysed in a consistent and 
comparative way. This study therefore gives information on the presence of CDR3s of different 
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lengths (complexity of the repertoire) and skewing of a profile (diversity) but does not provide 
quantitative frequency of a specific TCR family usage.  
LN and PB starting material was obtained freshly and FACS cell sorting was utilised to collect 
CD4+ T-cells, which were PD-1hi or PD-1lo. For the initial FACS sorts we attempted to collect 
10000 cells of each population of CD4+ PD-1hi, CD4+ PD-1lo, from both the PB and LN FNA 
of CLL patients and PB of healthy controls. This would then rule out the potential criticism of 
using unequal cell numbers for assessing the TCR. However this was technically challenging 
as the sort had to be interrupted 3 times to remove the tubes. This compromised the ability to 
collect cells from very small samples such as LN FNA where cells were invariably lost during 
the processing. Therefore in later experiments the total sort was collected. Regardless, there 
was no statistical difference in the number of T-cell sorted from CLL patients and normal 
controls in all subpopulations. There was a trend towards more PD-1hi T-cells isolated from 
the CLL patients vs normal PB. This was due to the length of time it took to sort PD-1hi T-cells 
from whole PB, which were found at relatively low frequency and large volumes of whole blood 
were required. In retrospect we could have performed a T-cell enrichment step prior to the 
sort but we wanted all samples to be handled in a consistent manner. If the fewer number of 
PD-1hi T-cells from normal controls led to a bias in the results then the normal control (with 
less cell numbers) would be anticipated to be more skewed i.e. have a less diverse repertoire 
than the CLL PD-1hi cells. In fact the opposite is true and the CLL PD-1hi T-cells were more 
skewed than the normal control PB despite more cells entering the experiment. This adds 
more power to the result as the expectation would be the bias favours the opposite result to 
be true. The only place this bias could therefore have had an impact was between diversity of 
the normal control PD-1hi and PD-1lo populations, which was not the question this study was 
aiming to answer. The normal control showed that 10,000 input T-cells enabled a normally 
distributed spectratype prolife. In two of the six normal control cases <10,000 cells were 
collected in the PB PD-1hi subset. There was skewing of the profile in these cases, as there 
was in PD-1hi subset where more than 10,000 cells were collected. There is published data 
which concurs with our findings that PD-1hi cells have skewed repertoires (Lin, Peacock et al. 
2007, Gros, Robbins et al. 2014), nonetheless cell numbers cannot be entirely excluded as a 
confounding variable in these two cases.  
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Overall our results have provided evidence for skewing of the CD4+ TCRV spectratype in 
the PD-1hi T-cells compared to PD-1lo T-cells in both LN and PB compartments in CLL. There 
was also increased skewing of the CLL CD4+ PB TCRV repertoire compared to age matched 
normal controls of both the PD-1hi and PD-1lo CD4+ T-cell subsets. Overall complexity of the 
CD4+ TCRVβ repertoire in CLL was the same between the PD-1hi and PD-1lo populations, 
but there was lower complexity of the TCRVβ repertoire overall in CLL PB compared to age 
matched controls.  
As we have demonstrated in chapter 3, it is within the lymph node that PD-1+ T-cells 
accumulate and therefore it is here that the repertoire is most skewed. This data was backed 
up with evidence from our HTS study that showed that there was skewing of the overall TCRVβ 
repertoire in CLL CD4+ PB T-cells, with apparent over and under usage of certain TCRVβ 
families, although this needs further elucidation in a larger cohort study. There were the same 
number of unique sequences in the CD4+T-cells whether derived from the LN or PB, however 
there was more clonality (less diversity) within the LN than the PB. Additionally when 2 LNs 
from the same patient were compared with the PB there was more overlapping sequence 
homology between the CD4+ T-cells derived from the 2 LNs than with the PB. Taken together 
this suggests that it is in the LN where the CD4+ T-cells are specifically responding to a 
common antigen. 
 In contrast to spectratyping, the HTS technology can be used to quantitate frequencies of 
TCRVβ usage and of individual clonotypes. HTS is an emerging technology for examining the 
TCR repertoire and there are many complexities and caveats that must be taken into 
consideration when attempting to quantify the TCR repertoire. HTS was first designed to 
sequence large regions of the genome, not very short CDR3 regions of the TCR which are 
not only different to the germline DNA but also highly variable (Robins 2013). A major problem 
is to accurately quantify the number and size of each of millions of TCRs. There are both 
biological and technical reasons for the difficulties encountered. From a technical perspective 
when sequencing the TCR there is the PCR enrichment step, which has the potential to 
introduce amplification bias and this is more critical here where quantification analysis is 
undertaken. If gDNA is used as the template a multiplex PCR amplification is employed in 
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order to capture all the VDJ rearrangements. One primer set PCR amplification is not possible 
as the distance between the constant and J region is too large and there is not enough 
homology between the V and J regions (Robins, Campregher et al. 2009, Sherwood, 
Desmarais et al. 2011). Therefore errors may be introduced from differences in the 
amplification efficiency of certain primer pairs. In order to try an overcome this Carlson et al 
have developed a solution whereby they generated a complete set of synthetic TCRVβ 
molecules. As the precise quantity of the synthetic TCRV that enters the PCR is known it can 
be ascertained which primer pairs under or over amplify the product relative to the others. 
Then the amount of primer is titrated up or down in a sequential fashion until nearly all the 
bias is removed and any remaining differences were removed by a mathematical algorithm 
(Carlson, Emerson et al. 2013). Quantitative PCR amplification is much easier if the starting 
target material is mRNA. This is because the introns have been removed and there is a 
constant region 3’ of the J region in the transcript. The PCR amplification can then have a 
single constant universal primer at the 5’ end and a multiplex of V  primers although this of 
course can still add in amplification bias it is much smaller than in a complex multiplex PCR 
(Robins 2013).  
An alternative option would be to use 5’ RACE-PCR (Rapid Amplification of cDNA Ends) 
sequencing, which removes primer bias but is not without limitations as there are potential 
biases dependant on transcript length and GC content. The PCR itself can introduce random 
errors and these sequence errors are compounded with each PCR cycle. However it must be 
remembered that these one off sequence errors effect an exponentially smaller fraction of the 
total PCR pool with every cycle. Biological factors can also play a key role in introducing errors. 
Firstly RNA is difficult to work with as it degrades quickly and there is a variable amount of 
mRNA produced by different T-cell subsets as stated earlier. This may introduce an unwanted 
amplification bias from one subset of T-cells. Some groups have introduced T-cell line spiking 
experiments but no robust method has been described to overcome this problem and T-cell 
lines themselves have high quantities of mRNA compared to primary T-cells (Robins, 
Desmarais et al. 2012). When HTS is used to assess the TCR repertoire there are further 
considerations to take into account associated with the technology chosen (Bolotin, Mamedov 
et al. 2012, Robins 2013). When sequencing gDNA code errors can usually be readily 
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detected. However when sequencing highly variable low frequency regions, such as the TCR, 
sequencing errors may be missed and inaccurately assigned as a distinct TCRs which in 
reality may only vary from each other by one nucleotide (Baum, Venturi et al. 2012). Therefore 
small errors artificially introduced may lead to the generation of a false interpretation of TCR 
diversity. The 454 and Ion Torrent platforms lead to a high rate of insertions and deletions 
(indels) due to their defective ability to sequence homopolymers. This occurs because on 
these platforms, as discussed earlier, sequencing does not terminate after the addition of a 
single nucleotide, as occurs on the Illumina platform. Therefore the same nucleotide needs to 
be sequentially added again and again in adjacent positions to sequence the homopolymeric 
stretch. When the number of nucleotide additions are measured either by light (454) or redox 
(Ion Torrent) the total number of nucleotides may be incorrectly calculated. This is because 
the light or redox signal is not entirely linearly proportionate to the number of nucleotides 
added and this can result in frameshift errors (Loman, Misra et al. 2012). This leads to a 
particular problem when sequencing the TCR because the D segment often contain 
homopolymer stretches of G nucleotides. The Illumina platform causes less indels (as the 
sequencing is terminated every time a nucleotide is added) but it is still susceptible to position 
dependent errors which are then consistently layered in the same region (Nakamura, Oshima 
et al. 2011). In HTS single template molecules are sequenced many times which means that 
an error is then compounded. Sanger sequencing has the advantage that the large number of 
template molecules means the occasional sequence error is of lower impact (Baum, Venturi 
et al. 2012). Bolotin et al recently published a comparative study of these three HTS 
technologies; they sequenced the same TCR rearranged genes from replicate samples and 
found profound discrepancies in terms of diversity and abundance (Bolotin, Mamedov et al. 
2012). They go on to suggest biological and computational mechanisms to identify true 
variance from sequence artefacts. It is clear a cross platform collaborative approach is needed 
to address these issues.  
Therefore these issues need to be fully resolved before HTS is universally adopted as the gold 
standard for TCR analysis. Nonetheless since the work presented here was complete 
significant developments in bioinformatics have made HTS of the TCRVβ a more attractive. 
The HTS results in our study complemented the spectratyping data. We have found that the 
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overall TCRV family usage by CD4+ T-cells is similar between the LN and PB but that overall 
there is more clonality in the LN derived CD4+ T-cells compared to PB. Importantly, there was 
more similarities between 2 distinct lymph nodes from the same patient, than between the LN 
and PB suggesting there may be a different antigenic drive between compartments.  
Taken together, the work here has confirmed that the PD-1hi subset of CD4+ T-cells in CLL 
show evidence of TCR oligoclonality and these cells predominate in the LN. This suggests 
that within the LN there are antigen specific interactions that lead to the expansion of certain 
T-cell clones within the LN. The nature of the antigen and the role these cells play in disease 
pathogenesis is, however, uncertain. This is an important question given the increasing 
interest in harnessing tumour infiltrating lymphocytes in cancer therapeutics, and the 
availability of antibodies that block the PD-1 / PD-L1 axis. Preliminary experiments that explore 
this are presented in the next chapter.  
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Chapter 6 An in vitro model of CLL LN T-cells and effects of 
blocking the PD-1 / PD-L1 axis   
6.1 Introduction 
In the preceding chapters it has been shown that T-cells derived from CLL LN show a different 
phenotype to those found in the PB of the same patient. CD4+ T-cells accumulate in the LN 
of CLL patients and these cells show a phenotype of chronic antigenic stimulation. We have 
hypothesised that these phenotypic changes provide evidence of T-cell activation and antigen 
experience that occurs within the LN. As previously outlined, it is accepted that it is within the 
LN that CD4+ T-cells make contact with CLL cells and the tumour proliferates. We have shown 
that the Ki67+ proliferating CLL cells are in close contact with PD-1+ CD4+ T-cells. Therefore 
it may be considered appropriate to suggest that functional studies of T-cells in CLL should 
only be undertaken utilising these T-cells derived from the tumour microenvironment. An 
obvious question is whether a co-culture system between autologous CD4+ T-cells derived 
from the LN could protect CLL cells from apoptosis and promote their proliferation in vitro 
without prior stimulation. Or indeed whether the CD8+ PD-1+ T-cells could be rescued from 
exhaustion and mount an anti-tumour response. Ideally this could be achieved by setting up 
a series of co-culture experiments with autologous T-cells derived from both the LN and PB. 
Unfortunately this was not feasible due to the small numbers of T-cells which could be sorted 
from the LN FNA sample. Therefore methods were designed to try and recapitulate the tumour 
microenvironment using T-cells sourced from the PB. Activated CD4+ T-cells co-cultured with 
CLL cells is an established method of maintaining CLL cells in culture. Our group and others 
have previously reported the use of CD3/CD28 bead stimulated T-cells to protect CLL cells 
from apoptosis in vitro (Patten, Devereux et al. 2005, Prieto, Sanchez et al. 2005). Os et al 
also reported that CLL cells proliferative in response to specific T-cell help (Os, Burgler et al. 
2013). This approach has therefore been used to in vitro model the tumour microenvironment.  
In this pilot study we first sought to identify whether pre-stimulating PB T-cells changes their 
phenotype to one comparable to those found in the LN. We specifically were interested in 
mimicking the PD-1hi phenotype. In health, PD-1 is known to be inducible upon stimulation 
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and during chronic infection (Agata, Kawasaki et al. 1996, Barber, Wherry et al. 2006). As part 
of the normal immune response engagement of PD-1 by its ligands, PD-L1 or PD-L2, leads to 
negative regulation of the immune system, with decreased cell proliferation and inhibition of 
cytokine production (Freeman, Long et al. 2000, Latchman, Wood et al. 2001). The changes 
are hierarchical where first there is loss of proliferation, then inhibition of IL-2 production, TNFα 
before IFN-γ, accompanied by  expression of PD-1, LAG-3, TIM-3 and CTLA-4 (Wherry 2011). 
These changes have already been shown in CLL derived T-cells where “exhausted” PD-1+ 
CD4+ and CD8+ T-cells secrete low levels of IFN-γ and TNF (Riches, Davies et al. 2013). 
Interestingly in our study despite the high levels of PD-1 we did not detect high levels of PD-
L1 on resting CLL cells from either the LN or PB in keeping with Xerri et al. (Xerri, Chetaille et 
al. 2008). This is in contrast to the TCL-1 transgenic mouse model of CLL that has constitutive 
PD-L1 expression on the tumour cells (Gassner, Zaborsky et al. 2015). Therefore, following 
establishment of an in vitro model, the next aim of this study is to identify whether stimulating 
T-cells in vitro increases the PD-L1 or PD-L2 levels on CLL cells.  
Our next aim was to block PD-1 and assess the phenotypic changes induced. Huge interest 
has been generated in the possibility of harnessing the PD-1 / PD-L1 axis to restore T-cell 
function to aid the clearance of viruses, and more recently cancers. Barber et al authored the 
seminal paper in Nature which used an anti PD-L1 blocking antibody to restore function of 
exhausted CD8 T-cells to clear mice chronically infected LCMV (Barber, Wherry et al. 2006). 
PD-1 / PD-L1 blockade in lymphoid malignancies is a less straightforward proposition; here 
the cells are both the immune system and the malignant tumour. Hodgkin disease is the 
lymphoma where PD-L1 blockade is the most well studied, but here lies a very specific 
scenario. The Reed-Sternberg cells harbour 9p24.1 amplifications; which encodes for PD-L1 
and leads to its constitutive activation; independent of T-cell stimulation and IFN-γ. Several 
groups have reported that tumour infiltrating lymphocytes in Hodgkin lymphoma express PD-
1, and that the number of PD-1+ T-cells is an independent negative prognostic factor for OS 
(Muenst, Hoeller et al. 2009). Early phase studies of the anti-PD-1 drug Nivolumab in Hodgkin 
lymphoma have shown an 87% response rate (Ansell, Lesokhin et al. 2015).   
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In CLL the unanswered question is what happens when T-cells are playing dual roles; where 
the CD4+ T-cells may be supporting the tumour survival and a proportion of cytotoxic T-cells 
may be directed against the tumour; PD-1 blockade may be a double edged sword. Therefore 
in this study we set out to block the PD-1 / PD-L1 axis in primary CLL cells in culture and 
assess the phenotypic changes this induces on both the CD4 and CD8 T-cells. 
6.1.1 Experimental Approach 
In this chapter we plan to identify whether the T-cell phenotype of CLL LN is mimicked by 
stimulating T-cells derived from previously cryopreserved CLL PBMCs. This would support 
the rationale of using stimulated PB derived CLL T-cells as in vitro model for the LN 
microenvironment, which then gives weight to using this approach for in vitro functional studies 
and investigation of the PD-1 / PD-L1 axis.  
T-cell stimulation can be undertaken by several means. We chose to use CD3/CD28 bead 
stimulation, as this was the method our group previously published to activate T-cells and 
which supported CLL cells in vitro (Patten, Devereux et al. 2005). The proprietary 
Dynabeads® are superpara-magnetic polymer beads coated with mouse anti-human IgG 
monoclonal antibodies against CD3 and CD28. The CD3 antibody is specifically directed 
against the epsilon chain of human CD3. These beads are designed to mimic the in vivo 
physiologic stimulation of T-cells by APCs; although clearly this is still a non-specific method 
of TCR stimulation. These activated T-cells have been shown to produce IL-2, GM-CSF, IFN-
γ and TNF (Bonyhadi, Frohlich et al. 2005) and it is established that IFN-γ induces PD-L1 in 
the normal immune system (Dong, Strome et al. 2002). We are interested in identifying if PD-
L1 can be upregulated on CLL cells by stimulating the T-cells to produce IFN-γ. In order to 
investigate the effects of T-cell stimulation we planned to undertake time course experiments; 
harvesting the T-cells at 24 hours, 48 hours and 5 days post stimulation to identify the most 
appropriate length of time for T-cell stimulation. We went on to look at blocking the PD-1/PD-
L1 axis in vitro using a monoclonal antibody against PD-1. 
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6.2 Aim 
Therefore the primary aim of this chapter is to assess whether stimulating CLL PB T-cells can 
lead to phenotypic changes that mimic the CD4+ T-cells found in CLL LN FNAs from our data 
presented in chapter 3. Following this we plan to investigate the effects of blocking the PD-1 
/ PD-L1 axis in vitro. 
6.3 Materials and Methods   
6.3.1 Ethics 
Patients with a diagnosis of CLL were invited to take part in the study. Ethical approval for this 
study was granted under NREC: 08/H0906/94 044. Patients were given the patient information 
sheet and adequate time to consider their entry into the study. Written informed consent was 
gained according to the Declaration of Helsinki, 2008.  
6.3.2 Primary Patient Material 
PB was collected from CLL patients and PBMCs isolated by Ficoll Histopaque® (Sigma 
Aldrich) density centrifugation as described in 2.2.1. PBMCs were previously cryopreserved 
and thawed on the day of the experiment. 
6.3.3 PBMC Culture 
PBMCs were cultured in 24 well plates at 1x106 cells per well, resuspended in 500µl of CLL 
media. Cells were cultured for 24 hours, 48 hours and 5 days in a humidified CO2 incubator 
at 37oC. 
6.3.4 CD3/CD28 Stimulation of T-cells 
Dynabeads® Human T-Activator CD3/CD28 magnetic beads (Fisher Scientific) were used to 
stimulate T-cells. These beads are superparamagnetic polymer beads of a uniform size 
coated with monoclonal antibodies against CD3 and CD28. Prior to use Dynabeads® were 
resuspended in the vial by vortexing. The beads were washed by aliquoting the desired 
amount into an equal volume of buffer and mixing. The tube was then placed on the magnet 
(DynaMagTM) for 1 minute and the supernatant discarded. The washed beads were then 
resuspended in the same volume of culture medium as they were initially suspended in. 10µl 
of beads were incubated per 1x106 cells. Incubation of the cells was undertaken in the 
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humidified CO2 incubator at 37oC with the beads for 24 hours, 48 hours and 5 days. At the 
required time-point, cells were harvested and beads were removed by vigorously pipetting the 
sample. Then the sample was placed back in the magnet for 2 minutes. The supernatant 
containing the washed activated cells was then transferred to a fresh tube for flow cytometry.  
6.3.5 Blocking PD-1 
Functional grade anti-human PD-1 (eBioscience) was used to block PD-1 in culture. 10µg of 
anti-PD-1 was used per 1 x106 cells. The J116 monoclonal antibody inhibits PD-1 signal 
transduction but does not block binding of the PD-L1 ligand. The blocking antibody was added 
immediately prior to the anti-CD3/CD28 beads were added to the PBMCs in culture at time 0. 
Cells were harvested at 24 hours, 48 hours and 5 days. Effective PD-1 blocking using this 
method has been published by several groups (Dong, Strome et al. 2002, Saudemont, Jouy 
et al. 2005, Jurado, Alvarez et al. 2008).  
6.3.6 Intracellular Cytokine Measurement 
For those experiments were intracellular cytokines were to be measured, Brefeldin A (BD 
GolgiPlugTM) was added to the PBMCs in culture 12 hours prior to harvesting the cells, at a 
volume of 1µl per well. Brefeldin A is a protein transport inhibitor and blocks the intracellular 
transport in vitro, as a result cytokines can accumulate in the cells enabling their detection by 
flow cytometry. 
6.3.7 Flow Cytometry Antibodies 
Flow cytometry antibodies used in this chapter are detailed in Table 6-1. 
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Table 6-1 Flow cytometry antibodies 
Antigen Clone Conjugation Volume Company 
CD3 UCHT1 V500 5µl BD Biosciences 
CD4 RPA-T4 PE 10µl AbD Serotec 
CD4 RPA-T4 PerCp-Cy5.5 2.5µl eBioscience 
CD5 UCHT2 Pe-Cy7 10µl BioLegend 
CD5 MF7-14.5 APC  5µl AbD Serotec 
CD8 OKT8 Pacific Blue™ 10µl eBioscience 
CD8 OKT8 eFluor® 450 2.5µl eBioscience 
CD19 SJ25-C1 Pacific Blue™ 2.5µl Invitrogen 
CD19 HIB19 eFluor® 450 2.5µl eBioscience 
CD25  MEM-181 FITC 5µl AbD Serotec 
CD28 CD28.2 APC 10µl eBioscience 
CD69 FN50 PE 10µl BioLegend 
CD152 (CTLA-4) 14D3 Biotin 1µl eBioscience 
CD154 (CD40L) 24-31 PE 10µl eBioscience 
CD273 (PD-L2) MIH18 PE 10µl BD Biosciences 
CD274 (PD-L1) MIH1 FITC 10µl BD Biosciences 
CD279 (PD-1) MIH4 Alexa Fluor® 647 5µl AbD Serotec 
IFN-γ G2-4 FITC 5µl eBioscience 
Streptavidin N/A FITC 1 µl eBioscience 
 
6.3.8 Flow Cytometry Panels 
The following flow cytometry panels were developed for the work presented here. 
Viability Panel 
Fluorochrome FITC PE APC 7-AAD Pacific 
Blue 
Antigen Annexin V CD4 CD5  CD8 
 
Stimulation Panel A 
Fluorochrome FITC PE PerCP-
Cy5 




PD-L1 PD-L2 CD4 CD5 PD-1 CD8 
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Stimulation Panel B 






CTLA-4 CD40L CD4 PD-1 CD8 
 
Stimulation Panel C 
Fluorochrome FITC PE PerCP-
Cy5 




CD25 CD69 CD4 CD5 CD28 CD8 
 
Stimulation Panel D 
Fluorochrome FITC PE PerCP-
Cy5 




IFN-γ CD69 CD4 CD8 Viability CD3 
 
Stimulation Panel E 








PD-L1 PD-L2 CD4 CD5 PD-1 Viability  CD19 
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6.3.9 Staining Cell Surface Antigens for Flow Cytometry 
Cells were resuspended in 100µl CLL media and labelled for flow cytometry according to 2.7.1. 
Directly conjugated +/- biotinylated antibodies were added at appropriate titrated volume as 
described in Table 6-1 according in the panels outlined in 6.3.8. Viability of cells was checked 
using Annexin V as per 2.7.4. 
6.3.10 Intracellular Cytokine Staining  
For the intracellular cytokine staining panels a viability dye was used to ensure the integrity of 
the cells under investigation. Fixable viability dye eFluor® 780 (eBioscience) is a viability dye 
that irreversibly labels dead cells. Unlike 7-AAD, cells can then go on to be washed, fixed, 
permeabilised, and stained for intracellular antigens. The method for intracellular cytokine 
staining is as follows. Cells were washed twice and resuspended in PBS. 1µl fixable viability 
dye was added and cells were incubated for 10 minutes at RT.  Cells were washed twice and 
then stained for cell surface antigens as previously described. Following the last wash cells 
were resuspended in 250µl BD Cytofix/CytopermTM fixation buffer (BD Biosciences) for 20 
mins at 4C. 1ml BD Perm/Wash buffer (x10 perm wash diluted in distilled water) was added 
to cells and incubated for 15 minutes in the dark. Cells were then washed and resuspended 
in 50µl Perm/Wash buffer. Intracellular antibodies were added at the appropriate volume and 
incubated for 20 minutes at RT in the dark. Then cells were washed twice in 1ml BD 
Perm/Wash and resuspended for flow cytometry.  
6.3.11 Compensation Matrix 
Either cells or compensation beads were used to create the compensation matrix. As outlined 
in 2.7.5. 
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6.3.12 BD FACSCanto II (BD Biosciences) 
The BD FACSCanto II configuration 4-2-2 has 3 lasers allowing 8 colour flow cytometry. The 
cytometer setup is shown in 2.7.6. 
6.3.13 Flow Cytometry Data and Statistical Analysis 
Samples were collected and analysed using FACSDiva software (BD Biosciences). 
Percentage positivity and/or mean fluorescence intensity (MFI) values were obtained as 
appropriate. Statistical analysis was performed using GraphPad Prism® (Graph Pad Inc.). For 
comparisons to be made between samples from the same patient, first a D’Agostino and 
Pearson omnibus normality test was performed on the whole sample group and then paired t-
tests for those that passed and a Wilcoxon matched pairs test for those that did not. A p-value 
of <0.05 was considered statistically significant. For comparison between un-paired t-test was 
used and a p-value of <0.05 was considered statistically significant. Results are expressed +/- 
standard error of the mean.  
6.4 Patient Material 
6.4.1 Demographics of Patients  
PB sampling was undertaken on 13 patients with a diagnosis of CLL. The demographics of 
the patient group are outlined in Table 6-2.  
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Table 6-2 Demographics of CLL patients 
Patient Demographics  n = 13 
Age  Years  44-79 65 
Sex  Male  8 62% 
Female  5 38% 
CMV Status IgG Pos 0 0% 
IgG Neg 10 77% 
Unknown  3 23% 
Binet Stage  A  5 38% 
B  5 38% 
C  3 24% 
Cytogenetics / FISH  Normal  3 23% 
13q-  3 23% 
11q-  4 31% 
17p-  0 0% 
Trisomy 12  3 23% 
CD38 status <30% 9 69% 
>30% 4 31% 
Mutational status  Mutated  




IGVH >98% homology 
to germline 
9 69% 
Unknown  1 8% 
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6.5 Results 
6.5.1 T-cells are viable after 48 hours of culture following stimulation  
CLL autologous T-cells were stimulated in culture with CD3/CD28 beads, as described in 
6.3.4, for up to 5 days. CLL and T-cell viability was checked at time points 0 hours, 24 hours, 
48 hours and 5 days using Annexin V and 7-AAD by flow cytometric analysis. Cell viability 
was universally >95% at 48 hours. At the 5 day time point cultured PBMCs were >50% positive 
for Annexin V and 7-AAD and therefore this time point was not used. 
6.5.2 Activation markers can be induced on PB CLL T-cells by CD3/CD28 bead 
stimulation  
We measured the levels of activation in the CLL autologous T-cells at baseline and at 24 and 
48 hours of stimulation with CD3/CD28 beads. This was to validate that the stimulation was 
successful. CD69 levels increased after 24 hours and further still after 48 hours of stimulation 
in both the CD4+ and CD8+ T-cell populations. See Figure 6-1. CD4+ CD69+ post 24 hours 
culture without stimulation vs CD3/CD28 stimulation; 2.69% +/- 0.95 vs 58.12% +/- 5.30; n=13, 
p=<0.0001. CD4+ CD69+ post 48 hours culture without stimulation vs stimulation; 3.46% +/- 
1.02 vs 68.82% +/- 5.23; n=9, p=<0.0001.  
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Figure 6-1 CD69 is upregulated on CD4+ T-cells from CLL PB following CD3/CD28 stimulation 
at 24 hours and further still at 48 hours 
CLL autologous PB T-cells were stimulated in culture with Dynabeads® Human T-Activator 
CD3/CD28 magnetic beads (Fisher Scientific). 10µl of beads were incubated per 1x106 cells. 
At the required time-point, cells were harvested and beads were removed prior to flow 
cytometry. Levels of CD69 were measured on CD4+ T-cells at time 0 (Time 0), 24 hours (Time 
24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and without (unstim). The 
percentage of CD4+ T-cells that expressed CD69+ increased after 24 hours of stimulation 
(n=13, p=<0.0001) and further still after 48 hours (n=9, p=<0.0001). Statistical analysis of all 
paired samples was performed on GraphPad Prism, first with a D’Agostino and Pearson 
omnibus normality test followed by paired t-test. 
  
 
The same was true of CD8+ T-cells, which significantly upregulated CD69 after CD3/CD28 
stimulation at 24 hours and further still at 48 hours. See Figure 6-2. CD8+ CD69+ 24 hours no 
stimulation vs CD3/CD28 stimulation; 4.76% +/- 1.96 vs 52.07% +/- 6.09; n=13, p=<0.0001. 
CD8+ CD69+ 48 hours no stimulation vs stimulation; 10.03% +/- 2.79 vs 81.03% +/- 4.37; n=9, 
p=<0.0001.  
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Figure 6-2 CD69 is upregulated on CD8+ T-cells from CLL PB following CD3/CD28 stimulation 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of CD69 were measured 
on CD8+ T-cells at time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with 
CD3/CD28 beads (stim) and without (unstim) by flow cytometry. The percentage of CD8+ T-
cells that expressed CD69+ increased after 24 hours of stimulation (n=13, p=<0.0001) and 
further still after 48 hours (n=9, p=<0.0001). Statistical analysis as Figure 6-1.  
 
CD25 was also upregulated by CD3/CD28 stimulation on both CD4+ and CD8+ T-cells. See 
Figure 6-3 and Figure 6-4. CD4+ CD25+ 24 hours unstimulated vs CD3/CD28 stimulation; 
11.41% +/- 1.69 vs 60.09% +/- 6.38; n=12, p=<0.0001. CD4+ CD25+ 48 hours of unstimulated 
vs CD3/CD28 stimulation; 7.48% +/- 1.02 vs 85.38% +/- 3.50; n=9, p=<0.0001. CD8+ CD25+ 
24 hours unstimulated vs CD3/CD28 stimulation; 3.67% +/- 1.15 vs 37.88% +/- 6.31; n=12, 
p=<0.0001. CD8+ CD25+ 48 hours unstimulated vs CD3/CD28 stimulation; 9.33% +/- 2.48 vs 
78.31% +/- 6.56; n=9, p=<0.0001.  
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Figure 6-3 CD25 is upregulated on CD4+ T-cells from CLL PB following CD3/CD28 stimulation 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of CD25 were measured 
on CD4+ T-cells at time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with 
CD3/CD28 beads (stim) and without (unstim) by flow cytometry. The percentage of CD4+ T-
cells that were CD25+ increased after 24 hours of stimulation (n=12, p=<0.0001) and further 
still after 48 hours (n=9, p=<0.0001). Statistical analysis as Figure 6-1. 
 
        
Figure 6-4 CD25 is upregulated on CD8+ T-cells from CLL PB following CD3/CD28 stimulation 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of CD25 were measured 
on CD8+ T-cells at time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with 
CD3/CD28 beads (stim) and without (unstim) by flow cytometry. The percentage of CD8+ T-
cells that were CD25 increased after 24 hours of stimulation (n=12, p=<0.0001) and further 
still after 48 hours (n=9, p=<0.0001). Statistical analysis as Figure 6-1. 
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6.5.3 Negative regulators of the immune system upregulate upon T-cell CD3/CD28 
stimulation 
CTLA-4 increases on activated CD4+ T-cells and we confirm here that stimulation of CLL T-
cells by CD3/CD28 increases levels of CTLA-4. See Figure 6-5. CD4+ CTLA-4+ 24 hours 
unstimulated vs CD3/CD28 stimulation; 11.25% +/- 3.72 vs 29.41% +/- 5.94; n=13, p=0.0013. 
CD4+ CTLA-4+ 48 hours unstimulated vs CD3/CD28 stimulation; 24.30% +/- 7.98 vs 58.07% 
+/- 8.16; n=11, p=0.0005.  
 
Figure 6-5 CTLA-4 is upregulated on CD4+ T-cells from CLL PB following CD3/CD28 
stimulation 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of CTLA-4 were measured 
on CD4+ T-cells at time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with 
CD3/CD28 beads (stim) and without (unstim) by flow cytometry. The percentage of CD4+ T-
cells that expressed CTLA-4 increased after 24 hours of stimulation (n=12, p=0.0013) and 
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6.5.4 PD-1 can be induced on CLL T-cells by CD3/CD28 bead stimulation 
Importantly we wanted to identify whether PD-1 could be induced by CD3/CD28 bead 
stimulation and found this to be the case for both the CD4+ and CD8+ populations. See Figure 
6-6. CD4+ PD-1+ 24 hours unstimulated vs CD3/CD28 stimulation; 43.43% +/- 7.38 vs 70.28% 
+/- 7.41; n=9, p=0.0002. CD4+ PD-1+ 48 hours unstimulated vs CD3/CD28 stimulation; 
41.85% +/- 9.27 vs 81.92% +/- 5.68; n=9, p=0.0008.  
 
Figure 6-6 PD-1 is upregulated on CD4+ T-cells from CLL PB on CD3/CD28 stimulation 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of PD-1 were measured 
on CD4+ T-cells at time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with 
CD3/CD28 beads (stim) and without (unstim) by flow cytometry. The percentage of CD4+ T-
cells that expressed PD-1 increased after 24 hours of stimulation (n=9, p=0.0002) and further 
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The same was found in CD8+ T-cells. See Figure 6-7. CD8+ PD-1hi 24 hours unstimulated 
vs CD3/CD28 stimulation; 55.65% +/- 5.53 vs 71.47% +/- 4.59; n=9, p=0.0195. CD8+ PD-1hi 
48 hours unstimulated vs CD3/CD28 stimulation; 56.04% +/- 8.06 vs 88.80% +/- 5.49; n=9, 
p=0.0011.  
 
Figure 6-7 PD-1 is upregulated on CD8+ T-cells from CLL PB on CD3/CD28 stimulation 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of PD-1 were measured 
on CD8+ T-cells at time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with 
CD3/CD28 beads (stim) and without (unstim) by flow cytometry. The percentage of CD8+ T-
cells that expressed PD-1 increased after 24 hours of stimulation (n=9, p=0.002) and further 
still after 48 hours (n=9, p=0.001). Statistical analysis as Figure 6-1. 
 
6.5.5 Resting levels of CD25 were higher on T-cells from cryopreserved CLL PBMCs 
compared to fresh whole blood and CD3/CD28 bead stimulation raised the level of CD25 
higher still 
Next we planned to compare whether the activation state of the stimulated T-cells was 
comparable to the in vivo T-cells derived from the LN FNA presented in chapter3.  It was not 
possible to match the samples as the LN FNA data was historical from chapter 3 where the 
resting LN FNA cells had been compared with resting PB cells. The same patients with 
palpable LNs willing to undergo matched FNA and PB sampling were not available at the final 
stages of the project, therefore it was necessary to utilise the LN FNA data from chapter 3 and 
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compare it with activated PB from another cohort of patients. As the work presented in this 
chapter is from a different cohort of patients and also the cells have been handled differently, 
i.e. in this chapter the PB cells are derived from previously cryopreserved PBMCs, we needed 
to undertake an analysis to control for the effect of both different unmatched patient cohorts 
and cryopreservation.  
First we compared the activation phenotype of the fresh PB T-cells from chapter 3 the 
previously cryopreserved PB samples from this chapter. In chapter 3 we found no difference 
in the expression of CD25 in the fresh PB T-cells compared to the LN FNA T-cells. 
Interestingly, here we found there was statistically less CD25 expression on the CD4+ T-cells 
that had been previously cryopreserved compared to our fresh PB control samples. CD4+ 
CD25 cryopreserved (n=8) vs fresh (n=17) PB; 12.98% +/- 4.70 vs 38.86% +/- 5.65; p=0.0057. 
See Figure 6-8. Unfortunately as the patients were not matched and the cohort is reasonably 
small, it cannot clearly be demonstrated that this is not simply a cohort effect. However, this 
result does concur with other studies where cryopreservation has been shown to lead to a 
downregulation of CD25 (Golab, Leveson-Gower et al. 2013). 
 
Figure 6-8 CD25 was present on a smaller percentage of CLL PB CD4+ T-cells when cells 
had been previously cryopreserved compared to fresh PB 
In chapter 3 we reported by flow cytometry that 38.86% +/- 5.65 of PB CD4+ T-cells (PB fresh) 
were also CD25+ (n=17). In the previously cryopreserved CD4+ T-cells presented here (PB 
Cryo) only 12.98% +/- 4.70 of CD4+ T-cells express CD25 (n=8). This reached statistical 
significance; p=0.0057. Statistical analysis was with a D’Agostino and Pearson omnibus 
normality test and unpaired t-test.  
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We went on to compare whether the amount of CD25 on stimulated T-cells mimicked the LN 
T-cells. We found that there was a marked increase in expression of CD25+ on previously 
cryopreserved PB CD4+ T-cells following 24 hours of CD3/CD28 bead stimulation compared 
to baseline, and that although the baseline levels were lower than that found in the LN, the 
activation lead to levels exceeding that in the LN FNA sample. CD4+ CD25+ LN (n=17) vs PB 
CD3/CD28 stimulation for 24 hours (n=12); 31.17% +/- 3.38 vs 60.09% +/- 6.39; p=0.0010. 
See Figure 6-9. 
 
Figure 6-9 CLL CD4+ T-cells that have been stimulated with CD3/CD28 beads have a higher 
percentage that are CD25+ compared to fresh LN FNA CD4+ T-cells 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of CD25 were measured 
on CD4+ T-cells after 24 hours of stimulation (PB stim). The level of CD25 was compared to 
that found on the unstimulated fresh CD4+ T-cells from the LN of CLL patients from Chapter 
3 (LN FNA). Statistical analysis was with a D’Agostino and Pearson omnibus normality test 
and unpaired t-test. There was statistically higher percentage of CD4+/CD25+ T-cells in the 
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6.5.6 Levels of CTLA-4 on CD4+ T-cells were the same on fresh and cryopreserved PB 
but CD3/CD28 bead stimulation does not mimic the levels found in the LN 
Unlike for CD25 we found baseline levels of CTLA-4 were the same on PB CD4+ T-cells 
whether they were previously cryopreserved or fresh and that CTLA-4 on CD4+ T-cells 
increased upon stimulation to levels higher than that found on the CD4+ T-cells derived from 
fresh CLL LN FNA. See Figure 6-10. Cryopreserved PB CD4+ CTLA-4 (n=10) vs fresh PB 
(n=13); 3.38% +/- 1.30 vs 1.77% +/- 0.46; p=0.779. LN CD4+ CTLA-4+ (n=13) vs PB CD4+ 
CTLA-4+ stimulated for 24 hours (n=13); 5.40% +/- 2.01 vs 29.40% +/- 5.94; p=0.0008.  
 
Figure 6-10 CTLA-4 expression is similar between CD4+ PB cells whether or not previously 
cryopreserved 
In chapter 3 we reported by flow cytometry that 1.77% +/- 0.46 of PB CD4+ T-cells (PB fresh) 
were also CTLA-4+ (n=13). In the previously cryopreserved CD4+ T-cells presented here (PB 
Cryo) 3.38% +/- 1.30 of CD4+ T-cells express CTLA-4 (n=10). This was not statistically 
significantly different; p=0.779. CLL autologous PB T-cells were stimulated as in Figure 6-1. 
Levels of CTLA-4 were measured on CD4+ T-cells after 24 hours of stimulation (PB stim). The 
level of CTLA-4 was compared to that found on the unstimulated fresh CD4+ T-cells from the 
LN of CLL patients from Chapter 3 (LN FNA). There was statistically higher percentage of 
CD4+/CTLA-4+ T-cells in the PB stim sample (n=13) than the LN FNA (n=13); p=0.0008. 
Statistical analysis was with a D’Agostino and Pearson omnibus normality test and unpaired 
t-test. 
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6.5.7 CD3/CD28 bead stimulation upregulates PD-1 on PB T-cells to levels similar to 
those found in LN FNA 
We have shown that PD-1 is upregulated on T-cells following CD3/CD28 bead stimulation on 
PB derived T-cells. Therefore we next wanted to answer whether this is this similar to that 
seen on LN derived T-cells. Again we initially wanted to ascertain whether the number of CD4+ 
PD-1+ cells was the same whether fresh or cryopreserved cells were used and found this was 
the case. CD4+ PD-1+ fresh PB cells (n=21) vs previously cryopreserved (n=7); 31.12% +/- 
3.59 vs 27.83% +/- 7.08; p=0.671. Next we investigated whether the 24 hour CD3/CD28 
stimulated PB CLL CD4+ T-cells expressed the same amount of PD-1 as LN FNA derived T-
cells and found they did. Stimulated PB CLL CD4+ T-cells (n=9) vs LN FNA (n=21); 70.28% 
+/- 7.42 vs 56.42% +/- 4.023 vs; p=0.118. See Figure 6-11. 
 
Figure 6-11 The level of PD-1 expression on CD4+ T-cells is unaffected by cryopreservation, 
and stimulation  of T-cells with CD3/CD28 beads for 24 hours increases PD-1 levels on CD4+ 
T-cells to the same level as found on LN FNA derived CD4+ T-cells. 
In chapter 3 we reported by flow cytometry that 31.12% +/- 3.59 of PB CD4+ T-cells (PB fresh) 
were also PD-1+ (n=21). In the previously cryopreserved CD4+ T-cells presented here (PB 
Cryo) 27.83% +/- 7.08 of CD4+ T-cells express PD-1 (n=7). This was not statistically 
significantly different; p=0.671. CLL autologous PB T-cells were stimulated as in Figure 6-1. 
Levels of PD-1 were measured on CD4+ T-cells after 24 hours of stimulation (PB stim) (n=9). 
The level of PD-1 was compared to that found on the unstimulated fresh CD4+ T-cells from 
the LN of CLL patients (n=21) from Chapter 3 (LN FNA) and were found to be similar; p=0.118. 
Statistical analysis was with a D’Agostino and Pearson omnibus normality test and unpaired 
t-test. 
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Next we asked the same question of CD8+ T-cells. Again we wanted to ascertain whether the 
number of CD8+ PD-1hi cells was the same whether fresh or cryopreserved cells used and 
we found the baseline levels of PD-1 to be the same. CD8+ PD-1hi fresh PB cells (n=20) vs 
previously cryopreserved (n=7); 41.44% +/- 3.94 vs 37.87% +/- 7.13; p=0.599.   
Next we showed that stimulating the PB T-cells with CD3/CD28 beads for 24 hours increases 
the PD-1 levels on CD4+ T-cells to those equivalent to the LN FNA. Stimulated PB CLL CD8+ 
T-cells (n=9) vs LN FNA CD8+ T-cells (n=20); 71.47 +/- 4.59 vs 71.07% +/- 3.54 vs; p=1.00. 
See Figure 6-12. 
 
Figure 6-12 The level of PD-1 expression on CD8+ T-cells is unaffected by cryopreservation, 
and stimulation  of T-cells with CD3/CD28 beads for 24 hours increases PD-1 levels on CD8+ 
T-cells to the same level as found on LN FNA derived CD8+ T-cells 
In chapter 3 we reported by flow cytometry that 41.44% +/- 3.94 of PB CD8+ T-cells (PB fresh) 
were also PD-1+ (n=20). In the previously cryopreserved CD8+ T-cells presented here (PB 
Cryo) 37.87% +/- 7.13 of CD4+ T-cells express PD-1 (n=7). This was not statistically 
significantly different; p=0.599. CLL autologous PB T-cells were stimulated as in Figure 6-1. 
Levels of PD-1 were measured on CD8+ T-cells after 24 hours of stimulation (PB stim) (n=9). 
The level of PD-1 was compared to that found on the unstimulated fresh CD4+ T-cells from 
the LN of CLL patients (n=20) from Chapter 3 (LN FNA) and were found to be similar; p=1.00. 
Statistical analysis was with a D’Agostino and Pearson omnibus normality test and unpaired 
t-test. 
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6.5.8 PD-L1 can be induced on CLL cells by co-culture with stimulated T-cells 
An interesting observation from chapter 3 was that in spite of the expression of PD-1 at 
significantly higher levels on the T-cells of CLL patients compared to normal controls, we found 
no evidence of PD-L1 expression on the tumour B-cell. Importantly we did not detect 
significant expression of PD-L1 on CLL cells derived from the LN microenvironment. In 
contrast there have been reports of PD-L1 expression on CLL cells (Grzywnowicz, Zaleska et 
al. 2012, Ramsay, Clear et al. 2012, Brusa, Serra et al. 2013). We have hypothesised that 
these apparently conflicting results may be as a result of in vitro CLL activation. We therefore 
sought to identify if T-cell stimulation would lead to expression of PD-L1 on CLL cells. In our 
study CD3/CD28 beads were added to unselected PBMCs, therefore we would predict the T-
cells would be activated directly by the beads and the CLL cells indirectly by the activated T-
cells. We compared baseline PD-L1 expression of the cohort of resting fresh CLL cells derived 
from the PB in chapter 3 and compared them to the previously cryopreserved CLL cells. PD-
L1 expression levels were no different between fresh and cryopreserved CLL cells. PD-L1 on 
fresh PB CLL cells (n=8) vs cryopreserved PB CLL cells (n=10): 1.01% +/- 0.59 vs 0.25% +/- 
0.13; n=8, p=0.435. See Figure 6-13. 
 
Figure 6-13 There was no difference in the baseline PD-L1 expression on fresh or previously 
cryopreserved CLL cells 
In chapter 3 we reported by flow cytometry that 1.01% +/- 0.59 of PB CLL B-cells (PB fresh) 
were also PD-L1+ (n=8). In the previously cryopreserved CLL B-cells presented here (PB 
Cryo) 0.25% +/- 0.13 of CLL B-cells express PD-L1 (n=10). This was not statistically 
significant; p=0.436. Statistical analysis was with a D’Agostino and Pearson omnibus 
normality test and unpaired t-test. 
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Next we compared levels of PD-L1 from fresh LN FNA CLL cells and compared them to CLL 
cells co-cultured for 24 hours with CD3/CD28 stimulated T-cells. We found that PD-L1 could 
be upregulated on CLL cells, particularly after prolonged stimulation. See Figure 6-14. CLL 
PD-L1 24 hours unstimulated culture vs CLL PD-L1 CD3/CD28 co-culture; 0.24% +/- 0.11 vs 
4.26% +/- 2.2; n=9, p=0.0078. CLL PD-L1 48 hours culture unstimulated  vs CLL PD-L1 48 
hours co-culture CD3/CD28 stimulated T-cells; 4.00% +/- 1.63 vs 21.32% +/- 6.24; n=9, 
p=0.027.  
 
Figure 6-14 PD-L1 can be upregulated on CLL cells by co-culture with CD3/CD28 bead 
stimulated T-cells 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of PD-L1 were measured 
on CLL B-cells at time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with CD3/CD28 
beads (stim) and without (unstim) by flow cytometry. The percentage of CLL B-cells that 
expressed PD-L1 increased after 24 hours of stimulation (n=9, p=0.0078) and further still after 
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Therefore we have shown that PD-L1 can be induced on CLL cells which are co-cultured with 
stimulated T-cells. The level of PD-L1 found on these CLL cells is much higher than that found 
on CLL LN derived cells from chapter 3 where very little expression was demonstrated on 
either these or PB derived CLL cells; p=0.0183. See Figure 6-15.  
 
Figure 6-15 Indirect CD3/CD28 bead stimulation of T-cells in co-culture with CLL cells for 24 
hours increases the PD-L1 on CLL cells from PB to levels above that found in the LN 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of PD-L1 were measured 
on CLL B-cells after 24 hours of stimulation (PB stim). The level of PD-L1 was compared to 
that found on the unstimulated fresh CLL B-cells from the LN of CLL patients from Chapter 3 
(LN). Statistical analysis was with a D’Agostino and Pearson omnibus normality test and 
unpaired t-test. There was statistically higher percentage of CLL/PD-L1+ B-cells in the PB stim 
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6.5.9 PB T-cells upregulate PD-L1 following CD3/CD28 bead stimulation 
It is becoming increasingly clear that the crosstalk between the activation and negative 
regulators of the immune system is complex and bidirectional. Therefore we chose to 
investigate whether the T-cells could also upregulate PD-L1 in response to stimulation and 
found that indeed was the case. We found PD-L1 is upregulated on the CD4+ and CD8+ T-
cells. CD4+ PD-L1 24 hours unstimulated vs CD4+ PD-L1 24 hours CD3/CD28 bead 
stimulation; 5.63% +/- 1.61 vs 28.27% +/- 6.51; n=9, p=0.0078. The upregulation of PD-L1 
was even more marked with prolonged stimulation. CD4+ PD-L1 48 hours unstimulated 
culture vs CD4+ PD-L1 48 hours CD3/CD28 bead stimulation culture; 11.61% +/- 2.72 vs 
66.20% +/- 5.41; n=9, p=0.0039. See Figure 6-16. 
 
Figure 6-16 PD-L1 upregulates on CD4+ CLL T-cells following CD3/CD28 bead stimulation 
and the upregulation increases further still with prolonged stimulation 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of PD-L1 were measured 
on CD4+ T-cells at time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with 
CD3/CD28 beads (stim) and without (unstim) by flow cytometry. The percentage of CD4+ T-
cells that expressed PD-L1 increased after 24 hours of stimulation (n=9, p=0.0078) and further 
still after 48 hours (n=9, p=0.0039). Statistical analysis as Figure 6-1. 
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The same is true from CD8+ T-cells which also upregulate PD-L1 upon CD3/CD8 bead 
stimulation. CD8+ PD-L1 24 hours unstimulated vs CD8+ PD-L1 24 hours CD3/CD28 bead 
stimulation; 8.03% +/- 2.12 vs 17.48% +/- 6.98; n=9, p=0.0234. Equally the levels of PD-L1 
increase further with prolonged stimulation. CD8+ PD-L1 48 hours unstimulated vs CD8+ PD-
L1+ 48 hours CD3/CD28 bead stimulation; 17.19% +/- 6.56 vs 62.09% +/- 8.56; n=9, 
p=0.0039. See Figure 6-17. 
 
Figure 6-17 PD-L1 upregulates on CD8+ CLL T-cells following CD3/CD28 bead stimulation 
and the upregulation increases further still with prolonged stimulation 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Levels of PD-L1 were measured 
on CD8+ T-cells at time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with 
CD3/CD28 beads (stim) and without (unstim) by flow cytometry. The percentage of CD8+ T-
cells that expressed PD-L1 increased after 24 hours of stimulation (n=9, p=0.0234) and further 
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6.5.10 PD-L2 is not expressed by PB CLL, CD4+ or CD8+ cells 
PD-L2 was not expressed by resting CLL B-cells nor CD4+ or CD8+ T-cells in the PB or LN 
FNA. CLL PB stimulation with CD3/CD28 beads did not upregulate PD-L2 on any cell even 
after prolonged 48 hour stimulation, n=12 (data not shown). 
6.5.11 Blocking the PD-1 / PD-L1 axis 
Much interest has been generated in modulating immune checkpoint signalling pathways to 
reverse the negative T-cell regulation in cancer. Blocking the PD-1/PD-L1 axis has been 
shown to increase the cytotoxic T-cell responses in several cancers. The effect of blocking 
PD-1 or PD-L1 in CLL has not yet been fully elucidated. We chose to block PD-1 in vitro and 
look for phenotypic changes in the CD4+ and CD8+ T-cells and CLL cells by flow cytometry. 
The J116 monoclonal antibody blocks PD-1 signal transduction, but does not block its binding 
to PD-L1.  
Blocking PD-1 signal transduction should increase the activation status of the T-cells. We 
undertook PD-1 blocking experiments on both the CD3/CD8 stimulated and unstimulated PB 
T-cells in culture at 24 and 48 hours as described in 6.3.5.  
6.5.12 Effects of blocking PD-1 on CLL PB T-cell CD25 expression 
Blocking PD-1 did not upregulate CD25 on resting PB CD4+. Pre-stimulated T-cells were also 
unaffected by PD-1 blockade at any time point. See Figure 6-18. CD4+ CD25+ unstimulated 
PB vs unstimulated PB + blocking antibody 24 hours: 11.41% +/- 4.09 vs 11.05% +/- 2.10; 
n=8, p=0.196. CD4+ CD25+ unstimulated PB vs unstimulated PB + blocking antibody 48 
hours: 9.78% +/- 1.85 vs 7.49% +/- 1.022; n=8, p=0.979. CD4+ CD25+ stimulated CD3/CD28 
PB vs stimulated PB + blocking antibody 24 hours: 60.09% +/- 6.39 vs 66.86% +/- 6.86; n=6, 
p=0.453. CD4+ CD25+ stimulated CD3/CD28 PB vs stimulated PB + blocking antibody 48 
hours: 85.38% +/- 3.50 vs 82.31 +/- 5.43; n=7, p=0.183.  
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Figure 6-18 Blocking PD-1 signal transduction did not alter CD25 expression in CD4+ T-cells.  
CLL autologous PB T-cells were stimulated as in Figure 6-1. Functional grade anti-human PD-
1 (eBioscience) was used to block PD-1 in culture. 10µg of anti-PD-1 was added per 1 x106 
cells immediately prior to the anti-CD3/CD28 beads were added. Cultures were set up with 
(+B) and without the blocking antibody. Levels of CD25 were measured on CD4+ T-cells at 
time 0 (Time 0), 24 hours (Time 24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and 
without (unstim) by flow cytometry. The percentage of CD4+ T-cells that expressed PD-L1 
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PD-1 blockade did increase levels of CD25 on previously stimulated CD8+ T-cells at 24 hours. 
There was no change in phenotype at any other time point. See  
Figure 6-19. CD8+ CD25+ stimulated CD3/CD28 PB vs stimulated PB + blocking antibody 24 
hours: 37.88% +/- 6.32 vs 40.84. % +/- 7.87; n=6, p=0.031. CD8+ T-cells expressing CD25 
unstimulated PB vs unstimulated PB + blocking antibody 24 hours: 3.67% +/- 1.16 vs 7.10% 
+/- 2.78; n=8, p=0.242. CD8+ T-cells expressing CD25 unstimulated PB vs unstimulated PB 
+ blocking antibody 48 hours: 9.32% +/- 2.49 +/- 7.18% +/- 3.20; n=8, p=0.844. CD8+ CD25+ 
stimulated CD3/CD28 PB vs stimulated PB + blocking antibody 48 hours: 78.321% +/- 6.56 
vs 82.21 +/- 6.31; n=7, p=0.954.  
 
 
Figure 6-19 Blocking PD-1 signal transduction does not alter CD25 expression on CD8+ T-
cells, except for pre-stimulated CD8+ T-cells at 24 hours 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Anti-human PD-1 was used to 
block PD-1 as described in Figure 6-18. Cultures were set up with (+B) and without the 
blocking antibody. Levels of CD25 were measured on CD8+ T-cells at time 0 (Time 0), 24 
hours (Time 24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and without (unstim) 
by flow cytometry. The percentage of CD8+ T-cells that expressed PD-L1 was unaffected by 
the addition of the blocking antibody at every time point except for pre-stimulated CD8+ T-
cells at 24 hours (p=0.031). 
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6.5.13 Blocking PD-1 does not alter CD69 expression on CD4+ or CD8+ PB T-cells 
Blocking PD-1 did not upregulate CD69 on resting PB CD4+ or CD8+ T-cells. Pre-stimulated 
T-cells were also unaffected by PD-1 blockade at any time point. See Figure 6-20. CD4+ 
CD69+ unstimulated PB vs unstimulated PB + blocking antibody 24 hours: 2.87% +/- 0.95 vs 
2.35% +/- 1.47; n=8, p=0.54. CD4+ CD69+ unstimulated PB vs unstimulated PB + blocking 
antibody 48 hours: 3.45% +/- 1.02 vs 3.45% +/- 0.91; n=8, p=0.328. CD4+ CD69+ stimulated 
CD3/CD28 PB vs stimulated PB + blocking antibody 24 hours: 58.12% +/- 5.31 vs 57.70 +/- 
7.67; n=7, p=0.105. CD4+ CD69+ stimulated CD3/CD28 PB vs stimulated PB + blocking 
antibody 48 hours: 68.82% +/- 5.25 vs 53.80% +/- 8.72; n=7, p=0.150.  
  
 
Figure 6-20 Blocking PD-1 signal transduction does not alter CD69 expression in CD4+ T-
cells 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Anti-human PD-1 was used to 
block PD-1 as described in Figure 6-18. Cultures were set up with (+B) and without the 
blocking antibody. Levels of CD69 were measured on CD4+ T-cells at time 0 (Time 0), 24 
hours (Time 24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and without (unstim) 
by flow cytometry. The percentage of CD4+ T-cells that expressed CD69 was unaffected by 
the addition of the blocking antibody at every time point. 
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The same held true for CD8+ T-cells. See Figure 6-21. CD8+ CD69+ unstimulated PB vs 
unstimulated PB + blocking antibody 24 hours: 4.76% +/- 1.98 vs 5.05% +/- 2.35; n=8, 
p=0.056. CD8+ CD69+ unstimulated PB vs unstimulated PB + blocking antibody 48 
hours:10.03% +/- 2.79 vs 7.39% +/- 2.48; n=8, p=0.700. CD8+ CD69+ stimulated CD3/CD28 
PB vs stimulated PB + blocking antibody 24 hours: 52.07% +/- 6.09 vs 56.73% +/- 9.89;  n=7, 
p=0.743. CD8+ CD69+ stimulated CD3/CD28 PB vs stimulated PB + blocking antibody 48 
hours: 81.03% +/- 4.37 vs 78.94% +/- 4.25; n=7, p=0.121.  
 
 
Figure 6-21 Blocking PD-1 signal transduction does not alter CD69 expression in CD8+ T-
cells 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Anti-human PD-1 was used to 
block PD-1 as described in Figure 6-18. Cultures were set up with (+B) and without the 
blocking antibody. Levels of CD69 were measured on CD8+ T-cells at time 0 (Time 0), 24 
hours (Time 24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and without (unstim) 
by flow cytometry. The percentage of CD8+ T-cells that expressed CD69 was unaffected by 
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6.5.14 Blocking PD-1 does not alter CTLA-4 expression on CD4+ PB T-cells 
Blocking PD-1 did not upregulate CTLA-4 on resting PB CD4 or CD8 T-cells. Pre-stimulated 
T-cells were also unaffected by PD-1 blockade at any time point. See Figure 6-22. CD4+ 
CTLA-4+ unstimulated PB vs unstimulated PB + blocking antibody 24 hours: 11.25% +/- 3.72 
vs 7.33% +/- 2.76; n=8, p=0.988. CD4+ CTLA-4+ unstimulated PB vs unstimulated PB + 
blocking antibody 48 hours: 24.30% +/- 7.98 vs 29.48% +/- 11.80; n=8, p=0.842. CD4+ CTLA-
4+ stimulated CD3/CD28 PB vs stimulated PB + blocking antibody 24 hours: 29.41% +/- 5.95 
vs 27.45% +/- 9.96; n=8, p=0.551. CD4+ CTLA-4+ stimulated CD3/CD28 PB vs stimulated PB 
+ blocking antibody 48 hours: 58.07% +/- 8.16 vs 62.81% +/- 9.04; n=8, p=0.631.  
 
Figure 6-22 Blocking PD-1 signal transduction does not alter CTLA-4 expression in CD4+ T-
cells 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Anti-human PD-1 was used to 
block PD-1 as described in Figure 6-18. Cultures were set up with (+B) and without the 
blocking antibody. Levels of CTLA-4 were measured on CD4+ T-cells at time 0 (Time 0), 24 
hours (Time 24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and without (unstim) 
by flow cytometry. The percentage of CD4+ T-cells that expressed CTLA-4 was unaffected by 
the addition of the blocking antibody at every time point. 
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The same held true for CD8+ T-cells, where PD-1 blockade unaffected CTLA-4 expression 
(data not shown). 
6.5.15 Blocking PD-1 does not change PD-1 expression levels on PB T-cells or CLL cells 
As for the stimulation experiments, the PD-1 blockade was performed on unselected CLL PB 
cells. Blocking PD-1 did not upregulate itself on resting PB CD4+ or CD8+ T-cells. Pre-
stimulated T-cells were also unaffected by PD-1 blockade at any time point. In addition, there 
was no effect of the PD-1 blockade on CLL cells expression of PD-1. See Figure 6-23. CD4+ 
PD-1hi unstimulated PB vs unstimulated PB + blocking antibody 24 hours: 43.43% +/- 7.36 vs 
47.47% +/- 10.11; n=6, p=0.729. CD4+ PD-1hi unstimulated PB vs unstimulated PB + blocking 
antibody 48 hours: 41.85% +/- 9.27 vs 41.88% +/- 10.99; n=5, p=0.696. CD4+ PD-1hi 
stimulated CD3/CD28 PB vs stimulated PB + blocking antibody 24 hours: 70.28% +/- 7.42 vs 
74.88% +/- 8.89; n=5, p=0.085. CD4+ PD-1hi stimulated CD3/CD28 PB vs stimulated PB + 
blocking antibody 48 hours: 81.92% +/- 5.66 vs 80.94% +/- 6.19; n=5, p=0.695.  
 
Figure 6-23 Blocking PD-1 signal transduction does not alter PD-1 expression in CD4+ T-cells 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Anti-human PD-1 was used to 
block PD-1 as described in Figure 6-18. Cultures were set up with (+B) and without the 
blocking antibody. Levels of PD-1 were measured on CD4+ T-cells at time 0 (Time 0), 24 
hours (Time 24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and without (unstim) 
by flow cytometry. The percentage of CD4+ T-cells that expressed PD-1 was unaffected by 
the addition of the blocking antibody at every time point. 
- 305 - 
Again the same was true for CD8+ T-cells expressing PD-1. See Figure 6-24. CD8+ PD-1hi 
unstimulated PB vs unstimulated PB + blocking antibody 24 hours: 55.65% +/- 5.53 vs 51.63% 
+/- 7.94; n=6, p=0.869. CD8+ PD-1hi unstimulated PB vs unstimulated PB + blocking antibody 
48 hours: 56.04% +/- 8.06 vs 57.54% +/- 13.42; n=5, p=0.515. CD8+ PD-1hi stimulated 
CD3/CD28 PB vs stimulated PB + blocking antibody 24 hours: 71.47% +/- 4.59 vs 67.38% +/- 
6.14; n=5, p=0.593. CD8+ PD-1hi stimulated CD3/CD28 PB vs stimulated PB + blocking 
antibody 48 hours: 88.80% +/- 5.49 vs 92.76% +/- 2.76; n=5, p=0.730.  
 
Figure 6-24 Blocking PD-1 signal transduction does not alter PD-1 expression on CD8+ T-
cells 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Anti-human PD-1 was used to 
block PD-1 as described in Figure 6-18. Cultures were set up with (+B) and without the 
blocking antibody. Levels of PD-1 were measured on CD8+ T-cells at time 0 (Time 0), 24 
hours (Time 24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and without (unstim) 
by flow cytometry. The percentage of CD8+ T-cells that expressed PD-1 was unaffected by 
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Levels of PD-1 on CLL B-cells themselves were also unaffected. See Figure 6-25. CLL PD-
1hi unstimulated PB vs unstimulated PB + blocking antibody 24 hours: 72.83% +/- 6.52 vs 
77.62% +/- 9.63; n=6, p=0.306. CLL PD-1hi unstimulated PB vs unstimulated PB + blocking 
antibody 48 hours: 73.62% +/- 6.75 vs 77.78% +/- 8.39; n=5, p=0.659. CLL PD-1hi stimulated 
CD3/CD28 PB vs stimulated PB + blocking antibody 24 hours:74.37% +/- 6.39 vs 77.16 +/- 
8.70; n=5, p=0.627. CLL PD-1hi stimulated CD3/CD28 PB vs stimulated PB + blocking 
antibody 48 hours: 79.74% +/- 7.72 vs 82.22% +/- 6.22; n=5, p=0.138.  
 
Figure 6-25 Blocking PD-1 signal transduction does not alter PD-1 expression on CLL cells 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Anti-human PD-1 was used to 
block PD-1 as described in Figure 6-18. Cultures were set up with (+B) and without the 
blocking antibody. Levels of PD-1 were measured on CLL B-cells at time 0 (Time 0), 24 hours 
(Time 24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and without (unstim) by flow 
cytometry. The percentage of CLL B-cells that expressed PD-1 was unaffected by the addition 
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6.5.16 Blocking PD-1 does not alter PD-L1 expression on PB CLL cells 
Blocking PD-1 on CLL PBMCs did not upregulate PD-L1 on resting CLL cells. CLL cells in the 
presence of stimulated T-cells were also unaffected by PD-1 blockade at any time point. See 
Figure 6-26. CLL PD-L1+ unstimulated PB vs unstimulated PB + blocking antibody 24 hours: 
0.24% +/- 0.11 vs 0.13% +/- 0.13; n=6, p=0.518. CLL  PD-L1+ unstimulated PB vs 
unstimulated PB + blocking antibody 48 hours: 4.00% +/- 1.63 vs 1.56% +/- 0.46; n=5, 
p=0.542. CLL PD-L1+ stimulated CD3/CD28 PB vs stimulated PB + blocking antibody 24 
hours: 4.26% +/- 2.26 vs 0.845 +/- 0.29; n=5, p=1.00. CLL PD-L1+ stimulated CD3/CD28 PB 
vs stimulated PB + blocking antibody 48 hours: 21.32% +/- 6.243 vs 14.10% +/- 4.78; n=5, 
p=0.134. 
 
Figure 6-26 Blocking PD-1 signal transduction does not alter PD-L1 expression on CLL cells 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Anti-human PD-1 was used to 
block PD-1 as described in Figure 6-18. Cultures were set up with (+B) and without the 
blocking antibody. Levels of PD-L1 were measured on CLL B-cells at time 0 (Time 0), 24 hours 
(Time 24) and 48 hours (Time 48), with CD3/CD28 beads (stim) and without (unstim) by flow 
cytometry. The percentage of CLL B-cells that expressed PD-L1 was unaffected by the 
addition of the blocking antibody at every time point. 
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The same was true for the CD4+ and CD8+ T-cells, where blocking PD-1 had no effect on 
levels of PD-L1 (data not shown). 
6.5.17 Intracellular IFN-γ secretion 
The PD-1 blocking experiments did not reveal consistent phenotypic changes in this study. 
We therefore went on to perform a preliminary experiment to look for changes in levels of 
intracellular IFN-γ in response to T-cell stimulation and PD-1 blockade as described in 6.3.6. 
This experiment showed an increase in IFN-γ following stimulation and that levels in this 
patient increased following PD-1 blockade. This work requires ongoing study using cells from 
a larger cohort of patients and is a fascinating area for future study. See Figure 6-27.  
 
Figure 6-27 IFN-γ increased following stimulation and PD-1 blocking in this experiment 
CLL autologous PB T-cells were stimulated as in Figure 6-1. Anti-human PD-1 was used to 
block PD-1 as described in Figure 6-18. Cultures were set up with (+B) and without the 
blocking antibody. Levels of IFN-γ were measured by intracellular cytokine staining of CD4+ 
T-cells at time point 24 hours (Time 24) with (stim) and without (unstim) CD3/CD28 beads as 
described. The percentage of CD4+ T-cells that positively labelled for intracellular IFN-γ 
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6.6 Discussion 
Having shown, in chapter 3, that LN derived T-cells appear to have undergone antigen 
induced activation, we have attempted to mimic the situation in the LN using CD3/CD28 bead 
stimulation of PB CLL T-cells. The results from this chapter have demonstrated that 
stimulating CLL T-cells from cryopreserved PB mononuclear cells can lead to phenotypic 
changes more similar to those found in CLL LN samples. To mimic APC dependent activation 
we used CD3/CD28 beads to stimulate the T-cells. This resulted in upregulation of PD-1 on 
PB CLL T-cells to levels consistent with those found in the LN. This provides further evidence 
that the phenotypic changes in CLL LNs may be a consequence of antigenic stimulation. 
Prolonged T-cell stimulation led to a greater level of T-cell activation than that seen in T-cells 
directly sampled from the CLL LN. This apparent overstimulation led to situation where the 
phenotypic markers of activation were increased to higher levels on the CD3/CD28 stimulated 
CLL PB T-cells than those found on the in vivo LN FNA T-cells. The TCR dependant negative 
T-cell regulator CTLA-4 was also expressed at higher levels on the in vitro cultured PB T-cells 
following CD3/CD28 stimulation than on the fresh LN FNA derived T-cells. This suggests, in 
this pilot study, that the in vitro stimulation method was too strong. Nonetheless these results 
indicate that further optimisation experiments could result in a model representative of LN 
derived T-cells. To address this we could have reduced the length of time of CD3/CD28 
stimulation, considered CD3 stimulation alone or utilised alternate methods of T-cell 
stimulation. Stimulation with phytohaemagglutinin (PHA), a mitogenic lectin, could have been 
used although this is a very non-specific approach and we would predict that all T-cells would 
be non-specifically stimulated to express PD-1. CD3/CD28 stimulation is more akin to APC 
stimulation than PHA although it is still not entirely reflective of the in vivo situation. An 
alternate experimental approach could have been to activate T-cells by superantigen 
stimulation such as with Staphylococcal Enterotoxin B (SEB). Superantigen stimulation would 
have been of interest in light of the results of the data already presented here in this thesis; 
the spectratyping and HTS data from chapter 5 has shown that the PD-1hi T-cells in CLL are 
skewed across many TCRVβ families which could be in response to a superantigen. The ideal 
experiment would be to attempt to stimulate the T-cells with the candidate antigen, antigens 
or superantigen involved in the pathogenesis of CLL. Subsequent work in our laboratory has 
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been focused on stimulating CLL cells with a variety of autoantigens such as whole CLL cells 
and the cytoskeletal proteins, cofilin and vimentin.  
A very significant result of this study was that TCR stimulation of T-cells co-cultured with CLL 
cells caused significant upregulation of PD-L1 on both the T-cells and the tumour cells in this 
in vitro model. We had not demonstrated PD-L1 expression on CLL cells derived from the 
fresh LN FNA in chapter 3. Dong et al have previously reported that PD-L1 can be upregulated, 
as a result of IFN-γ secreted by activated T-cells, on tumour cells, epithelial cells B-cells and 
the T-cells themselves (Dong, Strome et al. 2002). The upregulation of PD-L1 on the tumour 
CLL cells potentially has important clinical relevance and could be a target for therapy. In the 
normal immune response if PD-1 is blocked, T-cells are activated and produce IFN-γ, the IFN-
γ in turn upregulates PD-L1 (Dong, Strome et al. 2002). We have shown that CLL T-cells can 
secrete IFN-γ upon stimulation and levels were increased further by PD-1 blockade. This 
clearly needs further study but nonetheless this preliminary work suggests that PD-1 blockade 
does increase IFN-γ secretion in CLL. Brusa et al have subsequently published supportive 
data whereby they found PD-L1 to be upregulated on CLL cells via interaction with CD3/CD28 
stimulated T-cells (Brusa, Serra et al. 2013). They went on to co-culture primary CLL B-cells 
and stimulated T-cells with an anti-PD-L1 monoclonal antibody, which lead to an increase in 
CD8+ IFN-γ expression, and conversely co-culture with recombinant soluble PD-L1 
decreased IFN-γ levels.  
McClanahan et al have recently published a study of PD-L1 blockade in the Eµ-TCL-1 
transgenic mouse model of CLL (McClanahan, Hanna et al. 2015). They found that the mice 
treated with PD-L1 blockade did not develop CLL in a transfer model, the CD8+ cytotoxic 
effector functions and immune synapse were restored and the T-cell proliferation normalised. 
Gassner previously published very similar findings in the same mouse model using a PD-1 
blocker (Gassner, Zaborsky et al. 2015). This is of interest although, in contrast to our findings 
in primary human CLL cells, the murine model has constitutive expression of PD-L1. In this 
model the malignant B-cells in the mouse peritoneal cavity seemed to be unaffected by PD-
L1 blockade, suggesting a protective niche and revealing there is a potential for tumour 
escape.  
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The major difficulty comes in unpicking the consequences of blocking the PD-1 / PD-L1 axis 
when all 3 of the main players of the hosts immune system, B-cells, CD4+ and CD8+ T-cells, 
all express PD-1 and PD-L1 to variable degrees. Butte et al have reported that PD-L1 is also 
a ligand of CD80, which is present on antigen resting cells, including CLL cells themselves, 
and that CD80 might bind PD-L1 preferentially over CD28 to downregulate immune responses 
(Butte, Keir et al. 2007). To add further to the complexity it is now increasingly understood that 
myeloid cells also express PD-L1 in response to IFN-γ secretion and play a role in T-cell 
suppression. This was first demonstrated in chronic hepatitis B infection (Chen, Zhang et al. 
2007). PD-L1 has more recently been shown to be expressed by myeloid derived suppressor 
cells (MDSCs) in the PB of CLL patients (Ramsay, Clear et al. 2012, Jitschin, Braun et al. 
2014). It is speculated that this suppression of T-cells by MDSCs is a further mechanism by 
which tumour cells are given the opportunity to proliferate (Curiel, Wei et al. 2003, Wilcox, 
Feldman et al. 2009). In the Eµ-TCL-1 mouse model McClanahan et al demonstrated that PD-
L1 blockade increased the number of splenic macrophages, increased the levels of MHC 
Class II molecules on dendritic cells and reduced monocytes. Clearly there is a complex 
crosstalk between the co-stimulatory molecules and negative regulators in CLL, playing their 
part in disease proliferation, tumour clearance and T-cell immune dysfunction. 
In the preliminary work presented here we blocked PD-1 directly using the monoclonal 
antibody J116. Although the PD-1 blockade did not, in general, alter the in vitro surface 
phenotype of the CD4+ T-cells, CD8+ T-cells or CLL cells, this is an area of great interest 
where there is clearly a need for further optimisation and study. There was one exception, 
where CD25 expression was upregulated on pre-stimulated CD8+ T-cells following co-culture 
with the anti-PD-1 antibody for 24 hours. There could be several explanations for these results. 
It is feasible that the blockade was not complete, and future experiments would include 
controls to prove the blocking was effective. If the PD-1 blockade here was partial, this would 
explain the change in surface expression of CD25 on pre-stimulated CD8+ T-cells and the 
increase IFN-γ secretion of CD4+ T-cells, following 24 incubation with anti-PD-1. This partial 
blockade may have been insufficient to fully overcome the negative regulation and therefore 
did not lead to other phenotypic changes. The amount of PD-1 antibody used is reported to 
block PD-1 signal transduction in a transfected cell line, and it is feasible that this is not the 
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same concentration as that is required to block PD-1 in primary patient cells. Future assays 
would include a titration experiment to identify the optimal concentration. In addition this 
preliminary work was performed on PBMCs where the T-cell to CLL ratio is not reflective of 
the LN microenvironment. Taking this work forward, T-cells could be selected and replaced at 
defined ratios to CLL cells to try and more closely mimic the situation found in CLL lymph 
nodes.  
To date PD-1 blockade in primary CLL cells and in vivo is poorly studied. A single phase 1 
clinical trial of Pidilizumab (CT-011) an anti-PD-1 monoclonal antibody, has been reported in 
patients with advanced haematological malignancies including a very small number of CLL 
patients (Berger, Rotem-Yehudar et al. 2008). Of the 3 CLL patients, 2 were reported to have 
stable disease. Such is the interest in harnessing the PD-1 / PD-L1 axis in CLL that a clinical 
trial has been given ethical approval in the United States (NCI-2015-00844). This study uses 
a combination of Nivolumab and Ibrutinib in relapsed refractory CLL. This trial follows the 
principle that PD-L1 blockade alone will not be sufficient to eradicate the established tumour 
and combination of BTK inhibition and PD-1 blockade seems an attractive proposition. This is 
particularly important in view of the data that BCR signalling may be negatively regulated by 
PD-1. The concern would be that blockade of PD-1 on the B-cells may in fact upregulate the 
BCR signalling pathway and give CLL a proliferative advantage. It of course remains to be 
elucidated what will be the effect of removing the brakes on the CD4+ and CD8+ T-cells, B-
cells and MDSCs in CLL and future work should investigate the functional properties and 
cellular interactions further.   
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Chapter 7 Final Discussion 
The overall aim of this thesis was to characterise the T-cell component of the CLL lymph node 
microenvironment.  The role of the tumour microenvironment in CLL is of interest both to gain 
a better understanding of the pathobiology of the disease, and to identify potential therapeutic 
targets. Historically CLL was thought to be a disease of quiescent naïve B-cells with a defect 
in apoptosis and PB CLL B-cells were shown to be mainly in the G0 or G1 phase of the cell 
cycle supporting this hypothesis (Dameshek 1967, Andreeff, Darzynkiewicz et al. 1980). 
However in vivo studies using deuterium uptake revealed that CLL has a significant 
proliferative component with a tumour birth rate up to 1% per day (Messmer, Messmer et al. 
2005). In addition, there is now increasing evidence that this proliferation take place within 
proliferation centres of the LN microenvironment (Swerdlow, Murray et al. 1984, Ben-Ezra, 
Burke et al. 1989). It is here that CLL tumour cells are in close contact with supportive 
elements of the tumour microenvironment.  It is well documented that when cultured in vitro 
CLL cells die rapidly by apoptosis; but can be rescued by co-culture with a variety of elements 
of the microenvironment, including activated T-cells (Patten, Buggins et al. 2008, Pascutti, Jak 
et al. 2013), vascular endothelium (Buggins, Pepper et al. 2010), and stromal cells 
(Panayiotidis, Jones et al. 1996, Lagneaux, Delforge et al. 1999, Kay, Shanafelt et al. 2007). 
Our group has previously reported that within LN proliferating CLL cells are in close contact 
with activated CD4+ T-cells (Patten, Buggins et al. 2008).  
Further evidence for the role of T-cells in CLL pathogenesis comes from the murine xenograft 
model of CLL where engraftment and proliferation of the B-cell clone is dependent upon the 
presence of activated human CD4+ T-cells (Bagnara, Kaufman et al. 2011). Taken together 
these findings support a disease model in which quiescent peripheral blood tumour cells 
transit into and out of secondary lymphoid tissues, where interactions that promote survival 
and proliferation of the malignant clone take place. Therefore we were especially interested in 
studying these CD4+ T-cells further.  
To date there has been extensive study of the phenotype and functional abnormalities of PB 
derived T-cells in CLL, in contrast there has been little investigation of the T-cells from the LN 
microenvironment.  
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The first challenge of this study was to identify a method to access the T-cells of the LN in an 
unselected group of CLL patients. Previously published studies have focused primarily on LN 
tissue derived from FFPE; this approach has several shortcoming which have been 
extensively reviewed here. In summary patients that have a lymph node biopsy are a highly 
selected group, the material is fixed making RNA extraction challenging and only limited 
phenotyping can be undertaken on a slide based assay. We therefore utilised the technique 
of LN FNA and found this to be a feasible and safe method to obtain cells from the LN, allowing 
for multiparametric flow cytometry. This ethically approved study had no reported adverse 
incidents or any safety reports for the duration of the study.   
In chapter 3 we present the phenotyping profile of the T-cells derived from the CLL LN tumour 
microenvironment using multiparameter flow cytometry. We found that up to 40% of the 
lymphocytes within the LN to be T-cells, compared to just 5% in the PB. Despite the small 
relative percentage of T-cells in the CLL PB this still represents a massive expansion in the 
total T-cell count compared to age matched healthy controls; confirming data from previously 
published series (Mellstedt and Choudhury 2006). We found the majority of the LN derived T-
cells were CD4+ Th cells by immunophenotyping, a finding only previously reported on LN 
biopsy sections (Swerdlow, Murray et al. 1984, Schmid and Isaacson 1994, Bonato, Pittaluga 
et al. 1998). Interestingly we found the relative proportion of CD4+ T-cells to be much higher 
in the LN compartment compared to the PB of the same patient. It has been reported by 
several groups that the PB derived CD4+ T-cells in CLL have a phenotype of chronic activation 
and a bias towards effector memory phenotype with a relative decrease in naïve T-cells 
(Motta, Chiarini et al. 2010, Walton, Lydyard et al. 2010, Nunes, Wong et al. 2012). We found 
an even greater proportion of the LN CD4+ T-cells to be skewed towards an effector memory 
phenotype than in the PB, suggesting that it is within the LN microenvironment that the T-cells 
are subjected to antigenic stimulation. This is in contrast to the normal LN in which naïve and 
central memory T-cells predominate (Khan, Shariff et al. 2002). Additionally we have shown 
the LN derived T-cells to have higher levels of the costimulatory molecule CD28 and the 
negative regulators CTLA-4 and PD-1, than the T-cells of the PB. High levels of PD-1 
expression on CLL PB T-cells compared to normal controls has now been confirmed by 
several other groups (Nunes, Wong et al. 2012, Brusa, Serra et al. 2013, Riches, Davies et 
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al. 2013). We report here for the first time the levels of PD-1 expression are even higher on 
CD4+ and CD8+ T-cells derived from the LN compared to those from the PB of the same 
patient taken at the same time. This strongly suggests that it interactions within the LN, most 
likely involving ongoing interaction with antigen(s), that are responsible for the high levels of 
PD-1 and other regulatory molecules found in patients with CLL.  
In order to confirm these results we utilised the technique of multiparameter 
immunofluorescence microscopy on FFPE lymph nodes. Conventional immunohistochemistry 
on FFPE is limited in that only one antigen can be labelled at a time. The number of antigens 
that can be investigated simultaneously is superior when using fluorescently labelled 
antibodies, although not currently to the same magnitude as flow cytometry. The technology 
is rapidly changing and advances in confocal microscopy and availability of new fluorophores 
is making it increasingly feasible to label FFPE slide samples with more and more antigens. 
We confirmed by 3 colour immunofluorescence microscopy there was an accumulation within 
the CLL LN of CD4+ PD-1+ T-cells and that these were in close contact with Ki67+ proliferating 
tumour cells. This complements a recent study reporting that the PD-1 T-cells within the lymph 
node are in contact with PD-L1+ CLL cells (Brusa, Serra et al. 2013). In a normal germinal 
centre B-cell help is specifically offered by Tfh cells so we looked for evidence of a similar 
germinal centre like reaction in the CLL LN. We found that only a small proportion of the CD4+ 
PD-1+ T- cells co-expressed ICOS and therefore the majority were not Tfh cells; nonetheless 
they still accounted for approximately 9% of all CD4 T-cells in a CLL lymph node. The 
significance of this is not clear. A direct comparison with a normal LN was not available as 
here the Tfh cells here are very specifically distributed in the germinal centre. Ahearne et al 
have recently reported an increased number of circulating CD4+ CXCR5+ ICOS+ cells in CLL 
patients compared to normal controls and that IL-21 and IL-4 promotes CLL proliferation in 
vitro, which are the major cytokines secreted by Tfh cells (Ahearne, Willimott et al. 2013). We 
confirmed this phenotypic finding and additionally showed no clear differences between the 
relative proportions of Tfh cells between the PB and the LN FNA. The mechanism for the Tfh 
accumulation is unknown but may be as a result of the CLL cell secreting favourable cytokines 
into the tumour microenvironment. Our group has previously reported that CLL cells secrete 
high levels of IL-6 which is required for Tfh cell development (Buggins, Patten et al. 2008).  
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Taken together our results provide indirect evidence for antigenic stimulation of the CD4+ T-
cells occurring within the lymph node; moreover, it can be hypothesised that the PD-1+ T-cells 
are specifically driven in response to the tumour. Supporting evidence for antigenic drive 
comes from studies of the malignant B-cell in CLL. It is now generally accepted that CLL are 
not naïve but have evidence of previous antigen experience, although the cell of origin is still 
debated (Seifert, Sellmann et al. 2012). Gene expression profiling of CLL B-cells have shown 
similarities to that of a normal memory B-cells and that the phenotype is that of an activated 
antigen experienced B-cell, including surface expression of CD23, CD25, CD69, CD71 and 
CD27 (Damle, Ghiotto et al. 2002). Further evidence for antigen drive in CLL comes from 
studies of the BCR. It is becoming increasingly clear that signalling through the BCR is of 
critical importance in CLL pathogenesis and it is subject to ongoing stimulation (Stevenson, 
Krysov et al. 2011, Woyach, Johnson et al. 2012). Gene expression profiling has shown that 
the BCR activation takes place preferentially within the CLL LN microenvironment (Herishanu, 
Perez-Galan et al. 2011). Non-random IGHV usage and the presence of homologous BCR 
subsets and stereotypes also suggest a specific antigen drive (Agathangelidis, Darzentas et 
al. 2012). CLL B-cells show significant skewing in their IGHV gene usage and several studies 
have shown that, in up to 20% of unrelated CLL patients, there is expression of BCRs with 
such striking homology to each other, that it would suggest specificity to the same antigen 
(Messmer, Albesiano et al. 2004, Tobin, Thunberg et al. 2004, Widhopf, Rassenti et al. 2004, 
Chiorazzi, Rai et al. 2005, Ghia, Stamatopoulos et al. 2005, Stamatopoulos, Belessi et al. 
2007). This phenomenon could not possibly occur by random chance and the probability 
independent clones would carry the same BCR would be in the region of 1 in 1012. 
This has led investigators to try and identify putative candidate antigens. BCRs from 
unmutated CLL cases appear to be polyreactive and some BCRs show affinity for self-
antigens including cytoskeletal proteins, non-muscle myosin heavy chain IIA and vimentin, 
which are expressed by cells undergoing apoptosis (Herve, Xu et al. 2005). Several groups 
have found affinity of BCRs for a variety of non-self-antigens including bacteria, fungal 
elements and viruses including CMV (Landgren, Rapkin et al. 2007, Kostareli, Hadzidimitriou 
et al. 2009, Steininger, Rassenti et al. 2009). CLL patients are immunosuppressed and have 
an increased incidence of bacterial, fungal and viral infections making this a plausible 
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hypothesis, although the cause and effect could be debated (Francis, Karanth et al. 2006). An 
interesting study, using an in vitro reconstitution system, suggested that CLL BCRs can 
possess an intrinsic antigen-independent capacity to elicit a calcium signal, which is a 
fascinating concept (Duhren-von Minden, Ubelhart et al. 2012).  
Although the exact mechanism of BCR activation in CLL remains uncertain, there is good 
evidence that both antigen dependant and independent mechanisms could operate 
(Hewamana, Alghazal et al. 2008, Muzio, Apollonio et al. 2008, Gobessi, Laurenti et al. 2009, 
Zhuang, Hawkins et al. 2010, Le Roy, Deglesne et al. 2012). Our hypothesis is that the T-cell 
accumulation in CLL is as a result of specific antigenic stimulation. Investigation of the PB 
TCR repertoire from CLL patients supports this. Compared to age matched normal controls, 
the overall TCR repertoire in CLL PB shows oligoclonality in both the CD4+ and CD8+ T-cells 
(Wen, Mellstedt et al. 1990, Farace, Orlanducci et al. 1994, Serrano, Monteiro et al. 1997, 
Rezvany, Jeddi-Tehrani et al. 1999, Goolsby, Kuchnio et al. 2000). To date, however, no study 
has investigated the TCR repertoire in CLL LNs.  
Having shown phenotypic evidence of T-cell interactions with antigen in CLL LNs, we went on 
to assess the TCR repertoire of the PB and LN, focusing on the CD4+ PD-1hi compartment; 
as it was this subset that we found to be co-localised with proliferating tumour cells. At the 
time this laboratory work was undertaken spectratyping was the gold standard technology for 
assessing the TCR repertoire. HTS is now becoming increasingly utilised although the 
technology and necessary bioinformatics techniques are still evolving. One of the major 
advantages of HTS is that it is quantitative, whereas spectratyping is can only identify gross 
changes within individual TCRVβ families. The advantage of spectratyping, however, is that it 
is informative regarding global changes in the repertoire and allows direct comparison of 
samples. We confirmed the finding of a skewed repertoire in CLL derived PB CD4+ T-cells 
compared to normal age matched controls. We additionally found that the CD4+ PD-1hi T-cell 
populations from the PB of normal individuals and CLL patients showed an even more skewed 
TCR repertoire compared to the PD-1lo counterparts. The CLL PD-1hi T-cells were skewed 
whether or not they were derived from the PB or LN, however as the frequency of PD-1hi cells 
is greater in the LN it is highly suggestive of antigen drive within this proliferative compartment. 
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Skewing of the spectratype was observed across numerous TCRVβ families, suggesting the 
T-cell response is not a clonal expansion to a single antigen. Data from HTS confirmed a 
skewed overall TCR repertoire in CLL and that within this repertoire there were a number of 
high frequency clonotypes. These clonotypes showed low homology between PB and LN but 
greater frequency of overlap between two LNs taken from the same patient, further supporting 
a role for a LN localised antigen(s). It is thus clear that CLL T-cells show evidence of 
oligoclonality and that the repertoire is more restricted in the LN than the PB. What remains 
unclear, however, is the nature of the putative antigen(s) and whether it could be the same as 
those involved in BCR activation. The number of changes we identified in the repertoire, 
however, make it more likely that multiple antigens are involved.  
Confounding variables exist when studying the TCR repertoire of the PB and include the 
observation that there is a marked skewing of the TCR repertoire as a consequence of normal 
ageing and with previous exposure to common viral infections such as CMV. In a healthy 
elderly population CMV specific CD8+ T-cells can account for up to half the T-cell repertoire 
(Khan, Shariff et al. 2002, Savva, Pachnio et al. 2013).  However CMV reactivation is rare in 
untreated CLL individuals suggesting an intact T-cell response to the virus remains, on a 
background of T-cell dysregulation (te Raa, Pascutti et al. 2014). It is also acknowledged that 
the T-cell abnormalities in CLL are not just restricted to CMV seropositive individuals and that 
there is still a vast T-cell expansion of dysregulated T-cells with abnormal phenotype even in 
CMV seronegative individuals (Riches, Davies et al. 2013, te Raa, Pascutti et al. 2014). The 
data we have presented here supports the observation that CMV alone cannot explain the T-
cell phenotype changes or the TCRVβ repertoire skewing in CLL.   
A plausible alternative hypothesis is that the TCR, like the BCR, is responding to self-derived 
antigens. Several groups have reported a definable population of T-cells in CLL PB with 
recognition of self-antigens including Rh antigen (Hall, Vickers et al. 2005), immunoglobulin 
framework (Trojan, Schultze et al. 2000) or CDR3 motifs (Rezvany, Jeddi-Tehrani et al. 2000). 
Others have demonstrated a small, but definable, population of anti-leukaemic CD8+ T-cells 
with a measurable specific tumour driven antigen response. CLL derived T-cells have shown 
in vitro responses to tumour idiotypes (Os, Burgler et al. 2013), tumour lysates (Goddard, 
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Prentice et al. 2003) and intact leukaemia cells themselves (Krackhardt, Harig et al. 2002). 
These have been the subject of interest especially with the possibility of expanding them by 
vaccination or indeed if they are “exhausted” PD-1hi cytotoxic T-cells they could be potentially 
be reinvigorated by PD-1 blockade.  
PD-1 and PD-L1 blockade in cancer therapy is a rapidly expanding area of research. This field 
of study was opened up by the observation that PD-1 was expressed by “exhausted” CD8+ 
T-cells in response to chronic antigenic stimulation by viruses, such as hepatitis and HIV. 
Barber et al authored the seminal paper in Nature in 2006, where they blocked PD-L1 in mice 
and restored the function of the exhausted CD8 T-cells; which in turn cleared the animals of 
chronic LCMV infection (Barber, Wherry et al. 2006). It is now well described that CD8+ PD-
1+ T-cells can be rescued from exhaustion and mount an anti-leukaemic effect in several 
cancers which has generated huge scientific interest. Anti PD-L1 antibodies have shown to 
promote tumour regression in melanoma, bladder cancer, renal carcinoma and non-small cell 
lung cancer (Brahmer 2012, Powles, Eder et al. 2014). Several anti-PD-1 drugs have reached 
the clinic since the work in this thesis was undertaken (Sharma and Allison 2015). 
Pembrolizumab was FDA approved in September 2014 for advanced metastatic melanoma 
(Hamid, Robert et al. 2013, Robert, Ribas et al. 2014). Nivolumab was FDA approved in 
December 2014 for melanoma, and in March 2015 for lung cancer (Robert, Ribas et al. 2014).  
In order to study the functional PD-1 / PD-L1 axis in CLL PB we have presented here a small 
pilot study aimed at recapitulating the phenotype of the T-cells from the LN microenvironment 
in an in vitro model. Ideally we would have used cells directly obtained from the LN FNA but 
this was technically not feasible due to the relatively small numbers of T-cells obtained using 
this technique. Therefore we sought to identify a method to mimic the T-cell phenotype from 
the LN tumour microenvironment. We activated PB CLL derived T-cells with CD3/CD28 
superparamagnetic polymer beads and found PD-1 was upregulated on both CD4+ and CD8+ 
T-cells to levels akin to those found in the LN. However, other activation and co-stimulation 
markers were raised to levels far in excess of those found in vivo, and therefore to take this 
work forward the method of stimulation needs to be optimised. One direction our group has 
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taken is to stimulate PB CLL T-cells with putative antigens involved in CLL pathogenesis 
including apoptosis derived proteins, cofilin and vimentin, and this work is on-going.  
It has been previously reported that resting PB CLL cells express PD-L1, however, we were 
unable to confirm this (Ramsay, Clear et al. 2012). Interestingly we did find that CLL PB cells 
upregulate PD-L1 during in vitro co-culture with CD3/CD28 stimulated T-cells. A possible 
explanation for the apparent discrepancy in our results is that in the Ramsay paper there was 
manipulation of the CLL cells, which induced PD-L1 expression, which only became apparent 
in our study following co-culture with CD3/CD28 beads. The ability of PD-L1 to be upregulated 
on CLL cells does suggest the PD-1 / PD-L1 axis could be a potential therapeutic target in 
CLL. However, the precise effect of inhibiting these interactions remains unclear. The 
expression of PD-1 and PD-L1 on both T and B lymphocytes, as well as myeloid cells adds to 
the complexity, and inhibiting these interactions could unmask both pro and anti-tumour 
effects. 
Early phase studies of the anti-PD-1 drug Nivolumab in Hodgkin lymphoma have shown an 
87% response rate (Ansell, Lesokhin et al. 2015). However it must be remembered Hodgkin 
lymphoma is a very specific scenario where the Reed Sternberg cells constitutively express 
PD-L1 and therefore the mechanism of action may not be directly comparable. In our study 
we set out to block the PD-1 / PD-L1 axis in primary CLL PBMCs using an anti-PD-1 antibody. 
This antibody prevents PD-1 downstream signalling and looked for phenotypic changes on 
both the CD4+ and CD8+ T-cells. We did not demonstrate overall that blocking of the PD-1 
changed the phenotype of the CD4+ or CD8+ T-cells, although we have shown that blocking 
PD-1 can increase IFN-γ expression and this clearly requires extensive future study. This is 
an important interaction to investigate, as the effects of immune checkpoint inhibition in CLL 
remain unknown, and as noted above, the critical unanswered question is what happens when 
T-cells are playing dual roles; with CD4+ T-cells potentially supporting the tumour survival and 
a proportion of cytotoxic T-cells may be directed against the tumour. Here PD-1 blockade may 
be a double edged sword and is thus a very exciting avenue for future research. It is also 
becoming increasingly clear that the crosstalk between the stimulation, co-stimulation and 
negative immune checkpoint regulators is complex and multidirectional. The molecules have 
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multiple ligand partners on many cell types whose interaction is yet to be fully elucidated and 
cannot be studied in isolation. 
Although immune checkpoint inhibitors may be incorporated into treatment algorithms of CLL 
in the future, perhaps a more pertinent question currently is what effects will BCR inhibitors 
have on the T-cell compartment in CLL, and this is an exciting area for future research. The 
treatment paradigm for CLL is rapidly changing and drugs that specifically target B-cell 
signalling are already routinely used in clinical practice. Ibrutinib, a BTK inhibitor, and 
Idelalisib, a PI3kinase inhibitor, have shown very promising results even in patients with 
chemotherapy refractory disease. It would be of interest to study what T-cell changes are 
induced by these drugs, and to identify whether these influence, for example, response to 
treatment, disease progression and treatment failure.  
Drugs that inhibit B-cell signalling may influence the T-cell component of CLL by direct and/or 
indirect mechanisms. As discussed in this thesis, it is well established that the CLL cells 
themselves induce changes in T-cells. Therefore quantitative and functional changes in the 
CLL B-cells, as a result of treatment with BCR inhibitors, would be predicted to lead to changes 
in T-cell numbers and function. Direct effects of these drugs on T-cells, also requires further 
evaluation. To date Ibrutinib is the most well studied. BTK is expressed in B-cells and myeloid 
cells but not in T-cells, however there is mounting evidence that Ibrutinib effects are not limited 
to targeting BTK. Several studies have shown that Ibrutinib has other off-target effects 
(Kokhaei, Jadidi-Niaragh et al. 2016). Dubovsky et al found that Ibrutinib inhibits IL-2 inducible 
tyrosine kinase (ITK) in T-cells (Dubovsky, Beckwith et al. 2013). This inhibits the proliferation 
of Th2 T-cells, and conversely Th1 T-cells are rescued by the activation of the resting 
lymphocyte kinase (RIK) compensatory signalling pathway which is not expressed by Th2 
cells. This leads to a selective pressure and a drive towards a Th1 phenotype.  
There is now also growing evidence that treatment of CLL patients with Ibrutinib can reverse 
some of the T-cell defects in vivo (Fraietta, Beckwith et al. 2016, Niemann, Herman et al. 
2016). Niemann et al report that single agent Ibrutinib treatment significantly reduces the 
number of T-cells with a specific reduction in the number of Th17 T-cells. Interestingly they 
also report a reduction in the CD4+ PD-1+ population. In vitro murine studies revealed Ibrutinib 
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directly inhibits Th17 T-cells, confirming the drug’s off-target effects. The inducible T-cell 
changes by Ibrutinib in vivo are of interest specifically when considering the emerging 
therapeutic field of CAR-T cells.  
To generate a CAR-T cell, allogeneic or autologous, T-cells are expanded and manipulated 
to express a chimeric antigen receptor; in this case targeting CD19. All clinical CAR-T cell 
studies reported to date utilise T-cells from an autologous source. In CLL there is a discernible 
disadvantage of using autologous T-cells to manufacture a CAR-T product, as using 
dysfunctional exhausted T-cells with a reduced ability to proliferate in vitro would potentially 
render the CAR-T product suboptimal. Evidence to support this comes from the clinical trial 
data which show inferior results of autologous CD19 CAR-T trials in CLL compared to acute 
lymphoblastic leukaemia (ALL) (Brentjens, Riviere et al. 2011, Kochenderfer, Dudley et al. 
2012, Davila, Riviere et al. 2014, Porter, Hwang et al. 2015). However, if Ibrutinib could 
overcome the T-cell dysfunction then this might enhance the ability to generate autologous 
CAR-T cells and their resultant efficacy may be increased. Fraietta et al have very recently 
reported that prior treatment of CLL patients with Ibrutinib did in fact enable the manufacture 
of a CD19 directed CAR-T product with superior efficacy (Fraietta, Beckwith et al. 2016). They 
showed that treatment of CLL patients with Ibrutinib for more than 5 months restored T-cell 
function to that of healthy controls ex vivo. This included a reduction in levels of PD-1 
expression on CD8 T-cells. In 3 patients treated with prolonged Ibrutinib therapy they showed 
superior T-cell proliferation ex vivo and they were able to generate CAR-T cells with enhanced 
proliferation and engraftment in a xenograft model. They found that CD8+ T-cells with the 
lowest baseline expression of PD-1 were most able to expand and generate a successful 
CAR-T product. These results suggest that future therapeutics combining BCR inhibition and 
immune signalling blockade will be of significant interest.  
It can be readily appreciated therefore that there are many potential avenues for future 
research in CLL. The ultimate aim would be to prevent individuals with MBL and early stage 
CLL progressing to advanced stage CLL and removing the need for therapy at all. It is clear 
that gaining a detailed understanding of the pathobiology of MBL and CLL and its complex 
interactions within the tumour microenvironment will play an important role in achieving that 
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aim. We need an understanding of these interactions to reveal under what circumstances a 
B-cell clone is allowed to expand, acquire deleterious genetic abnormalities and progress to 
an uncontrolled malignant proliferation.  Then strategies could potentially be employed to 
prevent individuals from developing symptomatic CLL. Until such a time we need to continue 
research into drug therapeutics. Targeted therapies such as monoclonal antibodies, BCR 
inhibition, and immune checkpoint blockade all give promise for a chemotherapy free future 
for CLL patients. A specific understanding of the effects of these therapeutics, and a 
knowledge of how they disrupt the complex interactions in the tumour microenvironment, 
whether alone or in combination, is a research area of immediate need. It is imperative, 
therefore, that clinical trials utilising these agents incorporate laboratory research at every step 
and that clinicians and scientists work together to undertake truly translational research.  
Taken together, understanding the CLL microenvironment is a challenge. The immune system 
is host, invader, defender, friend and foe. The lymph node is the niche in which all the players 
live in a complex milieu. We have demonstrated here some key new aspects in the 
understanding of CLL pathogenesis and importantly present data that supports the hypothesis 
that T-cell accumulation in CLL LNs is as a result of a yet unknown specific antigenic 
stimulation. It is hoped that this work, and that that follows on from it, will contribute further to 
the understanding of the pathobiology of CLL and ultimately benefit CLL patients.  
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